<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2501233168
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        KEYTRUDA 25 mg/ml Concentrate For Solution For Infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PEMBROLIZUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        14680.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSD INTERNATIONAL GMBH T/A MSD" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSD INTERNATIONAL GMBH T/A MSD
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MERCK SHARP & DOHME
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XC 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>KEYTRUDA contains the active substance pembrolizumab, which is a monoclonal antibody. KEYTRUDA works by helping your immune system fight your cancer.</p><p>&nbsp;</p><p>KEYTRUDA is used in adults to treat:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a kind of skin cancer called melanoma</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a kind of lung cancer called non‑small cell lung cancer</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a kind of cancer called classical Hodgkin lymphoma</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a kind of cancer called bladder cancer (urothelial carcinoma)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a kind of head and neck cancer called head and neck squamous cell carcinoma.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a kind of kidney cancer called renal cell carcinoma</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a kind of cancer that is determined to be microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) in the colon or rectum (called colorectal cancer), uterus (called endometrial cancer), stomach (called gastric cancer), small bowel (called small intestine cancer), or bile duct or gallbladder (called biliary tract cancer)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a kind of stomach cancer called gastric or gastro-oesophageal junction adenocarcinoma</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a kind of cancer called oesophageal carcinoma</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a kind of breast cancer called triple‑negative breast cancer</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a kind of uterine cancer called endometrial carcinoma</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a kind of cancer called cervical cancer</p><p>&nbsp;</p><p>KEYTRUDA is used in children and adolescents:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aged 3&nbsp;years and older to treat a kind of cancer called classical Hodgkin lymphoma</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aged 12&nbsp;years and older to treat a kind of cancer called melanoma.</p><p>&nbsp;</p><p>People get KEYTRUDA when their cancer has spread or cannot be taken out by surgery.</p><p>&nbsp;</p><p>People get KEYTRUDA after they have had surgery to remove melanoma, non-small cell lung cancer, &nbsp;or renal cell carcinoma to help prevent their cancer from coming back (adjuvant therapy).</p><p>&nbsp;</p><p>People get KEYTRUDA before surgery (neoadjuvant therapy) to treat non-small cell lung cancer or triple‑negative breast cancer and then continue getting KEYTRUDA after surgery (adjuvant therapy) to help prevent their cancer from coming back.</p><p>&nbsp;</p><p>KEYTRUDA may be given in combination with other anti‑cancer medicines. It is important that you also read the package leaflets for these other medicines. If you have any questions about these medicines, ask your doctor</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You should not be given KEYTRUDA</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to pembrolizumab or any of the other ingredients of this medicine (listed in section&nbsp;6 &ldquo;Contents of the pack and other information&rdquo;). Talk to your doctor if you are not sure.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor or nurse before receiving KEYTRUDA.</p><p>&nbsp;</p><p>Before you get KEYTRUDA, tell your doctor if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have an autoimmune disease (a condition where the body attacks its own cells)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have pneumonia or inflammation of your lungs (called pneumonitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; were previously given ipilimumab, another medicine for treating melanoma, and experienced serious side effects because of that medicine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; had an allergic reaction to other monoclonal antibody therapies</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have or have had chronic viral infection of the liver, including hepatitis B (HBV) or hepatitis C (HCV)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have liver damage</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have kidney damage</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have had a solid organ transplant or a bone marrow (stem cell) transplant that used donor stem cells (allogeneic)</p><p>&nbsp;</p><p>When you get KEYTRUDA, you can have some serious side effects. These side effects can sometimes become life‑threatening and can lead to death. These side effects may happen anytime during treatment or even after your treatment has ended. You may experience more than one side effect at the same time.</p><p>&nbsp;</p><p>If you have any of the following conditions, call or see your doctor right away. Your doctor may give you other medicines in order to prevent more severe complications and reduce your symptoms. Your doctor may withhold the next dose of KEYTRUDA or stop your treatment with KEYTRUDA.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lungs, which may include shortness of breath, chest pain or coughing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the intestines, which may include diarrhoea or more bowel movements than usual, black, tarry, sticky stools or stools with blood or mucus, severe stomach pain or tenderness, nausea, vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver, which may include nausea or vomiting, feeling less hungry, pain on the right side of stomach, yellowing of skin or whites of eyes, dark urine or bleeding or bruising more easily than normal</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the kidneys, which may include changes in the amount or colour of your urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of hormone glands (especially the thyroid, pituitary and adrenal glands), which may include rapid heartbeat, weight loss, increased sweating, weight gain, hair loss, feeling cold, constipation, deeper voice, muscle aches, dizziness or fainting, headaches that will not go away or unusual headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; type 1 diabetes, including diabetic ketoacidosis (acid in the blood produced from diabetes), symptoms may include feeling more hungry or thirsty than usual, need to urinate more often or weight loss, feeling tired or feeling sick, stomach pain, fast and deep breathing, confusion, unusual sleepiness, a sweet smell to your breath, a sweet or metallic taste in your mouth, or a different odour to your urine or sweat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the eyes, which may include changes in eyesight</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation in the muscles, which may include muscle pain or weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the heart muscle, which may include shortness of breath, irregular heartbeat, feeling tired, or chest pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas, which may include abdominal pain, nausea and vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the skin, which may include rash, itching, skin blistering, peeling or sores, and/or ulcers in mouth or in lining of nose, throat, or genital area</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an immune disorder that can affect the lungs, skin, eyes and/or lymph nodes (sarcoidosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the brain, which may include confusion, fever, memory problems or seizures (encephalitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain, numbness, tingling, or weakness in the arms or legs; bladder or bowel problems including needing to urinate more frequently, urinary incontinence, difficulty urinating and constipation (myelitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation and scarring of the bile ducts, which may include pain in the upper right part of the stomach, swelling of the liver or spleen, fatigue, itching, or yellowing of the skin or the whites of eyes (cholangitis sclerosing)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the stomach (gastritis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased function of the parathyroid gland, which may include muscle cramps or spasms, fatigue and weakness (hypoparathyroidism)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infusion reactions, which may include shortness of breath, itching or rash, dizziness or fever</p><p>&nbsp;</p><p><strong>Complications, including graft‑versus‑host‑disease (GVHD), in people with bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). </strong>These complications can be severe and can lead to death. They may occur if you had this kind of transplant in the past or if you get it in the future. Your doctor will monitor you for signs and symptoms, which may include skin rash, liver inflammation, abdominal pain, or diarrhoea.</p><p>&nbsp;</p><p>Children and adolescents</p><p>Do not give KEYTRUDA to children under 18&nbsp;years of age, except for children:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with classical Hodgkin lymphoma aged 3&nbsp;years and older</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with melanoma aged 12&nbsp;years and older.</p><p>&nbsp;</p><p>Other medicines and KEYTRUDA</p><p>Tell your doctor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking other medicines that make your immune system weak. Examples of these may include corticosteroids, such as prednisone. These medicines may interfere with the effect of KEYTRUDA. However, once you are treated with KEYTRUDA, your doctor may give you corticosteroids to reduce the side‑effects that you may have with KEYTRUDA. Corticosteroids may also be given to you before receiving KEYTRUDA in combination with chemotherapy to prevent and/or treat nausea, vomiting, and other side effects caused by chemotherapy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Pregnancy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must not use KEYTRUDA if you are pregnant unless your doctor specifically recommends it.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant, think you may be pregnant or are planning to have a baby, tell your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; KEYTRUDA can cause harm or death to your unborn baby.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are a woman who could become pregnant, you must use adequate birth control while you are being treated with KEYTRUDA and for at least 4&nbsp;months after your last dose.</p><p>&nbsp;</p><p>Breast‑feeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are breast‑feeding, tell your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not breast‑feed while taking KEYTRUDA.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is not known if KEYTRUDA passes into your breast milk.</p><p>&nbsp;</p><p>Driving and using machines</p><p>KEYTRUDA has a minor effect on your ability to drive or use machines. Feeling dizzy, tired or weak are possible side effects of KEYTRUDA. Do not drive or use machines after you have been given KEYTRUDA unless you are sure you are feeling well.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>KEYTRUDA will be given to you in a hospital or clinic under the supervision of a doctor experienced in cancer treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose of KEYTRUDA in adults is either 200&nbsp;mg every 3&nbsp;weeks or 400&nbsp;mg every 6&nbsp;weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose of KEYTRUDA in children and adolescents aged 3&nbsp;years and older with classical Hodgkin lymphoma and adolescents aged 12&nbsp;years and older with melanoma, is 2&nbsp;mg/kg bodyweight (up to a maximum of 200&nbsp;mg) every 3&nbsp;weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will give you KEYTRUDA through an infusion into your vein (intravenous) for about 30&nbsp;minutes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will decide how many treatments you need.</p><p>&nbsp;</p><p>If you miss an appointment to get KEYTRUDA</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call your doctor right away to reschedule your appointment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is very important that you do not miss a dose of this medicine.</p><p>&nbsp;</p><p>If you stop receiving KEYTRUDA</p><p>Stopping your treatment may stop the effect of the medicine. Do not stop treatment with KEYTRUDA unless you have discussed this with your doctor.</p><p>&nbsp;</p><p>If you have any further questions about your treatment, ask your doctor.</p><p>&nbsp;</p><p>You will also find this information in the patient card you have been given by your doctor. It is important that you keep this card and show it to your partner or caregivers.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>When you get KEYTRUDA, you can have some serious side effects. See section&nbsp;2.</p><p>&nbsp;</p><p>The following side effects have been reported with pembrolizumab alone:</p><p>&nbsp;</p><p>Very common (may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in the number of red blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced thyroid gland activity</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling less hungry</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea; stomach pain; nausea; vomiting; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching; skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in muscle and bones; joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling tired; unusual tiredness or weakness; swelling; fever</p><p>&nbsp;</p><p>Common (may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lung infection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in the number of platelets (bruising or bleeding more easily); decrease in the number of white blood cell (neutrophils; lymphocytes)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reactions related to the infusion of the medicine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; overactive thyroid gland; hot flush</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased sodium, potassium, or calcium in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble sleeping</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness; inflammation of the nerves causing numbness, weakness, tingling or burning pain of the arms and legs; lack of energy; change in your sense of taste</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal heart rhythm</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lungs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the intestines; dry mouth</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; red raised rash sometimes with blisters; inflammation of the skin; patches of skin which have lost colour; dry, itchy skin; hair loss; acne‑like skin problem</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain, aches or tenderness; pain in arms or legs; joint pain with swelling</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flu‑like illness; chills</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased liver enzyme levels in the blood; increased calcium in the blood; abnormal kidney function test</p><p>&nbsp;</p><p>Uncommon (may affect up to 1 in 100 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a decreased number of white blood cells (leukocytes); inflammation response against platelets; an increased number of white blood cells (eosinophils)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an immune disorder that can affect the lungs, skin, eyes and/or lymph nodes (sarcoidosis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased secretion of hormones produced by the adrenal glands; inflammation of the pituitary gland situated at the base of the brain; inflammation of the thyroid</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; type 1 diabetes, including diabetic ketoacidosis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a condition in which the muscles become weak and tire easily; seizure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the eyes; eye pain, irritation, itchiness or redness; uncomfortable sensitivity to light; seeing spots</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the heart muscle, which may present as shortness of breath, irregular heartbeat, feeling tired, or chest pain; accumulation of fluid around the heart; inflammation of the covering of the heart</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas; inflammation of the stomach; a sore that develops on the inside lining of your stomach or upper part of your small intestine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thickened, sometimes scaly, skin growth; small skin bumps, lumps or sores; hair colour changes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the sheath that surrounds tendons</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the kidneys</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of amylase, an enzyme that breaks down starch</p><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a condition called haemophagocytic lymphohistiocytosis, where the immune system makes too many infection fighting cells called histiocytes and lymphocytes that may cause various symptoms; inflammation response against red blood cells; feeling weak, lightheaded, short of breath or if your skin looks pale (signs of low level of red blood cells, possibly due to a type of anaemia called pure red cell aplasia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased function of the parathyroid gland, which may present as muscle cramps or spasms, fatigue and weakness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a temporary inflammation of the nerves that causes pain, weakness, and paralysis in the extremities (Guillain-Barr&eacute; syndrome); inflammation of the brain, which may present as confusion, fever, memory problems or seizures (encephalitis); pain, numbness, tingling, or weakness in the arms or legs; bladder or bowel problems including needing to urinate more frequently, urinary incontinence, difficulty urinating and constipation (myelitis); swelling of the optic nerve that may result in vision loss in one or both eyes, pain with eye movement, and/or loss of colour vision (optic neuritis); inflammation of the membrane around the spinal cord and brain, which may present as neck stiffness, headache, fever, eye sensitivity to light, nausea or vomiting (meningitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the blood vessels</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack or reduction of digestive enzymes made by the pancreas (pancreatic exocrine insufficiency); a hole in the small intestines; coeliac disease (characterised by symptoms such as stomach pain, diarrhoea, and bloating after consuming gluten-containing foods)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the bile ducts</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching, skin blistering, peeling or sores, and/or ulcers in mouth or in lining of nose, throat, or genital area (Stevens-Johnson syndrome or toxic epidermal necrolysis); tender red bumps under the skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disease in which the immune system attacks the glands that make moisture for the body, such as tears and saliva (Sjogren&rsquo;s syndrome)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the bladder, which may present as frequent and/or painful urination, urge to pass urine, blood in urine, pain or pressure in lower abdomen</p><p>&nbsp;</p><p>&nbsp;</p><p>The following side effects have been reported in clinical studies with pembrolizumab in combination with chemotherapy:</p><p>&nbsp;</p><p>Very common (may affect more than 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in the number of red blood cells; decreased number of white blood cells (neutrophils); decrease in the number of platelets (bruising or bleeding more easily)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced thyroid gland activity</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased potassium in the blood; feeling less hungry</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble sleeping</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the nerves causing numbness, weakness, tingling or burning pain of the arms and legs; headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath; cough</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea; vomiting; nausea; stomach pain; constipation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss; itching; skin rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the muscles and bones; joint pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling tired; unusual tiredness or weakness; fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood level of the liver enzyme alanine aminotransferase; increased blood level of the liver enzyme aspartate aminotransferase</p><p>&nbsp;</p><p>Common (may affect up to 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lung infection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased number of white blood cells (neutrophils) with a fever; decreased number of white blood cells (leukocytes, lymphocytes)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reaction related to the infusion of the medicine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased secretion of hormones produced by the adrenal glands; inflammation of the thyroid; overactive thyroid gland</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased sodium or calcium in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness; change in your sense of taste; lack of energy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal heart rhythm</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lungs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the intestines; inflammation of the stomach; dry mouth</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; red raised rash, sometimes with blisters; inflammation of the skin; acne‑like skin problem; dry, itchy skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain, aches or tenderness; pain in arms or legs; joint pain with swelling</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden kidney damage</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling; flu‑like illness; chills</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased bilirubin in the blood; increased blood level of the liver enzyme alkaline phosphatase; abnormal kidney function test; increased calcium in the blood</p><p>&nbsp;</p><p>Uncommon (may affect up to 1 in 100 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an increased number of white blood cells (eosinophils)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pituitary gland situated at the base of the brain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; type 1 diabetes, including diabetic ketoacidosis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the brain, which may present as confusion, fever, memory problems or seizures (encephalitis); seizure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the heart muscle, which may present as shortness of breath, irregular heartbeat, feeling tired, or chest pain; accumulation of fluid around the heart; inflammation of the covering of the heart</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the blood vessels</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas; a sore that develops on the inside lining of your stomach or upper part of your small intestine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thickened, sometimes scaly, skin growth; patches of skin which have lost colour; small skin bumps, lumps or sores</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the sheath that surrounds tendons</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the kidneys; inflammation of the bladder, which may present as frequent and/or painful urination, urge to pass urine, blood in urine, pain or pressure in lower abdomen</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of amylase, an enzyme that breaks down starch</p><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation response against red blood cells or platelets</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an immune disorder that can affect the lungs, skin, eyes and/or lymph nodes (sarcoidosis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased function of the parathyroid gland, which may present as muscle cramps or spasms, fatigue and weakness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a condition in which the muscles become weak and tire easily; a temporary inflammation of the nerves that causes pain, weakness, and paralysis in the extremities (Guillain-Barr&eacute; syndrome); swelling of the optic nerve that may result in vision loss in one or both eyes, pain with eye movement, and/or loss of colour vision (optic neuritis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the eyes; eye pain, irritation, itchiness or redness; uncomfortable sensitivity to light; seeing spots</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack or reduction of digestive enzymes made by the pancreas (pancreatic exocrine insufficiency); a hole in the small intestines; coeliac disease (characterised by symptoms such as stomach pain, diarrhoea, and bloating after consuming gluten-containing foods)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the bile ducts</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching, skin blistering, peeling or sores, and/or ulcers in mouth or in lining of nose, throat, or genital area (Stevens‑Johnson syndrome); tender red bumps under the skin; hair colour changes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disease in which the immune system attacks the glands that make moisture for the body, such as tears and saliva (Sjogren&rsquo;s syndrome)</p><p>&nbsp;</p><p>&nbsp;</p><p>The following side effects have been reported in clinical studies with pembrolizumab in combination with axitinib or lenvatinib:</p><p>&nbsp;</p><p><strong>Very common (may affect more than 1 in 10 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary infections (increased frequency in urination and pain in passing urine)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in the number of red blood cells</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced thyroid gland activity</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling less hungry</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache; change in your sense of taste</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath; cough</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea; stomach pain; nausea; vomiting; constipation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash; itching</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain; pain in the muscles and bones; muscle pain, aches or tenderness; pain in arms or legs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling tired; unusual tiredness or weakness; swelling; fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of lipase, an enzyme that breaks down fats; increased liver enzyme levels in the blood; abnormal kidney function test</p><p>&nbsp;</p><p>Common (may affect up to 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lung infection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased number of white blood cells (neutrophils, lymphocytes, leukocytes); decrease in the number of platelets (bruising or bleeding more easily)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reaction related to the infusion of the medicine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased secretion of hormones produced by the adrenal glands; overactive thyroid gland; inflammation of the thyroid</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased sodium, potassium, or calcium in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble sleeping</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness; inflammation of the nerves causing numbness, weakness, tingling or burning pain of the arms and legs; lack of energy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal heart rhythm</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lungs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the intestines; inflammation of the pancreas; inflammation of the stomach; dry mouth</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; red raised rash, sometimes with blisters; inflammation of the skin; dry skin; acne‑like skin problem; hair loss</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain with swelling</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the kidneys</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flu‑like illness; chills</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of amylase, an enzyme that breaks down starch; increased bilirubin in the blood; increased blood levels of a liver enzyme known as alkaline phosphatase; increased calcium in the blood</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an increased number of white blood cells (eosinophils)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pituitary gland situated at the base of the brain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; type 1 diabetes, including diabetic ketoacidosis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a condition in which the muscles become weak and tire easily; inflammation of the brain, which may present as confusion, fever, memory problems or seizures (encephalitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the eyes; eye pain, irritation, itchiness or redness; uncomfortable sensitivity to light; seeing spots</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the heart muscle, which may present as shortness of breath, irregular heartbeat, feeling tired, or chest pain; accumulation of fluid around the heart</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the blood vessels</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a sore that develops on the inside lining of your stomach or upper part of your small intestine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry, itchy skin; thickened, sometimes scaly, skin growth; patches of skin which have lost colour; small skin bumps, lumps or sores; hair colour changes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the sheath that surrounds tendons</p><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased function of the parathyroid gland, which may present as muscle cramps or spasms, fatigue and weakness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the optic nerve that may result in vision loss in one or both eyes, pain with eye movement, and/or loss of colour vision (optic neuritis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a hole in the small intestines</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching, skin blistering, peeling or sores, and/or ulcers in mouth or in lining of nose, throat, or genital area (toxic epidermal necrolysis or Stevens‑Johnson syndrome)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disease in which the immune system attacks the glands that make moisture for the body, such as tears and saliva (Sjogren&rsquo;s syndrome)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the bladder, which may present as frequent and/or painful urination, urge to pass urine, blood in urine, pain or pressure in lower abdomen</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Other</strong><strong> side effects </strong><strong>that </strong><strong>have been reported with </strong><strong>frequency not known (cannot be estimated from the available data)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack or reduction of digestive enzymes made by the pancreas (pancreatic exocrine insufficiency); coeliac disease (characterised by symptoms such as stomach pain, diarrhoea, and bloating after consuming gluten-containing foods)</p><p>&nbsp;</p><p>Rash is more common when KEYTRUDA is given in combination with enfortumab vedotin than when KEYTRUDA is given alone.</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via National Pharmacovigilance and Drug Safety Centre (NPC), SFDA. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and vial label after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C&nbsp;&ndash;&nbsp;8&deg;C).</p><p>Do not freeze.</p><p>Store in the original carton in order to protect from light.</p><p>&nbsp;</p><p>From a microbiological point of view, the product, once diluted, should be used immediately. The diluted solution must not be frozen. If not used immediately, chemical and physical in‑use stability of KEYTRUDA has been demonstrated for 96&nbsp;hours at 2&ordm;C to 8&ordm;C. This 96‑hour hold may include up to 6&nbsp;hours at room temperature (at or below 25&deg;C). If refrigerated, the vials and/or intravenous bags must be allowed to come to room temperature prior to use.</p><p>&nbsp;</p><p>Do not store any unused portion of the infusion solution for reuse. Any unused medicine or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is pembrolizumab.</p><p>&nbsp;</p><p>One vial of 4&nbsp;mL contains 100&nbsp;mg of pembrolizumab.</p><p>Each mL of concentrate contains 25&nbsp;mg of pembrolizumab.</p><p>&nbsp;</p><p>The other ingredients are L‑histidine, L‑histidine hydrochloride monohydrate, sucrose, polysorbate&nbsp;80 and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What KEYTRUDA looks like and contents of the pack
	KEYTRUDA is a clear to slightly opalescent, colourless to slightly yellow solution, pH 5.2 – 5.8.
It is available in cartons containing one glass vial. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder</p><p>Merck Sharp &amp; Dohme B.V.</p><p>Waarderweg 39</p><p>2031 BN Haarlem</p><p>The Netherlands</p><p>&nbsp;</p><p>Manufacturer</p><p>MSD Ireland (Carlow)</p><p>Dublin Road, Carlow, Ireland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in  October 2024

To report any side effect(s):
•	Saudi Arabia: 
The National Pharmacovigilance Centre (NPC):
Fax: +966-11-205-7662
SFDA Call Center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: https://ade.sfda.gov.sa

•	Other GCC States: 
Please contact the relevant competent authority.

This is a Medicament
	Medicament  is  a  product  which  affects  your  health  and  its  consumption  contrary  to instructions is dangerous for you.
	Follow strictly the doctor’s prescription, the method of use and the instructions  of the pharmacist who sold the medicament.
	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
	Do not by yourself interrupt the period of treatment prescribed for you.
	Do not repeat the same prescription without consulting your doctor.
	Keep all medicaments out of reach of children.

Council of Arab Health Ministers 
Union of Arab Pharmacists
This patient information leaflet is approved by the Saudi Food and Drug Authority
















	The following information is intended for healthcare professionals only:
	
	Preparation and administration of the infusion
	•	Do not shake the vial. 
	•	Equilibrate the vial to room temperature (at or below 25°C).
	•	Prior to dilution, the vial of liquid can be out of refrigeration (temperatures at or below 25°C) for up to 24 hours.
	•	Parenteral medicinal products should be inspected visually for particulate matter and discolouration prior to administration. The concentrate is a clear to slightly opalescent, colourless to slightly yellow solution. Discard the vial if visible particles are observed.
	•	Withdraw the required volume up to 4 mL (100 mg) of concentrate and transfer into an intravenous bag containing sodium chloride 9 mg/mL (0.9%) or glucose 50 mg/mL (5%) to prepare a diluted solution with a final concentration ranging from 1 to 10 mg/mL. Each vial contains an excess fill of 0.25 mL (total content per vial 4.25 mL) to ensure the recovery of 4 mL of concentrate. Mix diluted solution by gentle inversion.
	•	From a microbiological point of view, the product, once diluted, should be used immediately. The diluted solution must not be frozen. If not used immediately, chemical and physical in use stability of KEYTRUDA has been demonstrated for 96 hours at 2°C to 8°C. This 96 hour hold may include up to 6 hours at room temperature (at or below 25°C). If refrigerated, the vials and/or intravenous bags must be allowed to come to room temperature prior to use. Translucent to white proteinaceous particles may be seen in diluted solution. Administer the infusion solution intravenously over 30 minutes using a sterile, non pyrogenic, low protein binding 0.2 to 5 µm in line or add on filter.
	•	Do not co administer other medicinal products through the same infusion line.
	•	KEYTRUDA is for single use only. Discard any unused portion left in the vial.
	
	Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي كيترودا على المادة الفعالة بيمبروليزوماب، وهو جسم مضاد<sup> </sup>وحيد النسيلة.</p><p dir="RTL">يعمل كيترودا على مساعدة جهازك المناعي لمحاربة السرطان.</p><p dir="RTL">يُستخدم كيترودا لدى المرضى الكبار البالغين لمعالجة ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من سرطان الجلد يعرف بـالميلانوما (سرطان الخلايا الصبغية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من سرطان الرئة يعرف بسرطان الرئة ذو الخلايا غير الصغيرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من سرطان الدم يعرف بليمفوما هودجكين الكلاسيكية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من سرطان المثانة البولية يعرف بسرطان بطانة المثانة البولية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من سرطان الرأس والرقبة يسمى سرطان الخلايا الحرشفية للرأس والعنق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من سرطان الكلى يسمى سرطان خلايا الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من سرطان القولون أو المستقيم الذي تم تحديده على أنه يتضمن درجة عالية من عدم استقرار السائل الميكروي (MSI-H) أو قصور في البروتين المسؤول عن إصلاح عدم التطابق في الحمض النووي (dMMR) (يسمى سرطان القولون والمستقيم) ، وسرطان الرحم (يسمى سرطان بطانة الرحم) ، والمعدة (يسمى سرطان المعدة) أو الأمعاء الدقيقة (يُسمى سرطان الأمعاء الدقيقة) ، أو القناة الصفراوية أو المرارة (يُسمى سرطان القناة الصفراوية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من سرطان المعدة يسمى سرطان المعدة أو سرطان الواقع بين نقطة التقاء المعدة بالمرييء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من السرطان يسمى سرطان المريء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من سرطان الثدي يسمى سرطان الثدي ثلاثي السلبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من سرطان الرحم يسمى سرطان بطانة الرحم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من السرطان يسمى سرطان عنق الرحم</p><p dir="RTL">يستخدم كيترودا في الأطفال والمراهقين :<br />- من عمر 3 ثلاث سنوات فما فوق لعلاج نوع من السرطان يسمى ليمفوما هودجكين الكلاسيكية<br />- من عمر 12 ثنتي عشرة سنة فما فوق لعلاج نوع من السرطان يسمى سرطان الجلد.</p><p dir="RTL">يستخدم كيترودا لدى المرضى في حال انتشار السرطان لديهم أوفي حال تعذر إزالة الورم بالجراحة &nbsp;لديهم.</p><p dir="RTL">كما يُستخدم كيترودا لدى المرضى ممن خضعوا لعملية جراحية لإزالة سرطان الجلد أو سرطان الرئة ذو الخلايا غير الصغيرة أو سرطان خلايا الكلى وذلك للمساعدة في منع عودة السرطان (علاج داعم).</p><p dir="RTL">ويُستخدم كيترودا كذلك قبل الجراحة (علاج داعم قَبلي) لسرطان الرئة ذي الخلايا غير الصغيرة لعلاج سرطان الثدي ثلاثي السلبية ومن ثم يستمر العلاج بإستخدام كيترودا فيما بعد الجراحة (علاج داعم) للمساعدة في منع عودة السرطان.</p><p dir="RTL">يمكن إعطاء كيترودا بالاشتراك مع أدوية أخرى مضادة للسرطان. من المهم أن تقرأ أيضًا النشرات الداخلية لتلك الأدوية الأخرى. إذا كان لديك أي أسئلة حول هذه الأدوية، اسأل طبيبك</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا يجب أن تتلقى العلاج بكيترودا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية نحو بيمروليزوماب أو أيّ من المكونات الأخرى لهذا الدواء (مذكورة في الفقرة رقم 6 &quot;محتويات العبوة ومعلومات أخرى<strong>&quot;). </strong>تحدث إلى طبيبك إذا لم تكن متأكدا.</p><p dir="RTL">التحذيرات والاحتياطات:&nbsp;<br />تحدث إلى طبيبك أو الممرض قبل تلقيك العلاج بكيترودا<sup>.</sup><br /><br />أخبر طبيبك قبل أن تتلقى العلاج بكيترودا إذا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من أحد أمراض المناعة الذاتية (حالة مرضية يهاجم الجسم فيها خلاياه الخاصة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من الالتهاب الرئوي الجرثومي أو غير الجرثومي (يسمى التهاب الرئة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سبق لك العلاج بإبيليموماب، وهو أحد الأدوية المستخدمة لعلاج الميلانوما وواجهت أعراضًا جانبية شديدة بسببه.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرّضت لردود فعل تحسسية تجاه العلاج بالأجسام المضادة ذات النسيلة الواحدة الأخرى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك أو سبق وتعرّضت لعدوى فيروسية مزمنة في الكبد ، بما في ذلك التهاب الكبد الوبائي نوع بي (HBV) أو التهاب الكبد الوبائي نوع سي (HCV)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مُصابًا بعدوى فيروس نقص المناعة البشري (HIV)، أو متلازمة نقص المناعة المكتسبة (الإيدز&quot;AIDS&quot;)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مُصابًا بتلف في الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مُصابًا بتلف في الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خضعت في السابق لزرع أحد الأعضاء أو زرع النّخاع ( خلايا جذعية) باستخدام خلايا جذعية من مانح (خَيْفي)</p><p dir="RTL">قد تواجه بعض الأعراض الجانبية الخطيرة عند تلقيك العلاج بكيترودا. يمكن أن تصبح هذه الأعراض الجانبية مهددة للحياة في بعض الأحيان ويمكن أن تؤدي إلى الموت. كما أنها قد تحدث في أي وقت أثناء العلاج أو حتى بعد انتهاء العلاج. قد تواجه أكثر من عَرَض جانبي في نفس الوقت.</p><p dir="RTL">اتصل أو راجع طبيبك على الفور إذا تعرّضت لأيّ من الحالات المذكورة أدناه. قد يصِف لك طبيبك أدوية أخرى من أجل منع حدوث مضاعفات أكثر حدة وللحد من الأعراض لديك. قد يلجأ طبيبك إلى إيقاف الجرعة التالية من كيترودا أو إيقاف علاجك بكيترودا نهائيًّا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرئتين والذي قد يشمل ضيقًا في التنفس، ألم في الصدر أو السعال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأمعاء والذي قد يشمل الإسهال، أو زيادة حركة الأمعاء أكثر من المعتاد، براز لزج وأسود كالقطران، أو براز مصحوب بالدم والمخاط، آلام شديدة في المعدة أو إيلام، غثيان وقيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد والذي قد يشمل غثيان وقيء ، قلة الشعور بالجوع ، ألم في الجهة اليمنى من البطن ، اصفرار الجلد أو بياض العينين ، بول غامق اللون ، نزيف أو حدوث كدمات بسهولة أكثر من المعتاد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكلى والذي قد يشتمل على تغير في لون أو كمية البول لديك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; التهاب الغدد التي تفرز هرمونات (خاصةً الغدة الدرقية ، الغدة النخامية والغدة الكظرية) والذي قد يشتمل على تسارع نبض القلب ، نقص في الوزن ، زيادة التعرق ، زيادة الوزن ، تساقط الشعر ، الإحساس بالبرودة ، إمساك ، بحة في الصوت ، آلام في العضلات ، دوار أو إغماء ، صداع مستمر أو صداع غير معتاد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; مرض السكري من النوع الأول ، بما في ذلك الحماض الكيتوني السكري (ظهور الحمض في الدم الناتج عن مرض السكري) ، قد تشتمل الأعراض الشعور بالجوع أو العطش أكثر من المعتاد ، والحاجة إلى التبول بكثرة أو فقدان الوزن ، والشعور بالتعب أو الشعور بالمرض ، وآلام في المعدة ، والتنفس السريع والعميق ، والارتباك ، والنعاس غير المعتاد ، وظهور رائحة فواكه في أنفاسك ، وطعم حلو أو معدني في فمك ، أو رائحة مختلفة للبول أو العرق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; التهاب العينين والذي قد يشتمل على تغير في القدرة على الإبصار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; التهاب العضلات والذي قد يشتمل على آلام أو ضعف في العضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; التهاب عضلة القلب والذي قد يشتمل على ضيق في التنفس ، عدم انتظام النبض ، الشعور بالتعب أو ألم في الصدر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس والذي قد يشمل ألم في البطن ، غثيان وقيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجلد والذي قد يشتمل على طفح ، حكة ، تبثّر أو تقشّر أو تقرّح الجلد ، و/أو تقرحات في الفم أو في بطانة الأنف أو الحلق أو المناطق التناسلية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;اضطراب مناعي يمكن أن يؤثر على الرئتين والجلد والعينين و/أو الغدد الليمفاوية (الساركويد)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; التهاب الدماغ ، والذي قد يظهر على شكل ارتباك أو حمّى أو مشاكل في الذاكرة أو نوبات (التهاب الدماغ)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; ألم ، تنميل ، وخز ، أو ضعف في الذراعين أو الساقين. مشاكل في المثانة أو الأمعاء ، بما في ذلك الحاجة إلى التبول بشكل متكرر ، وسلس البول ، وصعوبة التبول ، والإمساك (التهاب النخاع).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; التهاب وتندب في القنوات الصفراوية ، والذي قد يشتمل على ألم في الجزء العلوي الأيمن من البطن ، وتورم الكبد أو الطحال ، والتعب ، والحكة ، أو اصفرار الجلد أو بياض العينين (التهابُ القنوات الصفراوية المُصلِب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;التهاب المعدة (التهاب المعدة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;انخفاض وظيفة الغدة جار الدرقية، &nbsp;والذي قد يشتمل على تقلصات أو تشنجات العضلات ، والتعب &nbsp;&nbsp;<br />&nbsp; والضعف (قصور جارات الدرق)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل ناجمة عن التسريب الوريدي للدواء والذي قد يشمل ضيق في التنفس ، طفح أو حكة ، دوار أو حُمّى</p><p dir="RTL">قد تحدث مضاعفات ، تشمل مرض الطُّعم حِيَالَ المَضيف (GVHD) ، لدى الأشخاص ممن خضعوا لزرع نخاع العظم (الخلايا الجذعية) باستخدام الخلايا الجذعية من مانح (زرع خَيْفِي) . يمكن أن تكون هذه المضاعفات شديدة ويمكن أن تؤدي إلى الموت. قد تحدث إذا كنت قد أجريت هذا النوع من عمليات الزرع في الماضي أو ستخضع لها في المستقبل. سيقوم طبيبك بمراقبتك بحثًا عن العلامات والأعراض التي قد تشمل طفح جلدي أو التهاب الكبد أو ألم البطن أو الإسهال.</p><p dir="RTL">الأطفال والمراهقون</p><p dir="RTL">لا ينبغي استخدام كيترودا لدى الأطفال والمراهقين الذين تقل أعمارهم عن 18 ثماني عشرة سنة باستثناء:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال بعمر 3 ثلاث سنوات فما فوق ممن يعانون من سرطان الغدد الليمفاوية هودجكين الكلاسيكي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال بعمر 12 ثنتي عشرة سنة فما فوق ممن يعانون من سرطان الجلد</p><p dir="RTL">الأدوية الأخرى وكيترودا</p><p dir="RTL">أخبر طبيبك:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية أخرى تُضعف عمل جهازك المناعي. من أمثلة هذه الأدوية الستيرويدات القشرية مثل البريدنيزون. قد تتداخل هذه الأدوية مع تأثير كيترودا. ومع ذلك ، قد يصف لك طبيبك الستيرويدات القشرية عند علاجك بكيترودا وذلك للتخفيف من الأعراض الجانبية التي قد تعاني منها بسبب كيترودا.<br />يمكن أيضًا إعطاءك الستيرويدات القشرية قبل تلقيك كيترودا مع العلاج الكيميائي لمنع حدوث و/أو لعلاج الغثيان والقيء والأعراض الجانبية الأخرى الناجمة عن العلاج الكيميائي.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت تتناول أو تناولت مؤخرًا أو إذا كنت ستتناول أيّ أدوية أخرى فيما بعد.</p><p dir="RTL">الحمل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; ينبغي تجنب استخدام كيترودا إذا كنتِ حاملًا إلا إذا أوصى طبيبك باستخدامه على وجه التحديد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا ، أو إذا كنت تعتقدين أنك قد تكونين حاملًا أو تخططين للحمل، فاخبري طبيبك قبل تلقيك العلاج بهذا الدواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; قد يتسبب كيترودا في إلحاق الأذى أو الموت لجنينك قبل ولادته.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديكِ القدرة على الحمل ، فإنه ينبغي عليك اختيار وسيلة منع حمل مناسبة أثناء علاجك بكيترودا ولمدة 4 أربعة أشهر على الأقل بعد الجرعة الأخيرة.</p><p dir="RTL"><sup>&nbsp;</sup>&nbsp;&nbsp;الرضاعة الطبيعية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبري طبيبك إذا كنت ترضعين طبيعيًّا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب الامتناع عن إرضاع طفلك طبيعي أثناء تلقيك العلاج بكيترودا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من غير المعروف إلى الآن إذا كان كيترودا يُفرز في حليب الام أم لا.</p><p dir="RTL">القيادة واستخدام الآلات</p><p dir="RTL">كيترودا له تأثير بسيط على قدرتك على القيادة أو استخدام الآلات. الشعور بالدوخة والتعب أو الضعف &nbsp;من الأعراض الجانبية المُحتملة لكيترودا. &nbsp;تجنّب&nbsp; القيادة واستخدام أيّ أدوات أو آلات بعد تلقيك العلاج بكيترودا ، إلا إذا كنت متأكدًا تمامًا أنك على ما يرام.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سوف تتلقى العلاج بكيترودا في مستشفى أو في عيادة طبية تحت إشراف طبيب أخصائي بعلاج السرطان.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها من كيترودا هي إما 200 مجم كل 3 أسابيع أو 400 مجم كل 6 أسابيع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها من كيترودا لدى الأطفال والمراهقين الذين تتراوح أعمارهم بين 3 ثلاث سنوات وما فوق والذين يعانون من سرطان الغدد الليمفاوية هودجكين الكلاسيكي والمراهقين الذين تتراوح أعمارهم بين 12 ثنتي عشرة سنة وما فوق والذين يعانون من سرطان الجلد، هي 2 مجم/كجم من وزن الجسم (200 مجم بحد أقصى) كل 3 أسابيع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; سيقوم طبيبك بإعطائك كيترودا عن طريق التسريب الوريدي لمدة 30 ثلاثين دقيقة .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; سيقرر طبيبك عدد الجرعات التي تحتاجها.</p><p dir="RTL">في حال فاتك أحد المواعيد لتلقي العلاج بكيترودا</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتصل بطبيبك فورًا لإعادة جدولة موعدك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من الضروري جدًّا ألا تُفوّت أيّ جرعة من هذا الدواء.</p><p dir="RTL">في حال التوقف عن تلقي العلاج بكيترودا</p><p dir="RTL">قد يؤدي إيقافك للعلاج بكيترودا إلى إيقاف مفعول هذا الدواء. لا تتوقف عن العلاج بكيترودا إلا إذا ناقشت هذا الموضوع مع طبيبك.</p><p dir="RTL">اسأل طبيبك إذا كان لديك أيّ أسئلة أخرى عن هذا العلاج.</p><p dir="RTL">سوف تجد هذه المعلومات أيضًا في بطاقة المريض التي يقدمها لك طبيبك. من المهم أن تحتفظ في البطاقة وتظهرها لشريكك أو من يقوم على رعايتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية ، يُمكن أن يُسبّب هذا الدواء أعراضًا جانبية، ومع ذلك فإنها لا تحدث لدى جميع المرضى.</p><p dir="RTL">&nbsp;قد تحدث لك بعض الأعراض الجانبية الخطيرة عند تلقيك العلاج بكيترودا (انظر الفقرة رقم 2).</p><p dir="RTL">تم الإبلاغ عن الأعراض الجانبية التالية أثناء تلقّي العلاج ببيمبروليزوماب&nbsp; بمفرده :</p><p dir="RTL">شائعة جدًّا (قد تؤثر على أكثر من شخص من بين 10 أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد كريات الدم الحمراء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدني نشاط الغدة الدّرقية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلّة الشعور بالجوع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس ؛ سعال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال ؛ ألم في البطن ؛ غثيان ؛ قيء ؛ إمساك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة ؛ طفح جلدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات والعظام ؛ ألم المفاصل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب ؛ التعب أو الضعف غير العادي ؛ تورّم ؛ حمى</p><p dir="RTL">شائعة (قد تؤثر على ما يصل إلى شخص من بين 10 أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب رئوي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح الدموية (حدوث الكدمات أو النزيف بسهولة أكثر) ؛ انخفاض عدد خلايا الدم البيضاء (العدلات &ndash; الخلايا اللمفاوية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل تتعلّق بالتسريب الوريدي للدواء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط نشاط الغدة الدرقية ؛ نوبات من احمرار الوجه والرّقبة &quot;الهبّات السّاخنة&quot;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الصوديوم والبوتاسيوم أوالكالسيوم في الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة ؛ التهاب الأعصاب الذي يسبب خدر أو ضعف أو وخز أو ألم حارق في الذراعين والساقين ؛ نقص الطاقة ؛ تغير في حاسة الذوق لديك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب نبض القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;التهاب الرئتين &quot;غير الجرثومي&quot;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;التهاب الأمعاء ؛ جفاف الفم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أحمر مع ظهور بثور في بعض الأحيان ؛ التهاب الجلد؛ بقع جلدية باهتة ؛ جفاف الجلد مع حكة ؛ تساقط الشعر ؛ مشاكل جلدية تشبه حب الشباب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات ، أوجاع أو إيلام ؛ ألم في الذراعين أو الساقين ؛ آلام المفاصل مع تورم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;مرض يشبه الانفلونزا ؛ قشعريرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ارتفاع مستويات أنزيم الكبد في الدم ؛ ارتفاع مستوى الكالسيوم في الدم ؛ نتائج غير طبيعية لوظائف الكلى</p><p dir="RTL">غير شائعة (قد تؤثر على ما يصل إلى شخص من بين 100 مئة شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء (الكريات البيض) . استجابة التهابية ضد الصفائح الدموية . زيادة عدد خلايا الدم البيضاء (الحمضات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب مناعي قد يؤثر على الرئتين ، الجلد ، العينين، و/أو العقد الليمفاوية (ورم حُبَيبِي &quot;الساركويد&quot;)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في إفراز هرمونات الغدة الكظرية ؛ التهاب الغدة النخامية التي تقع عند قاعدة الدماغ ؛ التهاب الغدة الدرقية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء السكري من النوع الأول بما في ذلك الحماض السكّري الكيتوني</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة تصبح العضلات معها ضعيفة وتتعب بسرعة ، تشنجات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العينين ؛ ألم في العينين ؛ تهيج وحكه أواحمرار في العينين ؛ حساسية مزعجة تجاه الضوء ؛ ظهور بُقع في مجال الرؤية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب عضلة القلب ؛ والذي قد يظهر على شكل ضيق في التنفس ، عدم انتظام ضربات القلب ، الشعور بالتعب ، أو ألم في الصدر ؛ تجمع السوائل حول القلب ؛ التهاب الغشاء المحيط بالقلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التهاب المعدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور قرحة في البطانة الداخلية للمعدة أو الجزء العلوي من الأمعاء الدقيقة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نمو جلدي سميك ذو قشور أحيانًا ؛ التهاب الجلد ،&nbsp; تغير في&nbsp; لون الشعر ؛ نتوءات وتقرحات وتكتلات جلدية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأغشية المحيطة بالأوتار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى أنزيم الأميلاز الذي يعمل على تكسير النشاء</p><p dir="RTL">نادرة (قد تؤثر على ما يصل إلى شخص واحد من بين 1000 ألف شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة تسمى كثرة المُنسِجات اللمفاوية البلعمية &quot;داء البلعمة&quot;، حيث يقوم الجهاز المناعي بإنتاج عدد كبير جدًا من الخلايا المقاومة للعدوى والتي تسمى الخلايا المنسجات والخلايا الليمفاوية التي قد تسبب أعراضًا مختلفة ؛ التهابات كردود فعل ضد خلايا الدم الحمراء تظهر عل شكل شعور بالضعف، الدوار ، ضيق التنفس أو شحوب البشرة (علامات انخفاض عدد خلايا الدم الحمراء ، ربما بسبب نوع من فقر الدم يسمى عدم تنسّج&nbsp; الكريّة الحمراء النقيّ).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض وظيفة الغدة جار الدرقية ، والتي قد تظهر على شكل تشنجات أو تشنجات عضلية ، وتعب وضعف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب مؤقت في الأعصاب يسبب ألم ، ضعف وشلل في الأطراف (متلازمة غيلان باريه)؛ التهاب الدماغ ، والذي قد يظهر على شكل ارتباك أو حمى أو مشاكل في الذاكرة أو نوبات (التهاب الدماغ) ؛ ألم ، تنميل ، وخز ، أو ضعف في الذراعين أو الساقين. مشاكل في المثانة أو الأمعاء بما في ذلك الحاجة إلى التبول بشكل متكرر ، وسلس البول ، وصعوبة التبول والإمساك (التهاب النخاع) ؛&nbsp; تورم العصب البصري الذي قد يؤدي إلى فقدان الرؤية في إحدى العينين أو كلتيهما ، وألم أثناء حركة العين، و/أو فقدان رؤية الألوان (التهاب العصب البصري) ؛ التهاب الغشاء المحيط بالحبل الشوكي والدماغ ، والذي قد يظهر على شكل تصلب في الرقبة ، أو صداع ، أو حمى ، أو حساسية العين للضوء ، أو غثيان أو قيء (التهاب السحايا) .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص أو تقليل الإنزيمات الهضمية التي يصنعها البنكرياس (قصور إفراز البنكرياس) ؛ ثقب في الأمعاء الدقيقة. مرض الاضطرابات الهضمية (يتميز بأعراض مثل آلام المعدة والإسهال والانتفاخ بعد تناول الأطعمة التي تحتوي على الغلوتين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القنوات الصفراوية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة ، تبثر أو تقشُّر أو تقرُّح الجلد ، و/أو تقرُّحات في الفم أو بطانة الأنف أو الحلق أو المناطق التناسلية (تقشّر الأنسجة المتموتة البشروية التسمّمي أو متلازمة ستيفنز جونسون) ؛ نتوءات حمراء مؤلمة تحت الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض يقوم فيه الجهاز المناعي بمهاجمة الغدد التي تنتج الرطوبة في الجسم مثل الدموع واللعاب (متلازمة شوغرن)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المثانة ، والذي قد يظهر على شكل تبول متكرر و/أو مؤلم ، الرغبة المُلحّة في التبول ، ظهور دم في البول ، ألم أو ضغط في أسفل البطن.</p><p dir="RTL">تم الإبلاغ عن الأعراض الجانبية التالية في التجارب السريرية التي أُجريت عند استخدام بيمبروليزوماب مع العلاج الكيميائي:</p><p dir="RTL"><strong>شائعة جداً (قد تؤثر على أكثر من شخص من بين 10 عشرة أشخاص)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدم الحمراء ؛ انخفاض عدد خلايا الدم البيضاء (العدلات) ؛</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد الصفائح الدموية (حدوث كدمات أو نزيف بسهولة أكبر)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدني في نشاط الغدة الدرقيّة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى البوتاسيوم في الدم ؛ قلة الشعور بالجوع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأعصاب مما يسبب تنميل أو ضعف أو وخز أو ألم حارق في الذراعين والساقين ؛ صداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس ؛ سعال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال ؛ غثيان ؛ قيء ؛ إمساك ؛ ألم في البطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر ، طفح جلدي ؛ حكّة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات والعظام؛ آلام المفاصل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب أو الضعف غير المعتاد ؛&nbsp; حمّى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى أنزيم الكبد ألانين أمينوترانسفيراز في الدم ؛ زيادة مستوى أنزيم الكبد أسبارتات أمينوترانسفيراز في الدم</p><p dir="RTL"><strong>شائعة (قد تؤثر على ما يصل إلى شخص من بين 10 عشرة أشخاص)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الرئتين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء (العَدَلات) مع الحمّى ؛ انخفاض عدد خلايا الدم البيضاء (الكريات البيضاء و الخلايا الليمفاوية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;رد فعل متعلق بتسريب الدواء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;انخفاض إفراز الهرمونات التي تنتجها الغدد الكظرية ؛ التهاب الغدة الدرقية ؛ فرط نشاط الغدة الدرقية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;انخفاض مستوى الصوديوم أو الكالسيوم في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة ؛ تغير في حاسة التذوق لديك ؛ قلّة الطاقة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;جفاف العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;اضطراب ضربات القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ارتفاع ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التهاب الرئتين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التهاب الأمعاء ؛ التهاب المعدة ؛ جفاف الفم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التهاب الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;طفح جلدي أحمر مرتفع ، مع ظهور بثور أحيانًا ؛ مشاكل جلدية شبيهه بحب الشباب ؛ التهاب الجلد ؛ جفاف الجلد مع حكّة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;ألم في العضلات أو أوجاع ؛ ألم في الذراعين أو الساقين ؛ ألم في المفاصل مع تورم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;فشل الكلى الحاد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;تورم ؛ مرض شبيه بالانفلونزا ؛ قشعريرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; زيادة البيليروبين في الدم؛ زيادة مستوى الدم من إنزيم الكبد الفوسفاتيز القلوي؛ اختبار غير طبيعي لوظائف الكلى؛ زيادة الكالسيوم في الدم</p><p dir="RTL">غير شائعة (قد تؤثر على ما يصل إلى شخص من بين 100 مئة شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع عدد خلايا الدم البيضاء (الحَمضات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الغدة النخامية الموجودة في قاعدة الدماغ</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء السكر من النوع 1؛ بما في ذلك الحماض السكري الكيتوني</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الدماغ ، والذي قد يظهر على شكل ارتباك ، حمى، مشاكل في الذاكرة أو نوبات (التهاب الدماغ) ؛ تشنجات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب عضلة القلب والذي قد يظهر على شكل ضيق في التنفس ، عدم انتظام ضربات القلب ، الشعور بالتعب ، أو ألم في الصدر ؛ تراكم السوائل حول القلب ؛ التهاب غلاف القلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس ؛ التهاب المعدة ؛ ظهور قرحة في البطانة الداخلية للمعدة أو الجزء العلوي من الأمعاء الدقيقة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نمو جلدي سميك ذو قشور أحيانًا ؛ بقع جلدية باهتة ؛ نتوءات أو تقرحات أو كتل جلدية صغيرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأغشية المحيطة بالأوتار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكلى ؛ التهاب المثانة ، والذي قد يظهر على شكل تبول متكرر و/أو مؤلم، الرغبة المُلحّة في التبول ، ظهور دم في البول ، ألم أو ضغط في أسفل البطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى أنزيم الأميلاز الذي يعمل على تكسير النشاء؛</p><p dir="RTL"><strong>نادرة (قد تؤثر على ما يصل إلى 1 واحد من كل 1000 ألف شخص)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاستجابة الالتهابية ضد خلايا الدم الحمراء أو الصفائح الدموية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب مناعي يمكن أن يؤثر على الرئتين ، الجلد، العينين و/أو الغدد الليمفاوية (الساركويد).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض وظيفة الغدة جار الدرقية ، والتي قد تظهر على شكل تقلصات أو تشنجات عضلية ، وتعب وضعف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة تصبح فيها العضلات ضعيفة وتتعب بسهولة ؛ التهاب مؤقت للأعصاب يسبب الألم والضعف والشلل في الأطراف (متلازمة غيلان باريه) ؛ تورم العصب البصري الذي قد يؤدي إلى فقدان البصر في إحدى العينين أو كلتيهما ، وألم مع حركة العين ، و / أو فقدان رؤية الألوان (التهاب العصب البصري).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العينين. ألم في العين ، تهيج ، حكة أو احمرار. حساسية غير مريحة للضوء. رؤية البقع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص أو تقليل الإنزيمات الهضمية التي يصنعها البنكرياس (قصور إفراز البنكرياس) ؛ ثقب في الأمعاء الدقيقة. مرض الاضطرابات الهضمية (يتميز بأعراض مثل آلام المعدة والإسهال والانتفاخ بعد تناول الأطعمة التي تحتوي على الغلوتين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القنوات الصفراوية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة ، تبثر أو تقشُّر أو تقرُّح الجلد ، و/أو تقرُّحات في الفم أو بطانة الأنف أو الحلق أو المناطق التناسلية (تقشّر الأنسجة المتموتة البشروية التسمّمي أو متلازمة ستيفنز جونسون) ؛ نتوءات حمراء مؤلمة تحت الجلد ؛ تغير لون الشعر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض يقوم فيه الجهاز المناعي بمهاجمة الغدد التي تنتج الرطوبة للجسم مثل الدموع واللعاب (متلازمة شوغرن)</p><p dir="RTL">تم الإبلاغ عن الأعراض الجانبية التالية في التجارب السريرية التي أُجريت على بيمبروليزوماب عند استخدامه مع أكسيتينيب أو لينفاتينيب:</p><p dir="RTL">شائعة جدًّا (قد تؤثر على أكثر من شخص واحد من بين 10 عشرة أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات المسالك البولية (زيادة تكرار التبول وألم عند التبول) .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدم الحمراء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدني نشاط الغدة الدرقية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة الشعور بالجوع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع الرأس؛ تغير في حاسة الذوق لديك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس؛ سعال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال ؛ آلام في البطن ؛ غثيان ؛ القيء ؛ إمساك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي ؛ حكّة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل ؛ ألم في العضلات والعظام ؛. آلام العضلات أو الأوجاع أو الإيلام ؛ ألم في الذراعين أو الساقين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب ؛ التعب أو الضعف غير المعتاد ؛ تورّم ؛ حمّى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات أنزيم الليباز في الدم وهو المسؤول عن تكسير الدهون ؛ ارتفاع مستوى أنزيمات الكبد في الدم ؛ نتائج غير طبيعية لوظائف الكلى</p><p dir="RTL"><strong>شائعة (قد تؤثر على ما يصل إلى شخص واحد من بين 10 عشرة أشخاص)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الرئتين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء (العدلات ، كريات الدم البيضاء ، الخلايا الليمفاوية) ؛ انخفاض في عدد الصفائح الدموية (حدوث كدمات أو نزيف بسهولة أكبر)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل متعلق بتسريب الدواء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض إفراز الهرمونات التي تنتجها الغدد الكظرية ؛ فرط نشاط الغدة الدرقية ؛ التهاب الغدة الدرقية ؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الصوديوم أو البوتاسيوم أو الكالسيوم في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة ؛ التهاب الأعصاب الذي يسبب خدر أو ضعف أو وخز أو ألم حارق في الذراعين والساقين ؛ نقص الطاقة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب ضربات القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;التهاب الرئتين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأمعاء ؛ التهاب البنكرياس ؛ التهاب المعدة ؛ جفاف الفم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أحمر مرتفع ، مع ظهور بثور أحيانًا ؛ التهاب الجلد ؛ جفاف الجلد ؛ مشاكل جلدية شبيهه بحب الشباب ؛ تساقط الشعر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل مع تورم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض شبيه بالانفلونزا ؛ قشعريرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى أنزيم الأميلاز في الدم ، وهو الإنزيم الذي يكسر النشاء ؛ زيادة مستوى البيليروبين في الدم ؛ زيادة مستويات أنزيم الكبد المعروف باسم الفوسفاتيز القلوي في الدم ؛ زيادة&nbsp; مستوى الكالسيوم في الدم.<u> </u></p><p dir="RTL">غير شائعة (قد تؤثر على ما يصل إلى شخص واحد من بين 100 مئة شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع عدد خلايا الدم البيضاء (الحمضات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الغدة النخامية الواقعة في قاعدة الدماغ</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء السكري من النوع 1 بما في ذلك الحماض السكري الكيتوني</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة تصبح فيها العضلات ضعيفة وتُنهك بسهولة ؛ التهاب الدماغ والذي قد يظهر على شكل ارتباك ، حمّى، مشاكل في الذاكرة أو تشنّجات (التهاب الدماغ)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العينين ؛ ألم في العين ، تهيج ، حكة أو احمرار ؛ حساسية غير مريحة للضوء ؛ رؤية البقع<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في مجال الرؤية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;التهاب في عضلة القلب ، والذي قد يظهر على شكل ضيق في التنفس أو عدم انتظام ضربات القلب<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو الشعور بالتعب أو ألم في الصدر ؛ تراكم السوائل حول القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;التهاب الأوعية الدموية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور قرحة في البطانة الداخلية للمعدة أو الجزء العلوي من الأمعاء الدقيقة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الجلد مصحوب بحكة ؛ نمو جلدي سميك، مُتقشّر في بعض الأحيان ؛ بقع جلدية باهتة ؛&nbsp; نتوءات جلدية صغيرة ، كتل أو تقرحات ؛ تغيّر لون الشعر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأغشية المحيطة بالأوتار</p><p dir="RTL"><strong>نادرة (قد تؤثر على ما يصل إلى 1 من كل 1000 ألف شخص)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض وظيفة الغدة جار الدرقية ، والتي قد تظهر على شكل تقلصات أو تشنجات عضلية ، وتعب وضعف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم العصب البصري الذي قد يؤدي إلى فقدان الرؤية في إحدى العينين أو كلتيهما ، وألم عند حركة العين ، و/أو فقدان رؤية الألوان (التهاب العصب البصري) .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثقب في الأمعاء الدقيقة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة، تبثر أو تقشُّر أو تقرُّح الجلد ، و/أو تقرُّحات في الفم أو بطانة الأنف أو الحلق أو المناطق التناسلية (تقشّر الأنسجة المتموتة البشروية التسمّمي أو متلازمة ستيفنز جونسون)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض يقوم فيه الجهاز المناعي بمهاجمة الغدد التي تنتج الرطوبة في الجسم مثل الدموع واللعاب (متلازمة شوغرن)</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المثانة ، والذي قد يظهر على شكل تبول متكرر و/أو مؤلم ، الرغبة المُلحّة في التبول ، ظهور دم في البول ، ألم أو ضغط في أسفل البطن.</p><p dir="RTL">الآثار الجانبية الأخرى التي تم الإبلاغ عنها بتواتر غير معروف (لا يمكن تقديرها من البيانات المتاحة):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص أو تقليل الإنزيمات الهضمية التي يصنعها البنكرياس (قصور إفراز البنكرياس) . مرض الاضطرابات الهضمية (يتميز بأعراض مثل آلام المعدة والإسهال والانتفاخ بعد تناول الأطعمة التي تحتوي على الغلوتين)</p><p dir="RTL">يكون الطفح الجلدي أكثر شيوعا عندما يتم إعطاء كيترودا مع إنفورتوماب فيدوتين مقارنة بإعطاء كيترودا بمفرده.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الإبلاغ عن الأعراض الجانبية</p><p dir="RTL">أبلغ طبيبك في حال حدوث أيّ أعراض جانبية لديك ، ويشتمل ذلك أيّ أعراض جانبية مُحتملة غير مُدرجة في هذه النشرة. كما يمكنك الإبلاغ عن الأعراض الجانبية بالاتصال مباشرة &quot;بالمركز الوطني للتيقظ والسلامة الدوائية ، التابع للهيئة العامة للغذاء والدواء بالمملكة العربية السعودية&quot;. يُمكنك المُساعدة في توفير مزيد من المعلومات عن سلامة هذا الدواء عند إبلاغك عن الأعراض الجانبية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:34.0pt; margin-right:34.0pt; text-align:right; text-indent:-34.0pt"><!--[if !supportLists]--></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ هذا الدواء بعيدًا عن مرأى ومُتناول الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الخارجية وعلى&nbsp; مُلصق &nbsp;الفيال بعدEXP</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ في الثلاجة (في درجة حرارة 2 درجة مئوية إلى ٨ درجة مئوية) لا يُجمد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ في العبوة الأصلية لحمايته من الضوء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ القارورة في الكرتون الخارجي لحمايتها من الضوء.</p><p dir="RTL">من الناحية المكروبيولوجية ، يجب استخدام المُنتج فورًا بعد تخفيفه. ينبغي عدم تجميد المحلول المُخفّف. مُدّة استقرار محلول كيترودا كيميائيًّا وفيزيائيًّا بعد تخفيفه وفي حال عدم استخدامه فورًا هي 96ساعة عند درجة حرارة ٢<sup>&deg;</sup> م إلى ٨<sup>&deg;</sup> م. هذه الـ 96 ساعة قد تشمل حفظه لمدة تصل إلى 6 ست ساعات عند درجة حرارة الغرفة (عند ٢٥<sup>&deg;</sup> م أو أقلّ). إذا تم حفظ الفيال و/أو الأكياس المُعدّة للتسريب الوريدي في الثلاجة فينبغي إخراجها من الثلاجة وتركها حتى تصل إلى درجة حرارة الغرفة قبل الاستخدام.</p><p dir="RTL">لا تُخزّن أيّ جزء غير مستخدم من محلول التسريب الوريدي وذلك بغرض إعادة استخدامه. يجب التخلُّص من أيّ محلول غير مُستخدم أو مواد النفايات بطريقة صحيحة حسب المتطلبات المحلية .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">محتويات كيترودا</p><p dir="RTL"><strong>المادة الفعالة:</strong> بيمبروليزوماب</p><p dir="RTL">تحتوي كل قارورة سعة 4 مل على بيمبروليزوماب 100مجم.</p><p dir="RTL">يحتوي كل 1مل من المحلول المُركّز على بيمبروليزوماب 25مجم.&nbsp;</p><p dir="RTL"><strong>المواد الأخرى: </strong>إل- هيستيدين، مونو هيدرات هيدروكلورايد إل- هيستيدين، سكروز، بوليسوربات 80 والماء المُخصص للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كيترودا عبارة عن سائل صافٍ أو غميم قليلًا، عديم اللون أو ذو لون مصفر قليلا. يتراوح الرقم الهيدروجيني له ما بين 5.2 &ndash; 5.8. يتوفر في عبوات كرتونية ، تحتوي كل عبوة على فيال زجاجية واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشركة المالكة لحقوق التسويق</p><p dir="RTL">ميرك شارب ودوهم بي في</p><p dir="RTL">39 وارديرواغ</p><p dir="RTL">2031 بي إن هارلم</p><p dir="RTL">هولندا<br />&nbsp;</p><p dir="RTL">الشركة الصانعة</p><p dir="RTL">ميرك شارب ودوهم المحدودة- إيرلندا (كارلو)</p><p dir="RTL">طريق دبلن ، كارلو ، إيرلندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على هذه النشرة ، نسخة اصدار أكتوبر 2024

للإبلاغ عن الأعراض الجانبية :
•	المملكة العربية السعودية:
المركز الوطني للتيقظ والسلامة الدوائية
للاتصال بالهيئة العامة للغذاء والدواء: 1999
البريد الالكتروني: npc.drug@sfda.gov.sa
الموقع الالكتروني: https://ade.sfda.gov.sa

•	دول الخليج الأخرى
الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.

(إنّ هذا الدواء)
- الدواء مستحضر يؤثر على صحتك واستهلاكه خلافًا للتعليمات يعرضك للخطر
- اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلاني الذي صرف لك الدواء
- إن الطبيب والصيدلاني هما الخبيران بالدواء وبنفعه ومخاطره
- لا تقطع مدة العلاج الموصوفة لك من تلقاء نفسك
- لا تكرر صرف الدواء بدون استشارة الطبيب
- لا تترك الأدوية في متناول أيدي الأطفال

مجلس وزراء الصحة العرب
واتحاد الصيادلة العرب
تمت الموافقة على نشرة المعلومات الخاصة بالمريض من قبل الهيئة العامة للغذاء والدواء بالمملكة العربية السعودية
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                KEYTRUDA 25 mg/mL concentrate for solution for infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One vial of 4 mL of concentrate contains 100 mg of pembrolizumab.
Each mL of concentrate contains 25 mg of pembrolizumab.

Pembrolizumab is a humanised monoclonal anti programmed cell death 1 (PD 1) antibody (IgG4/kappa isotype with a stabilising sequence alteration in the Fc region) produced in Chinese hamster ovary cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion.

Clear to slightly opalescent, colourless to slightly yellow solution, pH 5.2 – 5.8.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Melanoma</u></p><p>KEYTRUDA as monotherapy is indicated for the treatment of adults and adolescents aged 12&nbsp;years and older with advanced (unresectable or metastatic) melanoma.</p><p>&nbsp;</p><p>KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12&nbsp;years and older with Stage IIB, IIC or III melanoma and who have undergone complete resection (see section&nbsp;5.1).</p><p>&nbsp;</p><p><u>Non‑small cell lung carcinoma (NSCLC)</u></p><p>KEYTRUDA as monotherapy is indicated for the first‑line treatment of metastatic non‑small cell lung carcinoma in adults whose tumours express PD‑L1 with a &ge;&nbsp;50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.</p><p>&nbsp;</p><p>KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non‑squamous non‑small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations.</p><p>&nbsp;</p><p>KEYTRUDA, in combination with carboplatin and either paclitaxel or nab‑paclitaxel, is indicated for the first‑line treatment of metastatic squamous non‑small cell lung carcinoma in adults.</p><p>&nbsp;</p><p>KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic non‑small cell lung carcinoma in adults whose tumours express PD‑L1 with a &ge;&nbsp;1% TPS and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received targeted therapy before receiving KEYTRUDA.</p><p>&nbsp;</p><p>KEYTRUDA is indicated for the treatment of patients with resectable (tumors &ge;4 cm or node positive) NSCLC in combination with platinum containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery.</p><p>&nbsp;</p><p>KEYTRUDA, as monotherapy is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a &ge;4 cm), II, or IIIA NSCLC.</p><p><u>&nbsp;</u></p><p><u>Classical Hodgkin lymphoma (cHL)</u></p><p>KEYTRUDA as monotherapy is indicated for the treatment of adult and paediatric patients aged 3&nbsp;years and older with relapsed or refractory classical Hodgkin lymphoma<strong> </strong>who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.</p><p>&nbsp;</p><p><u>Urothelial carcinoma</u></p><p>KEYTRUDA, in combination with enfortumab vedotin, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma.</p><p>&nbsp;</p><p>KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum‑containing chemotherapy (see section&nbsp;5.1).</p><p>&nbsp;</p><p>KEYTRUDA is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. This indication was approved based on complete response rate and duration of response. Continued approval of this indication depends on verification and description of benefit in confirmatory trials.</p><p><u>&nbsp;</u></p><p><u>Head and neck squamous cell carcinoma (HNSCC)</u></p><p>KEYTRUDA, as monotherapy or in combination with platinum and 5‑fluorouracil (5‑FU) chemotherapy, is indicated for the first‑line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD‑L1 with a CPS &ge;&nbsp;1 (see section&nbsp;5.1).</p><p>&nbsp;</p><p>KEYTRUDA as monotherapy is indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express PD‑L1 with a &ge;&nbsp;50%&nbsp;TPS and progressing on or after platinum‑containing chemotherapy (see section&nbsp;5.1).</p><p>&nbsp;</p><p><u>Renal cell carcinoma (RCC)</u></p><p>KEYTRUDA, in combination with axitinib, is indicated for the first‑line treatment of advanced renal cell carcinoma in adults (see section&nbsp;5.1).</p><p>&nbsp;</p><p>KEYTRUDA, in combination with lenvatinib, is indicated for the first‑line treatment of advanced renal cell carcinoma in adults (see section&nbsp;5.1).</p><p>&nbsp;</p><p>KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions (for selection criteria, see section&nbsp;5.1).</p><p>&nbsp;</p><p><u>Microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) cancers</u></p><p><em>Colorectal cancer (CRC)</em></p><p>KEYTRUDA as monotherapy is indicated for adults with MSI-H or dMMR colorectal cancer in the following settings:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; first‑line treatment of metastatic colorectal cancer;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine‑based combination therapy.</p><p><em>&nbsp;</em></p><p><em>Non-colorectal cancers</em></p><p>KEYTRUDA as monotherapy is indicated for the treatment of the following MSI‑H or dMMR tumours in adults with:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum‑containing therapy in any setting and who are not candidates for curative surgery or radiation;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.</p><p>&nbsp;</p><p><u>Endometrial Carcinoma</u></p><p>KEYTRUDA, in combination with carboplatin and paclitaxel , followed by KEYTRUDA as monotherapy, is indicated for the treatment of patients with primary advanced or recurrent endometrial carcinoma.</p><p>&nbsp;</p><p><u>Gastric or gastro-oesophageal junction (GEJ) adenocarcinoma</u></p><p>KEYTRUDA, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS &ge;&nbsp;1 as determined by a validated test.</p><p>&nbsp;</p><p>KEYTRUDA, in combination with fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastro-oesophageal junction (GEJ) adenocarcinoma in adults whose tumours express PD‑L1 with a CPS &ge;&nbsp;1.</p><p>&nbsp;</p><p><u>Oesophageal carcinoma</u></p><p>KEYTRUDA, in combination with platinum and fluoropyrimidine‑based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma, in adults whose tumours express PD‑L1 with a CPS &ge;&nbsp;10 (see section&nbsp;5.1).</p><p>&nbsp;</p><p><u>Triple‑negative breast cancer (TNBC)</u></p><p>KEYTRUDA, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early‑stage triple‑negative breast cancer at high risk of recurrence (see section&nbsp;5.1).</p><p>&nbsp;</p><p>KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple‑negative breast cancer in adults whose tumours express PD‑L1 with a CPS&nbsp;&ge;&nbsp;10 and who have not received prior chemotherapy for metastatic disease (see section&nbsp;5.1).</p><p>&nbsp;</p><p><u>Endometrial carcinoma (EC) </u></p><p>KEYTRUDA, in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.</p><p>&nbsp;</p><p><u>Biliary Tract Carcinoma</u></p><p>KEYTRUDA, in combination with gemcitabine and cisplatin , is indicated for the treatment of patients with locally advanced unresectable or metastatic biliary tract carcinoma (BTC).</p><p>&nbsp;</p><p><u>Cervical Cancer</u></p><p>KEYTRUDA, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is indicated for the treatment of FIGO 2014 Stage III &ndash; IVA locally advanced cervical cancer in adults who have not received prior definitive therapy.</p><p>&nbsp;</p><p>KEYTRUDA, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD‑L1 with a CPS &ge;&nbsp;1</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapy must be initiated and supervised by specialist physicians experienced in the treatment of cancer.</p><p>&nbsp;</p><p><u>PD-L1 testing</u></p><p>If specified in the indication, patient selection for treatment with KEYTRUDA based on the tumour expression of PD-L1 should be confirmed by a validated test (see sections&nbsp;4.1, 4.4, 4.8 and 5.1).</p><p>&nbsp;</p><p><u>MSI/MMR testing </u></p><p>If specified in the indication, patient selection for treatment with KEYTRUDA based on MSI‑H/dMMR tumour status should be confirmed by a validated test (see sections pMMR/not MSI‑H testing for patients with EC).</p><p>For treatment with KEYTRUDA as combination therapy with lenvatinib, select patients based on MSI or MMR status in tumor specimens (see sections&nbsp;4.1 and 5.1).</p><p><u>&nbsp;</u></p><p><u>Posology</u></p><p>The recommended dose of KEYTRUDA in adults is either 200&nbsp;mg every 3&nbsp;weeks or 400&nbsp;mg every 6&nbsp;weeks administered as an intravenous infusion over 30&nbsp;minutes.</p><p>&nbsp;</p><p>The recommended dose of KEYTRUDA as monotherapy in paediatric patients aged 3&nbsp;years and older with cHL or patients aged 12&nbsp;years and older with melanoma is 2&nbsp;mg/kg bodyweight (bw) (up to a maximum of 200&nbsp;mg), every 3&nbsp;weeks administered as an intravenous infusion over 30&nbsp;minutes.</p><p>&nbsp;</p><p>For use in combination, see the Summary of Product Characteristics (SmPC) for the concomitant therapies.</p><p>&nbsp;</p><p>For urothelial carcinoma patients treated with KEYTRUDA in combination with enfortumab vedotin, administer KEYTRUDA after enfortumab vedotin when given on the same day.</p><p>&nbsp;</p><p>For urothelial carcinoma patients treated with KEYTRUDA in combination with enfortumab vedotin, the recommended initial dose of enfortumab vedotin is 1.25&nbsp;mg/kg (up to a maximum of 125&nbsp;mg for patients &ge;100&nbsp;kg) as an intravenous solution on Days 1 and 8 of a 21-day cycle until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p>Patients should be treated with KEYTRUDA until disease progression or unacceptable toxicity (and up to maximum duration of therapy if specified for an indication). Atypical responses (i.e. an initial transient increase in tumour size or small new lesions within the first few months followed by tumour shrinkage) have been observed. It is recommended to continue treatment for clinically stable patients with initial evidence of disease progression until disease progression is confirmed.</p><p>&nbsp;</p><p>For the adjuvant treatment of melanoma , NSCLC, &nbsp;or RCC, KEYTRUDA should be administered until disease recurrence, unacceptable toxicity, or for a duration of up to one year.</p><p>&nbsp;</p><p>For the neoadjuvant and adjuvant treatment of resectable NSCLC, patients should be treated with neoadjuvant KEYTRUDA in combination with chemotherapy for 12&nbsp;weeks or until disease progression that precludes definitive surgery or unacceptable toxicity, followed by adjuvant treatment with KEYTRUDA as monotherapy for 39&nbsp;weeks or until disease recurrence or unacceptable toxicity.</p><p>&nbsp;</p><p>&nbsp;</p><p>For the neoadjuvant and adjuvant treatment of TNBC, patients should be treated with neoadjuvant KEYTRUDA in combination with chemotherapy for 8&nbsp;doses of 200&nbsp;mg every 3&nbsp;weeks or 4&nbsp;doses of 400&nbsp;mg every 6&nbsp;weeks or until disease progression that precludes definitive surgery or unacceptable toxicity, followed by adjuvant treatment with KEYTRUDA as monotherapy for 9&nbsp;doses of 200&nbsp;mg every 3&nbsp;weeks or 5&nbsp;doses of 400&nbsp;mg every 6&nbsp;weeks or until disease recurrence or unacceptable toxicity. Patients who experience disease progression that precludes definitive surgery or unacceptable toxicity related to KEYTRUDA as neoadjuvant treatment in combination with chemotherapy should not receive KEYTRUDA monotherapy as adjuvant treatment.</p><p>&nbsp;</p><p><em>Dose delay or discontinuation (see also section&nbsp;4.4)</em></p><p>No dose reductions of KEYTRUDA are recommended. KEYTRUDA should be withheld or discontinued to manage adverse reactions as described in Table 1.</p><p>&nbsp;</p><p>Table 1: <strong>Recommended treatment modifications for KEYTRUDA</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:595px"><thead><tr><td style="vertical-align:top"><p><strong>Immune‑mediated adverse reactions</strong></p></td><td style="vertical-align:top"><p><strong>Severity </strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Treatment modification</strong></p></td></tr></thead><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonitis</p></td><td style="vertical-align:top"><p>Grade&nbsp;2</p></td><td style="vertical-align:top"><p>Withhold until adverse reactions recover to Grades&nbsp;0‑1<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Grades&nbsp;3 or 4, or recurrent Grade&nbsp;2</p></td><td style="vertical-align:top"><p>Permanently discontinue</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Colitis</p></td><td style="vertical-align:top"><p>Grades&nbsp;2 or 3</p></td><td style="vertical-align:top"><p>Withhold until adverse reactions recover to Grades&nbsp;0‑1<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;4 or recurrent Grade&nbsp;3</p></td><td style="vertical-align:top"><p>Permanently discontinue</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nephritis</p></td><td style="vertical-align:top"><p>Grade&nbsp;2 with creatinine &gt;&nbsp;1.5 to &le;&nbsp;3&nbsp;times upper limit of normal (ULN)</p></td><td style="vertical-align:top"><p>Withhold until adverse reactions recover to Grades&nbsp;0‑1<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;&ge;&nbsp;3 with creatinine &gt;&nbsp;3&nbsp;times ULN</p></td><td style="vertical-align:top"><p>Permanently discontinue</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Endocrinopathies</p></td><td style="vertical-align:top"><p>Grade&nbsp;2 adrenal insufficiency and hypophysitis</p></td><td style="vertical-align:top"><p>Withhold treatment until controlled by hormone replacement</p></td></tr><tr><td style="vertical-align:top"><p>Grades&nbsp;3 or 4 adrenal insufficiency or symptomatic hypophysitis</p><p>&nbsp;</p><p>Type 1 diabetes associated with Grade&nbsp;&ge;&nbsp;3 hyperglycaemia (glucose &gt;&nbsp;250&nbsp;mg/dL or &gt;&nbsp;13.9&nbsp;mmol/L) or associated with ketoacidosis</p><p>&nbsp;</p><p>Hyperthyroidism Grade&nbsp;&ge;&nbsp;3</p></td><td style="vertical-align:top"><p>Withhold until adverse reactions recover to Grades&nbsp;0‑1<sup>*</sup></p><p>&nbsp;</p><p>For patients with Grade&nbsp;3 or Grade&nbsp;4 endocrinopathies that improved to Grade&nbsp;2 or lower and are controlled with hormone replacement, if indicated, continuation of pembrolizumab may be considered after corticosteroid taper, if needed. Otherwise treatment should be discontinued.</p></td></tr><tr><td style="vertical-align:top"><p>Hypothyroidism</p></td><td style="vertical-align:top"><p>Hypothyroidism may be managed with replacement therapy without treatment interruption.</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatitis/non-HCC</p><p>&nbsp;</p><p><strong>NOTE:</strong> for RCC patients treated with <strong>pembrolizumab in combination with axitinib</strong> with liver enzyme elevations, see dosing guidelines following this table.</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Grade&nbsp;2 with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;&nbsp;3 to 5&nbsp;times ULN or total bilirubin &gt;&nbsp;1.5 to 3&nbsp;times ULN</p></td><td style="vertical-align:top"><p>Withhold until adverse reactions recover to Grades&nbsp;0‑1<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;&ge;&nbsp;3 with AST or ALT &gt;&nbsp;5&nbsp;times ULN or total bilirubin &gt;&nbsp;3&nbsp;times ULN</p></td><td style="vertical-align:top"><p>Permanently discontinue</p></td></tr><tr><td style="vertical-align:top"><p>In case of liver metastasis with baseline Grade&nbsp;2 elevation of AST or ALT, hepatitis with AST or ALT increases &ge;&nbsp;50% and lasts &ge;&nbsp;1&nbsp;week</p></td><td style="vertical-align:top"><p>Permanently discontinue</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatitis/HCC</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>AST or ALT with baseline &lt;2&nbsp;times ULN and increases to &ge;5&nbsp;times ULN; AST or ALT with baseline &ge;2&nbsp;times ULN and increases to &gt;3&nbsp;times baseline; or AST or ALT &gt;500&nbsp;U/L regardless of baseline levels</p><p>&nbsp;</p><p>Total bilirubin with baseline levels &lt;1.5&nbsp;mg/dL and increases to &gt;2&nbsp;mg/dL; total bilirubin with baseline levels &ge;1.5&nbsp;mg/dL and increases to &ge;2&nbsp;times baseline; or total bilirubin &gt;3.0&nbsp;mg/dL regardless of baseline levels</p></td><td style="vertical-align:top"><p>Withhold until adverse reactions recover to Grades&nbsp;0-1*</p></td></tr><tr><td style="vertical-align:top"><p>ALT &gt;20&nbsp;times ULN; Child Pugh score &ge;9&nbsp;points; gastrointestinal bleeding suggestive of portal hypertension; ascites; or encephalopathy</p></td><td style="vertical-align:top"><p>Permanently discontinue</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin reactions</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Grade&nbsp;3 or suspected Stevens‑Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)</p></td><td style="vertical-align:top"><p>Withhold until adverse reactions recover to Grades&nbsp;0‑1<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;4 or confirmed SJS or TEN</p></td><td style="vertical-align:top"><p>Permanently discontinue</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Other immune‑mediated adverse reactions</strong></p></td><td style="vertical-align:top"><p>Based on severity and type of reaction (Grade&nbsp;2 or Grade&nbsp;3)</p></td><td style="vertical-align:top"><p>Withhold until adverse reactions recover to Grades&nbsp;0‑1<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Grades&nbsp;3 or 4 myocarditis</p><p>Grades&nbsp;3 or 4 encephalitis</p><p>Grades&nbsp;3 or 4 Guillain‑Barr&eacute; syndrome</p></td><td style="vertical-align:top"><p>Permanently discontinue</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;4 or recurrent Grade&nbsp;3</p></td><td style="vertical-align:top"><p>Permanently discontinue</p></td></tr><tr><td style="vertical-align:top"><p><strong>Infusion‑related reactions</strong></p></td><td style="vertical-align:top"><p>Grades&nbsp;3 or 4</p></td><td style="vertical-align:top"><p>Permanently discontinue</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Note: toxicity grades are in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events Version&nbsp;4.0 (NCI‑CTCAE&nbsp;v.4).</p><p><sup>*</sup><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>If treatment‑related toxicity does not resolve to Grades&nbsp;0‑1 within 12&nbsp;weeks after last dose of KEYTRUDA, or if corticosteroid dosing cannot be reduced to &le;&nbsp;10&nbsp;mg prednisone or equivalent per day within 12&nbsp;weeks, KEYTRUDA should be permanently discontinued.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>The safety of re‑initiating pembrolizumab therapy in patients previously experiencing immune‑mediated myocarditis is not known.</p><p>&nbsp;</p><p>KEYTRUDA, as monotherapy or as combination therapy, should be permanently discontinued for Grade&nbsp;4 or recurrent Grade&nbsp;3 immune‑mediated adverse reactions, unless otherwise specified in Table&nbsp;1.</p><p>&nbsp;</p><p>For Grade 4 haematological toxicity, only in patients with cHL, KEYTRUDA should be withheld until adverse reactions recover to Grades 0‑1.</p><p>&nbsp;</p><p><em>KEYTRUDA in combination with axitinib in RCC</em></p><p>For RCC patients treated with KEYTRUDA in combination with axitinib, see the SmPC regarding dosing of axitinib. When used in combination with pembrolizumab, dose escalation of axitinib above the initial 5&nbsp;mg&nbsp;dose may be considered at intervals of six weeks or longer (see section&nbsp;5.1).</p><p><em>&nbsp;</em></p><p><em><u>For liver enzyme elevations, in patients with RCC being treated with KEYTRUDA in combination with axitinib:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If ALT or AST &ge;&nbsp;3&nbsp;times ULN but &lt;&nbsp;10&nbsp;times ULN without concurrent total bilirubin &ge;&nbsp;2&nbsp;times ULN, both KEYTRUDA and axitinib should be withheld until these adverse reactions recover to Grades 0‑1. Corticosteroid therapy may be considered. Rechallenge with a single medicine or sequential rechallenge with both medicines after recovery may be considered. If rechallenging with axitinib, dose reduction as per the axitinib SmPC may be considered.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If ALT or AST &ge;&nbsp;10&nbsp;times ULN or &gt;&nbsp;3&nbsp;times ULN with concurrent total bilirubin &ge;&nbsp;2&nbsp;times ULN, both KEYTRUDA and axitinib should be permanently discontinued and corticosteroid therapy may be considered.</p><p>&nbsp;</p><p><em><u>KEYTRUDA in combination with Lenvatinib</u></em></p><p>When administering KEYTRUDA in combination with lenvatinib, interrupt one or both or dose reduce or discontinue lenvatinib to manage adverse reactions as appropriate pembrolizumab. For recommendations for management of adverse reactions of lenvatinib, refer to the prescribing information for lenvatinib. No dose reductions are recommended for KEYTRUDA.</p><p>&nbsp;</p><p>Patients treated with KEYTRUDA must be given the patient card and be informed about the risks of KEYTRUDA (see also package leaflet).</p><p><em><u>&nbsp;</u></em></p><p><em><u>Special populations</u></em></p><p><em>Elderly</em></p><p>No dose adjustment is necessary in patients &ge;&nbsp;65&nbsp;years (see sections&nbsp;4.4 and 5.1).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment is needed for patients with mild or moderate renal impairment. KEYTRUDA has not been studied in patients with severe renal impairment (see sections&nbsp;4.4 and 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is needed for patients with mild or moderate hepatic impairment. KEYTRUDA has not been studied in patients with severe hepatic impairment (see sections&nbsp;4.4 and 5.2).</p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>The safety and efficacy of KEYTRUDA in children below 18&nbsp;years of age have not been established except in paediatric patients with melanoma or cHL. Currently available data are described in sections&nbsp;4.8, 5.1 and 5.2.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>KEYTRUDA is for intravenous use. It must be administered by infusion over 30&nbsp;minutes. KEYTRUDA must not be administered as an intravenous push or bolus injection.</p><p>&nbsp;</p><p>When administering KEYTRUDA as part of a combination with intravenous chemotherapy, KEYTRUDA should be administered first.</p><p>&nbsp;</p><p>For instructions on dilution of the medicinal product before administration, see section&nbsp;6.6</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p><u>&nbsp;</u></p><p><u>Assessment of PD‑L1 status</u></p><p>When assessing the PD‑L1 status of the tumour, it is important that a well‑validated and robust methodology is chosen to minimise false negative or false positive determinations.</p><p>&nbsp;</p><p><u>Immune‑</u> <u>mediated adverse reactions</u></p><p>Immune‑ mediated adverse reactions, including severe and fatal cases, have occurred in patients receiving pembrolizumab. Most immune‑ mediated adverse reactions occurring during treatment with pembrolizumab were reversible and managed with interruptions of pembrolizumab, administration of corticosteroids and/or supportive care. Immune‑related adverse reactions have also occurred after the last dose of pembrolizumab. Immune‑ mediated adverse reactions affecting more than one body system can occur simultaneously.</p><p>&nbsp;</p><p>For suspected immune‑ mediated adverse reactions, adequate evaluation to confirm aetiology or exclude other causes should be ensured. Based on the severity of the adverse reaction, pembrolizumab should be withheld and corticosteroids administered. Upon improvement to Grade&nbsp;&le;&nbsp;1, corticosteroid taper should be initiated and continued over at least 1&nbsp;month. Based on limited data from clinical studies in patients whose immune‑ mediated adverse reactions could not be controlled with corticosteroid use, administration of other systemic immunosuppressants can be considered.</p><p>&nbsp;</p><p>Pembrolizumab may be restarted within 12&nbsp;weeks after last dose of KEYTRUDA if the adverse reaction recovers to Grade&nbsp;&le;&nbsp;1 and corticosteroid dose has been reduced to &le;&nbsp;10&nbsp;mg prednisone or equivalent per day.</p><p>&nbsp;</p><p>Pembrolizumab must be permanently discontinued for any Grade&nbsp;3 immune‑ mediated adverse reaction that recurs and for any Grade&nbsp;4 immune‑ mediated adverse reaction toxicity, except for endocrinopathies that are controlled with replacement hormones (see sections&nbsp;4.2 and 4.8).</p><p>&nbsp;</p><p><em><u>Immune‑</u></em> <em><u>mediated pneumonitis</u></em></p><p>Pneumonitis has been reported in patients receiving pembrolizumab (see section&nbsp;4.8)<em>.</em> Patients should be monitored for signs and symptoms of pneumonitis. Suspected pneumonitis should be confirmed with radiographic imaging and other causes excluded. Corticosteroids should be administered for Grade&nbsp;&ge;&nbsp;2 events (initial dose of 1‑2&nbsp;mg/kg/day prednisone or equivalent followed by a taper); pembrolizumab should be withheld for Grade&nbsp;2 pneumonitis, and permanently discontinued for Grade&nbsp;3, Grade&nbsp;4 or recurrent Grade&nbsp;2 pneumonitis (see section&nbsp;4.2).</p><p>&nbsp;</p><p><em><u>Immune‑</u></em> <em><u>mediated colitis</u></em></p><p>Colitis has been reported in patients receiving pembrolizumab (see section&nbsp;4.8). Patients should be monitored for signs and symptoms of colitis, and other causes excluded. Corticosteroids should be administered for Grade&nbsp;&ge;&nbsp;2 events (initial dose of 1‑2&nbsp;mg/kg/day prednisone or equivalent followed by a taper); pembrolizumab should be withheld for Grade&nbsp;2 or Grade&nbsp;3 colitis, and permanently discontinued for Grade&nbsp;4 or recurrent Grade&nbsp;3 colitis (see section&nbsp;4.2). The potential risk of gastrointestinal perforation should be taken into consideration.</p><p>&nbsp;</p><p><em><u>Immune‑</u></em> <em><u>mediated hepatitis</u></em></p><p>Hepatitis has been reported in patients receiving pembrolizumab (see section&nbsp;4.8). Patients should be monitored for changes in liver function (at the start of treatment, periodically during treatment and as indicated based on clinical evaluation) and symptoms of hepatitis, and other causes excluded. Corticosteroids should be administered (initial dose of 0.5‑1&nbsp;mg/kg/day (for Grade&nbsp;2 events) and 1‑2&nbsp;mg/kg/day (for Grade&nbsp;&ge;&nbsp;3 events) prednisone or equivalent followed by a taper) and, based on severity of liver enzyme elevations, pembrolizumab should be withheld or discontinued (see section&nbsp;4.2).</p><p>&nbsp;</p><p><em><u>Immune‑</u></em> <em><u>mediated nephritis</u></em></p><p>Nephritis has been reported in patients receiving pembrolizumab (see section&nbsp;4.8). Patients should be monitored for changes in renal function, and other causes of renal dysfunction excluded. Corticosteroids should be administered for Grade&nbsp;&ge;&nbsp;2 events (initial dose of 1‑2&nbsp;mg/kg/day prednisone or equivalent followed by a taper) and, based on severity of creatinine elevations, pembrolizumab should be withheld for Grade&nbsp;2, and permanently discontinued for Grade&nbsp;3 or Grade&nbsp;4 nephritis (see section&nbsp;4.2).</p><p>&nbsp;</p><p><em><u>Immune‑</u></em> <em><u>mediated endocrinopathies</u></em></p><p>Severe endocrinopathies, including adrenal insufficiency, hypophysitis, type&nbsp;1 diabetes mellitus, diabetic ketoacidosis, hypothyroidism, and hyperthyroidism have been observed with pembrolizumab treatment.</p><p>&nbsp;</p><p>Long‑term hormone replacement therapy may be necessary in cases of immune‑ mediated endocrinopathies.</p><p>&nbsp;</p><p>Adrenal insufficiency (primary and secondary) has been reported in patients receiving pembrolizumab. Hypophysitis has also been reported in patients receiving pembrolizumab (see section&nbsp;4.8). Patients should be monitored for signs and symptoms of adrenal insufficiency and hypophysitis (including hypopituitarism) and other causes excluded. Corticosteroids to treat adrenal insufficiency and other hormone replacement should be administered as clinically indicated. Pembrolizumab should be withheld for Grade&nbsp;2 adrenal insufficiency or hypophysitis until the event is controlled with hormone replacement. Pembrolizumab should be withheld or discontinued for Grades&nbsp;3 or 4 adrenal insufficiency or symptomatic hypophysitis. Continuation of pembrolizumab may be considered, after corticosteroid taper, if needed (see section&nbsp;4.2). Pituitary function and hormone levels should be monitored to ensure appropriate hormone replacement.</p><p>&nbsp;</p><p>Type&nbsp;1 diabetes mellitus, including diabetic ketoacidosis, has been reported in patients receiving pembrolizumab (see section&nbsp;4.8). Patients should be monitored for hyperglycaemia or other signs and symptoms of diabetes. Insulin should be administered for type&nbsp;1 diabetes, and pembrolizumab should be withheld in cases of type 1 diabetes associated with Grade&nbsp;&ge;&nbsp;3 hyperglycaemia or ketoacidosis until metabolic control is achieved (see section&nbsp;4.2).</p><p>&nbsp;</p><p>Thyroid disorders, including hypothyroidism, hyperthyroidism and thyroiditis, have been reported in patients receiving pembrolizumab and can occur at any time during treatment. Hypothyroidism is more frequently reported in patients with HNSCC with prior radiation therapy. Patients should be monitored for changes in thyroid function (at the start of treatment, periodically during treatment and as indicated based on clinical evaluation) and clinical signs and symptoms of thyroid disorders. Hypothyroidism may be managed with replacement therapy without treatment interruption and without corticosteroids. Hyperthyroidism may be managed symptomatically. Pembrolizumab should be withheld for Grade&nbsp;&ge;&nbsp;3 until recovery to Grade&nbsp;&le;&nbsp;1 hyperthyroidism. Thyroid function and hormone levels should be monitored to ensure appropriate hormone replacement.</p><p>&nbsp;</p><p>For patients with Grade&nbsp;3 or Grade&nbsp;4 endocrinopathies that improved to Grade&nbsp;2 or lower and are controlled with hormone replacement, if indicated, continuation of pembrolizumab may be considered after corticosteroid taper, if needed. Otherwise treatment should be discontinued (see sections&nbsp;4.2 and 4.8).</p><p>&nbsp;</p><p><em><u>Immune‑</u></em> <em><u>mediated skin adverse reactions </u></em></p><p>Immune‑ mediated severe skin reactions have been reported in patients receiving pembrolizumab (see section&nbsp;4.8). Patients should be monitored for suspected severe skin reactions and other causes should be excluded. Based on the severity of the adverse reaction, pembrolizumab should be withheld for Grade&nbsp;3 skin reactions until recovery to Grade&nbsp;&le;&nbsp;1 or permanently discontinued for Grade&nbsp;4 skin reactions, and corticosteroids should be administered (see section&nbsp;4.2).</p><p>&nbsp;</p><p>Cases of Stevens‑Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in patients receiving pembrolizumab (see section&nbsp;4.8).&nbsp;For suspected SJS or TEN, pembrolizumab should be withheld and the patient should be referred to a specialised unit for assessment and treatment. If SJS or TEN is confirmed, pembrolizumab should be permanently discontinued (see section&nbsp;4.2).</p><p>&nbsp;</p><p>Caution should be used when considering the use of pembrolizumab in a patient who has previously experienced a severe or life‑threatening skin adverse reaction on prior treatment with other immune‑stimulatory anti-cancer agents.</p><p>&nbsp;</p><p><em><u>Other immune‑</u></em> <em><u>mediated adverse reactions</u></em></p><p>The following additional clinically significant, immune‑ mediated adverse reactions have been reported in clinical studies or in post‑marketing experience: uveitis, arthritis, myositis, myocarditis, pancreatitis, Guillain‑Barr&eacute; syndrome, myasthenic syndrome, haemolytic anaemia, sarcoidosis, encephalitis, myelitis, vasculitis, cholangitis sclerosing, gastritis, cystitis noninfective and hypoparathyroidism (see sections&nbsp;4.2 and&nbsp;4.8).</p><p>&nbsp;</p><p>Based on the severity and type of the adverse reaction, pembrolizumab should be withheld for Grade&nbsp;2 or Grade&nbsp;3 events and corticosteroids administered.</p><p>&nbsp;</p><p>Pembrolizumab may be restarted within 12&nbsp;weeks after last dose of KEYTRUDA if the adverse reaction recovers to Grade&nbsp;&le;&nbsp;1 and corticosteroid dose has been reduced to &le;&nbsp;10&nbsp;mg prednisone or equivalent per day.</p><p>&nbsp;</p><p>Pembrolizumab must be permanently discontinued for any Grade&nbsp;3 immune‑ mediated adverse reaction that recurs and for any Grade&nbsp;4 immune‑ mediated adverse reaction.</p><p>&nbsp;</p><p>For Grades&nbsp;3 or 4 myocarditis, encephalitis or Guillain‑Barr&eacute; syndrome, pembrolizumab should be permanently discontinued (see sections&nbsp;4.2 and 4.8).</p><p>&nbsp;</p><p><u>Transplant‑related adverse reactions</u></p><p>&nbsp;</p><p><em>Solid organ transplant rejection</em></p><p>Solid organ transplant rejection has been reported in the post‑marketing setting in patients treated with PD‑1 inhibitors. Treatment with pembrolizumab may increase the risk of rejection in solid organ transplant recipients. The benefit of treatment with pembrolizumab versus the risk of possible organ rejection should be considered in these patients.</p><p><u>&nbsp;</u></p><p><em>Complications of allogeneic Haematopoietic Stem Cell Transplant (HSCT)</em></p><p>&nbsp;</p><p>Allogeneic HSCT after treatment with pembrolizumab</p><p>Cases of graft‑versus-host‑disease (GVHD) and hepatic veno‑occlusive disease (VOD) have been observed in patients with cHL undergoing allogeneic HSCT after previous exposure to pembrolizumab. Until further data become available, careful consideration to the potential benefits of HSCT and the possible increased risk of transplant‑related complications should be made case by case (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Allogeneic HSCT prior to treatment with pembrolizumab</p><p>In patients with a history of allogeneic HSCT, acute GVHD, including fatal GVHD, has been reported after treatment with pembrolizumab. Patients who experienced GVHD after their transplant procedure may be at an increased risk for GVHD after treatment with pembrolizumab. Consider the benefit of treatment with pembrolizumab versus the risk of possible GVHD in patients with a history of allogeneic HSCT.</p><p><u>&nbsp;</u></p><p><u>Infusion‑related reactions</u></p><p>Severe infusion‑related reactions, including hypersensitivity and anaphylaxis, have been reported in patients receiving pembrolizumab (see section&nbsp;4.8). For Grades&nbsp;3 or 4 infusion reactions, infusion should be stopped and pembrolizumab permanently discontinued (see section&nbsp;4.2). Patients with Grades&nbsp;1 or 2 infusion reaction may continue to receive pembrolizumab with close monitoring; premedication with antipyretic and antihistamine may be considered.</p><p>&nbsp;</p><p><u>Use of pembrolizumab in combination with chemotherapy</u></p><p>Pembrolizumab in combination with chemotherapy should be used with caution in patients &ge;&nbsp;75&nbsp;years after careful consideration of the potential benefit/risk on an individual basis (see section&nbsp;5.1).</p><p><u>&nbsp;</u></p><p><u>Disease‑specific precautions</u></p><p><u>&nbsp;</u></p><p><em><u>Use of pembrolizumab in urothelial carcinoma patients who have received prior</u></em><u> <em>platinum‑containing chemotherapy</em></u></p><p>Physicians should consider the delayed onset of pembrolizumab effect before initiating treatment in patients with poorer prognostic features and/or aggressive disease. In urothelial carcinoma, a higher number of deaths within 2&nbsp;months was observed in pembrolizumab compared to chemotherapy (see section&nbsp;5.1). Factors associated with early deaths were fast progressive disease on prior platinum therapy and liver metastases.</p><p>&nbsp;</p><p><em><u>Use of pembrolizumab for first‑line treatment of patients with NSCLC</u></em></p><p>In general, the frequency of adverse reactions for pembrolizumab combination therapy is observed to be higher than for pembrolizumab monotherapy or chemotherapy alone, reflecting the contributions of each of these components (see sections&nbsp;4.2 and 4.8). A direct comparison of pembrolizumab when used in combination with chemotherapy to pembrolizumab monotherapy is not available.</p><p>&nbsp;</p><p>Physicians should consider the benefit/risk balance of the available treatment options (pembrolizumab monotherapy or pembrolizumab in combination with chemotherapy) before initiating treatment in previously untreated patients with NSCLC whose tumours express PD‑L1.</p><p>&nbsp;</p><p>In KEYNOTE-042, a higher number of deaths within 4&nbsp;months of treatment initiation followed by a long-term survival benefit was observed with pembrolizumab monotherapy compared to chemotherapy (see section&nbsp;5.1).</p><p><em><u>&nbsp;</u></em></p><p><em><u>Use of pembrolizumab for first‑line treatment of patients with HNSCC</u></em></p><p>In general, the frequency of adverse reactions for pembrolizumab combination therapy is observed to be higher than for pembrolizumab monotherapy or chemotherapy alone, reflecting the contributions of each of these components (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Physicians should consider the benefit/risk balance of the available treatment options (pembrolizumab monotherapy or pembrolizumab in combination with chemotherapy) before initiating treatment in patients with HNSCC whose tumours express PD‑L1 (see section&nbsp;5.1).</p><p><u>&nbsp;</u></p><p><em><u>Use of pembrolizumab for adjuvant treatment of patients with melanoma</u></em></p><p>A trend toward increased frequency of severe and serious adverse reactions in patients &ge;&nbsp;75&nbsp;years was observed. Safety data of pembrolizumab in the adjuvant melanoma setting in patients &ge;&nbsp;75&nbsp;years are limited.</p><p><u>&nbsp;</u></p><p><em><u>Use of pembrolizumab in combination with axitinib for first‑line treatment of patients with RCC</u></em></p><p>When pembrolizumab is given with axitinib, higher than expected frequencies of Grades&nbsp;3 and 4 ALT and AST elevations have been reported in patients with advanced RCC (see section&nbsp;4.8). Liver enzymes should be monitored before initiation of and periodically throughout treatment. More frequent monitoring of liver enzymes as compared to when the medicines are used in monotherapy may be considered. Medical management guidelines for both medicines should be followed (see section&nbsp;4.2 and refer to the SmPC for axitinib).</p><p><u>&nbsp;</u></p><p><em><u>Use of pembrolizumab for first‑line treatment of patients with MSI-H/dMMR CRC</u></em></p><p>In KEYNOTE-177, the hazard rates for overall survival events were greater for pembrolizumab compared with chemotherapy for the first 4&nbsp;months of treatment, followed by a long-term survival benefit for pembrolizumab (see section&nbsp;5.1).</p><p><u>&nbsp;</u></p><p><u>Patients excluded from clinical studies</u></p><p>Patients with the following conditions were excluded from clinical studies: active CNS metastases; ECOG PS &ge;&nbsp;2 (except for urothelial carcinoma and RCC); HIV infection, hepatitis&nbsp;B or hepatitis&nbsp;C infection (except for hepatocellular carcinoma); active systemic autoimmune disease; interstitial lung disease; prior pneumonitis requiring systemic corticosteroid therapy; a history of severe hypersensitivity to another monoclonal antibody; receiving immunosuppressive therapy and a history of severe immune‑ mediated adverse reactions from treatment with ipilimumab, defined as any Grade&nbsp;4 toxicity or Grade&nbsp;3 toxicity requiring corticosteroid treatment (&gt;&nbsp;10&nbsp;mg/day prednisone or equivalent) for greater than 12&nbsp;weeks. Patients with active infections were excluded from clinical studies and were required to have their infection treated prior to receiving pembrolizumab. Patients with active infections occurring during treatment with pembrolizumab were managed with appropriate medical therapy. Patients with clinically significant renal (creatinine &gt;&nbsp;1.5&nbsp;x&nbsp;ULN) or hepatic (bilirubin &gt;&nbsp;1.5&nbsp;x&nbsp;ULN, ALT, AST &gt;&nbsp;2.5&nbsp;x&nbsp;ULN in the absence of liver metastases) abnormalities at baseline were excluded from clinical studies, therefore information is limited in patients with severe renal and moderate to severe hepatic impairment.</p><p>&nbsp;</p><p>There are limited data on the safety and efficacy of KEYTRUDA in patients with ocular melanoma (see section&nbsp;5.1).</p><p>&nbsp;</p><p>After careful consideration of the potential increased risk, pembrolizumab may be used with appropriate medical management in these patients.</p><p>&nbsp;</p><p><u>Patient card</u></p><p>All prescribers of KEYTRUDA must be familiar with the Physician Information and Management Guidelines. The prescriber must discuss the risks of KEYTRUDA therapy with the patient. The patient will be provided with the patient card with each prescription.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No formal pharmacokinetic drug interaction studies have been conducted with pembrolizumab. Since pembrolizumab is cleared from the circulation through catabolism, no metabolic drug‑drug interactions are expected.</p><p>&nbsp;</p><p>The use of systemic corticosteroids or immunosuppressants before starting pembrolizumab should be avoided because of their potential interference with the pharmacodynamic activity and efficacy of pembrolizumab. However, systemic corticosteroids or other immunosuppressants can be used after starting pembrolizumab to treat immune‑related adverse reactions (see section&nbsp;4.4). Corticosteroids can also be used as premedication, when pembrolizumab is used in combination with chemotherapy, as antiemetic prophylaxis and/or to alleviate chemotherapy‑related adverse reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>Women of childbearing potential should use effective contraception during treatment with pembrolizumab and for at least 4&nbsp;months after the last dose of pembrolizumab.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>There are no data on the use of pembrolizumab in pregnant women. Animal reproduction studies have not been conducted with pembrolizumab; however, in murine models of pregnancy blockade of PD‑L1 signalling has been shown to disrupt tolerance to the foetus and to result in an increased foetal loss (see section&nbsp;5.3). These results indicate a potential risk, based on its mechanism of action, that administration of pembrolizumab during pregnancy could cause foetal harm, including increased rates of abortion or stillbirth. Human immunoglobulins G4 (IgG4) are known to cross the placental barrier; therefore, being an IgG4, pembrolizumab has the potential to be transmitted from the mother to the developing foetus. Pembrolizumab should not be used during pregnancy unless the clinical condition of the woman requires treatment with pembrolizumab.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>It is unknown whether pembrolizumab is secreted in human milk. Since it is known that antibodies can be secreted in human milk, a risk to the newborns/infants cannot be excluded. A decision should be made whether to discontinue breast‑feeding or to discontinue pembrolizumab, taking into account the benefit of breast‑feeding for the child and the benefit of pembrolizumab therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No clinical data are available on the possible effects of pembrolizumab on fertility. There were no notable effects in the male and female reproductive organs in monkeys based on 1‑month and 6‑month repeat<strong>-</strong>dose toxicity studies (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pembrolizumab has a minor influence on the ability to drive and use machines. In some patients, dizziness and fatigue have been reported following administration of pembrolizumab (see section&nbsp;4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Pembrolizumab is most commonly associated with immune‑ mediated adverse reactions. Most of these, including severe reactions, resolved following initiation of appropriate medical therapy or withdrawal of pembrolizumab (see &ldquo;Description of selected adverse reactions&rdquo; below). The frequencies included below and in Table&nbsp;2 are based on all reported adverse drug reactions, regardless of the investigator assessment of causality.</p><p>&nbsp;</p><p><em><u>Pembrolizumab in monotherapy (see section 4.2)</u></em></p><p>The safety of pembrolizumab as monotherapy has been evaluated in 7,631&nbsp;patients across tumour types and across four doses (2&nbsp;mg/kg bw every 3&nbsp;weeks, 200&nbsp;mg every 3&nbsp;weeks, or 10&nbsp;mg/kg bw every 2 or 3&nbsp;weeks) in clinical studies. In this patient population, the median observation time was 8.5&nbsp;months (range: 1&nbsp;day to 39&nbsp;months) and the most frequent adverse reactions with pembrolizumab were fatigue&nbsp;(31%), diarrhoea (22%), and nausea&nbsp;(20%). The majority of adverse reactions reported for monotherapy were of Grades&nbsp;1 or 2 severity. The most serious adverse reactions were immune‑mediated adverse reactions and severe infusion‑related reactions (see section&nbsp;4.4). The incidences of immune‑mediated adverse reactions were&nbsp;37% all Grades and&nbsp;9% for Grades&nbsp;3‑5 for pembrolizumab monotherapy in the adjuvant setting and&nbsp;25% all Grades and&nbsp;6% for Grades&nbsp;3‑5 in the metastatic setting. No new immune‑mediated adverse reactions were identified in the adjuvant setting.</p><p>&nbsp;</p><p><em><u>Pembrolizumab in combination with chemotherapy (see section</u></em><u>&nbsp;<em>4.2)</em></u></p><p>When pembrolizumab is administered in combination, refer to the SmPC for the respective combination therapy components prior to initiation of treatment.</p><p>&nbsp;</p><p>The safety of pembrolizumab in combination with chemotherapy has been evaluated in 5&nbsp;183 patients across tumour types receiving 200&nbsp;mg, 2&nbsp;mg/kg&nbsp;bw or 10&nbsp;mg/kg&nbsp;bw pembrolizumab every 3&nbsp;weeks, in clinical studies. In this patient population, the most frequent adverse reactions were anaemia&nbsp;(52%), nausea&nbsp;(52%), fatigue&nbsp;(35%), diarrhoea&nbsp;(33%), constipation&nbsp;(32%), vomiting&nbsp;(28%), decreased appetite&nbsp;(28%), neutrophil count decreased&nbsp;(27%) and neutropenia&nbsp;(25%). Incidences of Grades&nbsp;3‑5 adverse reactions in patients with NSCLC were 69% for pembrolizumab combination therapy and 61% for chemotherapy alone, in patients with HNSCC were 85% for pembrolizumab combination therapy and 84% for chemotherapy plus cetuximab, in patients with oesophageal carcinoma were 86% for pembrolizumab combination therapy and 83% for chemotherapy alone, in patients with TNBC were 80% for pembrolizumab combination therapy and 77% for chemotherapy alone, in patients with cervical cancer were 82% for pembrolizumab combination and 75% for chemotherapy, with or without bevacizumab, and in patients with gastric cancer were 71% for combination therapy (chemotherapy plus trastuzumab) and 65% for chemotherapy plus trastuzumab.</p><p>&nbsp;</p><p><em><u>Pembrolizumab in combination with tyrosine kinase inhibitor (TKI) (see section</u></em><u>&nbsp;<em>4.2)</em></u></p><p>When pembrolizumab is administered in combination with axitinib or lenvatinib, refer to the SmPC for axitinib or lenvatinib prior to initiation of treatment. For additional axitinib safety information for elevated liver enzymes see also section&nbsp;4.4.</p><p>&nbsp;</p><p>KEYTRUDA</p><p>The safety of pembrolizumab in combination with axitinib or lenvatinib in advanced RCC, and in combination with lenvatinib in advanced EC has been evaluated in a total of 1,456&nbsp;patients with advanced RCC or advanced EC receiving 200&nbsp;mg pembrolizumab every 3&nbsp;weeks with either axitinib 5&nbsp;mg twice daily or lenvatinib 20&nbsp;mg once daily in clinical studies, as appropriate. In these patient populations, the most frequent adverse reactions were diarrhoea&nbsp;(58%), hypertension&nbsp;(54%), hypothyroidism&nbsp;(46%), fatigue&nbsp;(41%), decreased appetite&nbsp;(40%), nausea&nbsp;(40%), arthralgia&nbsp;(30%), vomiting&nbsp;(28%), weight decreased&nbsp;(28%), dysphonia&nbsp;(28%), abdominal pain (28%), proteinuria&nbsp;(27%), palmar‑plantar erythrodysaesthesia syndrome&nbsp;(26%), rash (26%), stomatitis&nbsp;(25%), constipation&nbsp;(25%), musculoskeletal pain (23%), headache&nbsp;(23%) and cough (21%). Grades&nbsp;3‑5 adverse reactions in patients with RCC were 80% for pembrolizumab in combination with either axitinib or lenvatinib and 71% for sunitinib alone. In patients with EC, Grades 3-5 adverse reactions were 89% for pembrolizumab in combination with lenvatinib and 73% for chemotherapy alone.</p><p>&nbsp;</p><p><u>Tabulated summary of adverse reactions</u></p><p>Adverse reactions observed in clinical studies of pembrolizumab as monotherapy or in combination with chemotherapy or other anti‑tumour medicines or reported from post‑marketing use of pembrolizumab are listed in Table&nbsp;2. These reactions are presented by system organ class and by frequency. Frequencies are defined as: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000); and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness. Adverse reactions known to occur with pembrolizumab or combination therapy components given alone may occur during treatment with these medicinal products in combination, even if these reactions were not reported in clinical studies with combination therapy.</p><p>For additional safety information when pembrolizumab is administered in combination, refer to the SmPC for the respective combination therapy components.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Table 2: Adverse reactions in patients treated with pembrolizumab<sup>&dagger;</sup></strong></p><p><strong><sup>&nbsp;</sup></strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:95%"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Monotherapy</p></td><td style="vertical-align:top"><p>In combination with chemotherapy</p></td><td style="vertical-align:top"><p>In combination with axitinib or lenvatinib</p></td></tr></thead><tbody><tr><td colspan="2" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>urinary tract infection</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>pneumonia</p></td><td style="vertical-align:top"><p>pneumonia</p></td><td style="vertical-align:top"><p>pneumonia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>anaemia</p></td><td style="vertical-align:top"><p>anaemia, neutropenia, thrombocytopenia</p></td><td style="vertical-align:top"><p>anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>thrombocytopenia, neutropenia, lymphopenia</p></td><td style="vertical-align:top"><p>febrile neutropenia, leukopenia, lymphopenia</p></td><td style="vertical-align:top"><p>neutropenia, thrombocytopenia, lymphopenia, leukopenia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>leukopenia, immune thrombocytopenia, eosinophilia</p></td><td style="vertical-align:top"><p>eosinophilia</p></td><td style="vertical-align:top"><p>eosinophilia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>haemophagocytic lymphohistiocytosis, haemolytic anaemia, pure red cell aplasia</p></td><td style="vertical-align:top"><p>haemolytic anaemia, immune thrombocytopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>infusion<strong>-</strong>related reaction<sup>⁎</sup></p></td><td style="vertical-align:top"><p>infusion<strong>-</strong>related reaction<sup>⁎</sup></p></td><td style="vertical-align:top"><p>infusion<strong>-</strong>related reaction<sup>⁎</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>sarcoidosis<sup>⁎</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>sarcoidosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>solid organ transplant rejection</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>hypothyroidism<sup>⁎</sup></p></td><td style="vertical-align:top"><p>hypothyroidism<sup>⁎</sup></p></td><td style="vertical-align:top"><p>hypothyroidism</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>hyperthyroidism</p></td><td style="vertical-align:top"><p>adrenal insufficiency<sup>⁎</sup>, thyroiditis<sup>⁎</sup>, hyperthyroidism<sup>⁎</sup></p></td><td style="vertical-align:top"><p>adrenal insufficiency<sup>⁎</sup>, hyperthyroidism, thyroiditis<sup>⁎</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>adrenal insufficiency<sup>⁎</sup>, hypophysitis<sup>⁎</sup>, thyroiditis<sup>⁎</sup></p></td><td style="vertical-align:top"><p>hypophysitis<sup>⁎</sup></p></td><td style="vertical-align:top"><p>hypophysitis<sup>⁎</sup></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>hypoparathyroidism</p></td><td style="vertical-align:top"><p>hypoparathyroidism</p></td><td style="vertical-align:top"><p>hypoparathyroidism</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>decreased appetite</p></td><td style="vertical-align:top"><p>hypokalaemia, decreased appetite</p></td><td style="vertical-align:top"><p>decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>hyponatraemia, hypokalaemia, hypocalcaemia</p></td><td style="vertical-align:top"><p>hyponatraemia, hypocalcaemia</p></td><td style="vertical-align:top"><p>hyponatraemia, hypokalaemia, hypocalcaemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>type 1 diabetes mellitus<sup>⁎</sup></p></td><td style="vertical-align:top"><p>type 1 diabetes mellitus<sup>⁎</sup></p></td><td style="vertical-align:top"><p>type 1 diabetes mellitus<sup>⁎</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>insomnia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>insomnia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>insomnia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>neuropathy peripheral, headache</p></td><td style="vertical-align:top"><p>headache, dysgeusia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>dizziness, neuropathy peripheral, lethargy, dysgeusia</p></td><td style="vertical-align:top"><p>dizziness, dysgeusia, lethargy</p></td><td style="vertical-align:top"><p>dizziness, neuropathy peripheral, lethargy</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>myasthenic syndrome<sup>⁎</sup>, epilepsy</p></td><td style="vertical-align:top"><p>encephalitis<sup>⁎</sup>, epilepsy</p></td><td style="vertical-align:top"><p>myasthenic syndrome<sup>⁎</sup>, encephalitis<sup>⁎</sup></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Guillain‑Barr&eacute; syndrome<sup>⁎</sup>, encephalitis<sup>⁎</sup>, myelitis<sup>⁎</sup>, optic neuritis, meningitis (aseptic)<sup>⁎</sup></p></td><td style="vertical-align:top"><p>myasthenic syndrome, Guillain‑Barr&eacute; syndrome<sup>⁎</sup>, optic neuritis</p></td><td style="vertical-align:top"><p>optic neuritis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>dry eye</p></td><td style="vertical-align:top"><p>dry eye</p></td><td style="vertical-align:top"><p>dry eye</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>uveitis<sup>⁎</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>uveitis<sup>⁎</sup></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Vogt‑Koyanagi‑Harada syndrome</p></td><td style="vertical-align:top"><p>uveitis<sup>⁎</sup></p></td><td style="vertical-align:top"><p>Vogt‑Koyanagi‑Harada syndrome</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>cardiac arrhythmia<sup>&Dagger;</sup><sup> </sup>(including atrial fibrillation)</p></td><td style="vertical-align:top"><p>cardiac arrhythmia<sup>&Dagger;</sup><sup> </sup>(including atrial fibrillation)</p></td><td style="vertical-align:top"><p>cardiac arrhythmia<sup>&Dagger;</sup><sup> </sup>(including atrial fibrillation)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>myocarditis, pericardial effusion, pericarditis</p></td><td style="vertical-align:top"><p>myocarditis<sup>⁎</sup>, pericardial effusion, pericarditis</p></td><td style="vertical-align:top"><p>myocarditis, pericardial effusion</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypertension</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>hypertension</p></td><td style="vertical-align:top"><p>hypertension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>vasculitis<sup>⁎</sup></p></td><td style="vertical-align:top"><p>vasculitis<sup>⁎</sup></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>vasculitis<sup>⁎</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>dyspnoea, cough</p></td><td style="vertical-align:top"><p>dyspnoea, cough</p></td><td style="vertical-align:top"><p>dyspnoea, cough</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>pneumonitis<sup>⁎</sup></p></td><td style="vertical-align:top"><p>pneumonitis<sup>⁎</sup></p></td><td style="vertical-align:top"><p>pneumonitis<sup>⁎</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>diarrhoea, abdominal pain<sup>⁎</sup>, nausea, vomiting, constipation</p></td><td style="vertical-align:top"><p>diarrhoea, vomiting, nausea, abdominal pain<sup>⁎</sup>,<sup> </sup>constipation</p></td><td style="vertical-align:top"><p>diarrhoea, abdominal pain<sup>⁎</sup>, nausea, vomiting, constipation</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>colitis<sup>⁎</sup>, dry mouth</p></td><td style="vertical-align:top"><p>colitis<sup>⁎</sup>, gastritis<sup>⁎</sup>, dry mouth</p></td><td style="vertical-align:top"><p>colitis<sup>⁎</sup>, pancreatitis<sup>⁎</sup>, gastritis<sup>⁎</sup>, dry mouth</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>pancreatitis<sup>⁎</sup>, gastritis<sup>⁎</sup>, gastrointestinal ulceration<sup>⁎</sup></p></td><td style="vertical-align:top"><p>pancreatitis<sup>⁎</sup>, gastrointestinal ulceration<sup>⁎</sup></p></td><td style="vertical-align:top"><p>gastrointestinal ulceration<sup>⁎</sup></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>pancreatic exocrine insufficiency, small intestinal perforation, &nbsp;coeliac disease</p></td><td style="vertical-align:top"><p>pancreatic exocrine insufficiency, small intestinal perforation, &nbsp;coeliac disease</p></td><td style="vertical-align:top"><p>small intestinal perforation</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>pancreatic exocrine insufficiency, coeliac disease</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>hepatitis<sup>⁎</sup></p></td><td style="vertical-align:top"><p>hepatitis<sup>⁎</sup></p></td><td style="vertical-align:top"><p>hepatitis<sup>⁎</sup></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>cholangitis sclerosing</p></td><td style="vertical-align:top"><p>cholangitis sclerosing<sup>⁎</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>pruritus<sup>⁎</sup>, rash<sup>⁎</sup></p></td><td style="vertical-align:top"><p>alopecia, pruritus<sup>⁎</sup>, rash<sup>⁎</sup></p></td><td style="vertical-align:top"><p>rash<sup>⁎</sup>, pruritus<sup>⁎</sup></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>severe skin reactions<sup>⁎</sup>, erythema, dermatitis, dry skin, vitiligo<sup>⁎</sup>, eczema, alopecia, dermatitis acneiform</p></td><td style="vertical-align:top"><p>severe skin reactions<sup>⁎</sup>, erythema, dermatitis, dry skin, dermatitis acneiform, eczema</p></td><td style="vertical-align:top"><p>severe skin reactions<sup>⁎</sup>, dermatitis, dry skin, erythema, dermatitis acneiform, alopecia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>psoriasis, lichenoid keratosis<sup>⁎</sup>, papule, hair colour changes</p></td><td style="vertical-align:top"><p>psoriasis, vitiligo<sup>⁎</sup>, papule</p></td><td style="vertical-align:top"><p>eczema, lichenoid keratosis<sup>⁎</sup>, psoriasis, vitiligo<sup>⁎</sup>, papule, hair colour changes</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Stevens‑Johnson syndrome, erythema nodosum, toxic epidermal necrolysis</p></td><td style="vertical-align:top"><p>Stevens‑Johnson syndrome, lichenoid keratosis<sup>⁎</sup>, erythema nodosum, hair colour changes</p></td><td style="vertical-align:top"><p>toxic epidermal necrolysis, Stevens‑Johnson syndrome</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>musculoskeletal pain<sup>⁎</sup>, arthralgia</p></td><td style="vertical-align:top"><p>musculoskeletal pain<sup>⁎</sup>, arthralgia</p></td><td style="vertical-align:top"><p>arthralgia, musculoskeletal pain<sup>⁎</sup>, myositis<sup>⁎</sup>, pain in extremity</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>myositis<sup>⁎</sup>, pain in extremity, arthritis<sup>⁎</sup></p></td><td style="vertical-align:top"><p>myositis<sup>⁎</sup>, pain in extremity, arthritis<sup>⁎</sup></p></td><td style="vertical-align:top"><p>arthritis<sup>⁎</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>tenosynovitis<sup>⁎</sup></p></td><td style="vertical-align:top"><p>tenosynovitis<sup>⁎</sup></p></td><td style="vertical-align:top"><p>tenosynovitis<sup>⁎</sup></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Sjogren&rsquo;s syndrome</p></td><td style="vertical-align:top"><p>Sjogren&rsquo;s syndrome</p></td><td style="vertical-align:top"><p>Sjogren&rsquo;s syndrome</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>acute kidney injury</p></td><td style="vertical-align:top"><p>nephritis<sup>⁎</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>nephritis<sup>⁎</sup></p></td><td style="vertical-align:top"><p>nephritis<sup>⁎</sup>, cystitis noninfective</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>cystitis noninfective</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>cystitis noninfective</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>fatigue, asthenia, oedema<sup>⁎</sup>, pyrexia</p></td><td style="vertical-align:top"><p>fatigue, asthenia, pyrexia</p></td><td style="vertical-align:top"><p>fatigue, asthenia, oedema<sup>⁎</sup>, pyrexia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>influenza‑like illness, chills</p></td><td style="vertical-align:top"><p>oedema<sup>⁎</sup>, influenza‑like illness, chills</p></td><td style="vertical-align:top"><p>influenza‑like illness, chills</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>alanine aminotransferase increased, aspartate aminotransferase increased</p></td><td style="vertical-align:top"><p>lipase increased, alanine aminotransferase increased, aspartate aminotransferase increased, blood creatinine increased</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, hypercalcaemia, blood bilirubin increased, blood creatinine increased</p></td><td style="vertical-align:top"><p>blood bilirubin increased, blood alkaline phosphatase increased, blood creatinine increased, hypercalcaemia</p></td><td style="vertical-align:top"><p>amylase increased, blood bilirubin increased, blood alkaline phosphatase increased, hypercalcaemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>amylase increased</p></td><td style="vertical-align:top"><p>amylase increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><sup>&dagger;</sup>Adverse reaction frequencies presented in Table 2 may not be fully attributable to pembrolizumab alone but may contain contributions from the underlying disease or from other medicinal products used in a combination.</p><p><sup>&Dagger;</sup>Based upon a standard query including bradyarrhythmias and tachyarrhythmias.</p><p><sup>⁎</sup>The following terms represent a group of related events that describe a medical condition rather than a single event:</p><p>&sect;&nbsp; infusion‑related reaction (drug hypersensitivity, anaphylactic reaction, anaphylactoid reaction, hypersensitivity, infusion‑related hypersensitivity reaction, cytokine release syndrome and serum sickness)</p><p>&sect;&nbsp; sarcoidosis (cutaneous sarcoidosis and pulmonary sarcoidosis)</p><p>&sect;&nbsp; hypothyroidism (myxoedema, immune-mediated hypothyroidism and autoimmune hypothyroidism)</p><p>&sect;&nbsp; adrenal insufficiency (Addison&rsquo;s disease, adrenocortical insufficiency acute and secondary adrenocortical insufficiency)</p><p>&sect;&nbsp; thyroiditis (autoimmune thyroiditis, silent thyroiditis, thyroid disorder, thyroiditis acute and immune-mediated thyroiditis)</p><p>&sect;&nbsp; hyperthyroidism (Basedow&rsquo;s disease)</p><p>&sect;&nbsp; hypophysitis (hypopituitarism and lymphocytic hypophysitis)</p><p>&sect;&nbsp; type 1 diabetes mellitus (diabetic ketoacidosis)</p><p>&sect;&nbsp; myasthenic syndrome (myasthenia gravis, including exacerbation)</p><p>&sect;&nbsp; encephalitis (autoimmune encephalitis and noninfective encephalitis)</p><p>&sect;&nbsp; Guillain‑Barr&eacute; syndrome (axonal neuropathy and demyelinating polyneuropathy)</p><p>&sect;&nbsp; myelitis (including transverse myelitis)</p><p>&sect;&nbsp; meningitis aseptic (meningitis and meningitis noninfective)</p><p>&sect;&nbsp; uveitis (chorioretinitis, iritis and iridocyclitis)</p><p>&sect;&nbsp; myocarditis (autoimmune myocarditis)</p><p>&sect;&nbsp; vasculitis (central nervous system vasculitis, aortitis and giant cell arteritis)</p><p>&sect;&nbsp; pneumonitis (interstitial lung disease, organising pneumonia, immune-mediated pneumonitis, immune-mediated lung disease and autoimmune lung disease)</p><p>&sect;&nbsp; abdominal pain (abdominal discomfort, abdominal pain upper and abdominal pain lower)</p><p>&sect;&nbsp; colitis (colitis microscopic, enterocolitis, enterocolitis haemorrhagic, autoimmune colitis and immune-mediated enterocolitis)</p><p>&sect;&nbsp; gastritis (gastritis erosive and gastritis haemorrhagic)</p><p>&sect;&nbsp; pancreatitis (autoimmune pancreatitis, pancreatitis acute and immune-mediated pancreatitis)</p><p>&sect;&nbsp; gastrointestinal ulceration (gastric ulcer and duodenal ulcer)</p><p>&sect;&nbsp; hepatitis (autoimmune hepatitis, immune‑mediated hepatitis, drug induced liver injury and acute hepatitis)</p><p>&sect;&nbsp; cholangitis sclerosing (immune-mediated cholangitis)</p><p>&sect;&nbsp; pruritus (urticaria, urticaria papular and pruritus genital)</p><p>&sect;&nbsp; rash (rash erythematous, rash macular, rash maculo‑papular, rash papular, rash pruritic, rash vesicular and genital rash)</p><p>&sect;&nbsp; severe skin reactions (exfoliative rash, pemphigus, and Grade&nbsp;&ge;&nbsp;3 of the following: cutaneous vasculitis, dermatitis bullous, dermatitis exfoliative, dermatitis exfoliative generalised, erythema multiforme, lichen planus, oral lichen planus, pemphigoid, pruritus, pruritus genital, rash, rash erythematous, rash maculo‑papular, rash pruritic, rash pustular, skin necrosis and toxic skin eruption)</p><p>&sect;&nbsp; vitiligo (skin depigmentation, skin hypopigmentation and hypopigmentation of the eyelid)</p><p>&sect;&nbsp; lichenoid keratosis (lichen planus and lichen sclerosus)</p><p>&sect;&nbsp; musculoskeletal pain (musculoskeletal discomfort, back pain, musculoskeletal stiffness, musculoskeletal chest pain and torticollis)</p><p>&sect;&nbsp; myositis (myalgia, myopathy, necrotising myositis, polymyalgia rheumatica and rhabdomyolysis)</p><p>&sect;&nbsp; arthritis (joint swelling, polyarthritis, joint effusion, autoimmune arthritis and immune-mediated arthritis)</p><p>&sect;&nbsp; tenosynovitis (tendonitis, synovitis and tendon pain)</p><p>&sect;&nbsp; nephritis (autoimmune nephritis, immune-mediated nephritis, tubulointerstitial nephritis and renal failure, renal failure acute, or acute kidney injury with evidence of nephritis, nephrotic syndrome, glomerulonephritis, glomerulonephritis membranous and glomerulonephritis acute)</p><p>&sect;&nbsp; oedema (oedema peripheral, generalised oedema, fluid overload, fluid retention, eyelid oedema and lip oedema, face oedema, localised oedema and periorbital oedema)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Pembrolizumab in combination with enfortumab vedotin (see section&nbsp;4.2)</u></em></p><p>When pembrolizumab is administered in combination with enfortumab vedotin, refer to the SmPC for enfortumab vedotin prior to initiation of treatment.</p><p>&nbsp;</p><p>The safety of pembrolizumab in combination with enfortumab vedotin has been evaluated among 564&nbsp;patients with unresectable or metastatic urothelial carcinoma receiving 200&nbsp;mg pembrolizumab on Day&nbsp;1 and enfortumab vedotin 1.25&nbsp;mg/kg on Days&nbsp;1 and 8 of each 21‑day cycle.</p><p>Overall, the incidence of adverse reactions for pembrolizumab in combination with enfortumab vedotin was observed to be higher than for pembrolizumab monotherapy reflecting the contribution of enfortumab vedotin and the longer duration of treatment of the combination therapy.</p><p>Adverse reactions were generally similar to those observed in patients receiving pembrolizumab or enfortumab vedotin as monotherapy. The incidence of rash maculo‑papular was 36% all Grades (10% Grades 3-4), which is higher than observed in pembrolizumab monotherapy.</p><p>Generally, adverse event frequencies were higher in patients &ge;&nbsp;65&nbsp;years of age compared to &lt;&nbsp;65&nbsp;years of age, particularly for serious adverse events (56.3% and 35.3%, respectively) and &ge;&nbsp;Grade&nbsp;3 events (80.3% and 64.2%, respectively), similar to observations with the chemotherapy comparator.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>Data for the following immune‑ mediated adverse reactions are based on patients who received pembrolizumab across four doses (2&nbsp;mg/kg bw every 3&nbsp;weeks, 10&nbsp;mg/kg bw every 2 or 3&nbsp;weeks, or 200&nbsp;mg every 3&nbsp;weeks) in clinical studies (see section&nbsp;5.1). The management guidelines for these adverse reactions are described in section&nbsp;4.4.</p><p>&nbsp;</p><p><em><u>Immune‑</u></em> <em><u>mediated adverse reactions (see section&nbsp;4.4)</u></em></p><p><u>&nbsp;</u></p><p><em>Immune‑</em> <em>mediated&nbsp; pneumonitis</em></p><p>Pneumonitis occurred in 324&nbsp;(4.2%) patients, including Grade&nbsp;2, 3, 4 or 5 cases in 143&nbsp;(1.9%), 81&nbsp;(1.1%), 19&nbsp;(0.2%) and 9&nbsp;(0.1%) patients, respectively, receiving pembrolizumab. The median time to onset of pneumonitis was 3.9&nbsp;months (range 2&nbsp;days to 27.2&nbsp;months). The median duration was 2.0&nbsp;months (range 1&nbsp;day to 51.0+&nbsp;months). Pneumonitis occurred more frequently in patients with a history of prior thoracic radiation (8.1%) than in patients who did not receive prior thoracic radiation (3.9%). Pneumonitis led to discontinuation of pembrolizumab in 131&nbsp;(1.7%) patients. Pneumonitis resolved in 196&nbsp;patients, 6 with sequelae.</p><p>&nbsp;</p><p>&nbsp;</p><p>In patients with NSCLC, pneumonitis occurred in 230&nbsp;(6.1%), including Grade 2, 3, 4 or 5&nbsp;cases in 103&nbsp;(2.7%), 63&nbsp;(1.7%), 17&nbsp;(0.4%) and 10&nbsp;(0.3%), respectively. In patients with locally advanced or metastatic NSCLC, pneumonitis occurred in 8.9% with a history of prior thoracic radiation. In patients with cHL, the incidence of pneumonitis (all Grades) ranged from 5.2% to 10.8% for cHL patients in KEYNOTE-087&nbsp;(n=210) and KEYNOTE-204&nbsp;(n=148), respectively.</p><p>&nbsp;</p><p><em>Immune‑</em> <em>mediated colitis</em></p><p>Colitis occurred in 158&nbsp;(2.1%)&nbsp;patients, including Grade&nbsp;2, 3 or 4 cases in 49&nbsp;(0.6%), 82&nbsp;(1.1%) and 6&nbsp;(0.1%) patients, respectively, receiving pembrolizumab. The median time to onset of colitis was 4.3&nbsp;months (range 2&nbsp;days to 24.3&nbsp;months). The median duration was 1.1&nbsp;month (range 1&nbsp;day to 45.2&nbsp;months). Colitis led to discontinuation of pembrolizumab in 48&nbsp;(0.6%) patients. Colitis resolved in 132&nbsp;patients, 2 with sequelae. In patients with CRC treated with pembrolizumab as monotherapy (n=153), the incidence of colitis was 6.5% (all Grades) with 2.0% Grade&nbsp;3 and 1.3% Grade&nbsp;4.</p><p><em>&nbsp;</em></p><p><em>Immune‑</em> <em>mediated hepatitis</em></p><p>Hepatitis occurred in 80&nbsp;(1.0%) patients, including Grade&nbsp;2, 3 or 4 cases in 12&nbsp;(0.2%), 55&nbsp;(0.7%) and 8&nbsp;(0.1%) patients, respectively, receiving pembrolizumab. The median time to onset of hepatitis was 3.5&nbsp;months (range 8&nbsp;days to 26.3&nbsp;months). The median duration was 1.3&nbsp;months (range 1&nbsp;day to 29.0+&nbsp;months). Hepatitis led to discontinuation of pembrolizumab in 37&nbsp;(0.5%) patients. Hepatitis resolved in 60&nbsp;patients.</p><p>&nbsp;</p><p><em>Immune‑</em> <em>mediated nephritis </em></p><p>Nephritis occurred in 37&nbsp;(0.5%) patients, including Grade&nbsp;2, 3 or 4 cases in 11&nbsp;(0.1%), 19&nbsp;(0.2%) and 2&nbsp;(&lt;&nbsp;0.1%) patients, respectively, receiving pembrolizumab as monotherapy. The median time to onset of nephritis was 4.2&nbsp;months (range 12&nbsp;days to 21.4&nbsp;months). The median duration was 3.3&nbsp;months (range 6&nbsp;days to 28.2+&nbsp;months). Nephritis led to discontinuation of pembrolizumab in 17&nbsp;(0.2%) patients. Nephritis resolved in 25&nbsp;patients, 5 with sequelae. In patients with non‑squamous NSCLC treated with pembrolizumab in combination with pemetrexed and platinum chemotherapy (n=488), the incidence of nephritis was 1.4% (all Grades) with 0.8% Grade&nbsp;3 and 0.4% Grade&nbsp;4.</p><p>&nbsp;</p><p><em>Immune‑</em> <em>mediated endocrinopathies</em></p><p><em>Immune‑mediated endocrinopathies</em></p><p>Adrenal insufficiency occurred in 74&nbsp;(1.0%) patients, including Grade&nbsp;2, 3 or 4&nbsp;cases in 34&nbsp;(0.4%), 31&nbsp;(0.4%) and 4&nbsp;(0.1%) patients, respectively, receiving pembrolizumab. The median time to onset of adrenal insufficiency was 5.4&nbsp;months (range 1&nbsp;day to 23.7&nbsp;months). The median duration was not reached (range 3&nbsp;days to 40.1+&nbsp;months). Adrenal insufficiency led to discontinuation of pembrolizumab in 13&nbsp;(0.2%) patients. Adrenal insufficiency resolved in 28&nbsp;patients, 11 with sequelae.</p><p>&nbsp;</p><p>Hypophysitis occurred in 52&nbsp;(0.7%) patients, including Grade&nbsp;2, 3 or 4&nbsp;cases in 23&nbsp;(0.3%), 24&nbsp;(0.3%) and 1&nbsp;(&lt;&nbsp;0.1%) patients, respectively, receiving pembrolizumab. The median time to onset of hypophysitis was 5.9&nbsp;months (range 1&nbsp;day to 17.7&nbsp;months). The median duration was 3.6&nbsp;months (range 3&nbsp;days to 48.1+&nbsp;months). Hypophysitis led to discontinuation of pembrolizumab in 14&nbsp;(0.2%) patients. Hypophysitis resolved in 23&nbsp;patients, 8 with sequelae.</p><p>&nbsp;</p><p>Hyperthyroidism occurred in 394&nbsp;(5.2%) patients, including Grade&nbsp;2 or 3 cases in 108&nbsp;(1.4%) and 9&nbsp;(0.1%) patients, respectively, receiving pembrolizumab. The median time to onset of hyperthyroidism was 1.4&nbsp;months (range 1&nbsp;day to 23.2&nbsp;months). The median duration was 1.6&nbsp;months (range 4&nbsp;days to 43.1+&nbsp;months). Hyperthyroidism led to discontinuation of pembrolizumab in 4&nbsp;(0.1%) patients. Hyperthyroidism resolved in 326&nbsp;(82.7%) patients, 11 with sequelae. In patients with melanoma, NSCLC and RCC treated with pembrolizumab monotherapy in the adjuvant setting (n=2,060), the incidence of hyperthyroidism was 11.0%, the majority of which were Grade&nbsp;1 or&nbsp;2.</p><p>&nbsp;</p><p>Hypothyroidism occurred in 939&nbsp;(12.3%) patients, including Grade&nbsp;2 or 3 cases in 687&nbsp;(9.0%) and 8&nbsp;(0.1%) patients, respectively, receiving pembrolizumab. The median time to onset of hypothyroidism was 3.4&nbsp;months (range 1&nbsp;day to 25.9&nbsp;months). The median duration was not reached (range 2&nbsp;days to 63.0+&nbsp;months). Hypothyroidism led to discontinuation of pembrolizumab in 6&nbsp;(0.1%) patients. Hypothyroidism resolved in 216&nbsp;(23.0%) patients, 16 with sequelae. In patients with cHL (n=389) the incidence of hypothyroidism was 17%, all of which were Grade&nbsp;1 or&nbsp;2. In patients with HNSCC treated with pembrolizumab as monotherapy (n=909), the incidence of hypothyroidism was 16.1% (all Grades) with 0.3% Grade 3. In patients with HNSCC treated with pembrolizumab in combination with platinum and 5‑FU chemotherapy (n=276), the incidence of hypothyroidism was&nbsp;15.2%, all of which were Grade&nbsp;1 or&nbsp;2. In patients treated with pembrolizumab in combination with axitinib or lenvatinib (n=1,456), the incidence of hypothyroidism was 46.2% (all Grades) with 0.8% Grade&nbsp;3 or 4. In patients with melanoma, NSCLC and RCC treated with pembrolizumab monotherapy in the adjuvant setting (n=2,060), the incidence of hypothyroidism was 18.5%, the majority of which were Grade&nbsp;1 or&nbsp;2.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Immune‑</em> <em>mediated skin adverse reactions</em></p><p>Immune‑ mediated severe skin reactions occurred in 130&nbsp;(1.7%) patients, including Grade&nbsp;2, 3, 4 or 5 cases in 11&nbsp;(0.1%), 103&nbsp;(1.3%), 1 (&lt;&nbsp;0.1%) and 1 (&lt;&nbsp;0.1%) patients, respectively, receiving pembrolizumab. The median time to onset of severe skin reactions was 2.8&nbsp;months (range 2&nbsp;days to 25.5&nbsp;months). The median duration was 1.9&nbsp;months (range 1&nbsp;day to 47.1+&nbsp;months). Severe skin reactions led to discontinuation of pembrolizumab in 18&nbsp;(0.2%) patients. Severe skin reactions resolved in 95&nbsp;patients, 2 with sequelae.</p><p><em>&nbsp;</em></p><p>Rare cases of SJS and TEN, some of them with fatal outcome, have been observed (see sections&nbsp;4.2 and 4.4).</p><p>&nbsp;</p><p><em><u>Complications of allogeneic HSCT in cHL </u></em></p><p>Of 14&nbsp;patients in KEYNOTE‑013 who proceeded to allogeneic HSCT after treatment with pembrolizumab, 6&nbsp;patients reported acute GVHD and 1&nbsp;patient reported chronic GVHD, none of which were fatal. Two patients experienced hepatic VOD, one of which was fatal. One patient experienced engraftment syndrome post-transplant.</p><p>&nbsp;</p><p>Of 32&nbsp;patients in KEYNOTE‑087 who proceeded to allogeneic HSCT after treatment with pembrolizumab, 16&nbsp;patients reported acute GVHD and 7&nbsp;patients reported chronic GVHD, two of which were fatal. No patients experienced hepatic VOD. No patients experienced engraftment syndrome post-transplant.</p><p>&nbsp;</p><p>Of 14&nbsp;patients in KEYNOTE‑204 who proceeded to allogeneic HSCT after treatment with pembrolizumab, 8&nbsp;patients reported acute GVHD and 3&nbsp;patients reported chronic GVHD, none of which were fatal. No patients experienced hepatic VOD. One patient experienced engraftment syndrome post-transplant.</p><p>&nbsp;</p><p><em><u>Elevated liver enzymes when pembrolizumab is combined with axitinib in RCC</u></em></p><p>In a clinical study of previously untreated patients with RCC receiving pembrolizumab in combination with axitinib, a higher than expected incidence of Grades&nbsp;3 and 4 ALT increased&nbsp;(20%) and AST increased&nbsp;(13%) were observed. The median time to onset of ALT increased was 2.3&nbsp;months (range: 7&nbsp;days to 19.8&nbsp;months). In patients with ALT &ge;&nbsp;3&nbsp;times ULN (Grades&nbsp;2‑4, n=116), ALT resolved to Grades&nbsp;0‑1 in 94%. Fifty‑nine percent of the patients with increased ALT received systemic corticosteroids. Of the patients who recovered, 92&nbsp;(84%) were rechallenged with either pembrolizumab&nbsp;(3%) or axitinib&nbsp;(31%) monotherapy or with both (50%). Of these patients, 55% had no recurrence of ALT &gt;&nbsp;3&nbsp;times ULN, and of those patients with recurrence of ALT &gt;&nbsp;3&nbsp;times ULN, all recovered. There were no Grade&nbsp;5 hepatic events.</p><p>&nbsp;</p><p><em><u>Laboratory abnormalities </u></em></p><p>In patients treated with pembrolizumab monotherapy, the proportion of patients who experienced a shift from baseline to a Grade&nbsp;3 or 4 laboratory abnormality was as follows: 9.4% for lymphocytes decreased, 7.4% for sodium decreased, 5.8% for haemoglobin decreased, 5.3% for phosphate decreased, 5.3% for glucose increased, 3.3% for ALT increased, 3.1% for AST increased, 2.6% for alkaline phosphatase increased, 2.3% for potassium decreased, 2.1% for potassium increased, 1.9% for neutrophils decreased, 1.8% for platelets decreased, 1.8% for calcium increased, 1.7% for bilirubin increased, 1.5% for calcium decreased, 1.4% for albumin decreased, 1.3% for creatinine increased, 1.2% for glucose decreased, 0.8% for leucocytes decreased, 0.7% for magnesium increased, 0.5% for sodium increased, 0.4% for haemoglobin increased, and 0.2% for magnesium decreased.</p><p>&nbsp;</p><p>In patients treated with pembrolizumab in combination with chemotherapy, the proportion of patients who experienced a shift from baseline to a Grade&nbsp;3 or 4 laboratory abnormality was as follows: 39.9% for neutrophils decreased, 25.5% for lymphocytes decreased, 23.3% for leucocytes decreased, 20.8% for haemoglobin decreased, 13.7% for platelets decreased, 10.4% for sodium decreased, 7.7% for potassium decreased, 7.3% for phosphate decreased, 5.7% for ALT increased, 5.5% for glucose increased, 5.3% for AST increased, 3.6% for bilirubin increased, 3.5% for calcium decreased, 3.4% for potassium increased, 3.1% for creatinine increased, 2.8% for alkaline phosphatase increased, 2.6% for albumin decreased, 1.7% for calcium increased, 1.0% for glucose decreased, 0.5% for sodium increased and 0.1% for haemoglobin increased.</p><p>&nbsp;</p><p>In patients treated with pembrolizumab in combination with axitinib or lenvatinib, the proportion of patients who experienced a shift from baseline to a Grade&nbsp;3 or 4 laboratory abnormality was as follows: 23.0% for lipase increased (not measured in patients treated with pembrolizumab and axitinib), 12.0% for lymphocyte decreased, 11.4% for sodium decreased, 11.2% for amylase increased, 11.2% for triglycerides increased, 10.4% for ALT increased, 8.9% for AST increased, 7.8% for glucose increased, 6.8% for phosphate decreased, 6.1% for potassium decreased, 5.1% for potassium increased, 4.5% for cholesterol increased, 4.4% for creatinine increased, 4.2% for haemoglobin decreased, 4.0% for magnesium decreased, 3.5% for neutrophils decreased, 3.1% for alkaline phosphatase increased, 3.0% for platelets decreased, 2.8% for bilirubin increased, 2.2% for calcium decreased, 1.7% for white blood cells decreased, 1.6% for magnesium increased, 1.5% for prothrombin INR increased, 1.4% for glucose decreased, 1.2% for albumin decreased, 1.2% for calcium increased, 0.4% for sodium increased, and 0.1% for haemoglobin increased.</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p>In clinical studies in patients treated with pembrolizumab 2&nbsp;mg/kg bw every three&nbsp;weeks, 200&nbsp;mg every three&nbsp;weeks, or 10&nbsp;mg/kg bw every two or three weeks as monotherapy, 36&nbsp;(1.8%) of 2,034&nbsp;evaluable patients tested positive for treatment‑emergent antibodies to pembrolizumab, of which 9 (0.4%) patients had neutralising antibodies against pembrolizumab. There was no evidence of an altered pharmacokinetic or safety profile with anti‑pembrolizumab binding or neutralising antibody development.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>The safety of pembrolizumab as monotherapy has been evaluated in 161&nbsp;paediatric patients aged 9&nbsp;months to 17&nbsp;years with advanced melanoma, lymphoma, or PD‑L1 positive advanced, relapsed, or refractory solid tumours at 2&nbsp;mg/kg bw every 3&nbsp;weeks in the Phase I/II study KEYNOTE‑051. The cHL population (n=22) included patients 11 to 17&nbsp;years of age. The safety profile in paediatric patients was generally similar to that seen in adults treated with pembrolizumab. The most common adverse reactions (reported in at least 20% of paediatric patients) were pyrexia&nbsp;(33%), vomiting&nbsp;(30%), headache&nbsp;(26%), abdominal pain&nbsp;(22%), anaemia&nbsp;(21%), cough&nbsp;(21%) and constipation&nbsp;(20%). The majority of adverse reactions reported for monotherapy were of Grades&nbsp;1 or 2 severity. Seventy‑six&nbsp;(47.2%) patients had 1 or more Grades&nbsp;3 to 5 adverse reactions of which 5&nbsp;(3.1%) patients had 1 or more adverse reactions that resulted in death. The frequencies are based on all reported adverse drug reactions, regardless of the investigator assessment of causality. Long-term safety data of pembrolizumab in adolescents with Stage IIB, IIC and III melanoma treated in the adjuvant setting are currently unavailable.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia:</p><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no information on overdose with pembrolizumab.</p><p>&nbsp;</p><p>In case of overdose, patients must be closely monitored for signs or symptoms of adverse reactions, and appropriate symptomatic treatment instituted.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors. ATC code: L01FF02</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>KEYTRUDA is a humanised monoclonal antibody which binds to the programmed cell death‑1 (PD‑1) receptor and blocks its interaction with ligands PD‑L1 and PD‑L2. The PD‑1 receptor is a negative regulator of T‑cell activity that has been shown to be involved in the control of T‑cell immune responses. KEYTRUDA potentiates T‑cell responses, including anti‑tumour responses, through blockade of PD‑1 binding to PD‑L1 and PD‑L2, which are expressed in antigen presenting cells and may be expressed by tumours or other cells in the tumour microenvironment.</p><p>&nbsp;</p><p>The anti-angiogenic effect of lenvatinib (multi-TKI) in combination with the immune-stimulatory effect of pembrolizumab (anti-PD-1) results in a tumour microenvironment with greater T‑cell activation to help overcome primary and acquired resistance to immunotherapy and may improve tumour responses compared to either treatment alone. In preclinical murine models, PD-1 plus TKI inhibitors have demonstrated enhanced anti-tumour activity compared to either agent alone.</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy and safety</u></p><p>Pembrolizumab doses of 2&nbsp;mg/kg bw every 3&nbsp;weeks, 10&nbsp;mg/kg bw every 3&nbsp;weeks, and 10&nbsp;mg/kg bw every 2&nbsp;weeks were evaluated in melanoma or previously treated NSCLC clinical studies. Based on the modelling and simulation of dose/exposure relationships for efficacy and safety for pembrolizumab, there are no clinically significant differences in efficacy or safety among the doses of 200&nbsp;mg every 3&nbsp;weeks, 2&nbsp;mg/kg bw every 3&nbsp;weeks, and 400&nbsp;mg every 6&nbsp;weeks (see section&nbsp;4.2).</p><p>&nbsp;</p><p><em><u>Melanoma</u></em></p><p><em><u>KEYNOTE‑006: Controlled study in melanoma patients na&iuml;ve to treatment with ipilimumab</u></em></p><p>The safety and efficacy of KEYTRUDA were investigated in KEYNOTE‑006, a multicentre, open‑label, controlled, Phase III study for the treatment of advanced melanoma in patients who were na&iuml;ve to ipilimumab. Patients were randomised (1:1:1) to receive KEYTRUDA 10&nbsp;mg/kg bw every 2 (n=279) or 3&nbsp;weeks (n=277) or ipilimumab 3&nbsp;mg/kg bw every 3&nbsp;weeks (n=278). Patients with BRAF V600E mutant melanoma were not required to have received prior BRAF inhibitor therapy.</p><p>&nbsp;</p><p>Patients were treated with KEYTRUDA until disease progression or unacceptable toxicity. Clinically stable patients with initial evidence of disease progression were permitted to remain on treatment until disease progression was confirmed. Assessment of tumour status was performed at 12&nbsp;weeks, then every 6&nbsp;weeks through Week&nbsp;48, followed by every 12&nbsp;weeks thereafter.</p><p>&nbsp;</p><p>Of the 834&nbsp;patients, 60% were male, 44% were &ge;&nbsp;65&nbsp;years (median age was 62&nbsp;years [range 18‑89]) and 98% were white. Sixty‑five percent of patients had M1c stage, 9% had a history of brain metastases, 66% had no and 34% had one prior therapy. Thirty‑one percent had an ECOG Performance Status of 1, 69% had ECOG Performance Status of 0 and 32% had elevated LDH. BRAF mutations were reported in 302&nbsp;(36%) patients. Among patients with BRAF mutant tumours, 139&nbsp;(46%) were previously treated with a BRAF inhibitor.</p><p>&nbsp;</p><p>The primary efficacy outcome measures were progression‑free survival (PFS; as assessed by Integrated Radiology and Oncology Assessment [IRO] review using Response Evaluation Criteria in Solid Tumours [RECIST], version&nbsp;1.1) and overall survival (OS). Secondary efficacy outcome measures were objective response rate (ORR) and response duration. Table&nbsp;3 summarises key efficacy measures in patients na&iuml;ve to treatment with ipilimumab at the final analysis performed after a minimum of 21&nbsp;months of follow‑up. Kaplan‑Meier curves for OS and PFS based on the final analysis are shown in Figures&nbsp;1 and 2.</p><p>&nbsp;</p><p>Table&nbsp;3: Efficacy results in KEYNOTE‑006</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p>Endpoint</p></td><td style="vertical-align:top"><p><strong>KEYTRUDA</strong> <strong>10&nbsp;mg/kg bw every 3&nbsp;weeks</strong></p><p><strong>n=277</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA</strong> <strong>10&nbsp;mg/kg bw every 2&nbsp;weeks</strong></p><p><strong>n=279</strong></p></td><td style="vertical-align:top"><p><strong>Ipilimumab</strong></p><p><strong>3&nbsp;mg/kg bw every 3&nbsp;weeks</strong></p><p><strong>n=278</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>OS</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>119 (43%)</p></td><td style="vertical-align:top"><p>122 (44%)</p></td><td style="vertical-align:top"><p>142 (51%)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>*</sup> (95%&nbsp;CI)<sup> </sup></p></td><td style="vertical-align:top"><p>0.68 (0.53, 0.86)</p></td><td style="vertical-align:top"><p>0.68 (0.53, 0.87)</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>Not reached</p><p>(24, NA)</p></td><td style="vertical-align:top"><p>Not reached</p><p>(22, NA)</p></td><td style="vertical-align:top"><p>16</p><p>(14, 22)</p></td></tr><tr><td style="vertical-align:top"><p>PFS</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>183 (66%)</p></td><td style="vertical-align:top"><p>181 (65%)</p></td><td style="vertical-align:top"><p>202 (73%)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>*</sup> (95%&nbsp;CI)<sup> </sup></p></td><td style="vertical-align:top"><p>0.61 (0.50, 0.75)</p></td><td style="vertical-align:top"><p>0.61 (0.50, 0.75)</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>4.1</p><p>(2.9, 7.2)</p></td><td style="vertical-align:top"><p>5.6</p><p>(3.4, 8.2)</p></td><td style="vertical-align:top"><p>2.8</p><p>(2.8, 2.9)</p></td></tr><tr><td style="vertical-align:top"><p>Best objective response</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR % (95% CI)</p></td><td style="vertical-align:top"><p>36%</p><p>(30, 42)</p></td><td style="vertical-align:top"><p>37%</p><p>(31, 43)</p></td><td style="vertical-align:top"><p>13%</p><p>(10, 18)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>13%</p></td><td style="vertical-align:top"><p>12%</p></td><td style="vertical-align:top"><p>5%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>23%</p></td><td style="vertical-align:top"><p>25%</p></td><td style="vertical-align:top"><p>8%</p></td></tr><tr><td style="vertical-align:top"><p>Response duration<strong><sup>&Dagger;</sup></strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>Not reached</p><p>(2.0, 22.8+)</p></td><td style="vertical-align:top"><p>Not reached</p><p>(1.8, 22.8+)</p></td><td style="vertical-align:top"><p>Not reached</p><p>(1.1+, 23.8+)</p></td></tr><tr><td style="vertical-align:top"><p>% ongoing at 18&nbsp;months</p></td><td style="vertical-align:top"><p>68%<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>71%<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>70%<sup>&sect;</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp; Hazard ratio (KEYTRUDA compared to ipilimumab) based on the stratified Cox proportional hazard model</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on stratified log‑rank test</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on patients with a best objective response as confirmed complete or partial response</p><p><sup>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Based on Kaplan‑Meier estimation</p><p>NA = not available</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure&nbsp;1: Kaplan‑Meier curve for overall survival by treatment arm in </strong></p><p><strong>KEYNOTE‑006 (intent to treat population)</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Figure&nbsp;2: Kaplan‑Meier curve for progression‑free survival by treatment arm in KEYNOTE‑006 (intent to treat population)</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>KEYNOTE‑002: Controlled study in melanoma patients previously treated with ipilimumab</u></em></p><p>The safety and efficacy of KEYTRUDA were investigated in KEYNOTE‑002, a multicentre, double‑blind, controlled study for the treatment of advanced melanoma in patients previously treated with ipilimumab and if BRAF V600 mutation‑positive, with a BRAF or MEK inhibitor. Patients were randomised (1:1:1) to receive KEYTRUDA at a dose of 2 (n=180) or 10&nbsp;mg/kg bw (n=181) every 3&nbsp;weeks or chemotherapy (n=179; including dacarbazine, temozolomide, carboplatin, paclitaxel, or carboplatin+paclitaxel). The study excluded patients with autoimmune disease or those receiving immunosuppression; further exclusion criteria were a history of severe or life‑threatening immune‑ mediated adverse reactions from treatment with ipilimumab, defined as any Grade&nbsp;4 toxicity or Grade&nbsp;3 toxicity requiring corticosteroid treatment (&gt;&nbsp;10&nbsp;mg/day prednisone or equivalent dose) for greater than 12&nbsp;weeks; ongoing adverse reactions &ge;&nbsp;Grade&nbsp;2 from previous treatment with ipilimumab; previous severe hypersensitivity to other monoclonal antibodies; a history of pneumonitis or interstitial lung disease; HIV, hepatitis&nbsp;B or hepatitis&nbsp;C infection and ECOG Performance Status &ge;&nbsp;2.</p><p>&nbsp;</p><p>Patients were treated with KEYTRUDA until disease progression or unacceptable toxicity. Clinically stable patients with initial evidence of disease progression were permitted to remain on treatment until disease progression was confirmed. Assessment of tumour status was performed at 12&nbsp;weeks, then every 6&nbsp;weeks through Week&nbsp;48, followed by every 12&nbsp;weeks thereafter. Patients on chemotherapy who experienced independently<strong>-</strong>verified progression of disease after the first scheduled disease assessment were able to crossover and receive 2&nbsp;mg/kg bw or 10&nbsp;mg/kg bw of KEYTRUDA every 3&nbsp;weeks in a double‑blind fashion.</p><p>&nbsp;</p><p>Of the 540&nbsp;patients, 61% were male, 43% were &ge;&nbsp;65&nbsp;years (median age was 62&nbsp;years [range 15‑89]) and 98% were white. Eighty‑two percent had M1c stage, 73% had at least two and 32% of patients had three or more prior systemic therapies for advanced melanoma. Forty‑five percent had an ECOG Performance Status of 1, 40% had elevated LDH and 23% had a BRAF mutated tumour.</p><p>&nbsp;</p><p>The primary efficacy outcome measures were PFS as assessed by IRO using RECIST version&nbsp;1.1 and OS. Secondary efficacy outcome measures were ORR and response duration. Table&nbsp;4 summarises key efficacy measures at the final analysis in patients previously treated with ipilimumab, and the Kaplan‑Meier curve for PFS is shown in Figure&nbsp;3. Both KEYTRUDA arms were superior to chemotherapy for PFS, and there was no difference between KEYTRUDA doses. There was no statistically significant difference between KEYTRUDA and chemotherapy in the final OS analysis that was not adjusted for the potentially confounding effects of crossover. Of the patients randomised to the chemotherapy arm, 55% crossed over and subsequently received treatment with KEYTRUDA.</p><p>Table&nbsp;4: Efficacy results in KEYNOTE‑002</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:464px"><thead><tr><td style="vertical-align:top"><p>Endpoint</p></td><td style="vertical-align:top"><p><strong>KEYTRUDA</strong> <strong>2&nbsp;mg/kg bw every 3&nbsp;weeks</strong></p><p><strong>n=180</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA</strong> <strong>10&nbsp;mg/kg bw every 3&nbsp;weeks</strong></p><p><strong>n=181</strong></p></td><td style="vertical-align:top"><p><strong>Chemotherapy</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>n=179</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>PFS</p></td><td colspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>150 (83%)</p></td><td style="vertical-align:top"><p>144 (80%)</p></td><td style="vertical-align:top"><p>172 (96%)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>*</sup> (95% CI)<sup> </sup></p></td><td style="vertical-align:top"><p>0.58 (0.46, 0.73)</p></td><td style="vertical-align:top"><p>0.47 (0.37, 0.60)</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>2.9 (2.8, 3.8)</p></td><td style="vertical-align:top"><p>3.0 (2.8, 5.2)</p></td><td style="vertical-align:top"><p>2.8 (2.6, 2.8)</p></td></tr><tr><td style="vertical-align:top"><p>OS</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>123 (68%)</p></td><td style="vertical-align:top"><p>117 (65%)</p></td><td style="vertical-align:top"><p>128 (72%)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>*</sup> (95% CI)<sup> </sup></p></td><td style="vertical-align:top"><p>0.86 (0.67, 1.10)</p></td><td style="vertical-align:top"><p>0.74 (0.57, 0.96)</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>0.1173</p></td><td style="vertical-align:top"><p>0.0106<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>13.4 (11.0, 16.4)</p></td><td style="vertical-align:top"><p>14.7 (11.3, 19.5)</p></td><td style="vertical-align:top"><p>11.0 (8.9, 13.8)</p></td></tr><tr><td style="vertical-align:top"><p>Best objective response</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ORR % (95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>22% (16, 29)</p></td><td style="vertical-align:top"><p>28% (21, 35)</p></td><td style="vertical-align:top"><p>5% (2, 9)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>7%</p></td><td style="vertical-align:top"><p>0%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>19%</p></td><td style="vertical-align:top"><p>20%</p></td><td style="vertical-align:top"><p>5%</p></td></tr><tr><td style="vertical-align:top"><p>Response duration<strong><sup>&sect;</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>22.8</p><p>(1.4+, 25.3+)</p></td><td style="vertical-align:top"><p>Not reached</p><p>(1.1+, 28.3+)</p></td><td style="vertical-align:top"><p>6.8</p><p>(2.8, 11.3)</p></td></tr><tr><td style="vertical-align:top"><p>% ongoing at 12 months</p></td><td style="vertical-align:top"><p>73%<sup> &para;</sup></p></td><td style="vertical-align:top"><p>79%<sup> &para;</sup></p></td><td style="vertical-align:top"><p>0%<sup> &para;</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hazard ratio (KEYTRUDA compared to chemotherapy) based on the stratified Cox proportional hazard model</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on stratified log‑rank test</p><p><sup>&Dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Not statistically significant after adjustment for multiplicity</p><p><sup>&sect;</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Based on patients with a best objective response as confirmed complete or partial response from the final analysis</p><p><sup>&para;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Based on Kaplan‑Meier estimation</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure&nbsp;3: Kaplan‑Meier curve for progression‑free survival by treatment arm in KEYNOTE‑002 (intent to treat population)</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>&nbsp;</u></em></p><p><em><u>&nbsp;</u></em></p><p><em><u>KEYNOTE‑001: Open</u></em><em><u>‑label study in melanoma patients</u></em><em><u> na&iuml;ve and previously treated with ipilimumab</u></em></p><p>The safety and efficacy of KEYTRUDA for patients with advanced melanoma were investigated in an uncontrolled, open‑label study, KEYNOTE‑001. Efficacy was evaluated for 276&nbsp;patients from two defined cohorts, one which included patients previously treated with ipilimumab (and if BRAF V600 mutation‑positive, with a BRAF or MEK inhibitor) and the other which included patients na&iuml;ve to treatment with ipilimumab. Patients were randomly assigned to receive KEYTRUDA at a dose of 2&nbsp;mg/kg bw every 3&nbsp;weeks or 10&nbsp;mg/kg bw every 3&nbsp;weeks. Patients were treated with KEYTRUDA until disease progression or unacceptable toxicity. Clinically stable patients with initial evidence of disease progression were permitted to remain on treatment until disease progression was confirmed. Exclusion criteria were similar to those of KEYNOTE‑002.</p><p>&nbsp;</p><p>Of the 89&nbsp;patients receiving 2&nbsp;mg/kg bw of KEYTRUDA who were previously treated with ipilimumab, 53% were male, 33% were &ge;&nbsp;65&nbsp;years of age and the median age was 59&nbsp;years (range 18‑88). All but two patients were white. Eighty‑four percent had M1c stage<em> </em>and 8% of patients had a history of brain metastases. Seventy percent had at least two and 35% of patients had three or more prior systemic therapies for advanced melanoma. BRAF mutations were reported in 13% of the study population. All patients with BRAF mutant tumours were previously treated with a BRAF inhibitor.</p><p>&nbsp;</p><p>Of the 51&nbsp;patients receiving 2&nbsp;mg/kg bw of KEYTRUDA who were na&iuml;ve to treatment with ipilimumab, 63% were male, 35% were &ge;&nbsp;65&nbsp;years of age and the median age was 60&nbsp;years (range 35‑80). All but one patient was white. Sixty‑three percent had M1c stage<em> </em>and 2% of patients had a history of brain metastases. Forty‑five percent had no prior therapies for advanced melanoma. BRAF mutations were reported in 20&nbsp;(39%) patients. Among patients with BRAF mutant tumours, 10&nbsp;(50%) were previously treated with a BRAF inhibitor.</p><p>&nbsp;</p><p>The primary efficacy outcome measure was ORR as assessed by independent review using RECIST&nbsp;1.1. Secondary efficacy outcome measures were disease control rate (DCR; including complete response, partial response and stable disease), response duration, PFS and OS. Tumour response was assessed at 12‑week intervals. Table&nbsp;5 summarises key efficacy measures in patients previously treated or na&iuml;ve to treatment with ipilimumab, receiving KEYTRUDA at a dose of 2&nbsp;mg/kg bw based on a minimum follow‑up time of 30 months for all patients.</p><p>&nbsp;</p><p>Table&nbsp;5: Efficacy results in KEYNOTE‑001</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p>Endpoint</p></td><td style="vertical-align:top"><p><strong>KEYTRUDA 2&nbsp;mg/kg bw every 3&nbsp;weeks in patients previously treated with ipilimumab</strong></p><p><strong>n=89</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA 2&nbsp;mg/kg bw every 3&nbsp;weeks in patients na&iuml;ve to treatment with ipilimumab</strong></p><p><strong>n=51</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Best objective response<sup>*</sup> by IRO<strong><sup>&dagger;</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ORR %, (95% CI)</p></td><td style="vertical-align:top"><p>26% (17, 36)</p></td><td style="vertical-align:top"><p>35% (22, 50)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>7%</p></td><td style="vertical-align:top"><p>12%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>19%</p></td><td style="vertical-align:top"><p>24%</p></td></tr><tr><td style="vertical-align:top"><p>Disease control rate %<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>48%</p></td><td style="vertical-align:top"><p>49%</p></td></tr><tr><td style="vertical-align:top"><p>Response duration<strong><sup>&sect;</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>30.5 (2.8+, 30.6+)</p></td><td style="vertical-align:top"><p>27.4 (1.6+, 31.8+)</p></td></tr><tr><td style="vertical-align:top"><p>% ongoing at 24 months<sup>&para;</sup></p></td><td style="vertical-align:top"><p>75%</p></td><td style="vertical-align:top"><p>71%</p></td></tr><tr><td style="vertical-align:top"><p>PFS</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>4.9 (2.8, 8.3)</p></td><td style="vertical-align:top"><p>4.7 (2.8, 13.8)</p></td></tr><tr><td style="vertical-align:top"><p>PFS rate at 12 months</p></td><td style="vertical-align:top"><p>34%</p></td><td style="vertical-align:top"><p>38%</p></td></tr><tr><td style="vertical-align:top"><p>OS</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>18.9 (11, not available)</p></td><td style="vertical-align:top"><p>28.0 (14, not available)</p></td></tr><tr><td style="vertical-align:top"><p>OS rate at 24 months</p></td><td style="vertical-align:top"><p>44%</p></td><td style="vertical-align:top"><p>56%</p></td></tr></tbody></table><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes patients without measurable disease at baseline by independent radiology</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; IRO = Integrated radiology and oncologist assessment using RECIST&nbsp;1.1</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on best response of stable disease or better</p><p><sup>&sect;</sup> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on patients with a confirmed response by independent review, starting from the date the response was first recorded; n=23 for patients previously treated with ipilimumab; n=18 for patients na&iuml;ve to treatment with ipilimumab</p><p><sup>&para;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Based on Kaplan‑Meier estimation</p><p>&nbsp;</p><p>Results for patients previously treated with ipilimumab (n=84) and na&iuml;ve to treatment with ipilimumab (n=52) who received 10&nbsp;mg/kg bw of KEYTRUDA every 3&nbsp;weeks were similar to those seen in patients who received 2&nbsp;mg/kg bw of KEYTRUDA every 3&nbsp;weeks.</p><p>&nbsp;</p><p><em>Sub‑population analyses</em></p><p>&nbsp;</p><p><u>BRAF mutation status in melanoma </u></p><p>A subgroup analysis was performed as part of the final analysis of KEYNOTE‑002 in patients who were BRAF wild type (n=414; 77%) or BRAF mutant with prior BRAF treatment (n=126; 23%) as summarised in Table 6.</p><p>&nbsp;</p><p><strong>Table&nbsp;6: Efficacy results by BRAF mutation status in KEYNOTE‑002</strong></p><p><strong><u>&nbsp;</u></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>BRAF wild type</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>BRAF mutant</strong> <strong>with prior BRAF treatment</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Endpoint</p></td><td style="vertical-align:top"><p><strong>KEYTRUDA</strong> <strong>2&nbsp;mg/kg bw every 3&nbsp;weeks (n=136)</strong></p></td><td style="vertical-align:top"><p><strong>Chemotherapy</strong></p><p><strong>(n=137)</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA</strong> <strong>2&nbsp;mg/kg bw every 3&nbsp;weeks (n=44)</strong></p></td><td style="vertical-align:top"><p><strong>Chemotherapy (n=42)</strong></p></td></tr><tr><td style="vertical-align:top"><p>PFS Hazard ratio<sup>*</sup> (95% CI)<sup> </sup></p></td><td style="vertical-align:top"><p>0.50&nbsp;(0.39, 0.66)</p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>0.79&nbsp;(0.50, 1.25)</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>OS Hazard ratio<sup>*</sup> (95% CI)<sup> </sup></p></td><td style="vertical-align:top"><p>0.78&nbsp;(0.58, 1.04)</p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>1.07&nbsp;(0.64, 1.78)</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>ORR %</p></td><td style="vertical-align:top"><p>26%</p></td><td style="vertical-align:top"><p>6%</p></td><td style="vertical-align:top"><p>9%</p></td><td style="vertical-align:top"><p>0%</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp; <sup> </sup>Hazard ratio (KEYTRUDA compared to chemotherapy) based on the stratified Cox proportional hazard model</p><p>&nbsp;</p></td></tr></tbody></table><p>A subgroup analysis was performed as part of the final analysis of KEYNOTE‑006 in patients who were BRAF wild type (n=525; 63%), BRAF mutant without prior BRAF treatment (n=163; 20%) and BRAF mutant with prior BRAF treatment (n=139; 17%) as summarised in Table 7.</p><p>&nbsp;</p><p><strong>Table&nbsp;7: Efficacy results by BRAF mutation status in KEYNOTE‑006</strong></p><p><strong><u>&nbsp;</u></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:671px"><tbody><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>BRAF wild type</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>BRAF mutant</strong> <strong>without prior BRAF treatment</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>BRAF mutant</strong> <strong>with prior BRAF treatment</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Endpoint</p></td><td style="vertical-align:top"><p><strong>KEYTRUDA 10&nbsp;mg/kg bw every 2 or 3&nbsp;weeks (pooled)</strong></p></td><td style="vertical-align:top"><p><strong>Ipilimumab (n=170)</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA 10&nbsp;mg/kg bw every 2 or 3&nbsp;weeks (pooled)</strong></p></td><td style="vertical-align:top"><p><strong>Ipilimumab (n=55)</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA 10&nbsp;mg/kg bw every 2 or 3&nbsp;weeks (pooled)</strong></p></td><td style="vertical-align:top"><p><strong>Ipilimumab (n=52)</strong></p></td></tr><tr><td style="vertical-align:top"><p>PFS Hazard ratio<sup>*</sup> (95% CI)<sup> </sup></p></td><td style="vertical-align:top"><p>0.61&nbsp;(0.49, 0.76)</p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>0.52&nbsp;(0.35, 0.78)</p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>0.76&nbsp;(0.51, 1.14)</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>OS Hazard ratio<sup>*</sup> (95% CI)<sup> </sup></p></td><td style="vertical-align:top"><p>0.68&nbsp;(0.52, 0.88)</p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>0.70&nbsp;(0.40, 1.22)</p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>0.66&nbsp;(0.41, 1.04)</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>ORR %</p></td><td style="vertical-align:top"><p>38%</p></td><td style="vertical-align:top"><p>14%</p></td><td style="vertical-align:top"><p>41%</p></td><td style="vertical-align:top"><p>15%</p></td><td style="vertical-align:top"><p>24%</p></td><td style="vertical-align:top"><p>10%</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp; Hazard ratio (KEYTRUDA compared to ipilimumab) based on the stratified Cox proportional hazard model</p><p>&nbsp;</p></td></tr></tbody></table><p><u>PD‑L1 status in melanoma</u></p><p>A subgroup analysis was performed as part of the final analysis of KEYNOTE‑002 in patients who were PD‑L1 positive (PD‑L1 expression in &ge;&nbsp;1% of tumour and tumour‑associated immune cells relative to all viable tumour cells &ndash; MEL score) vs. PD‑L1 negative. PD‑L1 expression was tested retrospectively by immunohistochemistry (IHC) assay with the 22C3 anti‑PD‑L1 antibody. Among patients who were evaluable for PD‑L1 expression (79%), 69% (n=294) were PD‑L1 positive and 31% (n=134) were PD‑L1 negative. Table 8 summarises efficacy results by PD‑L1 expression.</p><p>&nbsp;</p><p><strong>Table&nbsp;8: Efficacy results by PD‑L1 expression in KEYNOTE‑002</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:623px"><thead><tr><td style="vertical-align:top"><p>Endpoint</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA 2&nbsp;mg/kg bw every 3&nbsp;weeks</strong></p></td><td style="vertical-align:top"><p><strong>Chemotherapy </strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA 2&nbsp;mg/kg bw every 3&nbsp;weeks</strong></p></td><td style="vertical-align:top"><p><strong>Chemotherapy</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>PD‑L1 positive</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>PD‑L1 negative</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>PFS Hazard ratio<sup>*</sup></p><p>(95% CI)<sup> </sup></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.55 (0.40, 0.76)</p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>0.81 (0.50, 1.31)</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>OS Hazard ratio<sup>*</sup></p><p>(95% CI)<sup> </sup></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.90&nbsp;(0.63, 1.28)</p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>1.18&nbsp;(0.70, 1.99)</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>ORR %</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>25%</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>10%</p></td><td style="vertical-align:top"><p>8%</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>&nbsp;</sup></p></td><td colspan="5" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp; Hazard ratio (KEYTRUDA compared to chemotherapy) based on the stratified Cox proportional hazard model</p><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>A subgroup analysis was performed as part of the final analysis of KEYNOTE‑006 in patients who were PD‑L1 positive (n=671; 80%) vs. PD‑L1 negative (n=150; 18%). Among patients who were evaluable for PD‑L1 expression (98%), 82% were PD‑L1 positive and 18% were PD‑L1 negative. Table 9 summarises efficacy results by PD‑L1 expression.</p><p>&nbsp;</p><p><strong>Table&nbsp;9: Efficacy results by PD‑L1 expression in KEYNOTE‑006</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:634px"><thead><tr><td style="vertical-align:top"><p>Endpoint</p></td><td style="vertical-align:top"><p><strong>KEYTRUDA 10&nbsp;mg/kg bw every 2 or 3&nbsp;weeks (pooled) </strong></p></td><td style="vertical-align:top"><p><strong>Ipilimumab</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA 10&nbsp;mg/kg bw every 2 or 3&nbsp;weeks (pooled)</strong></p></td><td style="vertical-align:top"><p><strong>Ipilimumab</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>PD‑L1 positive</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>PD‑L1 negative</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>PFS Hazard ratio<sup>*</sup> (95% CI)<sup> </sup></p></td><td style="vertical-align:top"><p>0.53&nbsp;(0.44, 0.65)</p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>0.87&nbsp;(0.58, 1.30)</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>OS Hazard ratio<sup>*</sup> (95% CI)<sup> </sup></p></td><td style="vertical-align:top"><p>0.63&nbsp;(0.50, 0.80)</p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>0.76&nbsp;(0.48, 1.19)</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>ORR %</p></td><td style="vertical-align:top"><p>40%</p></td><td style="vertical-align:top"><p>14%</p></td><td style="vertical-align:top"><p>24%</p></td><td style="vertical-align:top"><p>13%</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp; Hazard ratio (KEYTRUDA compared to ipilimumab) based on the stratified Cox proportional hazard model</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Ocular melanoma</u></p><p>In 20 subjects with ocular melanoma included in KEYNOTE‑001, no objective responses were reported; stable disease was reported in 6&nbsp;patients.</p><p><em><u>&nbsp;</u></em></p><p><em><u>KEYNOTE‑716: Placebo‑controlled study for the adjuvant treatment of patients with resected Stage IIB or IIC melanoma</u></em></p><p>The efficacy of KEYTRUDA was evaluated in KEYNOTE‑716, a multicentre, randomised, double‑blind, placebo‑controlled study in patients with resected Stage IIB or IIC melanoma. A total of 976&nbsp;patients were randomised (1:1) to receive KEYTRUDA 200&nbsp;mg every three weeks (or the paediatric [12 to 17&nbsp;years old] dose of 2&nbsp;mg/kg intravenously [up to a maximum of 200&nbsp;mg] every three weeks) (n=487) or placebo (n=489), for up to one year or until disease recurrence or until unacceptable toxicity. Randomisation was stratified by American Joint Committee on Cancer (AJCC) 8<sup>th</sup> edition T stage. Patients with active autoimmune disease or a medical condition that required immunosuppression or mucosal or ocular melanoma were ineligible. Patients who received prior therapy for melanoma other than surgery were ineligible. Patients underwent imaging every six months from randomisation through the 4<sup>th</sup> year, and then once in year 5 from randomisation or until recurrence, whichever came first.</p><p>&nbsp;</p><p>Among the 976&nbsp;patients, the baseline characteristics were: median age of 61&nbsp;years (range 16-87; 39% age 65 or older; 2 adolescent patients [one per treatment arm]); 60%&nbsp;male; and ECOG PS of 0 (93%) and 1 (7%). Sixty-four percent had Stage IIB and 35% had Stage IIC.</p><p>&nbsp;</p><p>The primary efficacy outcome measure was investigator‑assessed recurrence‑free survival (RFS) in the whole population, where RFS was defined as the time between the date of randomisation and the date of first recurrence (local, regional, or distant metastasis) or death, whichever occurred first. The secondary outcome measures were distant metastasis‑free survival (DMFS) and OS in the whole population. OS was not formally assessed at the time of this analysis. The study initially demonstrated a statistically significant improvement in RFS (HR 0.65; 95% CI 0.46, 0.92; p-Value = 0.00658) for patients randomised to the KEYTRUDA arm compared with placebo at its pre-specified interim analysis. Results reported from the pre-specified final analysis for RFS at a median follow-up of 20.5&nbsp;months are summarised in Table&nbsp;10 and Figure&nbsp;4. Updated RFS results at a median follow-up of 26.9&nbsp;months were consistent with the final analysis for RFS for patients randomised to the KEYTRUDA arm compared with placebo (HR 0.64; 95% CI 0.50, 0.84). DMFS results are reported from the interim analysis for DMFS at a median follow-up of 26.9&nbsp;months in Table&nbsp;10 and Figure&nbsp;5.</p><p>&nbsp;</p><p><strong>Table</strong>&nbsp;<strong>10: Efficacy results in KEYNOTE‑716</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:466px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA 200&nbsp;mg every 3&nbsp;weeks</strong></p><p><strong>n=487</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>n=489</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>RFS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>72 (15%)</p></td><td style="vertical-align:top"><p>115 (24%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>NR (NR, NR)</p></td><td style="vertical-align:top"><p>NR (29.9, NR)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>* </sup>(95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.61 (0.45, 0.82)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value (stratified log-rank)<sup>&dagger;</sup></p></td><td colspan="2" style="vertical-align:bottom"><p>0.00046</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>DMFS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>63 (13%)</p></td><td style="vertical-align:top"><p>95 (19%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>NR (NR, NR)</p></td><td style="vertical-align:top"><p>NR (NR, NR)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>*</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.64 (0.47, 0.88)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup> </sup>(stratified log‑rank)</p></td><td colspan="2" style="vertical-align:bottom"><p>0.00292</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on the stratified Cox proportional hazard model</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nominal p‑Value based on log-rank test stratified by American Joint Committee on Cancer (AJCC) 8th edition T stage.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NR = not reached</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><strong>Figure</strong>&nbsp;<strong>4: Kaplan‑Meier curve for recurrence‑free survival </strong><strong>by treatment arm </strong><strong>in KEYNOTE‑716 </strong><strong>(intent to treat population)</strong></p><p>&nbsp;</p><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-family:"Arial",sans-serif'>Recurrence-Free
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="45" height="240" alt="Text Box: Recurrence-Free Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image004.png" /></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Number at Risk</strong></p><p>KEYTRUDA</p><p>Placebo</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp; <u>RFS rate at 18 months&nbsp;&nbsp;&nbsp; HR (95% CI)</u></strong></p><p><strong>KEYTRUDA &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;86%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.61 (0.45, 0.82)</strong></p><p><strong>Placebo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 77%</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>&nbsp;</u></em></p><p><strong>Figure&nbsp;5: Kaplan‑Meier curve for distant metastasis‑free survival </strong><strong>by treatment arm </strong><strong>in KEYNOTE‑716 </strong><strong>(intent to treat population)</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-family:"Arial",sans-serif'>Distant
    Metastases -Free Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="79" height="286" alt="Text Box: Distant Metastases -Free Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image006.png" /></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Number at Risk</strong></p><p>KEYTRUDA</p><p>Placebo</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp; <u>DMFS rate at 18 months&nbsp;&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp;&nbsp; p-value</u></strong></p><p><strong>KEYTRUDA &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;93%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.64 (0.47, 0.88)&nbsp;&nbsp; 0.00292</strong></p><p><strong>Placebo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 87%</strong></p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>&nbsp;</u></em></p><p><em><u>KEYNOTE‑054: Placebo‑controlled study for the adjuvant treatment of patients with completely resected Stage III melanoma</u></em></p><p>The efficacy of KEYTRUDA was evaluated in KEYNOTE‑054, a multicentre, randomised, double‑blind, placebo‑controlled study in patients with completely resected stage IIIA (&gt;&nbsp;1&nbsp;mm lymph node metastasis), IIIB or IIIC melanoma. A total of 1,019&nbsp;adult patients were randomised (1:1) to receive KEYTRUDA 200&nbsp;mg every three weeks (n=514) or placebo (n=505), for up to one year until disease recurrence or until unacceptable toxicity. Randomisation was stratified by AJCC 7<sup>th</sup> edition stage (IIIA vs. IIIB vs. IIIC 1‑3&nbsp;positive lymph nodes vs. IIIC &ge;&nbsp;4&nbsp;positive lymph nodes) and geographic region (North America, European countries, Australia and other countries as designated). Patients must have undergone lymph node dissection, and if indicated, radiotherapy within 13&nbsp;weeks prior to starting treatment. Patients with active autoimmune disease or a medical condition that required immunosuppression or mucosal or ocular melanoma were ineligible. Patients who received prior therapy for melanoma other than surgery or interferon for thick primary melanomas without evidence of lymph node involvement were ineligible. Patients underwent imaging every 12&nbsp;weeks after the first dose of KEYTRUDA for the first two years, then every 6&nbsp;months from year&nbsp;3 to 5, and then annually.</p><p>&nbsp;</p><p>Among the 1,019&nbsp;patients, the baseline characteristics were: median age of 54&nbsp;years (25% age 65 or older); 62%&nbsp;male; and ECOG PS of 0 (94%) and 1 (6%). Sixteen percent had stage IIIA; 46% had stage IIIB; 18% had stage IIIC (1‑3&nbsp;positive lymph nodes) and 20% had stage IIIC (&ge;&nbsp;4&nbsp;positive lymph nodes); 50% were BRAF V600 mutation positive and 44% were BRAF wild‑type. PD‑L1 expression was tested retrospectively by IHC assay with the 22C3 anti‑PD‑L1 antibody; 84% of patients had PD‑L1‑positive melanoma (PD‑L1 expression in &ge;&nbsp;1% of tumour and tumour‑associated immune cells relative to all viable tumour cells). The same scoring system was used for metastatic melanoma (MEL score).</p><p>&nbsp;</p><p>The primary efficacy outcome measures were investigator‑assessed RFS in the whole population and in the population with PD‑L1 positive tumours, where RFS was defined as the time between the date of randomisation and the date of first recurrence (local, regional, or distant metastasis) or death, whichever occurs first. The secondary outcome measures were DMFS and OS in the whole population and in the population with PD-L1 positive tumours. OS was not formally assessed at the time of these analyses. The study initially demonstrated a statistically significant improvement in RFS (HR 0.57; 98.4% CI 0.43, 0.74; p‑Value&nbsp;&lt;&nbsp;0.0001) for patients randomised to the KEYTRUDA arm compared with placebo at its pre‑specified interim analysis. Updated efficacy results with a median follow-up time of 45.5&nbsp;months are summarised in Table&nbsp;11 and Figures&nbsp;6 and 7.</p><p>&nbsp;</p><p><strong>Table&nbsp;11: Efficacy results in KEYNOTE‑054</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:410px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA</strong></p><p><strong>200&nbsp;mg every 3&nbsp;weeks</strong></p><p><strong>n=514</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>n=505</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>RFS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>203 (40%)</p></td><td style="vertical-align:top"><p>288 (57%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>21.4 (16.3, 27.0)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>*</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.59 (0.49, 0.70)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>DMFS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>173 (34%)</p></td><td style="vertical-align:top"><p>245 (49%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>40.0 (27.7, NR)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>*</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.60 (0.49, 0.73)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup> </sup>(stratified log‑rank)</p></td><td colspan="2" style="vertical-align:bottom"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on the stratified Cox proportional hazard model</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NR = not reached</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Figure&nbsp;6: Kaplan‑Meier curve for recurrence‑free survival </strong><strong>by treatment arm </strong><strong>in KEYNOTE‑054 </strong><strong>(intent to treat population)</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Placebo:</p><p>&nbsp;</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>lizumab:</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Recurrence-Free Survival (%)</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>RFS rate at 36 months&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HR (95% CI) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></strong></p><p><strong>KEYTRUDA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;64%&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.59 (0.49, 0.70) &nbsp;&nbsp;</strong></p><p><strong>Placebo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;44%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Figure&nbsp;7: Kaplan‑Meier curve for distant metastasis‑free survival </strong><strong>by treatment arm </strong><strong>in KEYNOTE‑054 </strong><strong>(intent to treat population)</strong></p><p>&nbsp;</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Placebo:</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA:</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Distant Metastasis-Free Survival (%)</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;<u>DMFS rate at 36 months&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HR (95% CI) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;p-value</u></strong></p><p><strong>KEYTRUDA &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;68%&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.60 (0.49, 0.73) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&lt;0.0001</strong></p><p><strong>Placebo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;52%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>RFS and DMFS benefit was consistently demonstrated across subgroups, including tumour PD-L1 expression, BRAF mutation status, and stage of disease (using AJCC 7<sup>th</sup> edition). These results were consistent when reclassified in a post-hoc analysis according to the current AJCC 8<sup>th</sup> edition staging system.</p><p>&nbsp;</p><p><em><u>NSCLC</u></em></p><p><em><u>KEYNOTE‑024: Controlled study of NSCLC patients </u></em><em><u>na&iuml;ve to treatment</u></em></p><p>The safety and efficacy of KEYTRUDA were investigated in KEYNOTE‑024, a multicentre, open‑label, controlled study for the treatment of previously untreated metastatic NSCLC. Patients had PD‑L1 expression with a &sup3;&nbsp;50% TPS based on the PD‑L1 IHC 22C3 pharmDx<sup>TM</sup> Kit. Patients were randomised (1:1) to receive KEYTRUDA at a dose of 200&nbsp;mg every 3&nbsp;weeks (n=154) or investigator&rsquo;s choice platinum‑containing chemotherapy (n=151; including pemetrexed+carboplatin, pemetrexed+cisplatin, gemcitabine+cisplatin, gemcitabine+carboplatin, or paclitaxel+carboplatin. Patients with non<strong>-</strong>squamous NSCLC could receive pemetrexed maintenance.). Patients were treated with KEYTRUDA until unacceptable toxicity or disease progression. Treatment could continue beyond disease progression if the patient was clinically stable and was considered to be deriving clinical benefit by the investigator. Patients without disease progression could be treated for up to 24&nbsp;months. The study excluded patients with EGFR or ALK genomic tumour aberrations; autoimmune disease that required systemic therapy within 2&nbsp;years of treatment; a medical condition that required immunosuppression; or who had received more than 30&nbsp;Gy of thoracic radiation within the prior 26&nbsp;weeks. Assessment of tumour status was performed every 9&nbsp;weeks. Patients on chemotherapy who experienced independently‑verified progression of disease were able to crossover and receive KEYTRUDA.</p><p>&nbsp;</p><p>Among the 305&nbsp;patients in KEYNOTE‑024, baseline characteristics were: median age 65&nbsp;years (54% age 65 or older); 61%&nbsp;male; 82%&nbsp;White, 15%&nbsp;Asian; and ECOG performance status 0 and 1 in 35% and 65%, respectively. Disease characteristics were squamous (18%) and non‑squamous (82%); M1 (99%); and brain metastases (9%).</p><p>&nbsp;</p><p>The primary efficacy outcome measure was PFS as assessed by blinded independent central review (BICR) using RECIST 1.1. Secondary efficacy outcome measures were OS and ORR (as assessed by BICR using RECIST 1.1). Table&nbsp;12 summarises key efficacy measures for the entire intent to treat (ITT) population. PFS and ORR results are reported from an interim analysis at a median follow‑up of 11&nbsp;months. OS results are reported from the final analysis at a median follow‑up of 25&nbsp;months.</p><p><strong>&nbsp;</strong></p><p><strong>Table&nbsp;12: Efficacy results in KEYNOTE‑024</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:455px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA 200&nbsp;mg every 3&nbsp;weeks</strong></p><p><strong>n=154</strong></p></td><td style="vertical-align:top"><p><strong>Chemotherapy</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>n=151</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>73 (47%)</p></td><td style="vertical-align:top"><p>116 (77%)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>*</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.50 (0.37, 0.68)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>10.3 (6.7, NA)</p></td><td style="vertical-align:top"><p>6.0 (4.2, 6.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>OS</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>73 (47%)</p></td><td style="vertical-align:top"><p>96 (64%)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>*</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.63 (0.47, 0.86)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.002</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>30.0</p><p>(18.3, NA)</p></td><td style="vertical-align:top"><p>14.2</p><p>(9.8, 19.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective response rate</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ORR % (95% CI)</p></td><td style="vertical-align:top"><p>45% (37, 53)</p></td><td style="vertical-align:top"><p>28% (21, 36)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>1%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>41%</p></td><td style="vertical-align:top"><p>27%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response duration</strong><strong><sup>&Dagger;</sup></strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>Not reached (1.9+, 14.5+)</p></td><td style="vertical-align:top"><p>6.3</p><p>(2.1+, 12.6+)</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;&nbsp;6 months</p></td><td style="vertical-align:top"><p>88%<strong><sup>&sect;</sup></strong></p></td><td style="vertical-align:top"><p>59%<sup>&para;</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hazard ratio (KEYTRUDA compared to chemotherapy) based on the stratified Cox proportional hazard model</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on stratified log‑rank test</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on patients with a best objective response as confirmed complete or partial response</p><p><sup>&sect;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan‑Meier estimates; includes 43 patients with responses of 6 months or longer</p><p><sup>&para;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan‑Meier estimates; includes 16 patients with responses of 6 months or longer</p><p>NA = not available</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure&nbsp;8: Kaplan‑Meier curve for progression‑free survival by treatment arm in </strong></p><p><strong>KEYNOTE‑024 (intent to treat population)</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Figure&nbsp;9: Kaplan‑Meier curve for overall survival by treatment arm in </strong></p><p><strong>KEYNOTE‑024 (intent to treat population)</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>In a subgroup analysis, a reduced survival benefit of KEYTRUDA compared to chemotherapy was observed in the small number of patients who were never‑smokers; however, due to the small number of patients, no definitive conclusions can be drawn from these data.</p><p>&nbsp;</p><p><em><u>KEYNOTE-042: Controlled study of NSCLC patients </u></em><em><u>na&iuml;ve to treatment</u></em></p><p>The safety and efficacy of KEYTRUDA were also investigated in KEYNOTE‑042, a multicentre, controlled study for the treatment of previously untreated locally advanced or metastatic NSCLC. The study design was similar to that of KEYNOTE‑024, except that patients had PD<strong>-</strong>L1 expression with a &sup3;&nbsp;1% TPS based on the PD<strong>-</strong>L1 IHC 22C3 pharmDx<sup>TM</sup> Kit. Patients were randomised (1:1) to receive KEYTRUDA at a dose of 200&nbsp;mg every 3&nbsp;weeks (n=637) or investigator&rsquo;s choice platinum<strong>-</strong>containing chemotherapy (n=637; including pemetrexed+carboplatin or paclitaxel+carboplatin. Patients with non<strong>-</strong>squamous NSCLC could receive pemetrexed maintenance.). Assessment of tumour status was performed every 9&nbsp;weeks for the first 45&nbsp;weeks, and every 12&nbsp;weeks thereafter.</p><p>&nbsp;</p><p>Among the 1,274&nbsp;patients in KEYNOTE‑042, 599 (47%) had tumours that expressed PD<strong>-</strong>L1 with TPS &ge;&nbsp;50% based on the PD<strong>-</strong>L1 IHC 22C3 pharmDx<sup>TM</sup> Kit. The baseline characteristics of these 599&nbsp;patients included: median age 63&nbsp;years (45% age 65 or older); 69%&nbsp;male; 63%&nbsp;White and 32%&nbsp;Asian; 17% Hispanic or Latino; and ECOG performance status 0 and 1 in 31% and 69%, respectively. Disease characteristics were squamous (37%) and non<strong>-</strong>squamous (63%); stage IIIA (0.8%); stage IIIB (9%); stage IV (90%); and treated brain metastases (6%).</p><p>&nbsp;</p><p>The primary efficacy outcome measure was OS. Secondary efficacy outcome measures were PFS and ORR (as assessed by BICR using RECIST 1.1). The study demonstrated a statistically significant improvement in OS for patients whose tumours expressed PD<strong>-</strong>L1 TPS &ge;&nbsp;1% randomised to KEYTRUDA monotherapy compared to chemotherapy (HR 0.82; 95% CI 0.71, 0.93 at the final analysis) and in patients whose tumours expressed PD<strong>-</strong>L1 TPS &ge;&nbsp;50% randomised to KEYTRUDA monotherapy compared to chemotherapy. Table&nbsp;13 summarises key efficacy measures for the TPS &sup3;&nbsp;50% population at the final analysis performed at a median follow<strong>-</strong>up of 15.4&nbsp;months. The Kaplan<strong>-</strong>Meier curve for OS for the TPS &ge;&nbsp;50% population based on the final analysis is shown in Figure&nbsp;10.</p><p>&nbsp;</p><p><strong>Table&nbsp;13: Efficacy results </strong><strong>(PD-L1 TPS </strong><strong>&sup3;</strong><strong>&nbsp;50%) </strong><strong>in KEYNOTE‑042</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:455px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA</strong> <strong>200&nbsp;mg every 3&nbsp;weeks</strong></p><p><strong>n=299</strong></p></td><td style="vertical-align:top"><p><strong>Chemotherapy</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>n=300</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>OS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>180 (60%)</p></td><td style="vertical-align:top"><p>220 (73%)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>*</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.70 (0.58, 0.86)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.0003</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>20.0 (15.9, 24.2)</p></td><td style="vertical-align:top"><p>12.2 (10.4, 14.6)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>PFS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>238 (80%)</p></td><td style="vertical-align:top"><p>250 (83%)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>*</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.84 (0.70, 1.01)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>6.5 (5.9, 8.5)</p></td><td style="vertical-align:top"><p>6.4 (6.2, 7.2)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Objective response rate</strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR % (95% CI)</p></td><td style="vertical-align:top"><p>39% (34, 45)</p></td><td style="vertical-align:top"><p>32% (27, 38)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>0.3%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>38%</p></td><td style="vertical-align:top"><p>32%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Response duration</strong><strong><sup>&Dagger;</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>22.0</p><p>(2.1+, 36.5+)</p></td><td style="vertical-align:top"><p>10.8</p><p>(1.8+, 30.4+)</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;&nbsp;18 months</p></td><td style="vertical-align:top"><p>57%</p></td><td style="vertical-align:top"><p>34%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hazard ratio (KEYTRUDA compared to chemotherapy) based on the stratified Cox proportional hazard model</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on stratified log‑rank test</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on patients with a best objective response as confirmed complete or partial response</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure&nbsp;10: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE‑042 (patients with PD-L1 expression TPS&nbsp;&ge;&nbsp;50%, intent to treat population)</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>The results of a post-hoc exploratory subgroup analysis indicated a trend towards reduced survival benefit of KEYTRUDA compared to chemotherapy, during both the first 4&nbsp;months and throughout the entire duration of treatment, in patients who were never-smokers. However, due to the exploratory nature of this subgroup analysis, no definitive conclusions can be drawn.</p><p><em><u>&nbsp;</u></em></p><p><em><u>KEYNOTE‑189: Controlled study of combination therapy in non‑squamous NSCLC patients na&iuml;ve to treatment</u></em></p><p>The efficacy of KEYTRUDA in combination with pemetrexed and platinum chemotherapy was investigated in a multicentre, randomised, active‑controlled, double‑blind study, KEYNOTE‑189. Key eligibility criteria were metastatic non‑squamous NSCLC, no prior systemic treatment for metastatic NSCLC, and no EGFR or ALK genomic tumour aberrations. Patients with autoimmune disease that required systemic therapy within 2&nbsp;years of treatment; a medical condition that required immunosuppression; or who had received more than 30&nbsp;Gy of thoracic radiation within the prior 26&nbsp;weeks were ineligible. Patients were randomised (2:1) to receive one of the following regimens:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; KEYTRUDA 200&nbsp;mg with pemetrexed 500&nbsp;mg/m<sup>2</sup> and investigator&rsquo;s choice of cisplatin 75&nbsp;mg/m<sup>2 </sup>or carboplatin AUC 5&nbsp;mg/mL/min intravenously every 3&nbsp;weeks for 4&nbsp;cycles followed by KEYTRUDA 200&nbsp;mg and pemetrexed 500&nbsp;mg/m<sup>2 </sup>intravenously every 3&nbsp;weeks (n=410)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Placebo with pemetrexed 500&nbsp;mg/m<sup>2</sup> and investigator&rsquo;s choice of cisplatin 75&nbsp;mg/m<sup>2 </sup>or carboplatin AUC 5&nbsp;mg/mL/min intravenously every 3&nbsp;weeks for 4&nbsp;cycles followed by placebo and pemetrexed 500&nbsp;mg/m<sup>2 </sup>intravenously every 3&nbsp;weeks (n=206)</p><p>&nbsp;</p><p>Treatment with KEYTRUDA continued until RECIST&nbsp;1.1‑defined progression of disease as determined by the investigator, unacceptable toxicity, or a maximum of 24&nbsp;months. Administration of KEYTRUDA was permitted beyond RECIST‑defined disease progression by BICR or beyond discontinuation of pemetrexed if the patient was clinically stable and deriving clinical benefit as determined by the investigator. For patients who completed 24&nbsp;months of therapy or had a complete response, treatment with KEYTRUDA could be reinitiated for disease progression and administered for up to 1 additional year. Assessment of tumour status was performed at Week&nbsp;6 and Week&nbsp;12, followed by every 9&nbsp;weeks thereafter. Patients receiving placebo plus chemotherapy who experienced independently‑verified progression of disease were offered KEYTRUDA as monotherapy.</p><p>&nbsp;</p><p>Among the 616&nbsp;patients in KEYNOTE‑189, baseline characteristics were: median age of 64&nbsp;years (49% age 65 or older); 59%&nbsp;male; 94%&nbsp;White and 3%&nbsp;Asian; 43% and 56% ECOG performance status of 0 or 1 respectively; 31% PD‑L1 negative (TPS &lt;&nbsp;1%); and 18% with treated or untreated brain metastases at baseline.</p><p>&nbsp;</p><p>The primary efficacy outcome measures were OS and PFS (as assessed by BICR using RECIST 1.1). Secondary efficacy outcome measures were ORR and response duration, as assessed by BICR using RECIST 1.1. Table&nbsp;14 summarises key efficacy measures and Figures&nbsp;11 and 12 show the Kaplan‑Meier curves for OS and PFS based on the final analysis with a median follow-up of 18.8&nbsp;months.</p><p>&nbsp;</p><p><strong>Table&nbsp;14: Efficacy results in KEYNOTE‑189</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:472px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA + Pemetrexed + Platinum Chemotherapy</strong></p><p><strong>n=410</strong></p></td><td style="vertical-align:top"><p><strong>Placebo + Pemetrexed + Platinum Chemotherapy</strong></p><p><strong>n=206</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>OS</strong><strong><sup>*</sup></strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>258 (63%)</p></td><td style="vertical-align:top"><p>163 (79%)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.56 (0.46, 0.69)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.00001</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>22.0</p><p>(19.5, 24.5)</p></td><td style="vertical-align:top"><p>10.6</p><p>(8.7, 13.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>337 (82%)</p></td><td style="vertical-align:top"><p>197 (96%)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.49 (0.41, 0.59)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.00001</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>9.0 (8.1, 10.4)</p></td><td style="vertical-align:top"><p>4.9 (4.7, 5.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective response rate</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR<sup>&sect;</sup> % (95% CI)</p></td><td style="vertical-align:top"><p>48% (43, 53)</p></td><td style="vertical-align:top"><p>20% (15, 26)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>1.2%</p></td><td style="vertical-align:top"><p>0.5%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>47%</p></td><td style="vertical-align:top"><p>19%</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&para;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response duration</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>12.5</p><p>(1.1+, 34.9+)</p></td><td style="vertical-align:top"><p>7.1</p><p>(2.4, 27.8+)</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;&nbsp;12&nbsp;months<sup>#</sup></p></td><td style="vertical-align:top"><p>53%</p></td><td style="vertical-align:top"><p>27%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*</sup><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>A total of 113&nbsp;patients (57%) who discontinued study treatment in the placebo plus chemotherapy arm crossed over to receive monotherapy KEYTRUDA or received a checkpoint inhibitor as subsequent therapy</p><p><sup>&dagger;</sup><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Based on the stratified Cox proportional hazard model</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on stratified log‑rank test<sup> </sup></p><p><sup>&sect;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on patients with a best objective response as confirmed complete or partial response</p><p><sup>&para;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Miettinen and Nurminen method stratified by PD‑L1 status, platinum chemotherapy and smoking status</p><p><sup>#</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan‑Meier estimation</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure&nbsp;11: Kaplan‑Meier curve for overall survival by treatment arm in</strong></p><p><strong>KEYNOTE‑189 (intent to treat population)</strong></p><p>&nbsp;</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p><p>Control:</p><p>&nbsp;</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Overall Survival (%)</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA:</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp; <u>&nbsp;OS rate at 12 months&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OS rate at 24 months&nbsp;&nbsp;&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;p-value</u></strong></p><p><strong>KEYTRUDA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;70%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;46%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;0.56 (0.46, 0.69) &lt; 0.00001</strong></p><p><strong>Control&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;48%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27%</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong>Figure&nbsp;12: Kaplan‑Meier curve for progression‑free survival by treatment arm in</strong></p><p><strong>KEYNOTE‑189 (intent to treat population)</strong></p><p>&nbsp;</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp; <u>&nbsp;PFS rate at 12 months&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PFS rate at 24 months&nbsp;&nbsp;&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p-value</u></strong></p><p><strong>KEYTRUDA &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;39%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;0.49 (0.41, 0.59) &lt; 0.00001</strong></p><p><strong>Control&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3%</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p><p>Control:</p><p>&nbsp;</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Progression-Free Survival (%)</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA :</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>An analysis was performed in KEYNOTE‑189 in patients who had PD‑L1 TPS &lt;&nbsp;1% [KEYTRUDA combination: n=127 (31%) vs. chemotherapy: n=63 (31%)], TPS 1‑49% [KEYTRUDA combination: n=128 (31%) vs. chemotherapy: n=58 (28%)] or &ge;&nbsp;50% [KEYTRUDA combination: n=132 (32%) vs. chemotherapy: n=70 (34%)] (see Table&nbsp;15).</p><p>&nbsp;</p><p><strong>Table&nbsp;15: Efficacy results by PD‑L1 expression in KEYNOTE‑189</strong><sup>*</sup></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:578px"><thead><tr><td style="vertical-align:top"><p>Endpoint</p></td><td style="vertical-align:top"><p><strong>KEYTRUDA combination therapy</strong></p></td><td style="vertical-align:top"><p><strong>Chemotherapy</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA combination therapy</strong></p></td><td style="vertical-align:top"><p><strong>Chemotherapy</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA combination therapy</strong></p></td><td style="vertical-align:top"><p><strong>Chemotherapy</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>TPS &lt; 1%</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>TPS 1 to 49%</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>TPS &ge; 50%</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>OS Hazard ratio<sup>&dagger;</sup></p><p>(95% CI)<sup> </sup></p></td><td colspan="2"><p>0.51 (0.36, 0.71)</p></td><td colspan="2"><p>0.66 (0.46, 0.96)</p></td><td colspan="2"><p>0.59 (0.40, 0.86)</p></td></tr><tr><td style="vertical-align:top"><p>PFS Hazard ratio<sup>&dagger;</sup></p><p>(95% CI)<sup> </sup></p></td><td colspan="2"><p>0.67 (0.49, 0.93)</p></td><td colspan="2"><p>0.53 (0.38, 0.74)</p></td><td colspan="2"><p>0.35 (0.25, 0.49)</p></td></tr><tr><td style="vertical-align:top"><p>ORR %</p></td><td style="vertical-align:top"><p>33%</p></td><td style="vertical-align:top"><p>14%</p></td><td style="vertical-align:top"><p>50%</p></td><td style="vertical-align:top"><p>21%</p></td><td style="vertical-align:top"><p>62%</p></td><td style="vertical-align:top"><p>26%</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp; Based on final analysis</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp; Hazard ratio (KEYTRUDA combination therapy compared to chemotherapy) based on the stratified Cox proportional hazard model</p></td></tr></tbody></table><p>&nbsp;</p><p>At final analysis, a total of 57 NSCLC patients aged &ge;&nbsp;75&nbsp;years were enrolled in study KEYNOTE‑189 (35 in the KEYTRUDA combination and 22 in the control). A HR=1.54 [95% CI 0.76, 3.14] in OS and HR=1.12 [95% CI 0.56, 2.22] in PFS for KEYTRUDA combination vs. chemotherapy was reported within this study subgroup. Data about efficacy of KEYTRUDA in combination with platinum chemotherapy are limited in this patient population.</p><p>&nbsp;</p><p><em><u>KEYNOTE‑407: Controlled study of combination therapy in squamous NSCLC patients </u></em><em><u>na&iuml;ve to treatment</u></em></p><p>The efficacy of KEYTRUDA in combination with carboplatin and either paclitaxel or nab‑paclitaxel was investigated in Study KEYNOTE‑407, a randomised, double‑blind, multicentre, placebo‑controlled study. The key eligibility criteria for this study were metastatic squamous NSCLC, regardless of tumour PD‑L1 expression status, and no prior systemic treatment for metastatic disease. Patients with autoimmune disease that required systemic therapy within 2&nbsp;years of treatment; a medical condition that required immunosuppression; or who had received more than 30&nbsp;Gy of thoracic radiation within the prior 26&nbsp;weeks were ineligible. Randomisation was stratified by tumour PD‑L1 expression (TPS &lt;&nbsp;1% [negative] vs. TPS &ge;&nbsp;1%), investigator&rsquo;s choice of paclitaxel or nab‑paclitaxel, and geographic region (East Asia vs. non‑East Asia). Patients were randomised (1:1) to one of the following treatment arms via intravenous infusion:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; KEYTRUDA 200&nbsp;mg and carboplatin AUC 6&nbsp;mg/mL/min on Day&nbsp;1 of each 21‑day cycle for 4&nbsp;cycles, and paclitaxel 200&nbsp;mg/m<sup>2</sup> on Day&nbsp;1 of each 21‑day cycle for 4&nbsp;cycles or nab‑paclitaxel 100&nbsp;mg/m<sup>2</sup> on Days&nbsp;1, 8 and 15 of each 21‑day cycle for 4&nbsp;cycles, followed by KEYTRUDA 200&nbsp;mg every 3&nbsp;weeks. KEYTRUDA was administered prior to chemotherapy on Day&nbsp;1.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Placebo and carboplatin AUC 6&nbsp;mg/mL/min on Day&nbsp;1 of each 21‑day cycle for 4&nbsp;cycles and paclitaxel 200&nbsp;mg/m<sup>2</sup> on Day&nbsp;1 of each 21‑day cycle for 4&nbsp;cycles or nab‑paclitaxel 100&nbsp;mg/m<sup>2</sup> on Days&nbsp;1, 8 and 15 of each 21‑day cycle for 4&nbsp;cycles, followed by placebo every 3&nbsp;weeks.</p><p>&nbsp;</p><p>Treatment with KEYTRUDA or placebo continued until RECIST&nbsp;1.1‑defined progression of disease as determined by BICR, unacceptable toxicity, or a maximum of 24&nbsp;months. Administration of KEYTRUDA was permitted beyond RECIST‑defined disease progression if the patient was clinically stable and deriving clinical benefit as determined by the investigator.</p><p>&nbsp;</p><p>Patients in the placebo arm were offered KEYTRUDA as a single agent at the time of disease progression.</p><p>&nbsp;</p><p>Assessment of tumour status was performed every 6&nbsp;weeks through Week&nbsp;18, every 9&nbsp;weeks through Week&nbsp;45 and every 12&nbsp;weeks thereafter.</p><p>&nbsp;</p><p>A total of 559&nbsp;patients were randomised. The study population characteristics were: median age of 65&nbsp;years (range: 29 to 88); 55% age 65 or older; 81%&nbsp;male; 77%&nbsp;White; ECOG performance status of 0 (29%) and 1 (71%); and 8% with treated brain metastases at baseline. Thirty‑five percent had tumour PD‑L1 expression TPS &lt;&nbsp;1% [negative]; 19% were East Asian; and 60% received paclitaxel.</p><p>&nbsp;</p><p>The primary efficacy outcome measures were OS and PFS (as assessed by BICR using RECIST 1.1). Secondary efficacy outcome measures were ORR and response duration, as assessed by BICR using RECIST 1.1. Table&nbsp;16 summarises key efficacy measures and Figures&nbsp;13 and 14 show the Kaplan‑Meier curves for OS and PFS based on the final analysis with a median follow-up of 14.3&nbsp;months.</p><p>&nbsp;</p><p><strong>Table&nbsp;16: Efficacy results in KEYNOTE‑407</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:563px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA Carboplatin</strong></p><p><strong>Paclitaxel/Nab‑paclitaxel</strong></p><p><strong>n=278</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>Carboplatin</strong></p><p><strong>Paclitaxel/Nab‑paclitaxel</strong></p><p><strong>n=281</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>OS</strong><strong><sup>*</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>168 (60%)</p></td><td style="vertical-align:top"><p>197 (70%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>17.1 (14.4, 19.9)</p></td><td style="vertical-align:top"><p>11.6 (10.1, 13.7)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.71 (0.58, 0.88)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.0006</p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>217 (78%)</p></td><td style="vertical-align:top"><p>252 (90%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>8.0 (6.3, 8.4)</p></td><td style="vertical-align:top"><p>5.1 (4.3, 6.0)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.57 (0.47, 0.69)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective response rate</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ORR % (95% CI)</p></td><td style="vertical-align:top"><p>63% (57, 68)</p></td><td style="vertical-align:top"><p>38% (33, 44)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>2.2%</p></td><td style="vertical-align:top"><p>3.2%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>60%</p></td><td style="vertical-align:top"><p>35%</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&sect;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response duration</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>8.8 (1.3+, 28.4+)</p></td><td style="vertical-align:top"><p>4.9 (1.3+, 28.3+)</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge; 12&nbsp;months<sup>&para;</sup></p></td><td style="vertical-align:top"><p>38%</p></td><td style="vertical-align:top"><p>25%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp; A total of 138&nbsp;patients (51%) who discontinued study treatment in the placebo plus chemotherapy arm crossed over to receive monotherapy KEYTRUDA or received a checkpoint inhibitor as subsequent therapy</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp; Based on the stratified Cox proportional hazard model</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on stratified log‑rank test</p><p><sup>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Based on method by Miettinen and Nurminen</p><p><sup>&para;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan‑Meier estimation</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure&nbsp;13: Kaplan‑Meier Curve for Overall Survival in KEYNOTE‑407</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p><p>Control:</p><p>&nbsp;</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA :</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Overall Survival (%)</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp; <u>&nbsp;OS rate at 12 months&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OS rate at 18 months&nbsp;&nbsp;&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;p-value</u></strong></p><p><strong>KEYTRUDA&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;65%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;48%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;0.71 (0.58, 0.88) &nbsp;&nbsp;&nbsp;0.0006</strong></p><p><strong>Control&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;50%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;37%</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Figure&nbsp;14: Kaplan‑Meier Curve for Progression‑Free Survival in KEYNOTE‑407</strong></p><p>&nbsp;</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p><p>Control:</p><p>&nbsp;</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA :</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Progression-Free Survival (%)</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp; <u>&nbsp;PFS rate at 12 months&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PFS rate at 18 months&nbsp;&nbsp;&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p-value</u></strong></p><p><strong>KEYTRUDA &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;36%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;0.57 (0.47, 0.69) &nbsp;&lt; 0.0001</strong></p><p><strong>Control&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11%</strong></p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>An analysis was performed in KEYNOTE‑407 in patients who had PD‑L1 TPS &lt;&nbsp;1% [KEYTRUDA plus chemotherapy arm: n=95 (34%) vs. placebo plus chemotherapy arm: n=99 (35%)], TPS 1% to 49% [KEYTRUDA plus chemotherapy arm: n=103 (37%) vs. placebo plus chemotherapy arm: n=104 (37%)] or TPS &ge;&nbsp;50% [KEYTRUDA plus chemotherapy arm: n=73 (26%) vs. placebo plus chemotherapy arm: n=73 (26%)] (see Table&nbsp;17).</p><p>&nbsp;</p><p><strong>Table&nbsp;17: Efficacy results by PD‑L1 expression in KEYNOTE‑407</strong><sup>*</sup></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:578px"><thead><tr><td style="vertical-align:top"><p>Endpoint</p></td><td style="vertical-align:top"><p><strong>KEYTRUDA combination therapy</strong></p></td><td style="vertical-align:top"><p><strong>Chemotherapy</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA combination therapy</strong></p></td><td style="vertical-align:top"><p><strong>Chemotherapy</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA combination therapy</strong></p></td><td style="vertical-align:top"><p><strong>Chemotherapy</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>TPS &lt; 1%</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>TPS 1 to 49%</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>TPS &ge; 50%</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>OS Hazard ratio<sup>&dagger;</sup></p><p>(95% CI)<sup> </sup></p></td><td colspan="2"><p>0.79 (0.56, 1.11)</p></td><td colspan="2"><p>0.59 (0.42, 0.84)</p></td><td colspan="2"><p>0.79 (0.52, 1.21)</p></td></tr><tr><td style="vertical-align:top"><p>PFS Hazard ratio<sup>&dagger;</sup></p><p>(95% CI)<sup> </sup></p></td><td colspan="2"><p>0.67 (0.49, 0.91)</p></td><td colspan="2"><p>0.52 (0.38, 0.71)</p></td><td colspan="2"><p>0.43 (0.29, 0.63)</p></td></tr><tr><td style="vertical-align:top"><p>ORR %</p></td><td style="vertical-align:top"><p>67%</p></td><td style="vertical-align:top"><p>41%</p></td><td style="vertical-align:top"><p>55%</p></td><td style="vertical-align:top"><p>42%</p></td><td style="vertical-align:top"><p>64%</p></td><td style="vertical-align:top"><p>30%</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp; Based on final analysis</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp; Hazard ratio (KEYTRUDA combination therapy compared to chemotherapy) based on the stratified Cox proportional hazard model</p></td></tr></tbody></table><p>&nbsp;</p><p>At final analysis, a total of 65 NSCLC patients aged &ge;&nbsp;75&nbsp;years were enrolled in study KEYNOTE‑407 (34 in the KEYTRUDA combination and 31 in the control). An HR=0.81 [95% CI 0.43, 1.55] in OS, an HR=0.61 [95% CI 0.34, 1.09] in PFS, and an ORR of 62% and 45% for KEYTRUDA combination vs. chemotherapy was reported within this study subgroup. Data about efficacy of KEYTRUDA in combination with platinum chemotherapy are limited in this patient population.</p><p>&nbsp;</p><p><em><u>KEYNOTE-010: Controlled study of NSCLC patients previously treated with chemotherapy</u></em></p><p>The safety and efficacy of KEYTRUDA were investigated in KEYNOTE‑010, a multicentre, open‑label, controlled study for the treatment of advanced NSCLC in patients previously treated with platinum‑containing chemotherapy. Patients had PD‑L1 expression with a &sup3;&nbsp;1% TPS based on the PD‑L1 IHC 22C3 pharmDx<sup>TM</sup> Kit. Patients with EGFR activation mutation or ALK translocation also had disease progression on approved therapy for these mutations prior to receiving KEYTRUDA. Patients were randomised (1:1:1) to receive KEYTRUDA at a dose of 2 (n=344) or 10&nbsp;mg/kg bw (n=346) every 3&nbsp;weeks or docetaxel at a dose of 75&nbsp;mg/m<sup>2</sup> every 3&nbsp;weeks (n=343) until disease progression or unacceptable toxicity. The study excluded patients with autoimmune disease; a medical condition that required immunosuppression; or who had received more than 30&nbsp;Gy of thoracic radiation within the prior 26&nbsp;weeks. Assessment of tumour status was performed every 9&nbsp;weeks.</p><p>&nbsp;</p><p>The baseline characteristics for this population included: median age 63&nbsp;years (42% age 65 or older); 61%&nbsp;male; 72%&nbsp;White and 21% Asian and 34% and 66% with an ECOG performance status 0 and 1, respectively. Disease characteristics were squamous (21%) and non‑squamous (70%); stage IIIA (2%); stage IIIB (7%); stage IV (91%); stable brain metastases (15%) and the incidence of mutations was EGFR (8%) or ALK (1%). Prior therapy included platinum‑doublet regimen (100%); patients received one (69%) or two or more (29%) treatment lines.</p><p>&nbsp;</p><p>The primary efficacy outcome measures were OS and PFS as assessed by BICR using RECIST&nbsp;1.1. Secondary efficacy outcome measures were ORR and response duration. Table&nbsp;18 summarises key efficacy measures for the entire population (TPS &sup3;&nbsp;1%) and for the<s> </s>patients with TPS &sup3;&nbsp;50%, and Figure&nbsp;15 shows the Kaplan‑Meier curve for OS (TPS &sup3;&nbsp;1%), based on a final analysis with median follow‑up of 42.6&nbsp;months.</p><p>&nbsp;</p><p><strong>Table&nbsp;18: Response to KEYTRUDA 2 or 10&nbsp;mg/kg bw every 3&nbsp;weeks in previously treated patients with NSCLC in KEYNOTE‑010</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:606px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA </strong><strong>2&nbsp;mg/kg bw every 3&nbsp;weeks</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA </strong><strong>10&nbsp;mg/kg bw every 3&nbsp;weeks</strong></p></td><td style="vertical-align:top"><p><strong>Docetaxel</strong></p><p><strong>75&nbsp;mg/m<sup>2</sup> every 3&nbsp;weeks</strong></p></td></tr><tr><td><p><strong>TPS </strong><strong>&ge;</strong><strong>&nbsp;1%</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of patients</p></td><td style="vertical-align:top"><p>344</p></td><td style="vertical-align:top"><p>346</p></td><td style="vertical-align:top"><p>343</p></td></tr><tr><td style="vertical-align:top"><p><strong>OS</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>284 (83%)</p></td><td style="vertical-align:top"><p>264 (76%)</p></td><td style="vertical-align:top"><p>295 (86%)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>*</sup> (95% CI)</p></td><td style="vertical-align:top"><p>0.77 (0.66, 0.91)</p></td><td style="vertical-align:top"><p>0.61 (0.52, 0.73)</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>0.00128</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>10.4 (9.5, 11.9)</p></td><td style="vertical-align:top"><p>13.2 (11.2, 16.7)</p></td><td style="vertical-align:top"><p>8.4 (7.6, 9.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS</strong><strong><sup>&Dagger;</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>305 (89%)</p></td><td style="vertical-align:top"><p>292 (84%)</p></td><td style="vertical-align:top"><p>314 (92%)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>*</sup> (95% CI)</p></td><td style="vertical-align:top"><p>0.88 (0.75, 1.04)</p></td><td style="vertical-align:top"><p>0.75 (0.63, 0.89)</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>0.065</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>3.9 (3.1, 4.1)</p></td><td style="vertical-align:top"><p>4.0 (2.7, 4.5)</p></td><td style="vertical-align:top"><p>4.1 (3.8, 4.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective response rate</strong><strong><sup>&Dagger;</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ORR % (95% CI)</p></td><td style="vertical-align:top"><p>20% (16, 25)</p></td><td style="vertical-align:top"><p>21% (17, 26)</p></td><td style="vertical-align:top"><p>9% (6, 13)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>0%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>18%</p></td><td style="vertical-align:top"><p>18%</p></td><td style="vertical-align:top"><p>9%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response duration</strong><strong><sup>&Dagger;,&sect;</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>Not reached</p><p>(2.8, 46.2+)</p></td><td style="vertical-align:top"><p>37.8</p><p>(2.0+, 49.3+)</p></td><td style="vertical-align:top"><p>7.1</p><p>(1.4+, 16.8)</p></td></tr><tr><td style="vertical-align:top"><p>% ongoing<sup>&para;</sup></p></td><td style="vertical-align:top"><p>42%</p></td><td style="vertical-align:top"><p>43%</p></td><td style="vertical-align:top"><p>6%</p></td></tr><tr><td colspan="4"><p><strong>&nbsp;</strong></p></td></tr><tr><td><p><strong>TPS </strong><strong>&sup3;</strong><strong>&nbsp;50%</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of patients</p></td><td style="vertical-align:top"><p>139</p></td><td style="vertical-align:top"><p>151</p></td><td style="vertical-align:top"><p>152</p></td></tr><tr><td style="vertical-align:top"><p><strong>OS</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>97 (70%)</p></td><td style="vertical-align:top"><p>102 (68%)</p></td><td style="vertical-align:top"><p>127 (84%)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>*</sup> (95% CI)</p></td><td style="vertical-align:top"><p>0.56 (0.43, 0.74)</p></td><td style="vertical-align:top"><p>0.50 (0.38, 0.65)</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>15.8 (10.8, 22.5)</p></td><td style="vertical-align:top"><p>18.7 (12.1, 25.3)</p></td><td style="vertical-align:top"><p>8.2 (6.4, 9.8)</p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS</strong><strong><sup>&Dagger;</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>107 (77%)</p></td><td style="vertical-align:top"><p>115 (76%)</p></td><td style="vertical-align:top"><p>138 (91%)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>*</sup> (95% CI)</p></td><td style="vertical-align:top"><p>0.59 (0.45, 0.77)</p></td><td style="vertical-align:top"><p>0.53 (0.41, 0.70)</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>5.3 (4.1, 7.9)</p></td><td style="vertical-align:top"><p>5.2 (4.1, 8.1)</p></td><td style="vertical-align:top"><p>4.2 (3.8, 4.7)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective response rate</strong><strong><sup>&Dagger;</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ORR % (95% CI)</p></td><td style="vertical-align:top"><p>32% (24, 40)</p></td><td style="vertical-align:top"><p>32% (25, 41)</p></td><td style="vertical-align:top"><p>9% (5, 14)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>0%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>27%</p></td><td style="vertical-align:top"><p>28%</p></td><td style="vertical-align:top"><p>9%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response duration</strong><strong><sup>&Dagger;,&sect;</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>Not reached</p><p>(2.8, 44.0+)</p></td><td style="vertical-align:top"><p>37.5</p><p>(2.0+, 49.3+)</p></td><td style="vertical-align:top"><p>8.1</p><p>(2.6, 16.8)</p></td></tr><tr><td style="vertical-align:top"><p>% ongoing<sup>&para;</sup></p></td><td style="vertical-align:top"><p>55%</p></td><td style="vertical-align:top"><p>47%</p></td><td style="vertical-align:top"><p>8%</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hazard ratio (KEYTRUDA compared to docetaxel) based on the stratified Cox proportional hazard model</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on stratified log‑rank test</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Assessed by BICR using RECIST&nbsp;1.1</p><p><strong><sup>&sect;</sup></strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on patients with a best objective response as confirmed complete or partial response</p><p><sup>&para;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ongoing response includes all responders who at the time of analysis were alive, progression‑free, did not initiate new anti‑cancer therapies and had not been determined to be lost to follow‑up</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Figure&nbsp;15: Kaplan‑Meier curve for overall survival by treatment arm in KEYNOTE‑010 (</strong><strong>patients with</strong><strong> </strong><strong>PD‑L1 expression TPS </strong><strong>&sup3;</strong><strong>&nbsp;1%, </strong><strong>intent to treat population)</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Efficacy results were similar for the 2&nbsp;mg/kg bw and 10&nbsp;mg/kg bw KEYTRUDA arms. Efficacy results for OS were consistent regardless of the age of tumour specimen (new vs. archival) based on an intergroup comparison.</p><p>&nbsp;</p><p>In subgroup analyses, a reduced survival benefit of KEYTRUDA compared to docetaxel was observed for patients who were never‑smokers or patients with tumours harbouring EGFR activating mutations who received at least platinum‑based chemotherapy and a tyrosine kinase inhibitor; however, due to the small numbers of patients, no definitive conclusions can be drawn from these data.</p><p>&nbsp;</p><p>The efficacy and safety of KEYTRUDA in patients with tumours that do not express PD‑L1 have not been established.</p><p>&nbsp;</p><p><em><u>KEYNOTE‑671: Controlled trial for the neoadjuvant and adjuvant treatment of patients with resectable NSCLC</u></em></p><p>The efficacy of KEYTRUDA in combination with platinum‑containing chemotherapy given as neoadjuvant treatment and continued as monotherapy adjuvant treatment was investigated in KEYNOTE‑671, a multicenter, randomized, double‑blind, placebo‑controlled trial. Key eligibility criteria were previously untreated and resectable Stage&nbsp;II, IIIA, or IIIB (N2) NSCLC by AJCC 8<sup>th</sup> edition, regardless of tumor PD‑L1 expression. Patients with active autoimmune disease that required systemic therapy within 2&nbsp;years of treatment or a medical condition that required immunosuppression were ineligible. Randomization was stratified by stage (II vs. III), tumor PD‑L1 expression (TPS&nbsp;&ge;50% or &lt;50%), histology (squamous vs. non‑squamous), and geographic region (East&nbsp;Asia vs. non‑East Asia).</p><p>&nbsp;</p><p>Patients were randomized (1:1) to one of the following treatment arms:</p><p>o&nbsp;&nbsp; Treatment Arm A: neoadjuvant KEYTRUDA 200&nbsp;mg on Day&nbsp;1 in combination with cisplatin 75&nbsp;mg/m<sup>2</sup> and either pemetrexed 500&nbsp;mg/m<sup>2</sup> on Day&nbsp;1 or gemcitabine 1000&nbsp;mg/m<sup>2</sup> on Days&nbsp;1 and 8 of each 21‑day cycle for up to 4&nbsp;cycles. Following surgery, KEYTRUDA 200&nbsp;mg was administered every 3&nbsp;weeks for up to 13&nbsp;cycles.</p><p>o&nbsp;&nbsp; Treatment Arm B: neoadjuvant placebo on Day&nbsp;1 in combination with cisplatin 75&nbsp;mg/m<sup>2</sup> and either pemetrexed 500&nbsp;mg/m<sup>2</sup> on Day&nbsp;1 or gemcitabine 1000&nbsp;mg/m<sup>2</sup> on Days&nbsp;1 and 8 of each 21‑day cycle for up to 4&nbsp;cycles. Following surgery, placebo was administered every 3&nbsp;weeks for up to 13&nbsp;cycles.</p><p>&nbsp;</p><p>All study medications were administered via intravenous infusion. Treatment with KEYTRUDA or placebo continued until completion of the treatment (17&nbsp;cycles), disease progression that precluded definitive surgery, disease recurrence in the adjuvant phase, disease progression for those who did not undergo surgery or had incomplete resection and entered the adjuvant phase, or unacceptable toxicity. Assessment of tumor status was performed at baseline, Week&nbsp;7, and Week&nbsp;13 in the neoadjuvant phase and within 4&nbsp;weeks prior to the start of the adjuvant phase. Following the start of the adjuvant phase, assessment of tumor status was performed every 16&nbsp;weeks through the end of Year&nbsp;3, and then every 6&nbsp;months thereafter.</p><p>&nbsp;</p><p>The primary efficacy outcome measures were OS and investigator assessed event free survival (EFS). Secondary efficacy outcome measures were pathological complete response (pCR) rate and major pathological response (mPR) rate as assessed by blinded independent pathology review (BIPR).</p><p>&nbsp;</p><p>A total of 797&nbsp;patients in KEYNOTE-671 were randomized: 397&nbsp;patients to the KEYTRUDA arm and 400&nbsp;to the placebo arm. Baseline characteristics were: median age of 64&nbsp;years (range: 26 to 83), 45% age&nbsp;65 or older; 71%&nbsp;male; 61%&nbsp;White, 31%&nbsp;Asian, and 2.0%&nbsp;Black. Sixty‑three&nbsp;percent and 37% had ECOG performance of 0 or 1, respectively; 30% had Stage&nbsp;II and 70% had Stage&nbsp;III disease; 33% had TPS&nbsp;&ge;50% and 67% had TPS&nbsp;&lt;50%; 43% had tumors with squamous histology and 57% had tumors with non‑squamous histology; 31% were from the East Asian region.</p><p>&nbsp;</p><p>Eighty‑one&nbsp;percent of patients in the KEYTRUDA in combination with platinum‑containing chemotherapy arm had definitive surgery compared to 76% of patients in the platinum‑containing chemotherapy arm.</p><p>&nbsp;</p><p>The trial demonstrated statistically significant improvements in OS and EFS for patients randomized to KEYTRUDA in combination with platinum‑containing chemotherapy followed by KEYTRUDA monotherapy compared with patients randomized to placebo in combination with platinum‑containing chemotherapy followed by placebo alone. OS efficacy results with a median follow-up time of 29.8&nbsp;months (range: 0.4 to 62.0&nbsp;months) are summarized in Table 19 and Figure 16. EFS, pCR, and mPR efficacy results with a median follow-up time of 21.4&nbsp;months (range: 0.4 to 50.6&nbsp;months) are summarized in Table 19.</p><p>&nbsp;</p><p><strong>Table&nbsp;19: Efficacy Results in KEYNOTE‑671</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:645px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA with chemotherapy/KEYTRUDA</strong></p><p><strong>n=397</strong></p></td><td style="vertical-align:top"><p><strong>Placebo with chemotherapy/Placebo</strong></p><p><strong>n=400</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>OS</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of patients with event (%)</p></td><td style="vertical-align:top"><p>110 (28%)</p></td><td style="vertical-align:top"><p>144 (36%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months* (95% CI)</p></td><td style="vertical-align:top"><p>NR (NR, NR)</p></td><td style="vertical-align:top"><p>52.4 (45.7, NR)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.72 (0.56, 0.93)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.00517</p></td></tr><tr><td style="vertical-align:top"><p><strong>EFS</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of patients with event (%)</p></td><td><p>139 (35%)</p></td><td><p>205 (51%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months* (95% CI)</p></td><td><p>NR (34.1, NR)</p></td><td><p>17.0 (14.3, 22.0)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2"><p>0.58 (0.46, 0.72)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td><p><strong>pCR</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td></tr><tr><td><p>Number of patients with pCR</p></td><td><p>72</p></td><td><p>16</p></td></tr><tr><td><p>pCR Rate (%), (95% CI)</p></td><td><p>18.1 (14.5, 22.3)</p></td><td><p>4.0 (2.3, 6.4)</p></td></tr><tr><td><p>Treatment difference estimate (%), (95% CI)<sup>&sect;</sup></p></td><td colspan="2"><p>14.2 (10.1, 18.7)</p></td></tr><tr><td><p>p‑Value</p></td><td colspan="2"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td><p><strong>mPR</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Number of patients with mPR</p></td><td><p>120</p></td><td><p>44</p></td></tr><tr><td><p>mPR Rate (%), (95% CI)</p></td><td><p>30.2 (25.7, 35.0)</p></td><td><p>11.0 (8.1, 14.5)</p></td></tr><tr><td><p>Treatment difference estimate (%), (95% CI)<sup>&sect;</sup></p></td><td colspan="2"><p>19.2 (13.9, 24.7)</p></td></tr><tr><td><p>p‑Value</p></td><td colspan="2"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan‑Meier estimates</p><p><sup>&dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Based on Cox regression model with treatment as a covariate stratified by stage, tumor PD‑L1 expression, histology, and geographic region</p><p><sup>&Dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Based on stratified log‑rank test</p><p><sup>&sect;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Miettinen and Nurminen method stratified by stage, tumor PD-L1 expression, histology, and geographic region</p><p>NR = not reached</p><p>&nbsp;</p></td></tr></tbody></table><p>The final EFS analysis was performed at a median duration of follow-up of 29.8&nbsp;months after 422&nbsp;patient events (174&nbsp;for the KEYTRUDA arm and 248&nbsp;for the placebo arm). Median EFS was 47.2&nbsp;months (95%&nbsp;CI: 32.9, NR) for the KEYTRUDA arm and 18.3&nbsp;months (95%&nbsp;CI: 14.8, 22.1) for the placebo arm. The EFS HR was 0.59 (95%&nbsp;CI: 0.48, 0.72). See Figure 17.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Figure&nbsp;16: Kaplan‑Meier Curve for Overall Survival by Treatment Arm in KEYNOTE‑671 (Intent to Treat Population)</strong></p><p>&nbsp;</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p><p>&nbsp;</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Number at Risk</strong></p><p>KEYTRUDA</p><p>Control</p><p>&nbsp;</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>OS Rate at 30 months&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HR (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;p-value</u></strong></p><p><strong>KEYTRUDA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 74%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.72 (0.56, 0.93)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.00517</strong></p><p><strong>Control&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 68%</strong></p><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-family:Arial'>Overall
    Survival (%)<o:p></o:p></span></p>
    <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-family:Arial'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="45" height="143" alt="Text Box: Overall Survival (%)

" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image018.png" /></p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Figure&nbsp;17: Kaplan‑Meier Curve for by Event‑Free Survival by Treatment Arm in KEYNOTE‑671 (Intent to Treat Population)</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><em><u>KEYNOTE-091: Controlled trial for the adjuvant treatment of patients with resected NSCLC</u></em></p><p>The efficacy of KEYTRUDA was investigated in KEYNOTE-091, a multicenter, randomized, triple-blind, placebo-controlled trial. Key eligibility criteria were completely resected stage&nbsp;IB (T2a&nbsp;&ge;4&nbsp;cm), II, or IIIA NSCLC by AJCC 7<sup>th</sup> edition, regardless of tumor PD-L1 expression status, no prior neoadjuvant radiotherapy and/or neoadjuvant chemotherapy, and no prior or planned adjuvant radiotherapy for the current malignancy. Patients may or may not have received adjuvant chemotherapy. Patients with autoimmune disease that required systemic therapy within 2&nbsp;years of treatment; a medical condition that required immunosuppression; or who had received more than 4&nbsp;cycles of adjuvant chemotherapy were ineligible. Randomization was stratified by stage (IB vs. II vs. IIIA), adjuvant chemotherapy (no adjuvant chemotherapy vs. adjuvant chemotherapy), PD-L1 status (TPS&nbsp;&lt;1% [negative] vs. TPS 1-49% vs. TPS&nbsp;&ge;50%), and geographic region (Western Europe vs. Eastern Europe vs. Asia vs. Rest of World). Patients were randomized (1:1) to receive KEYTRUDA 200&nbsp;mg or placebo intravenously every 3&nbsp;weeks.</p><p>&nbsp;</p><p>Treatment continued until RECIST&nbsp;1.1-defined disease recurrence as determined by the investigator, unacceptable toxicity, or approximately one year (18&nbsp;doses). Patients underwent imaging every 12&nbsp;weeks after the first dose of KEYTRUDA for the first year, then every 6&nbsp;months for years 2 to 3, and then annually up to the end of year&nbsp;5. After year&nbsp;5, imaging is performed as per local standard of care.</p><p>&nbsp;</p><p>Of 1177&nbsp;patients randomized, 1010&nbsp;(86%) received adjuvant platinum-based chemotherapy following resection. Among these 1010&nbsp;patients, the median age was 64&nbsp;years (range: 35 to 84), 49%&nbsp;age&nbsp;65 or older; 68%&nbsp;male; 77%&nbsp;White, 18%&nbsp;Asian; 86%&nbsp;current or former smokers; and 39% with ECOG PS of 1. Eleven percent had Stage&nbsp;IB, 57% had Stage&nbsp;II, and 31% had Stage&nbsp;IIIA disease. Thirty-nine percent had PD-L1 TPS&nbsp;&lt;1% [negative], 33% had TPS&nbsp;1‑49%, and 28% had TPS&nbsp;&ge;50%. Fifty-two percent were from Western Europe, 20% from Eastern Europe, 17% from Asia, and 11% from Rest of World.</p><p>&nbsp;</p><p>The primary efficacy outcome measures were investigator-assessed disease‑free survival (DFS) in the overall population and in the population with tumor PD‑L1 expression TPS&nbsp;&ge;50%, where DFS was defined as the time between the date of randomization and the date of first recurrence (local/regional recurrence, distant metastasis), a second malignancy, or death, whichever occurred first. Secondary efficacy outcome measures were investigator-assessed DFS in the population with tumor PD‑L1 expression TPS&nbsp;&ge;1%, and OS in the overall population and in the populations with tumor PD‑L1 expression TPS&nbsp;&ge;50% and TPS&nbsp;&ge;1%.</p><p>&nbsp;</p><p>The trial demonstrated a statistically significant improvement in DFS in the overall population [HR = 0.76 (95% CI: 0.63, 0.91; p = 0.00143)] at a pre-specified interim analysis for patients randomized to the KEYTRUDA arm compared to patients randomized to the placebo arm.&nbsp; OS results were not mature (18% with events in the overall population). The median follow-up time was 32.4&nbsp;months (range: 0.6 to 68&nbsp;months). Efficacy results for KEYNOTE-091 in in patients who received adjuvant chemotherapy are summarized in Table&nbsp;20 and Figure&nbsp;18.</p><p>&nbsp;</p><p><strong>Table&nbsp;20: Efficacy Results in KEYNOTE 091 for Patients Who Received Adjuvant Chemotherapy</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:336px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA</strong></p><p><strong>200&nbsp;mg every 3&nbsp;weeks</strong></p><p><strong>n=506</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>n=504</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>DFS</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td><p>177 (35%)</p></td><td><p>231 (46%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>58.7</p><p>(39.2, NR)</p></td><td style="vertical-align:top"><p>34.9</p><p>(28.6, NR)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio* (95% CI)</p></td><td colspan="2"><p>0.73 (0.60, 0.89)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*&nbsp; Based on the unstratified univariate Cox regression model</p><p>NR = not reached</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Figure 18: Kaplan-Meier Curve for Disease-Free Survival by Treatment Arm in KEYNOTE‑091 for patients who received adjuvant chemotherapy</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Number at Risk</strong></p><p>KEYTRUDA</p><p>Placebo</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm</strong></p><p><strong>KEYTRUDA</strong></p><p><strong>Placebo</strong></p></td></tr></tbody></table><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;mso-bidi-font-size:
    9.0pt;font-family:"Arial",sans-serif'>Disease-Free Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="50" height="183" alt="Text Box: Disease-Free Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image022.png" /></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><em><u>Classical Hodgkin lymphoma</u></em></p><p><em><u>KEYNOTE‑204: Controlled study in patients with relapsed or refractory classical Hodgkin lymphoma&nbsp;(cHL)</u></em></p><p>The efficacy of KEYTRUDA was investigated in KEYNOTE‑204, a randomised, open-label, active‑controlled study conducted in 304&nbsp;patients with relapsed or refractory cHL. Patients with active, non‑infectious pneumonitis, an allogeneic HSCT within the past 5&nbsp;years&nbsp;(or &gt;&nbsp;5&nbsp;years but with symptoms of GVHD), active autoimmune disease, a medical condition that required immunosuppression, or an active infection requiring systemic therapy were ineligible for the study. Randomisation was stratified by prior ASCT&nbsp;(yes vs. no) and disease status after frontline therapy (primary refractory vs. relapse less than 12&nbsp;months after completion vs. relapse 12&nbsp;months or more after completion). Patients were randomised (1:1) to one of the following treatment arms:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; KEYTRUDA 200&nbsp;mg<sup> </sup>intravenously every 3&nbsp;weeks</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brentuximab vedotin (BV) 1.8&nbsp;mg/kg bw intravenously every 3&nbsp;weeks.</p><p>&nbsp;</p><p>Patients received KEYTRUDA 200&nbsp;mg intravenously every 3&nbsp;weeks until unacceptable toxicity or documented disease progression, or a maximum of 35&nbsp;cycles. Limited data are currently available on response duration following KEYTRUDA discontinuation at cycle 35. Response was assessed every 12&nbsp;weeks, with the first planned post-baseline assessment at Week&nbsp;12.</p><p>&nbsp;</p><p>Among the 304&nbsp;patients in KEYNOTE-204, there is a subpopulation consisting of 112&nbsp;patients who failed a transplant before enrolling and 137 who failed 2 or more prior therapies and were ineligible for ASCT at the time of enrolment. The baseline characteristics of these 249&nbsp;patients were: median age 34&nbsp;years (11% age 65 or older); 56% male; 80% White and 7% Asian and 58% and 41% with an ECOG performance status 0 and 1, respectively. Approximately 30% were refractory to frontline chemotherapy and ~&nbsp;45% had received prior ASCT. Nodular-sclerosis was the more represented cHL histological subtype (~&nbsp;81%) and bulky disease, B symptoms and bone marrow involvement were present in approximately 21%, 28% and 4% of patients, respectively.</p><p>&nbsp;</p><p>The primary efficacy outcome was PFS and the secondary efficacy outcome measure was ORR, both assessed by BICR according to the 2007 revised International Working Group (IWG) criteria. The additional primary efficacy outcome measure, OS, was not formally assessed at the time of the analysis. In the ITT population, the median follow-up time for 151&nbsp;patients treated with KEYTRUDA was 24.9&nbsp;months (range: 1.8 to 42.0&nbsp;months). The initial analysis resulted in a HR for PFS of 0.65 (95% CI: 0.48, 0.88) with a one-sided p value of 0.0027. The ORR was 66% for KEYTRUDA compared to 54% for standard treatment with a p-Value of 0.0225. Table&nbsp;21 summarises the efficacy results in the subpopulation. Efficacy results in this subpopulation were consistent with the ITT population. The Kaplan-Meier curve for PFS for this subpopulation is shown in Figure&nbsp;19.</p><p><em><u>&nbsp;</u></em></p><p><strong>Table&nbsp;21: Efficacy results in cHL patients who failed a transplant before enrolling or who failed 2 or more prior therapies and were ineligible for ASCT in KEYNOTE‑204</strong></p><p><em><u>&nbsp;</u></em></p><table border="0" cellspacing="0" cellpadding="0" style="width:598px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Pembrolizumab</strong></p><p><strong>&nbsp;</strong></p><p><strong>200&nbsp;mg every 3&nbsp;weeks</strong></p><p><strong>n=124</strong></p></td><td style="vertical-align:top"><p><strong>Brentuximab</strong></p><p><strong>vedotin</strong></p><p><strong>1.8&nbsp;mg/kg bw every 3&nbsp;weeks</strong></p><p><strong>n=125</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>PFS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>68 (55%)</p></td><td style="vertical-align:top"><p>75 (60%)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>*</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.66 (0.47, 0.92)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>12.6 (8.7, 19.4)</p></td><td style="vertical-align:top"><p>8.2 (5.6, 8.8)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Objective response rate</strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR<strong><sup>&Dagger;</sup></strong> % (95% CI)</p></td><td style="vertical-align:top"><p>65% (56.3, 73.6)</p></td><td style="vertical-align:top"><p>54% (45.3, 63.3)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>27%</p></td><td style="vertical-align:top"><p>22%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>39%</p></td><td style="vertical-align:top"><p>33%</p></td></tr><tr><td style="vertical-align:top"><p>Stable disease</p></td><td style="vertical-align:top"><p>12%</p></td><td style="vertical-align:top"><p>23%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Response duration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>20.5 (0.0+, 33.2+)</p></td><td style="vertical-align:top"><p>&nbsp;11.2 (0.0+, 33.9+)</p></td></tr><tr><td style="vertical-align:top"><p>Number (%<sup>&para;</sup>) of patients with duration &ge;&nbsp;6&nbsp;months</p></td><td style="vertical-align:top"><p>53 (80.8%)</p></td><td style="vertical-align:top"><p>28 (61.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Number (%<sup>&para;</sup>) of patients with duration &ge;&nbsp;12&nbsp;months</p></td><td style="vertical-align:top"><p>37 (61.7%)</p></td><td style="vertical-align:top"><p>17 (49.0%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on the stratified Cox proportional hazard model</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on patients with a best overall response as complete or partial response</p><p><sup>&para;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan‑Meier estimation</p><p>&nbsp;</p></td></tr></tbody></table><p><em><u>&nbsp;</u></em></p><p>&nbsp;</p><p><em><u>&nbsp;</u></em></p><p><em><u>&nbsp;</u></em></p><p><strong>Figure&nbsp;19: Kaplan‑Meier curve for progression-free survival by treatment arm in</strong></p><p><strong>cHL patients who failed a transplant before enrolling or who failed 2 or more prior therapies and were ineligible for ASCT in KEYNOTE‑204</strong></p><p><em><u>&nbsp;</u></em></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p><p>Brentuximab Vedotin:</p><p>&nbsp;</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA:</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Progression-Free Survival (%)</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp; <u>&nbsp;PFS rate at 12 months&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PFS rate at 24 months&nbsp;&nbsp;&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></strong></p><p><strong>&shy;&shy;KEYTRUDA &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;53%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 35%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;0.66 (0.47, 0.92) &nbsp;&nbsp;&nbsp;</strong></p><p><strong>Brentuximab Vedotin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;35%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24%</strong></p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>&nbsp;</u></em></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><em><u>&nbsp;</u></em></p><p><em><u>KEYNOTE‑087 and KEYNOTE‑013: Open‑label studies in patients with relapsed or refractory cHL</u></em></p><p>The efficacy of KEYTRUDA was investigated in KEYNOTE‑087 and KEYNOTE‑013, two multicentre, open‑label studies for the treatment of 241&nbsp;patients with cHL. These studies enrolled patients who failed ASCT and BV, who were ineligible for ASCT because they were unable to achieve a complete or partial remission to salvage chemotherapy and failed BV, or who failed ASCT and did not receive BV. Five study subjects were ineligible to ASCT due to reasons other than failure to salvage chemotherapy. Both studies included patients regardless of PD‑L1 expression. Patients with active, non‑infectious pneumonitis, an allogeneic transplant within the past 5&nbsp;years (or &gt;&nbsp;5&nbsp;years but with GVHD), active autoimmune disease or a medical condition that required immunosuppression were ineligible for either study. Patients received KEYTRUDA 200&nbsp;mg every 3&nbsp;weeks (n=210; KEYNOTE‑087) or 10&nbsp;mg/kg bw every 2&nbsp;weeks (n=31; KEYNOTE‑013) until unacceptable toxicity or documented disease progression.</p><p>&nbsp;</p><p>Among KEYNOTE‑087&nbsp;patients, the baseline characteristics were median age 35&nbsp;years (9% age 65 or older); 54%&nbsp;male; 88%&nbsp;White; and 49% and 51% had an ECOG performance status 0 and 1, respectively. The median number of prior lines of therapy administered for the treatment of cHL was 4 (range 1 to 12). Eighty‑one percent were refractory to at least one prior therapy, including 34% who were refractory to first line therapy. Sixty‑one percent of patients had received ASCT, 38% were transplant ineligible; 17% had no prior brentuximab vedotin use; and 37% of patients had prior radiation therapy. Disease subtypes were 81% nodular sclerosis, 11% mixed cellularity, 4% lymphocyte‑rich and 2% lymphocyte‑depleted.</p><p>&nbsp;</p><p>Among KEYNOTE‑013&nbsp;patients, the baseline characteristics were median age 32&nbsp;years (7% age 65 or older), 58%&nbsp;male, 94%&nbsp;White; and 45% and 55% had an ECOG performance status 0 and 1, respectively. The median number of prior lines of therapy administered for the treatment of cHL was 5 (range 2 to 15). Eighty‑four percent were refractory to at least one prior therapy, including 35% who were refractory to first line therapy. Seventy‑four percent of patients had received ASCT, 26% were transplant ineligible, and 45% of patients had prior radiation therapy. Disease subtypes were 97% nodular sclerosis and 3% mixed cellularity.</p><p>&nbsp;</p><p>The primary efficacy outcome measures (ORR and CRR) were assessed by BICR according to the IWG 2007 criteria. Secondary efficacy outcome measures were duration of response, PFS and OS. Response was assessed in KEYNOTE‑087 and KEYNOTE‑013 every 12 and 8&nbsp;weeks, respectively, with the first planned post‑baseline assessment at Week 12. Main efficacy results are summarised in Table&nbsp;22.</p><p>&nbsp;</p><p><strong>Table&nbsp;22: </strong><strong>Efficacy results in KEYNOTE‑087 and KEYNOTE‑013</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td><p><strong>KEYNOTE‑087<sup>*</sup></strong></p></td><td style="vertical-align:top"><p><strong>KEYNOTE‑013<sup>&dagger;</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td><p><strong>KEYTRUDA</strong></p><p><strong>200&nbsp;mg every 3&nbsp;weeks</strong></p><p><strong>n=210</strong></p></td><td><p><strong>KEYTRUDA</strong></p><p><strong>10&nbsp;mg/kg bw every 2&nbsp;weeks</strong></p><p><strong>n=31</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective response rate</strong><strong><sup>&Dagger;</sup></strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ORR % (95% CI)</p></td><td style="vertical-align:top"><p>71% (64.8, 77.4)</p></td><td style="vertical-align:top"><p>58% (39.1, 75.5)</p></td></tr><tr><td style="vertical-align:top"><p>Complete remission</p></td><td style="vertical-align:top"><p>28%</p></td><td style="vertical-align:top"><p>19%</p></td></tr><tr><td style="vertical-align:top"><p>Partial remission</p></td><td style="vertical-align:top"><p>44%</p></td><td style="vertical-align:top"><p>39%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response duration</strong><strong><sup>&Dagger;</sup></strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>16.6 (0.0+, 62.1+)<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>Not reached (0.0+, 45.6+)<sup>&para;</sup></p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;&nbsp;12‑months</p></td><td style="vertical-align:top"><p>59%<sup>#</sup></p></td><td style="vertical-align:top"><p>70%<sup>&THORN;</sup></p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;&nbsp;24‑months</p></td><td style="vertical-align:top"><p>45%<sup>&szlig;</sup></p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;&nbsp;60‑months</p></td><td style="vertical-align:top"><p>25%<sup>&agrave;</sup></p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p><strong>Time to response</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>2.8 (2.1, 16.5)<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>2.8 (2.4, 8.6)<sup>&para;</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>OS</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td><p>59 (28%)</p></td><td><p>6 (19%)</p></td></tr><tr><td style="vertical-align:top"><p>12‑month OS rate</p></td><td style="vertical-align:top"><p>96%</p></td><td style="vertical-align:top"><p>87%</p></td></tr><tr><td style="vertical-align:top"><p>24‑month OS rate</p></td><td style="vertical-align:top"><p>91%</p></td><td style="vertical-align:top"><p>87%</p></td></tr><tr><td style="vertical-align:top"><p>60‑month OS rate</p></td><td style="vertical-align:top"><p>71%</p></td><td style="vertical-align:top"><p>---</p></td></tr></tbody></table><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median follow‑up time of 62.9&nbsp;months</p><p><sup>&dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Median follow‑up time of 52.8&nbsp;months</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Assessed by BICR according to the IWG 2007 criteria by PET CT scans</p><p><sup>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Based on patients (n=150) with a response by independent review</p><p><sup>&para;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Based on patients (n=18) with a response by independent review</p><p><sup>#</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Based on Kaplan‑Meier estimation; includes 62&nbsp;patients with responses of 12&nbsp;months or longer</p><p><sup>&THORN;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Based on Kaplan‑Meier estimation; includes 7&nbsp;patients with responses of 12&nbsp;months or longer</p><p><sup>&szlig;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Based on Kaplan‑Meier estimation; includes 37&nbsp;patients with responses of 24&nbsp;months or longer</p><p><sup>&agrave;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Based on Kaplan‑Meier estimation; includes 4&nbsp;patients with responses of 60&nbsp;months or longer</p><p><u>&nbsp;</u></p><p><u>Efficacy in elderly patients </u></p><p>Overall, 46&nbsp;cHL patients &ge;&nbsp;65&nbsp;years were treated with KEYTRUDA in studies KEYNOTE‑087, KEYNOTE‑013 and KEYNOTE‑204. Data from these patients are too limited to draw any conclusion on efficacy in this population.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>KEYNOTE-A39: Controlled trial of combination therapy with enfortumab vedotin in urothelial carcinoma patients</u></em></p><p>The efficacy of KEYTRUDA in combination with enfortumab vedotin was investigated in KEYNOTE‑A39, an open-label, multicenter, randomized, active-controlled trial that enrolled 886&nbsp;platinum‑eligible patients with locally advanced or metastatic urothelial carcinoma. The trial excluded patients with autoimmune disease or a medical condition that required immunosuppression, active CNS metastases, ongoing sensory or motor neuropathy Grade&nbsp;&ge;2, or uncontrolled diabetes defined as hemoglobin&nbsp;A1C (HbA1c)&nbsp;&ge;8% or HbA1c&nbsp;&ge;7% with associated diabetes symptoms. Patients were considered cisplatin-ineligible if they had at least one of the following criteria: glomerular filtration rate clearance 30-59&nbsp;mL/min, ECOG PS&nbsp;&ge;2, Grade&nbsp;&ge;2 hearing loss, or NYHA Class&nbsp;III heart failure. Patients randomized to the gemcitabine and platinum-based chemotherapy arm were permitted to receive maintenance immunotherapy. Randomization was stratified by cisplatin eligibility (eligible or ineligible), PD-L1 expression [high (CPS&nbsp;&ge;10) or low (CPS&nbsp;&lt;10)], and liver metastases (present or absent). Patients were randomized (1:1) to one of the following treatment arms; all study medications were administered via intravenous infusion.</p><p><s>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s>KEYTRUDA 200&nbsp;mg over 30&nbsp;minutes on Day&nbsp;1 and enfortumab vedotin 1.25&nbsp;mg/kg on Days&nbsp;1 and 8 of each 21-day cycle.</p><p><s>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s>Gemcitabine 1000&nbsp;mg/m<sup>2</sup> on Days&nbsp;1 and 8 and investigator&rsquo;s choice of cisplatin 70&nbsp;mg/m<sup>2 </sup>or carboplatin (AUC&nbsp;4.5 or 5&nbsp;mg/mL/min according to local guidelines) on Day&nbsp;1 of each 21-day cycle.</p><p>&nbsp;</p><p>Treatment with KEYTRUDA and enfortumab vedotin continued until RECIST&nbsp;v1.1-defined progression of disease, unacceptable toxicity or, for KEYTRUDA, a maximum of 35&nbsp;cycles (up to approximately 2&nbsp;years). Treatment was permitted beyond RECIST&nbsp;v1.1‑defined disease progression if the treating investigator considered the patient to be deriving clinical benefit and the treatment was tolerated. Assessment of tumor status was performed every 9&nbsp;weeks for 18&nbsp;months and then every 12&nbsp;weeks thereafter. The major efficacy outcome measures were PFS as assessed by BICR according to RECIST&nbsp;v1.1 and OS. Additional outcome measures were ORR and DoR as assessed by BICR according to RECIST&nbsp;v1.1 and time to pain progression (TTPP).</p><p>&nbsp;</p><p>The study population characteristics were: median age of 69&nbsp;years; 77%&nbsp;male; and 67%&nbsp;White. Ninety‑five percent had M1 disease, and 5% had M0 disease. Seventy‑three percent had a primary tumor in the lower tract, and 27% of patients had a primary tumor in the upper tract. Fifty‑four percent were cisplatin-eligible, 58% were PD‑L1 high, and 72% of patients had visceral metastases, including 22% with liver metastases. Twenty percent had normal renal function, and 37%, 41% and 2% were characterized with mild, moderate, or severe renal impairment, respectively. Ninety‑seven percent had ECOG PS of 0‑1 and 3% had ECOG PS of 2. Eighty‑five percent of patients had transitional cell carcinoma (TCC) histology, 12% had TCC with mixed histology, and 6% had TCC with squamous differentiation.</p><p>&nbsp;</p><p>Thirty-two percent of patients receiving KEYTRUDA in combination with enfortumab vedotin went on to receive subsequent cancer-related therapies, compared to 70% in the gemcitabine and platinum-based chemotherapy arm. Thirty-two percent of patients in the gemcitabine and platinum-based chemotherapy arm received maintenance immunotherapy, and 26% received immunotherapy as first subsequent therapy after disease progression.</p><p>&nbsp;</p><p>The trial demonstrated a statistically significant improvement in OS, PFS, and ORR in patients randomized to KEYTRUDA in combination with enfortumab vedotin compared with patients randomized to gemcitabine and platinum‑based chemotherapy. Efficacy results were consistent across all pre-specified patient subgroups.</p><p>&nbsp;</p><p>The median follow-up time for 442&nbsp;patients treated with KEYTRUDA and enfortumab vedotin was 17.3&nbsp;months (range: 0.3 to 37.2&nbsp;months). Efficacy results are summarized in Table&nbsp;23 and Figures&nbsp;20 and 21.</p><p><strong>Table&nbsp;23: Efficacy Results in KEYNOTE</strong><strong>‑</strong><strong>A39</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:472px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA</strong></p><p><strong>200&nbsp;mg every 3&nbsp;weeks in combination with enfortumab vedotin</strong></p><p><strong>n=442</strong></p></td><td style="vertical-align:top"><p><strong>Gemcitabine + Platinum Chemotherapy with or without maintenance immunotherapy</strong></p><p><strong>n=444</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>OS</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>133 (30%)</p></td><td style="vertical-align:top"><p>226 (51%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>31.5 (25.4, NR)</p></td><td style="vertical-align:top"><p>16.1 (13.9, 18.3)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio* (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.47 (0.38, 0.58)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&dagger;<strong> </strong></sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>223 (50%)</p></td><td style="vertical-align:top"><p>307 (69%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>12.5 (10.4, 16.6)</p></td><td style="vertical-align:top"><p>6.3 (6.2, 6.5)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio* (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.45 (0.38, 0.54)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective Response Rate</strong><sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ORR<sup>&sect;</sup> % (95% CI)</p></td><td style="vertical-align:top"><p>68% (63.1, 72.1)</p></td><td style="vertical-align:top"><p>44% (39.7, 49.2)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&para;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>29%</p></td><td style="vertical-align:top"><p>12%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>39%</p></td><td style="vertical-align:top"><p>32%</p></td></tr><tr><td style="vertical-align:top"><p>Stable Disease</p></td><td style="vertical-align:top"><p>19%</p></td><td style="vertical-align:top"><p>34%</p></td></tr><tr><td style="vertical-align:top"><p>Disease Control Rate<sup>#</sup></p></td><td style="vertical-align:top"><p>86%</p></td><td style="vertical-align:top"><p>78%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response Duration</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>NR</p><p>(2.0+, 28.3+)</p></td><td style="vertical-align:top"><p>7.0</p><p>(1.5+, 30.9+)</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;6&nbsp;months<sup>&THORN;</sup></p></td><td style="vertical-align:top"><p>86%</p></td><td style="vertical-align:top"><p>61%</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;12&nbsp;months<sup>&THORN;</sup></p></td><td style="vertical-align:top"><p>67%</p></td><td style="vertical-align:top"><p>35%</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;18&nbsp;months<sup>&THORN;</sup></p></td><td style="vertical-align:top"><p>60%</p></td><td style="vertical-align:top"><p>19%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on the stratified Cox proportional hazard regression model</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Two-sided p-Value based on stratified log-rank test</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes only patients with measurable disease at baseline</p><p><sup>&sect;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on patients with a best overall response as confirmed complete or partial response</p><p><sup>&para;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Two-sided p-Value based on Cochran-Mantal-Haenszel test stratified by PD‑L1 expression, cisplatin eligibility and liver metastases</p><p><sup>#</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on best response of stable disease or better</p><p><sup>&THORN;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan-Meier estimation</p><p>NR = not reached</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Figure&nbsp;20: </strong><strong>Kaplan-Meier Curve for Overall Survival in KEYNOTE-A39</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA + EV</p><p>Chemotherapy</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>OS Rate at 6 months&nbsp;&nbsp;&nbsp; OS Rate at 12 months&nbsp;&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p-value&nbsp; </u></strong></p><p><strong>KEYTRUDA + EV&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 90%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 78%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.47 (0.38, 0.58)&nbsp;&nbsp;&nbsp; &lt;0.0001</strong></p><p><strong>Chemotherapy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 82%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 61%</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-family:Arial'>Overall
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Overall Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Figure&nbsp;21: Kaplan-Meier Curve for Progression-Free Survival in KEYNOTE-A39</strong></p><p><strong>&nbsp;</strong></p><p><!--[if RotText]><![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-family:Arial'>Progression-Free
     Survival (%)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Progression-Free Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp; <u>PFS Rate at 6 months&nbsp;&nbsp; PFS Rate at 12 months&nbsp;&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p-value </u></strong></p><p><strong>KEYTRUDA + EV&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 73%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 51%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.45 (0.38, 0.54)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;0.0001</strong></p><p><strong>Chemotherapy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 61%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22%</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA + EV</p><p>Chemotherapy</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>&nbsp;</u></em></p><p><em><u>KEYNOTE-869: Open-label trial of combination therapy with enfortumab vedotin in urothelial carcinoma patients ineligible for cisplatin-containing chemotherapy</u></em></p><p>The efficacy of KEYTRUDA in combination with enfortumab vedotin was investigated in KEYNOTE-869, a multi-cohort, multicenter trial that enrolled 121&nbsp;patients with locally advanced or metastatic urothelial carcinoma, who were cisplatin-ineligible and did not receive platinum-containing therapy in the locally advanced or metastatic setting. The trial excluded patients with autoimmune disease or a medical condition that required immunosuppression, active CNS metastases, ongoing sensory or motor neuropathy &ge;Grade 2, or uncontrolled diabetes defined as hemoglobin A1C (HbA1c) &ge;8% or HbA1c &ge;7% with associated diabetes symptoms. Cisplatin-ineligibility for patients in the dose-escalation cohort was determined by the investigator. Patients in cohort A were considered cisplatin-ineligible if they had at least one of the following criteria: creatinine clearance 30-59&nbsp;mL/min, ECOG PS&nbsp;&ge;2, hearing loss/dysfunction, age, or allergy to cisplatin. Patients in cohort K were considered cisplatin-ineligible if they had at least one of the following criteria: glomerular filtration rate clearance 30-59&nbsp;mL/min, ECOG PS&nbsp;&ge;2, Grade &ge;2 hearing loss, or NYHA Class III heart failure.</p><p>&nbsp;</p><p>Patients were treated in either the dose-escalation cohort (n=5) and cohort A (n=40) with KEYTRUDA 200&nbsp;mg over 30&nbsp;minutes on Day&nbsp;1 and enfortumab vedotin 1.25&nbsp;mg/kg on Days&nbsp;1 and 8 of each 21-day cycle, or in cohort K (n=76) where patients were stratified by the absence or presence of liver metastases and ECOG performance status and then randomized (1:1) to KEYTRUDA 200&nbsp;mg over 30&nbsp;minutes on Day&nbsp;1 and enfortumab vedotin 1.25&nbsp;mg/kg on Days&nbsp;1 and 8 of each 21-day cycle, or enfortumab vedotin 1.25&nbsp;mg/kg on Days&nbsp;1 and 8 of each 21-day cycle as monotherapy (n=73).</p><p>&nbsp;</p><p>Treatment with KEYTRUDA and enfortumab vedotin continued until RECIST&nbsp;v1.1-defined progression of disease, unacceptable toxicity, or for KEYTRUDA a maximum of 35&nbsp;cycles (up to approximately 2&nbsp;years). Treatment was permitted beyond RECIST&nbsp;v1.1-defined disease progression if the treating investigator considered the patient to be deriving clinical benefit, and the treatment was tolerated. Assessment of tumor status was performed every 9&nbsp;weeks for one year and then every 12&nbsp;weeks thereafter. The major efficacy outcome measures were ORR and DoR as assessed by BICR according to RECIST&nbsp;v1.1.</p><p>&nbsp;</p><p>The study population characteristics were: median age of 71&nbsp;years; 74%&nbsp;male; and 85%&nbsp;White. Ninety‑eight percent had M1 disease, and 3% had M0 disease. Sixty-three percent had a primary tumor in the lower tract, and 37% of patients had a primary tumor in the upper tract. Eighty-four percent of patients had visceral metastases, including 22% with liver metastases. Among the 121&nbsp;patients, 108&nbsp;patients were evaluable for CPS expression, of which 57% were CPS&lt;10 and 43% were CPS&ge;10. Sixty percent of patients had baseline creatinine clearance of &lt;60&nbsp;mL/min but &ge;&nbsp;30 mL/min, 85% had ECOG PS of 0-1 and 15% ECOG PS of 2. Thirty-nine percent of patients had transitional cell carcinoma (TCC) histology; 13% had TCC with squamous differentiation, and 48% had TCC with other histologic variants.</p><p>&nbsp;</p><p>The median follow-up time for patients treated with KEYTRUDA in combination with enfortumab vedotin in cohort K was 14.8&nbsp;months (range 0.6 to 26.2&nbsp;months) and for the dose-escalation cohort and cohort A was 44.7&nbsp;months (range 0.7 to 52.4&nbsp;months). Efficacy results are summarized in Table&nbsp;24.</p><p>&nbsp;</p><p><strong>Table&nbsp;24: Efficacy Results in KEYNOTE</strong><strong>‑</strong><strong>869</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:610px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA</strong></p><p><strong>200&nbsp;mg every 3&nbsp;weeks in combination with enfortumab vedotin</strong></p><p><strong>Cohort K</strong></p><p><strong>N=76</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA</strong></p><p><strong>200&nbsp;mg every 3&nbsp;weeks in combination with enfortumab vedotin</strong></p><p><strong>Dose Escalation and Cohort A</strong></p><p><strong>N=45</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective Response Rate</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ORR (95% CI)</p></td><td style="vertical-align:top"><p>65% (53, 75)</p></td><td style="vertical-align:top"><p>73% (58, 85)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Complete response rate</p></td><td style="vertical-align:top"><p>11%</p></td><td style="vertical-align:top"><p>16%</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Partial response rate</p></td><td style="vertical-align:top"><p>54%</p></td><td style="vertical-align:top"><p>58%</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of Response</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>NR (1.2, 24.2+)</p></td><td style="vertical-align:top"><p>22.1 (1.0+, 46.3+)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;6 months<sup>*</sup></p></td><td style="vertical-align:top"><p>84%</p></td><td style="vertical-align:top"><p>74%</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Time To Response</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>2.1 (1.1, 6.6)</p></td><td style="vertical-align:top"><p>1.9 (1.1, 13.2)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan-Meier estimation</p><p>NR = not reached</p></td></tr></tbody></table><p>&nbsp;</p><p>In the combined efficacy analysis of the dose escalation/cohort A and cohort K (n=121), ORR was 68% (95% CI: 59, 76) with the complete and partial response rates of 12% and 55%, respectively. Among the responding patients, 80% had responses of 6&nbsp;months or longer (based on Kaplan-Meier estimation).</p><p>&nbsp;</p><p>In cohort K, patients treated with KEYTRUDA in combination with enfortumab vedotin maintained their health-related quality of life (HRQoL), as assessed by the European Organisation for Research and Treatment of Cancer Core QoL Assessment (EORTC QLQ-C30), Brief Pain Inventory Short Form (BPI-SF), and the European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L).</p><p>&nbsp;</p><p><em><u>KEYNOTE‑045: Controlled study in urothelial carcinoma patients who have received prior platinum‑containing chemotherapy</u></em></p><p>The safety and efficacy of KEYTRUDA were evaluated in KEYNOTE‑045, a multicentre, open‑label, randomised (1:1), controlled study for the treatment of locally advanced or metastatic urothelial carcinoma in patients with disease progression on or after platinum‑containing chemotherapy. Patients must have received first‑line platinum‑containing regimen for locally advanced/metastatic disease or as neoadjuvant/adjuvant treatment, with recurrence/progression &le;&nbsp;12&nbsp;months following completion of therapy. Patients were randomised (1:1) to receive either KEYTRUDA 200&nbsp;mg every 3&nbsp;weeks (n=270) or investigator&rsquo;s choice of any of the following chemotherapy regimens all given intravenously every 3&nbsp;weeks (n=272): paclitaxel 175&nbsp;mg/m<sup>2 </sup>(n=84), docetaxel 75&nbsp;mg/m<sup>2 </sup>(n=84), or vinflunine 320&nbsp;mg/m<sup>2 </sup>(n=87). Patients were treated with KEYTRUDA until unacceptable toxicity or disease progression. Treatment could continue beyond progression if the patient was clinically stable and was considered to be deriving clinical benefit by the investigator. Patients without disease progression could be treated for up to 24&nbsp;months. The study excluded patients with autoimmune disease, a medical condition that required immunosuppression and patients with more than 2 prior lines of systemic chemotherapy for metastatic urothelial carcinoma. Patients with an ECOG performance status of 2 had to have a haemoglobin &ge;&nbsp;10&nbsp;g/dL, could not have liver metastases, and must have received the last dose of their last prior chemotherapy regimen &ge;&nbsp;3&nbsp;months prior to enrolment. Assessment of tumour status was performed at 9&nbsp;weeks after the first dose, then every 6&nbsp;weeks through the first year, followed by every 12&nbsp;weeks thereafter.</p><p>&nbsp;</p><p>Among the 542&nbsp;randomised patients in KEYNOTE‑045, baseline characteristics were: median age 66&nbsp;years (range: 26 to 88), 58% age 65 or older; 74%&nbsp;male; 72%&nbsp;White and 23%&nbsp;Asian; 56%&nbsp;ECOG performance status of 1 and 1% ECOG performance status of 2; and 96%&nbsp;M1 disease and 4% M0 disease. Eighty‑seven percent of patients had visceral metastases, including 34% with liver metastases. Eighty‑six percent had a primary tumour in the lower tract and 14% had a primary tumour in the upper tract. Fifteen percent of patients had disease progression following prior platinum‑containing neoadjuvant or adjuvant chemotherapy. Twenty‑one percent had received 2 prior systemic regimens in the metastatic setting. Seventy‑six percent of patients received prior cisplatin, 23% had prior carboplatin, and 1% was treated with other platinum‑based regimens.</p><p><u>&nbsp;</u></p><p>The primary efficacy outcomes were OS and PFS as assessed by BICR using RECIST v1.1. Secondary outcome measures were ORR (as assessed by BICR using RECIST v1.1) and duration of response. Table&nbsp;25 summarises the key efficacy measures for the ITT population at the final analysis. The Kaplan‑Meier curve based on the final analysis for OS is shown in Figure&nbsp;22. The study demonstrated statistically significant improvements in OS and ORR for patients randomised to KEYTRUDA as compared to chemotherapy. There was no statistically significant difference between KEYTRUDA and chemotherapy with respect to PFS.</p><p>&nbsp;</p><p><strong>Table&nbsp;25: Response to KEYTRUDA 200&nbsp;mg every 3&nbsp;weeks in patients with urothelial carcinoma previously treated with chemotherapy in KEYNOTE‑045</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:598px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Pembrolizumab</strong></p><p><strong>200&nbsp;mg every 3&nbsp;weeks</strong></p><p><strong>n=270</strong></p></td><td style="vertical-align:top"><p><strong>Chemotherapy</strong></p><p><strong>&nbsp;</strong></p><p><strong>n=272</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>OS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>200 (74%)</p></td><td style="vertical-align:top"><p>219 (81%)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>*</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.70 (0.57, 0.85)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>10.1 (8.0, 12.3)</p></td><td style="vertical-align:top"><p>7.3 (6.1, 8.1)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>PFS<sup>&Dagger;</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>233 (86%)</p></td><td style="vertical-align:top"><p>237 (87%)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>* </sup>(95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.96 (0.79, 1.16)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.313</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>2.1 (2.0, 2.2)</p></td><td style="vertical-align:top"><p>3.3 (2.4, 3.6)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Objective response rate<sup>&Dagger;</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR % (95% CI)</p></td><td style="vertical-align:top"><p>21% (16, 27)</p></td><td style="vertical-align:top"><p>11% (8, 15)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&sect;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>9%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>12%</p></td><td style="vertical-align:top"><p>8%</p></td></tr><tr><td style="vertical-align:top"><p>Stable disease</p></td><td style="vertical-align:top"><p>17%</p></td><td style="vertical-align:top"><p>34%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Response duration</strong><strong><sup>&Dagger;,&para;</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>Not reached</p><p>(1.6+, 30.0+)</p></td><td style="vertical-align:top"><p>4.4</p><p>(1.4+, 29.9+)</p></td></tr><tr><td style="vertical-align:top"><p>Number (%<sup>#</sup>) of patients with duration &ge;&nbsp;6 months</p></td><td style="vertical-align:top"><p>46 (84%)</p></td><td style="vertical-align:top"><p>8 (47%)</p></td></tr><tr><td style="vertical-align:top"><p>Number (%<sup>#</sup>) of patients with duration &ge;&nbsp;12 months</p></td><td style="vertical-align:top"><p>35 (68%)</p></td><td style="vertical-align:top"><p>5 (35%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hazard ratio (KEYTRUDA compared to chemotherapy) based on the stratified Cox proportional hazard model</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on stratified log‑rank test</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Assessed by BICR using RECIST 1.1</p><p><strong><sup>&sect;</sup></strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on method by Miettinen and Nurminen</p><p><sup>&para;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on patients with a best objective response as confirmed complete or partial response</p><p><sup>#</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan‑Meier estimation</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong>Figure&nbsp;22: Kaplan‑Meier curve for overall survival by treatment arm in KEYNOTE‑045 (intent to treat population)</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>An analysis was performed in KEYNOTE‑045 in patients who had PD‑L1 CPS&nbsp;&lt;&nbsp;10 [pembrolizumab: n=186 (69%) vs. chemotherapy: n=176 (65%)] or &ge;&nbsp;10 [pembrolizumab: n=74 (27%) vs. chemotherapy: n=90 (33%)] in both pembrolizumab‑ and chemotherapy‑treated arms (see Table&nbsp;26).</p><p>&nbsp;</p><p><strong>Table&nbsp;26: OS by PD‑L1 expression</strong></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:588px"><tbody><tr><td style="vertical-align:top"><p><strong>PD‑L1 Expression</strong></p></td><td style="vertical-align:top"><p><strong>Pembrolizumab</strong></p></td><td style="vertical-align:top"><p><strong>Chemotherapy</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>OS by PD‑L1 Expression</strong></p><p><strong>Number (%) of patients with event</strong><sup>*</sup></p></td><td style="vertical-align:top"><p><strong>Hazard</strong></p><p><strong>Ratio</strong><sup>&dagger;</sup><strong> (95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>CPS&nbsp;&lt;&nbsp;10</p></td><td style="vertical-align:top"><p>140 (75%)</p></td><td style="vertical-align:top"><p>144 (82%)</p></td><td style="vertical-align:top"><p>0.75 (0.59, 0.95)</p></td></tr><tr><td style="vertical-align:top"><p>CPS&nbsp;&ge;&nbsp;10</p></td><td style="vertical-align:top"><p>53 (72%)</p></td><td style="vertical-align:top"><p>72 (80%)</p></td><td style="vertical-align:top"><p>0.55 (0.37, 0.81)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Based on final analysis</p><p><sup>&dagger;</sup><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Hazard ratio (KEYTRUDA compared to chemotherapy) based on the stratified Cox proportional hazard model</p></td></tr></tbody></table><p>&nbsp;</p><p>Patient‑reported outcomes (PROs) were assessed using EORTC QLQ‑C30. A prolonged time to deterioration in EORTC QLQ‑C30 global health status/QoL was observed for patients treated with KEYTRUDA compared to investigator&rsquo;s choice chemotherapy (HR 0.70; 95% CI 0.55‑0.90). Over 15&nbsp;weeks of follow‑up, patients treated with KEYTRUDA had stable global health status/QoL, while those treated with investigator&rsquo;s choice chemotherapy had a decline in global health status/QoL. These results should be interpreted in the context of the open‑label study design and therefore taken cautiously.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>KEYNOTE-057: BCG-unresponsive high-risk non-muscle invasive bladder cancer</u></em></p><p>The efficacy of KEYTRUDA was investigated in KEYNOTE‑057, a multicenter, open-label, single-arm trial in 96&nbsp;patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. BCG-unresponsive high-risk NMIBC is defined as persistent disease despite adequate BCG therapy, disease recurrence after an initial tumor-free state following adequate BCG therapy, or T1 disease following a single induction course of BCG. Prior to treatment, all patients had received adequate BCG therapy, had undergone recent cystoscopic procedure(s) and transurethral resection of bladder tumor (TURBT) to remove all resectable disease (Ta and T1 components) and assure the absence of muscle invasive disease. Residual CIS (Tis components) not amenable to complete resection was acceptable. The trial excluded patients with muscle invasive (i.e., T2, T3, T4) locally advanced non-resectable or metastatic urothelial carcinoma, concurrent extra-vesical (i.e., urethra, ureter or renal pelvis) non-muscle invasive transitional cell carcinoma of the urothelium, autoimmune disease or a medical condition that required immunosuppression.</p><p>&nbsp;</p><p>Patients received KEYTRUDA 200&nbsp;mg every 3&nbsp;weeks until unacceptable toxicity, persistent or recurrent high-risk NMIBC, or progressive disease. Assessment of tumor status was performed every 12&nbsp;weeks, and patients without disease progression could be treated for up to 24&nbsp;months. The major efficacy outcome measures were complete response (as defined by negative results for cystoscopy [with TURBT/biopsies as applicable], urine cytology, and computed tomography urography [CTU] imaging) and duration of response.</p><p>&nbsp;</p><p>The study population characteristics were: median age 73&nbsp;years (69% age 65 or older); 84%&nbsp;male; 67%&nbsp;White; and 73% and 27% with an ECOG performance status of 0 or 1, respectively. Tumor pattern at study entry was CIS with T1 (13%), CIS with high-grade TA (25%), and CIS (63%). Baseline high-risk NMIBC disease status was 27%&nbsp;persistent and 73%&nbsp;recurrent. The median number of prior instillations of BCG was 12.</p><p>&nbsp;</p><p>The median follow-up time was 28.0&nbsp;months (range: 4.6 to 40.5&nbsp;months). Efficacy results are summarized in Table&nbsp;27.</p><p>&nbsp;</p><p><strong>Table 27: Efficacy Results for Patients with BCG-unresponsive, High-Risk NMIBC</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td><p><strong>n=96</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Complete Response Rate*</strong></p></td><td style="vertical-align:top"><p>41%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response Duration<sup>&dagger;</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>16.2 (0.0+, 30.4+)</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;6 months</p></td><td style="vertical-align:top"><p>78%<sup>&Dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;12 months</p></td><td style="vertical-align:top"><p>57%<sup>&sect;</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on negative cystoscopy (with TURBT/biopsies as applicable), urine cytology, and computed tomography urography (CTU imaging)</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Duration reflects period from the time complete response was achieved</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan-Meier estimates; includes 27 patients with responses of 6 months or longer</p><p><strong><sup>&sect;</sup></strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan-Meier estimates; includes 18 patients with responses of 12 months or longer</p></td></tr></tbody></table><p>&nbsp;</p><p>At the time of analysis, among the 96 patients there were no occurrences of progression to muscle-invasive disease (T2) or metastatic bladder cancer while on KEYTRUDA.</p><p>&nbsp;</p><p>Patients who had a complete response to KEYTRUDA in KEYNOTE-057 maintained their health-related quality of life (HRQoL), as assessed by the Functional Assessment of Cancer Therapy-Bladder Cancer (FACT-Bl), the Core Lower Urinary Tract Symptom Score (CLSS), and the European Quality of Life Five Dimensions Questionnaire (EQ-5D).</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><em><u>&nbsp;</u></em></p><p><em><u>Head and Neck Squamous Cell Carcinoma</u></em></p><p><em><u>KEYNOTE‑048: Controlled study of monotherapy and combination therapy in HNSCC patients na&iuml;ve to treatment in the recurrent or metastatic setting</u></em></p><p>The efficacy of KEYTRUDA was investigated in KEYNOTE‑048, a multicentre, randomised, open‑label, active‑controlled study in patients with histologically confirmed metastatic or recurrent HNSCC of the oral cavity, pharynx or larynx, who had not previously received systemic therapy for recurrent or metastatic disease and who were considered incurable by local therapies. Patients with nasopharyngeal carcinoma, active autoimmune disease that required systemic therapy within two years of treatment or a medical condition that required immunosuppression were ineligible for the study. Randomisation was stratified by tumour PD‑L1 expression (TPS&nbsp;&ge;&nbsp;50% or &lt;&nbsp;50%), HPV status (positive or negative), and ECOG PS (0 vs. 1). Patients were randomised 1:1:1 to one of the following treatment arms:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; KEYTRUDA 200&nbsp;mg every 3&nbsp;weeks</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; KEYTRUDA 200&nbsp;mg every 3&nbsp;weeks, carboplatin AUC 5&nbsp;mg/mL/min every 3&nbsp;weeks or cisplatin 100&nbsp;mg/m<sup>2</sup> every 3&nbsp;weeks, and&nbsp;5‑FU 1,000&nbsp;mg/m<sup>2</sup>/d 4&nbsp;days continuous every 3&nbsp;weeks (maximum of 6&nbsp;cycles of platinum and 5‑FU)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cetuximab 400&nbsp;mg/m<sup>2</sup> load then 250&nbsp;mg/m<sup>2</sup> once weekly, carboplatin AUC 5&nbsp;mg/mL/min every 3&nbsp;weeks or cisplatin 100&nbsp;mg/m<sup>2</sup> every 3&nbsp;weeks, and 5‑FU 1,000&nbsp;mg/m<sup>2</sup>/d 4&nbsp;days continuous every 3&nbsp;weeks (maximum of 6&nbsp;cycles of platinum and 5‑FU)</p><p><em><u>&nbsp;</u></em></p><p>Treatment with KEYTRUDA continued until RECIST&nbsp;1.1‑defined progression of disease as determined by the investigator, unacceptable toxicity, or a maximum of 24&nbsp;months. Administration of KEYTRUDA was permitted beyond RECIST‑defined disease progression if the patient was clinically stable and considered to be deriving clinical benefit by the investigator. Assessment of tumour status was performed at Week&nbsp;9 and then every 6&nbsp;weeks for the first year, followed by every 9&nbsp;weeks through 24&nbsp;months.</p><p>&nbsp;</p><p>Among the 882&nbsp;patients in KEYNOTE‑048, 754 (85%) had tumours that expressed PD‑L1 with a CPS&nbsp;&ge;&nbsp;1 based on the PD‑L1 IHC 22C3 pharmDx<sup>TM</sup> Kit. The baseline characteristics of these 754&nbsp;patients included: median age of 61&nbsp;years (range: 20 to&nbsp;94); 36% age&nbsp;65 or older; 82% male; 74% White and&nbsp;19% Asian; 61% ECOG performance status of&nbsp;1; and 77% former/current smokers. Disease characteristics were: 21% HPV positive and&nbsp;95% had stage IV disease (stage IVa 21%, stage IVb 6%, and stage IVc 69%).</p><p><em><u>&nbsp;</u></em></p><p>The primary efficacy outcome measures were OS and PFS (assessed by BICR according to RECIST&nbsp;1.1). The study demonstrated a statistically significant improvement in OS for all patients randomised to KEYTRUDA in combination with chemotherapy compared to standard treatment (HR 0.72; 95% CI 0.60‑0.87) and in patients whose tumours expressed PD‑L1 CPS&nbsp;&ge;&nbsp;1 randomised to KEYTRUDA monotherapy compared to standard treatment. Tables&nbsp;28 and 29 summarise key efficacy results for KEYTRUDA in patients whose tumours expressed PD‑L1 with a CPS &ge;&nbsp;1 in KEYNOTE‑048 at the final analysis performed at a median follow‑up of 13&nbsp;months for KEYTRUDA in combination with chemotherapy and at a median follow‑up of 11.5&nbsp;months for KEYTRUDA monotherapy. Kaplan<strong>‑</strong>Meier curves for OS based on the final analysis are shown in Figures&nbsp;23 and 24.</p><p><strong>&nbsp;</strong></p><p><strong>Table&nbsp;28: Efficacy results for KEYTRUDA plus chemotherapy in KEYNOTE‑048</strong> <strong>with PD‑L1 expression (CPS&nbsp;&ge;&nbsp;1)</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:533px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA +</strong></p><p><strong>Platinum Chemotherapy +</strong></p><p><strong>5‑FU</strong></p><p><strong>n=242</strong></p></td><td style="vertical-align:top"><p><strong>Standard</strong></p><p><strong>Treatment</strong><strong><sup>*</sup></strong></p><p><strong>n=235</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>OS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>177 (73%)</p></td><td style="vertical-align:top"><p>213 (91%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>13.6 (10.7, 15.5)</p></td><td style="vertical-align:top"><p>10.4 (9.1, 11.7)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.65 (0.53, 0.80)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.00002</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>PFS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>212 (88%)</p></td><td style="vertical-align:top"><p>221 (94%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>5.1 (4.7, 6.2)</p></td><td style="vertical-align:top"><p>5.0 (4.8, 6.0)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.84 (0.69, 1.02)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.03697</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Objective response rate</strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR<sup>&sect;</sup> % (95% CI)</p></td><td style="vertical-align:top"><p>36% (30.3, 42.8)</p></td><td style="vertical-align:top"><p>36% (29.6, 42.2)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>7%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>30%</p></td><td style="vertical-align:top"><p>33%</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&para;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.4586</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Response duration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>6.7 (1.6+, 39.0+)</p></td><td style="vertical-align:top"><p>4.3 (1.2+, 31.5+)</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;&nbsp;6&nbsp;months</p></td><td style="vertical-align:top"><p>54%</p></td><td style="vertical-align:top"><p>34%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cetuximab, platinum, and 5‑FU</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on the stratified Cox proportional hazard model</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on stratified log‑rank test</p><p><sup>&sect;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Response: Best objective response as confirmed complete response or partial response</p><p><sup>&para;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Miettinen and Nurminen method stratified by ECOG (0 vs. 1), HPV status (positive vs. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; negative) and PD‑L1 status (strongly positive vs. not strongly positive)</p></td></tr></tbody></table><p><em><u>&nbsp;</u></em></p><p><strong>Figure&nbsp;23: </strong><strong>Kaplan‑Meier curve for overall survival for KEYTRUDA plus chemotherapy in KEYNOTE‑048 with PD‑L1 expression (CPS &ge;</strong>&nbsp;<strong>1)</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA + Chemo</p><p>Standard</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>OS rate at 12 months&nbsp;&nbsp; OS rate at 24 months&nbsp;&nbsp; HR (95% CI)&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;p-value</u></strong></p><p><strong>KEYTRUDA+ Chemo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 55%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 31%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.65 (0.53, 0.80)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.00002</strong></p><p><strong>Standard&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 43%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17%</strong></p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Table&nbsp;29: Efficacy results for KEYTRUDA as monotherapy in KEYNOTE‑048 with PD‑L1 expression (CPS&nbsp;&ge;&nbsp;1)</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:517px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Pembrolizumab</strong></p><p><strong>n=257</strong></p></td><td style="vertical-align:top"><p><strong>Standard</strong></p><p><strong>Treatment</strong><strong><sup>*</sup></strong></p><p><strong>n=255</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>OS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>197 (77%)</p></td><td style="vertical-align:top"><p>229 (90%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>12.3 (10.8, 14.3)</p></td><td style="vertical-align:top"><p>10.3 (9.0, 11.5)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.74 (0.61, 0.90)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.00133</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>PFS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>228 (89%)</p></td><td style="vertical-align:top"><p>237 (93%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>3.2 (2.2, 3.4)</p></td><td style="vertical-align:top"><p>5.0 (4.8, 6.0)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>1.13 (0.94, 1.36)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.89580</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Objective response rate</strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR<sup>&sect;</sup> % (95% CI)</p></td><td style="vertical-align:top"><p>19.1% (14.5, 24.4)</p></td><td style="vertical-align:top"><p>35% (29.1, 41.1)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>14%</p></td><td style="vertical-align:top"><p>32%</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&para;</sup></p></td><td colspan="2" style="vertical-align:top"><p>1.0000</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Response duration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>23.4 (1.5+, 43.0+)</p></td><td style="vertical-align:top"><p>4.5 (1.2+, 38.7+)</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;&nbsp;6&nbsp;months</p></td><td style="vertical-align:top"><p>81%</p></td><td style="vertical-align:top"><p>36%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cetuximab, platinum, and 5‑FU</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on the stratified Cox proportional hazard model</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on stratified log‑rank test</p><p><sup>&sect;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Response: Best objective response as confirmed complete response or partial response</p><p><sup>&para;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Miettinen and Nurminen method stratified by ECOG (0 vs. 1), HPV status (positive &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vs. negative) and PD‑L1 status (strongly positive vs. not strongly positive)</p></td></tr></tbody></table><p><em><u>&nbsp;</u></em></p><p><strong>Figure&nbsp;24: Kaplan‑Meier curve for overall survival for KEYTRUDA as monotherapy in KEYNOTE‑048 with PD‑L1 expression (CPS&nbsp;&ge;&nbsp;1)</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA</p><p>Standard</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>OS rate at 12 months&nbsp;&nbsp; OS rate at 24 months &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HR (95% CI)&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;p-value</u></strong></p><p><strong>KEYTRUDA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 29%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.74 (0.61, 0.90)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.00133</strong></p><p><strong>Standard&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 44%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17%</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>An analysis was performed in KEYNOTE‑048 in patients whose tumours expressed PD‑L1 CPS&nbsp;&ge;&nbsp;20 [KEYTRUDA plus chemotherapy: n=126 (49%) vs. standard treatment: n=110 (43%) and KEYTRUDA monotherapy: n=133 (52%) vs. standard treatment: n=122 (48%)] (see Table&nbsp;30).</p><p>&nbsp;</p><p><strong>Table&nbsp;30: Efficacy results for KEYTRUDA plus chemotherapy and KEYTRUDA as monotherapy by PD‑L1 expression in KEYNOTE‑048 (</strong><strong>CPS&nbsp;&ge;&nbsp;20)</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:738px"><thead><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA +</strong></p><p><strong>Platinum Chemotherapy +</strong></p><p><strong>5‑FU</strong></p><p><strong>n=126</strong></p></td><td style="vertical-align:top"><p><strong>Standard Treatment</strong><strong><sup>*</sup></strong></p><p><strong>n=110</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA Monotherapy</strong></p><p><strong>n=133</strong></p></td><td style="vertical-align:top"><p><strong>Standard Treatment</strong><strong><sup>*</sup></strong></p><p><strong>n=122</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>OS</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>84 (66.7%)</p></td><td style="vertical-align:top"><p>98 (89.1%)</p></td><td style="vertical-align:top"><p>94 (70.7%)</p></td><td style="vertical-align:top"><p>108 (88.5%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>14.7 (10.3, 19.3)</p></td><td style="vertical-align:top"><p>11.0 (9.2, 13.0)</p></td><td style="vertical-align:top"><p>14.8 (11.5, 20.6)</p></td><td style="vertical-align:top"><p>10.7 (8.8, 12.8)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.60 (0.45, 0.82)</p></td><td colspan="2" style="vertical-align:top"><p>0.58 (0.44, 0.78)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.00044</p></td><td colspan="2" style="vertical-align:top"><p>0.00010</p></td></tr><tr><td style="vertical-align:top"><p>OS rate at 6 months (95% CI)</p></td><td style="vertical-align:top"><p>74.6 (66.0, 81.3)</p></td><td style="vertical-align:top"><p>80.0 (71.2, 86.3)</p></td><td style="vertical-align:top"><p>74.4 (66.1, 81.0)</p></td><td style="vertical-align:top"><p>79.5 (71.2, 85.7)</p></td></tr><tr><td style="vertical-align:top"><p>OS rate at 12 months (95% CI)</p></td><td style="vertical-align:top"><p>57.1 (48.0, 65.2)</p></td><td style="vertical-align:top"><p>46.1 (36.6, 55.1)</p></td><td style="vertical-align:top"><p>56.4 (47.5, 64.3)</p></td><td style="vertical-align:top"><p>44.9 (35.9, 53.4)</p></td></tr><tr><td style="vertical-align:top"><p>OS rate at 24 months (95% CI)</p></td><td style="vertical-align:top"><p>35.4 (27.2, 43.8)</p></td><td style="vertical-align:top"><p>19.4 (12.6, 27.3)</p></td><td style="vertical-align:top"><p>35.3 (27.3, 43.4)</p></td><td style="vertical-align:top"><p>19.1 (12.7, 26.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>106 (84.1%)</p></td><td style="vertical-align:top"><p>104 (94.5%)</p></td><td style="vertical-align:top"><p>115 (86.5%)</p></td><td style="vertical-align:top"><p>114 (93.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>5.8 (4.7, 7.6)</p></td><td style="vertical-align:top"><p>5.3 (4.9, 6.3)</p></td><td style="vertical-align:top"><p>3.4 (3.2, 3.8)</p></td><td style="vertical-align:top"><p>5.3 (4.8, 6.3)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.76 (0.58, 1.01)</p></td><td colspan="2" style="vertical-align:top"><p>0.99 (0.76, 1.29)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.02951</p></td><td colspan="2" style="vertical-align:top"><p>0.46791</p></td></tr><tr><td style="vertical-align:top"><p>PFS rate at 6 months (95% CI)</p></td><td style="vertical-align:top"><p>49.4 (40.3, 57.9)</p></td><td style="vertical-align:top"><p>47.2 (37.5, 56.2)</p></td><td style="vertical-align:top"><p>33.0 (25.2, 41.0)</p></td><td style="vertical-align:top"><p>46.6 (37.5, 55.2)</p></td></tr><tr><td style="vertical-align:top"><p>PFS rate at 12 months (95% CI)</p></td><td style="vertical-align:top"><p>23.9 (16.7, 31.7)</p></td><td style="vertical-align:top"><p>14.0 (8.2, 21.3)</p></td><td style="vertical-align:top"><p>23.5 (16.6, 31.1)</p></td><td style="vertical-align:top"><p>15.1 (9.3, 22.2)</p></td></tr><tr><td style="vertical-align:top"><p>PFS rate at 24 months (95% CI)</p></td><td style="vertical-align:top"><p>14.6 (8.9, 21.5)</p></td><td style="vertical-align:top"><p>5.0 (1.9, 10.5)</p></td><td style="vertical-align:top"><p>16.8 (10.9, 23.8)</p></td><td style="vertical-align:top"><p>6.1 (2.7, 11.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective response rate</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ORR<sup>&sect;</sup> % (95% CI)</p></td><td style="vertical-align:top"><p>42.9 (34.1, 52.0)</p></td><td style="vertical-align:top"><p>38.2 (29.1, 47.9)</p></td><td style="vertical-align:top"><p>23.3 (16.4, 31.4)</p></td><td style="vertical-align:top"><p>36.1 (27.6, 45.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response duration</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number of responders</p></td><td style="vertical-align:top"><p>54</p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>44</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>7.1 (2.1+, 39.0+)</p></td><td style="vertical-align:top"><p>4.2 (1.2+, 31.5+)</p></td><td style="vertical-align:top"><p>22.6 (2.7+, 43.0+)</p></td><td style="vertical-align:top"><p>4.2 (1.2+, 31.5+)</p></td></tr></tbody></table><p><sup>*</sup>&nbsp;&nbsp; Cetuximab, platinum, and 5‑FU</p><p><sup>&dagger;</sup>&nbsp;&nbsp; Based on the stratified Cox proportional hazard model</p><p><sup>&Dagger;</sup>&nbsp;&nbsp; Based on stratified log‑rank test</p><p><sup>&sect;</sup>&nbsp;&nbsp; Response: Best objective response as confirmed complete response or partial response</p><p><em><u>&nbsp;</u></em></p><p>An exploratory subgroup analysis was performed in KEYNOTE‑048 in patients whose tumours expressed PD‑L1 CPS&nbsp;<strong>&ge;</strong>&nbsp;1 to &lt;&nbsp;20 [KEYTRUDA plus chemotherapy: n=116 (45%) vs. standard treatment: n=125 (49%) and KEYTRUDA monotherapy: n=124 (48%) vs. standard treatment: n=133 (52%)] (see Table&nbsp;31).</p><p>&nbsp;</p><p><strong>Table&nbsp;31: Efficacy results for KEYTRUDA plus chemotherapy and KEYTRUDA as monotherapy by PD‑L1 expression in KEYNOTE‑048 (CPS&nbsp;&ge;&nbsp;1 to &lt;&nbsp;20</strong><strong>)</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:750px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA +</strong></p><p><strong>Platinum Chemotherapy +</strong></p><p><strong>5‑FU</strong></p><p><strong>n=116</strong></p></td><td style="vertical-align:top"><p><strong>Standard Treatment</strong><strong><sup>*</sup></strong></p><p><strong>n=125</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA Monotherapy</strong></p><p><strong>n=124</strong></p></td><td style="vertical-align:top"><p><strong>Standard Treatment</strong><strong><sup>*</sup></strong></p><p><strong>n=133</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>OS</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>93 (80.2%)</p></td><td style="vertical-align:top"><p>115 (92.0%)</p></td><td style="vertical-align:top"><p>103 (83.1%)</p></td><td style="vertical-align:top"><p>121 (91.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>12.7 (9.4, 15.3)</p></td><td style="vertical-align:top"><p>9.9 (8.6, 11.5)</p></td><td style="vertical-align:top"><p>10.8 (9.0, 12.6)</p></td><td style="vertical-align:top"><p>10.1 (8.7, 12.1)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.71 (0.54, 0.94)</p></td><td colspan="2" style="vertical-align:top"><p>0.86 (0.66, 1.12)</p></td></tr><tr><td style="vertical-align:top"><p>OS rate at 6 months (95% CI)</p></td><td style="vertical-align:top"><p>76.7 (67.9, 83.4)</p></td><td style="vertical-align:top"><p>77.4 (69.0, 83.8)</p></td><td style="vertical-align:top"><p>67.6 (58.6, 75.1)</p></td><td style="vertical-align:top"><p>78.0 (70.0, 84.2)</p></td></tr><tr><td style="vertical-align:top"><p>OS rate at 12 months (95% CI)</p></td><td style="vertical-align:top"><p>52.6 (43.1, 61.2)</p></td><td style="vertical-align:top"><p>41.1 (32.4, 49.6)</p></td><td style="vertical-align:top"><p>44.0 (35.1, 52.5)</p></td><td style="vertical-align:top"><p>42.4 (33.9, 50.7)</p></td></tr><tr><td style="vertical-align:top"><p>OS rate at 24 months (95% CI)</p></td><td style="vertical-align:top"><p>25.9 (18.3, 34.1)</p></td><td style="vertical-align:top"><p>14.5 (9.0, 21.3)</p></td><td style="vertical-align:top"><p>22.0 (15.1, 29.6)</p></td><td style="vertical-align:top"><p>15.9 (10.3, 22.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>106 (91.4%)</p></td><td style="vertical-align:top"><p>117 (93.6%)</p></td><td style="vertical-align:top"><p>113 (91.1%)</p></td><td style="vertical-align:top"><p>123 (92.5%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>4.9 (4.2, 5.3)</p></td><td style="vertical-align:top"><p>4.9 (3.7, 6.0)</p></td><td style="vertical-align:top"><p>2.2 (2.1, 2.9)</p></td><td style="vertical-align:top"><p>4.9 (3.8, 6.0)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.93 (0.71, 1.21)</p></td><td colspan="2" style="vertical-align:top"><p>1.25 (0.96, 1.61)</p></td></tr><tr><td style="vertical-align:top"><p>PFS rate at 6 months (95% CI)</p></td><td style="vertical-align:top"><p>40.1 (31.0, 49.0)</p></td><td style="vertical-align:top"><p>40.0 (31.2, 48.5)</p></td><td style="vertical-align:top"><p>24.2 (17.1, 32.0)</p></td><td style="vertical-align:top"><p>41.4 (32.8, 49.7)</p></td></tr><tr><td style="vertical-align:top"><p>PFS rate at 12 months (95% CI)</p></td><td style="vertical-align:top"><p>15.1 (9.1, 22.4)</p></td><td style="vertical-align:top"><p>11.3 (6.4, 17.7)</p></td><td style="vertical-align:top"><p>17.5 (11.4, 24.7)</p></td><td style="vertical-align:top"><p>12.1 (7.2, 18.5)</p></td></tr><tr><td style="vertical-align:top"><p>PFS rate at 24 months (95% CI)</p></td><td style="vertical-align:top"><p>8.5 (4.2, 14.7)</p></td><td style="vertical-align:top"><p>5.0 (1.9, 10.1)</p></td><td style="vertical-align:top"><p>8.3 (4.3, 14.1)</p></td><td style="vertical-align:top"><p>6.3 (2.9, 11.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective response rate</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ORR<sup>&Dagger;</sup> % (95% CI)</p></td><td style="vertical-align:top"><p>29.3 (21.2, 38.5)</p></td><td style="vertical-align:top"><p>33.6 (25.4, 42.6)</p></td><td style="vertical-align:top"><p>14.5 (8.8, 22.0)</p></td><td style="vertical-align:top"><p>33.8 (25.9,42.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response duration</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number of responders</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>45</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>5.6 (1.6+, 25.6+)</p></td><td style="vertical-align:top"><p>4.6 (1.4+, 31.4+)</p></td><td style="vertical-align:top"><p>NR (1.5+, 38.9+)</p></td><td style="vertical-align:top"><p>5.0 (1.4+, 38.7+)</p></td></tr></tbody></table><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp; Cetuximab, platinum, and 5‑FU</p><p>&dagger;&nbsp;&nbsp;&nbsp; Based on the stratified Cox proportional hazard model</p><p>&Dagger;&nbsp;&nbsp;&nbsp; Response: Best objective response as confirmed complete response or partial response</p><p><em><u>&nbsp;</u></em></p><p><em><u>KEYNOTE‑040: Controlled study in HNSCC patients previously treated with platinum‑containing chemotherapy</u></em></p><p>The safety and efficacy of KEYTRUDA were investigated in KEYNOTE‑040, a multicentre, open‑label, randomised, controlled study for the treatment of histologically confirmed recurrent or metastatic HNSCC of the oral cavity, pharynx or larynx in patients who had disease progression on or after platinum‑containing chemotherapy administered for recurrent or metastatic HNSCC or following platinum‑containing chemotherapy administered as part of induction, concurrent, or adjuvant therapy, and were not amenable to local therapy with curative intent. Patients were stratified by PD‑L1 expression (TPS &ge;&nbsp;50%), HPV status and ECOG performance status and then randomised (1:1) to receive either KEYTRUDA 200&nbsp;mg every 3&nbsp;weeks (n=247) or one of three standard treatments (n=248): methotrexate 40&nbsp;mg/m<sup>2</sup> once weekly (n=64), docetaxel 75&nbsp;mg/m<sup>2</sup> once every 3&nbsp;weeks (n=99), or cetuximab 400&nbsp;mg/m<sup>2</sup> loading dose and then 250&nbsp;mg/m<sup>2</sup> once weekly (n=71). Treatment could continue beyond progression if the patient was clinically stable and was considered to be deriving clinical benefit by the investigator. The study excluded patients with nasopharyngeal carcinoma, active autoimmune disease that required systemic therapy within 2&nbsp;years of treatment, a medical condition that required immunosuppression, or who were previously treated with 3 or more systemic regimens for recurrent and/or metastatic HNSCC. Assessment of tumour status was performed at 9&nbsp;weeks, then every 6&nbsp;weeks through Week&nbsp;52, followed by every 9&nbsp;weeks through 24&nbsp;months.</p><p>&nbsp;</p><p>Among the 495&nbsp;patients in KEYNOTE‑040, 129 (26%) had tumours that expressed PD‑L1 with a TPS&nbsp;&ge;&nbsp;50% based on the PD‑L1 IHC 22C3 pharmDx<sup>TM</sup> Kit. The baseline characteristics of these 129&nbsp;patients included: median age 62&nbsp;years (40%&nbsp;age 65 or older); 81%&nbsp;male; 78%&nbsp;White, 11%&nbsp;Asian, and 2%&nbsp;Black; 23% and 77% with an ECOG performance status 0 or 1, respectively; and 19% with HPV positive tumours. Sixty‑seven percent&nbsp;(67%) of patients had M1 disease and the majority had stage IV disease (stage IV&nbsp;32%, stage IVa&nbsp;14%, stage IVb&nbsp;4%, and stage IVc&nbsp;44%). Sixteen percent&nbsp;(16%) had disease progression following platinum‑containing neoadjuvant or adjuvant chemotherapy, and 84% had received 1‑2 prior systemic regimens for metastatic disease.</p><p>&nbsp;</p><p>The primary efficacy outcome was OS in the ITT population. The initial analysis resulted in a HR for OS of 0.82 (95% CI: 0.67, 1.01) with a one‑sided p‑Value of 0.0316. The median OS was 8.4&nbsp;months for KEYTRUDA compared to 7.1&nbsp;months for standard treatment. Table&nbsp;32 summarises the key efficacy measures for the TPS&nbsp;&ge;&nbsp;50% population. The Kaplan‑Meier curve for OS for the TPS&nbsp;&ge;&nbsp;50% population is shown in Figure&nbsp;25.</p><p>&nbsp;</p><p><strong>Table&nbsp;32: Efficacy of KEYTRUDA 200&nbsp;mg every 3</strong>&nbsp;<strong>weeks in HNSCC patients with TPS&nbsp;&ge;&nbsp;50% who were previously treated with platinum chemotherapy in KEYNOTE‑040</strong></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Pembrolizumab</strong></p><p><strong>200&nbsp;mg every 3</strong>&nbsp;<strong>weeks</strong></p><p><strong>n=64</strong></p></td><td style="vertical-align:top"><p><strong>Standard Treatment</strong><strong><sup>*</sup></strong></p><p><strong>n=65</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>OS</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Number (%) of patients with event</p></td><td style="vertical-align:top"><p>41 (64%)</p></td><td style="vertical-align:top"><p>56 (86%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.53 (0.35, 0.81)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; p‑Value<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.001</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Median in months (95% CI)</p></td><td style="vertical-align:top"><p>11.6 (8.3, 19.5)</p></td><td style="vertical-align:top"><p>6.6 (4.8, 9.2)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>PFS<sup>&sect;</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Number (%) of patients with event</p></td><td style="vertical-align:top"><p>52 (81%)</p></td><td style="vertical-align:top"><p>58 (89%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.58 (0.39, 0.86)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; p‑Value<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.003</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Median in months (95% CI)</p></td><td style="vertical-align:top"><p>3.5 (2.1, 6.3)</p></td><td style="vertical-align:top"><p>2.1 (2.0, 2.4)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Rate (%) at 6 months (95% CI)</p></td><td style="vertical-align:top"><p>40.1 (28.1, 51.9)</p></td><td style="vertical-align:top"><p>17.1 (8.8, 27.7)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Objective response rate<sup>&sect;</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR % (95% CI)</p></td><td style="vertical-align:top"><p>26.6 (16.3, 39.1)</p></td><td style="vertical-align:top"><p>9.2 (3.5, 19.0)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&para;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.0009</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complete response</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Partial response</p></td><td style="vertical-align:top"><p>22%</p></td><td style="vertical-align:top"><p>8%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stable disease</p></td><td style="vertical-align:top"><p>23%</p></td><td style="vertical-align:top"><p>23%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Response duration<sup>&sect;,#</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Median in months (range)</p></td><td style="vertical-align:top"><p>Not reached (2.7, 13.8+)</p></td><td style="vertical-align:top"><p>6.9 (4.2, 18.8)</p></td></tr><tr><td style="vertical-align:top"><p>Number (%<sup>&THORN;</sup>) of patients with duration &ge;&nbsp;6 months</p></td><td><p>9 (66)</p></td><td><p>2 (50)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methotrexate, docetaxel, or cetuximab</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hazard ratio (KEYTRUDA compared to standard treatment) based on the stratified Cox proportional hazard model</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One‑sided p‑Value based on log-rank test</p><p><sup>&sect;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Assessed by BICR using RECIST 1.1</p><p><sup>&para;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on method by Miettinen and Nurminen</p><p><sup>#</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on patients with a best objective response as confirmed complete or partial response</p><p><sup>&THORN;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan‑Meier estimation</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure&nbsp;</strong><strong>25</strong><strong>: </strong><strong>Kaplan‑Meier curve for overall survival by treatment arm in KEYNOTE‑040 patients with PD‑L1 expression (TPS&nbsp;&ge;&nbsp;50%)</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA</p><p>Standard Treatment</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>OS rate at 12 months&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HR (95% CI) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;p-value</u></strong></p><p><strong>KEYTRUDA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;47%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.53 (0.35, 0.81)&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.00136</strong></p><p><strong>Standard Treatment&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25%</strong></p></td></tr></tbody></table><p>&nbsp;</p><p><u>&nbsp;</u></p><p>&nbsp;</p><p><u>&nbsp;</u></p><p>&nbsp;</p><p><em><u>Renal cell carcinoma</u></em></p><p><em><u>KEYNOTE‑426: Controlled study of combination therapy with axitinib in RCC patients na&iuml;ve to treatment</u></em></p><p>The efficacy of KEYTRUDA in combination with axitinib was investigated in KEYNOTE‑426, a&nbsp;randomised, multicentre, open‑label, active‑controlled study conducted in patients with advanced RCC with clear cell component, regardless of PD‑L1 tumour expression status and International Metastatic RCC Database Consortium (IMDC) risk group categories. The study excluded patients with autoimmune disease or a medical condition that required immunosuppression. Randomisation was stratified by risk categories (favourable versus intermediate versus poor) and geographic region (North America versus Western Europe versus &ldquo;Rest of the World&rdquo;). Patients were randomised (1:1) to one of the following treatment arms:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; KEYTRUDA 200&nbsp;mg<sup> </sup>intravenously every 3&nbsp;weeks in combination with axitinib 5&nbsp;mg orally, twice daily. Patients who tolerated axitinib 5&nbsp;mg twice daily for 2&nbsp;consecutive treatment cycles (i.e. 6&nbsp;weeks) with no &gt; Grade&nbsp;2 treatment‑related adverse events to axitinib and with blood pressure well controlled to &le;&nbsp;150/90&nbsp;mm&nbsp;Hg were permitted dose escalation of axitinib to 7&nbsp;mg twice daily. Dose escalation of axitinib to 10&nbsp;mg twice daily was permitted using the same criteria. Axitinib could be interrupted or reduced to 3&nbsp;mg twice daily and subsequently to 2&nbsp;mg twice daily to manage toxicity.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sunitinib 50&nbsp;mg orally, once daily for 4&nbsp;weeks and then off treatment for 2&nbsp;weeks.</p><p>&nbsp;</p><p>Treatment with KEYTRUDA and axitinib continued until RECIST&nbsp;v1.1‑defined progression of disease as verified by BICR or confirmed by the investigator, unacceptable toxicity, or for pembrolizumab, a maximum of 24&nbsp;months. Administration of KEYTRUDA and axitinib was permitted beyond RECIST‑defined disease progression if the patient was clinically stable and considered to be deriving clinical benefit by the investigator. Assessment of tumour status was performed at baseline, after randomisation at Week&nbsp;12, then every 6&nbsp;weeks thereafter until Week&nbsp;54, and then every 12&nbsp;weeks thereafter.</p><p>&nbsp;</p><p>A total of 861&nbsp;patients were randomised. The study population characteristics were: median age of 62&nbsp;years (range: 26 to 90); 38% age 65 or older; 73%&nbsp;male; 79%&nbsp;White and 16%&nbsp;Asian; 80% had a Karnofsky Performance Score (KPS) 90‑100 and 20% had KPS 70‑80; patient distribution by IMDC risk categories was 31% favourable, 56% intermediate and 13% poor.</p><p>&nbsp;</p><p>The primary efficacy outcome measures were OS and PFS (as assessed by BICR using RECIST 1.1). Secondary efficacy outcome measures were ORR and response duration, as assessed by BICR using RECIST 1.1. The study demonstrated a statistically significant improvement in OS (HR 0.53; 95% CI 0.38, 0.74; p‑Value=0.00005) and PFS (HR 0.69; 95% CI 0.56, 0.84; p‑Value=0.00012) for patients randomised to the KEYTRUDA combination arm compared with sunitinib at its pre‑specified interim analysis. Table&nbsp;33 summarises key efficacy measures and Figures&nbsp;26 and 27 show the Kaplan‑Meier curves for OS and PFS based on the final analysis with a median follow‑up time of 37.7&nbsp;months.</p><p><u>&nbsp;</u></p><p><strong>Table&nbsp;33: Efficacy results in KEYNOTE‑426</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:563px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Pembrolizumab</strong></p><p><strong>Axitinib</strong></p><p><strong>n=432</strong></p></td><td style="vertical-align:top"><p><strong>Sunitinib</strong></p><p><strong>n=429</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>OS</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>193 (45%)</p></td><td style="vertical-align:top"><p>225 (52%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>45.7 (43.6, NA)</p></td><td style="vertical-align:top"><p>40.1 (34.3, 44.2)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>*</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.73 (0.60, 0.88)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.00062</p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS</strong><strong><sup>&Dagger;</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>286 (66%)</p></td><td style="vertical-align:top"><p>301 (70%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>15.7 (13.6, 20.2)</p></td><td style="vertical-align:top"><p>11.1 (8.9, 12.5)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>*</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.68 (0.58, 0.80)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.00001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective response rate</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ORR<sup>&sect;</sup> % (95% CI)</p></td><td style="vertical-align:top"><p>60 (56, 65)</p></td><td style="vertical-align:top"><p>40 (35, 44)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complete response</p></td><td style="vertical-align:top"><p>10%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Partial response</p></td><td style="vertical-align:top"><p>50%</p></td><td style="vertical-align:top"><p>36%</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&para;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response duration</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>23.6 (1.4+, 43.4+)</p></td><td style="vertical-align:top"><p>15.3 (2.3, 42.8+)</p></td></tr><tr><td style="vertical-align:top"><p>Number (%<sup>#</sup>) of patients with duration &ge;&nbsp;30&nbsp;months</p></td><td style="vertical-align:top"><p>87 (45%)</p></td><td style="vertical-align:top"><p>29 (32%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp; Based on the stratified Cox proportional hazard model</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nominal p-Value based on stratified log‑rank test</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Assessed by BICR using RECIST 1.1</p><p><sup>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Based on patients with a best objective response as confirmed complete or partial response</p><p><sup>&para;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nominal p‑Value based on Miettinen and Nurminen method stratified by IMDC risk group and geographic region.<sup> </sup>At the pre‑specified interim analysis of ORR (median follow‑up time of 12.8&nbsp;months), statistically significant superiority was achieved for ORR comparing KEYTRUDA plus axitinib with sunitinib p‑Value &lt;&nbsp;0.0001.</p><p><sup>#&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Based on Kaplan‑Meier estimation</p><p>NA = not available</p><p><s>&nbsp;</s></p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><strong>Figure</strong>&nbsp;<strong>26: Kaplan‑Meier curve for overall survival by treatment arm in</strong></p><p><strong>KEYNOTE‑426 (intent to treat population)</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Number at Risk</strong></p><p>KEYTRUDA + Axitinib</p><p>Sunitinib</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>OS rate at 12 months&nbsp;&nbsp; OS rate at 36 months&nbsp;&nbsp;&nbsp; HR (95% CI)&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;p-value</u></strong></p><p><strong>KEYTRUDA + Axitinib&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 90%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 63%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.73 (0.60, 0.88)&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.00062</strong></p><p><strong>Sunitinib&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 79%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 54%</strong></p></td></tr></tbody></table><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-family:"Arial",sans-serif'>Overall
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Overall Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Figure</strong>&nbsp;<strong>27: Kaplan‑Meier curve for progression‑free survival by treatment arm in</strong></p><p><strong>KEYNOTE‑426 (intent to treat population)</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Number at Risk</strong></p><p>KEYTRUDA + Axitinib</p><p>Sunitinib</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>PFS rate at 12 months&nbsp;&nbsp; PFS rate at 36 months &nbsp;&nbsp;&nbsp;&nbsp;HR (95% CI) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;p-value</u></strong></p><p><strong>KEYTRUDA + Axitinib&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;60%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 29%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.68 (0.58, 0.80)&nbsp;&nbsp; &lt;0.00001</strong></p><p><strong>Sunitinib&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 47%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15%</strong></p></td></tr></tbody></table><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-family:"Arial",sans-serif'>Progression-Free
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Progression-Free Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><p>&nbsp;</p><p>Subgroup analyses were performed in KEYNOTE‑426 in patients with PD‑L1 CPS&nbsp;&ge;&nbsp;1 [pembrolizumab/axitinib combination: n=243 (56%) vs. sunitinib: n=254 (59%)] and CPS&nbsp;&lt;&nbsp;1 [pembrolizumab/axitinib combination: n=167 (39%) vs. sunitinib: n=158 (37%)]. OS and PFS benefits were observed regardless of PD‑L1 expression level.</p><p>&nbsp;</p><p>The KEYNOTE‑426 study was not powered to evaluate efficacy of individual subgroups.</p><p>&nbsp;</p><p>At the pre-specified interim analysis, for the IMDC risk category, the OS hazard ratio (HR) for patients randomised to the KEYTRUDA combination arm compared with sunitinib in the favourable risk group was 0.64 (95% CI 0.24, 1.68), for the intermediate risk group the OS HR was 0.53 (95% CI 0.35, 0.82), and for the poor risk group the OS HR was 0.43 (95% CI 0.23, 0.81). The PFS HR (95% CI) for the favourable, intermediate and poor risk groups were 0.81 (0.53, 1.24), 0.69 (0.53, 0.90) and 0.58 (0.35, 0.94), respectively. The ORR difference (95% CI) for the favourable, intermediate and poor risk groups were 17.0% (5.3, 28.4), 25.5% (16.7, 33.9), and 31.5% (15.7, 46.2), respectively.</p><p>&nbsp;</p><p>Table<strong>&nbsp;</strong>34 summarises the efficacy measures by IMDC risk category based on the final OS analysis at a median follow-up of 37.7&nbsp;months.</p><p>&nbsp;</p><p><strong>Table&nbsp;34: Efficacy results in KEYNOTE‑426 by IMDC risk category</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:592px"><thead><tr><td style="vertical-align:top"><p><strong>Endpoint</strong><strong><sup>*</sup></strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA + Axitinib</strong></p><p><strong>n=432</strong></p></td><td style="vertical-align:top"><p><strong>Sunitinib</strong></p><p><strong>n=429</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA + Axitinib vs. Sunitinib</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>OS</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>12‑month OS rate, % (95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>OS HR (95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Favourable</p></td><td style="vertical-align:top"><p>95.6 (90.5, 98.0)</p></td><td style="vertical-align:top"><p>94.6 (89.0, 97.4)</p></td><td style="vertical-align:top"><p>1.17 (0.76, 1.80)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Intermediate</p></td><td style="vertical-align:top"><p>90.7 (86.2, 93.8)</p></td><td style="vertical-align:top"><p>77.6 (71.8, 82.3)</p></td><td style="vertical-align:top"><p>0.67 (0.52, 0.86)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Poor</p></td><td style="vertical-align:top"><p>69.6 (55.8, 79.9)</p></td><td style="vertical-align:top"><p>45.1 (31.2, 58.0)</p></td><td style="vertical-align:top"><p>0.51 (0.32, 0.81)</p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Median (95% CI), months</strong></p></td><td style="vertical-align:top"><p><strong>PFS HR (95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Favourable</p></td><td style="vertical-align:top"><p>20.7 (15.2, 28.9)</p></td><td style="vertical-align:top"><p>17.8 (12.5, 20.7)</p></td><td style="vertical-align:top"><p>0.76 (0.56, 1.03)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Intermediate</p></td><td style="vertical-align:top"><p>15.3 (12.5, 20.8)</p></td><td style="vertical-align:top"><p>9.7 (8.0, 12.4)</p></td><td style="vertical-align:top"><p>0.69 (0.55, 0.86)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Poor</p></td><td style="vertical-align:top"><p>4.9 (2.8, 12.4)</p></td><td style="vertical-align:top"><p>2.9 (2.7, 4.2)</p></td><td style="vertical-align:top"><p>0.53 (0.33, 0.84)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Confirmed ORR</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>% (95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>ORR difference, </strong></p><p><strong>% (95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Favourable</p></td><td style="vertical-align:top"><p>68.8 (60.4, 76.4)</p></td><td style="vertical-align:top"><p>50.4 (41.5, 59.2)</p></td><td style="vertical-align:top"><p>18.5 (6.7, 29.7)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Intermediate</p></td><td style="vertical-align:top"><p>60.5 (54.0, 66.8)</p></td><td style="vertical-align:top"><p>39.8 (33.7, 46.3)</p></td><td style="vertical-align:top"><p>20.7 (11.8, 29.2)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Poor</p></td><td style="vertical-align:top"><p>39.3 (26.5, 53.2)</p></td><td style="vertical-align:top"><p>11.5 (4.4, 23.4)</p></td><td style="vertical-align:top"><p>27.7 (11.7, 42.8)</p></td></tr></tbody></table><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; n (%) for favourable, intermediate and poor risk categories for pembrolizumab/axitinib vs. sunitinib were: 138 (32%) vs. 131 (31%); 238 (55%) vs. 246 (57%); 56 (13%) vs. 52 (12%), respectively</p><p><u>&nbsp;</u></p><p><em><u>KEYNOTE‑581: Controlled study of combination therapy with lenvatinib in RCC patients na&iuml;ve to </u></em><em><u>treatment</u></em></p><p>The efficacy of KEYTRUDA in combination with lenvatinib was investigated in KEYNOTE-581, a multicentre, open-label, randomised study conducted in 1,069&nbsp;patients with advanced RCC with clear cell component including other histological features such as sarcomatoid and papillary in the first‑line setting. Patients were enrolled regardless of PD-L1 tumour expression status. The study excluded patients with active autoimmune disease or a medical condition that required immunosuppression. Randomisation was stratified by geographic region (North America versus Western Europe versus &ldquo;Rest of the World&rdquo;) and Memorial Sloan Kettering Cancer Center (MSKCC) prognostic groups (favourable versus intermediate versus poor).</p><p>Patients were randomised (1:1:1) to one of the following treatment arms:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; KEYTRUDA 200&nbsp;mg intravenously every 3&nbsp;weeks up to 24&nbsp;months in combination with lenvatinib 20&nbsp;mg orally once daily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lenvatinib 18&nbsp;mg orally once daily in combination with everolimus 5&nbsp;mg orally once daily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sunitinib 50&nbsp;mg orally once daily for 4&nbsp;weeks then off treatment for 2&nbsp;weeks.<br />&nbsp;</p><p>Treatment continued until unacceptable toxicity or disease progression as determined by the investigator and confirmed by BICR using RECIST 1.1. Administration of KEYTRUDA with lenvatinib was permitted beyond RECIST-defined disease progression if the patient was clinically stable and considered by the investigator to be deriving clinical benefit. KEYTRUDA was continued for a maximum of 24&nbsp;months; however, treatment with lenvatinib could be continued beyond 24&nbsp;months. Assessment of tumour status was performed at baseline and then every 8&nbsp;weeks.</p><p>&nbsp;</p><p>Among the study population (355&nbsp;patients in the KEYTRUDA with lenvatinib arm and 357 in the sunitinib arm), the baseline characteristics were: median age of 62&nbsp;years (range: 29 to 88&nbsp;years), 41% age 65 or older; 74%&nbsp;male; 75%&nbsp;White, 21%&nbsp;Asian, 1%&nbsp;Black, and 2%&nbsp;other races; 17% and 83% of patients had a baseline KPS of 70 to 80 and 90 to 100, respectively; patient distribution by IMDC risk categories was 33%&nbsp;favourable, 56%&nbsp;intermediate and 10%&nbsp;poor, and by MSKCC prognostic groups was 27% favourable, 64%&nbsp;intermediate and 9%&nbsp;poor. Metastatic disease was present in 99% of the patients and locally advanced disease was present in 1%. Common sites of metastases in patients were lung&nbsp;(69%), lymph&nbsp;node&nbsp;(46%), and bone&nbsp;(26%).</p><p>&nbsp;</p><p>The primary efficacy outcome measure was PFS based on BICR using RECIST 1.1. Key secondary efficacy outcome measures included OS and ORR. The study demonstrated statistically significant improvements in PFS, OS, and ORR in patients randomised to KEYTRUDA in combination with lenvatinib compared with sunitinib. The median survival follow‑up time was 26.5&nbsp;months. The median duration of treatment for KEYTRUDA plus lenvatinib was 17.0&nbsp;months. Efficacy results for KEYNOTE‑581 are summarised in Table&nbsp;35 and Figures&nbsp;28 and 29. PFS results were consistent across pre‑specified subgroups, MSKCC prognostic groups and PD‑L1 tumour expression status. Efficacy results by MSKCC prognostic group are summarised in Table&nbsp;36.</p><p>&nbsp;</p><p><strong>Table&nbsp;36: Efficacy results in KEYNOTE‑581</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:472px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint </strong></p></td><td style="vertical-align:top"><p><strong>Pembrolizumab</strong></p><p><strong>200&nbsp;mg every 3&nbsp;weeks</strong></p><p><strong>and Lenvatinib</strong></p><p><strong>n=355</strong></p></td><td style="vertical-align:top"><p><strong>Sunitinib</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>n=357</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>PFS</strong><strong><sup>*</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>160 (45%)</p></td><td style="vertical-align:top"><p>205 (57%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>23.9 (20.8, 27.7)</p></td><td style="vertical-align:top"><p>9.2 (6.0, 11.0)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.39 (0.32, 0.49)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>OS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>80 (23%)</p></td><td style="vertical-align:top"><p>101 (28%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>NR (33.6, NR)</p></td><td style="vertical-align:top"><p>NR (NR, NR)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.66 (0.49, 0.88)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.0049</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Objective response rate</strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR<sup>&sect;</sup> % (95% CI)</p></td><td style="vertical-align:top"><p>71% (66, 76)</p></td><td style="vertical-align:top"><p>36% (31, 41)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>16%</p></td><td style="vertical-align:top"><p>4%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>55%</p></td><td style="vertical-align:top"><p>32%</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&para;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Response duration<sup>#</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>26 (1.6+, 36.8+)</p></td><td style="vertical-align:top"><p>15 (1.6+, 33.2+)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>The primary analysis of PFS included censoring for new anti-cancer treatment. Results for PFS with and without censoring for new anti‑cancer treatment were consistent.</p><p><sup>&dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Based on the stratified Cox proportional hazard model</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Two‑sided based on stratified log‑rank test</p><p><sup>&sect;</sup> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Response: Best objective response as confirmed complete response or partial response</p><p><sup>&para;</sup> &nbsp;&nbsp;&nbsp;&nbsp; Nominal two-sided p‑Value based on the stratified Cochran‑Mantel‑Haenszel (CMH) test. At the earlier pre‑specified final analysis of ORR (median follow‑up time of 17.3&nbsp;months), statistically significant superiority was achieved for ORR comparing KEYTRUDA plus lenvatinib with sunitinib, (odds ratio:&nbsp;3.84 [95%&nbsp;CI: 2.81, 5.26], p‑Value&lt;&nbsp;0.0001).</p><p><sup>#</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan‑Meier estimates</p><p>NR = not reached</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p>The primary OS analysis was not adjusted to account for subsequent therapies.</p><p><u>&nbsp;</u></p><p><strong>Figure</strong>&nbsp;<strong>28: Kaplan‑Meier curve for progression‑free survival by treatment arm in</strong></p><p><strong>KEYNOTE‑581</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA + Lenvatinib:</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p><p>Sunitinib:</p><p>&nbsp;</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;PFS rate at 12 months&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PFS rate at 18 months&nbsp;&nbsp;&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;p-value</u></strong></p><p><strong>KEYTRUDA + Lenvatinib&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;71%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;57%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.39 (0.32, 0.49) &nbsp;&nbsp;&lt;0.0001</strong></p><p><strong>Sunitinib&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;38%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;31%</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Progression-Free Survival (%)</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p>&nbsp;</p><p>&nbsp;</p><p>An updated OS analysis was performed when patients receiving KEYTRUDA and lenvatinib or sunitinib had a median survival follow‑up of 33.4&nbsp;months. The hazard ratio was 0.72&nbsp;(95% CI 0.55,&nbsp;0.93) with 105/355&nbsp;(30%) deaths in the combination arm and 122/357&nbsp;(34%) deaths in the sunitinib arm. This updated OS analysis was not adjusted to account for subsequent therapies.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Figure</strong>&nbsp;<strong>29: Kaplan‑Meier curve for overall survival by treatment arm in</strong></p><p><strong>KEYNOTE‑581</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p><p>Sunitinib:</p><p>&nbsp;</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA + Lenvatinib:</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Overall Survival (%)</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;OS rate at 12 months&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OS rate at 24 months&nbsp;&nbsp;&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</u></strong></p><p><strong>KEYTRUDA + Lenvatinib &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;91%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;80%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;0.72 (0.55, 0.93) &nbsp;&nbsp;&nbsp;</strong></p><p><strong>Sunitinib&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;80%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;70%</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>The KEYNOTE‑581 study was not powered to evaluate efficacy of individual subgroups. Table&nbsp;37 summarises the efficacy measures by MSKCC prognostic group from the pre‑specified primary analysis and the updated OS analysis.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table&nbsp;37: Efficacy results in KEYNOTE‑581 by MSKCC prognostic group</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:576px"><tbody><tr><td><p>&nbsp;</p></td><td colspan="2"><p><strong>KEYTRUDA + Lenvatinib<br />(n=355)</strong></p></td><td colspan="2"><p><strong>Sunitinib<br />(n=357)</strong></p></td><td style="vertical-align:bottom"><p><strong>KEYTRUDA + Lenvatinib vs. Sunitinib</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>Number of Patients </strong></p></td><td><p><strong>Number of Events </strong></p></td><td><p><strong>Number of Patients </strong></p></td><td><p><strong>Number of </strong><strong>Events </strong></p></td><td style="vertical-align:bottom">&nbsp;</td></tr><tr><td colspan="5"><p><strong>Progression‑Free Survival (PFS) by BICR<sup>*</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>PFS HR (95% CI)</strong></p></td></tr><tr><td><p>Favourable</p></td><td><p>&nbsp;96</p></td><td><p>&nbsp;39</p></td><td><p>&nbsp;97</p></td><td><p>&nbsp;60</p></td><td><p>0.36&nbsp;(0.23, 0.54)</p></td></tr><tr><td><p>Intermediate</p></td><td><p>&nbsp;227</p></td><td><p>&nbsp;101</p></td><td><p>&nbsp;228</p></td><td><p>&nbsp;126</p></td><td style="vertical-align:bottom"><p>0.44 (0.34, 0.58)</p></td></tr><tr><td><p>Poor</p></td><td><p>&nbsp;32</p></td><td><p>&nbsp;20</p></td><td><p>&nbsp;32</p></td><td><p>&nbsp;19</p></td><td style="vertical-align:bottom"><p>0.18&nbsp;(0.08, 0.42)</p></td></tr><tr><td colspan="5"><p><strong>Overall Survival (OS)</strong><strong><sup>*</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>OS HR&nbsp;(95% CI)</strong></p></td></tr><tr><td><p>Favourable<sup>&dagger;</sup></p></td><td><p>&nbsp;96</p></td><td><p>&nbsp;11</p></td><td><p>&nbsp;97</p></td><td><p>&nbsp;13</p></td><td style="vertical-align:bottom"><p>0.86&nbsp;(0.38, 1.92)</p></td></tr><tr><td><p>Intermediate</p></td><td><p>&nbsp;227</p></td><td><p>&nbsp;57</p></td><td><p>&nbsp;228</p></td><td><p>&nbsp;73</p></td><td><p>0.66&nbsp;(0.47, 0.94)</p></td></tr><tr><td><p>Poor</p></td><td><p>&nbsp;32</p></td><td><p>&nbsp;12</p></td><td><p>&nbsp;32</p></td><td><p>&nbsp;15</p></td><td style="vertical-align:bottom"><p>0.50&nbsp;(0.23, 1.08)</p></td></tr><tr><td colspan="5"><p><strong>Updated OS</strong><strong><sup>&Dagger;</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>OS HR&nbsp;(95% CI)</strong></p></td></tr><tr><td><p>Favourable<sup>&dagger;</sup></p></td><td><p>&nbsp;96</p></td><td><p>&nbsp;17</p></td><td><p>&nbsp;97</p></td><td><p>&nbsp;17</p></td><td style="vertical-align:bottom"><p>1.00&nbsp;(0.51, 1.96)</p></td></tr><tr><td><p>Intermediate</p></td><td><p>&nbsp;227</p></td><td><p>&nbsp;74</p></td><td><p>&nbsp;228</p></td><td><p>&nbsp;87</p></td><td style="vertical-align:bottom"><p>0.71&nbsp;(0.52, 0.97)</p></td></tr><tr><td><p>Poor</p></td><td><p>&nbsp;32</p></td><td><p>&nbsp;14</p></td><td><p>&nbsp;32</p></td><td><p>&nbsp;18</p></td><td style="vertical-align:bottom"><p>0.50&nbsp;(0.25, 1.02)</p></td></tr></tbody></table><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median follow‑up: 26.5&nbsp;months (data cutoff &ndash; 28 August 2020)</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interpretation of HR is limited by the low number of events (24/193 and 34/193)</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median follow‑up: 33.4&nbsp;months (data cutoff &ndash; 31 March 2021)</p><p><u>&nbsp;</u></p><p><em><u>KEYNOTE-B61: Open-label trial of combination therapy with lenvatinib in patients with advanced/metastatic non-clear cell RCC in the first-line setting</u></em></p><p>The efficacy of KEYTRUDA in combination with lenvatinib was investigated in KEYNOTE-B61, a multicenter, open-label, single-arm trial that enrolled 160&nbsp;patients with advanced/metastatic non-clear cell RCC in the first-line setting. Patients were enrolled regardless of PD-L1 tumor expression status. Patients with active autoimmune disease or a medical condition that required immunosuppression were ineligible.</p><p>&nbsp;</p><p>Patients received KEYTRUDA 400&nbsp;mg every 6&nbsp;weeks up to 24&nbsp;months in combination with lenvatinib 20&nbsp;mg orally once daily. Treatment continued until unacceptable toxicity or disease progression. Administration of KEYTRUDA with lenvatinib was permitted beyond RECIST-defined disease progression if the patient was considered by the investigator to be deriving clinical benefit. KEYTRUDA was continued for a maximum of 24&nbsp;months; however, lenvatinib could be continued beyond 24&nbsp;months.</p><p>&nbsp;</p><p>Among the 158&nbsp;treated patients, the baseline characteristics were: median age of 60&nbsp;years (range: 24 to 87&nbsp;years), 71%&nbsp;male; 86%&nbsp;White, 8%&nbsp;Asian, and 3%&nbsp;Black; 22% and 78% of patients had a baseline KPS of 70 to 80 and 90 to 100 respectively; histologic subtypes were 59% papillary, 18% chromophobe, 4% translocation, 1% medullary, 13% unclassified, and 6% other; patient distribution by IMDC risk categories was 35% favorable, 54% intermediate and 10% poor; Common sites of metastases in patients were lymph node (65%), lung (35%), bone (30%), and liver (21%).</p><p>&nbsp;</p><p>The primary efficacy outcome measure was ORR as assessed by BICR using RECIST 1.1. Secondary efficacy outcome measures included DOR and PFS (as assessed by BICR using RECIST 1.1), and OS. Efficacy results are summarized in Table&nbsp;38. Clinical activity was observed regardless of the histological subtype.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table&nbsp;38: Efficacy Results in KEYNOTE-B61</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td><p><strong>KEYTRUDA</strong></p><p><strong>400&nbsp;mg every 6&nbsp;weeks</strong></p><p><strong>and Lenvatinib</strong></p><p><strong>n=158</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Objective Response Rate*</strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR<sup>&dagger;</sup>, (95% CI)<sup> </sup></p></td><td style="vertical-align:top"><p>51% (43, 59)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>8%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>42%</p></td></tr><tr><td style="vertical-align:top"><p>Stable disease</p></td><td style="vertical-align:top"><p>32%</p></td></tr><tr><td style="vertical-align:top"><p>Disease control rate</p></td><td style="vertical-align:top"><p>82%</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Response Duration*<sup>,&Dagger;</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>19.5 (1.5+, 23.5+)</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;6 months</p></td><td style="vertical-align:top"><p>89%</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;12 months</p></td><td style="vertical-align:top"><p>76%</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;18 months</p></td><td style="vertical-align:top"><p>51%</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Time to Response</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>2.8 (2.5, 15.2)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>PFS*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>17.9 (15.1, 22.1)</p></td></tr><tr><td style="vertical-align:top"><p>12-month PFS rate (95% CI)</p></td><td style="vertical-align:top"><p>64% (56, 71)</p></td></tr><tr><td style="vertical-align:top"><p>18-month PFS rate (95% CI)</p></td><td style="vertical-align:top"><p>48% (39, 56)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>OS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>NR (NR, NR)</p></td></tr><tr><td style="vertical-align:top"><p>12-month OS rate (95% CI)</p></td><td style="vertical-align:top"><p>82% (75, 87)</p></td></tr><tr><td style="vertical-align:top"><p>18-month OS rate (95% CI)</p></td><td style="vertical-align:top"><p>73% (65, 79)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>*&nbsp;&nbsp; Assessed by BICR using RECIST 1.1</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp; Based on patients with a best overall response as confirmed complete or partial response<sup> </sup></p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp; Based on Kaplan-Meier estimates</p><p>NR = not reached</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><em><u>&nbsp;</u></em></p><p><em><u>KEYNOTE-564: Placebo-controlled study for the adjuvant treatment of patients with resected RCC</u></em></p><p>The efficacy of KEYTRUDA was investigated as adjuvant therapy for RCC in KEYNOTE‑564, a multicenter, randomized, double-blind, placebo-controlled study in 994 patients with intermediate-high or high risk of recurrence of RCC, or M1 no evidence of disease (NED). The intermediate-high risk category included: pT2 with Grade 4 or sarcomatoid features; pT3, any Grade without nodal involvement (N0) or distant metastases (M0). The high risk category included: pT4, any Grade N0 and M0; any pT, any Grade with nodal involvement and M0. The M1 NED category included patients with metastatic disease who had undergone complete resection of primary and metastatic lesions. Patients must have undergone a partial nephroprotective or radical complete nephrectomy (and complete resection of solid, isolated, soft tissue metastatic lesion(s) in M1 NED participants) with negative surgical margins &ge;4&nbsp;weeks prior to the time of screening. Patients with active autoimmune disease or a medical condition that required immunosuppression were ineligible. Patients were randomized (1:1) to receive KEYTRUDA 200&nbsp;mg every 3&nbsp;weeks (n=496) or placebo (n=498) for up to 1&nbsp;year, until disease recurrence, or until unacceptable toxicity. Randomization was stratified by metastasis status (M0, M1&nbsp;NED), within M0 group, further stratified by ECOG PS (0,1), and geographic region (US, non‑US). Patients underwent imaging every 12 weeks for the first 2 years from randomization, then every 16 weeks from year 3 to 5, and then every 24 weeks annually.</p><p>&nbsp;</p><p>Among the 994 patients, the baseline characteristics were: median age of 60&nbsp;years (range: 25 to 84), 33% age&nbsp;65 or older; 71%&nbsp;male; and 85% ECOG PS of 0 and 15% ECOG PS of 1. Ninety-four percent were N0; 83% had no sarcomatoid features; 86% were pT2 with Grade&nbsp;4 or sarcomatoid features or pT3; 8% were pT4 or with nodal involvement; and 6% were M1&nbsp;NED. Baseline characteristics and demographics were generally comparable between the KEYTRUDA and placebo arms.</p><p>&nbsp;</p><p>The primary efficacy outcome measure was investigator-assessed DFS. The key secondary outcome measure was OS. The study demonstrated statistically significant improvements in DFS and OS for patients randomized to the KEYTRUDA arm compared with placebo. At the pre-specified interim analysis with a median follow-up time of 23.9 months, the DFS HR was 0.68 (95% CI 0.53, 0.87; p-Value = 0.0010). Generally consistent results were observed across pre-specified subgroups. Efficacy results with a median follow-up time of 55.8 months are summarized in Table&nbsp;39 and Figures&nbsp;30 and 31.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table&nbsp;39: Efficacy Results in KEYNOTE‑564</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:486px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA</strong></p><p><strong>200 mg every 3 weeks</strong></p><p><strong>n=496</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>n=498</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>DFS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>174 (35%)</p></td><td style="vertical-align:top"><p>224 (45%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>(NR, NR)</p></td><td style="vertical-align:top"><p>(54.9, NR)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<strong>*</strong> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.72 (0.59, 0.87)</p></td></tr><tr><td style="vertical-align:top"><p>12-month DFS rate (95% CI)</p></td><td style="vertical-align:top"><p>86% (82, 88)</p></td><td style="vertical-align:top"><p>76% (72, 80)</p></td></tr><tr><td style="vertical-align:top"><p>24-month DFS rate (95% CI)</p></td><td style="vertical-align:top"><p>78% (74, 82)</p></td><td style="vertical-align:top"><p>67% (63, 71)</p></td></tr><tr><td style="vertical-align:top"><p>36-month DFS rate (95% CI)</p></td><td style="vertical-align:top"><p>72% (68, 76)</p></td><td style="vertical-align:top"><p>63% (58, 67)</p></td></tr><tr><td style="vertical-align:top"><p>48-month DFS rate (95% CI)</p></td><td style="vertical-align:top"><p>65% (60, 69)</p></td><td style="vertical-align:top"><p>57% (52, 61)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>OS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>55 (11%)</p></td><td style="vertical-align:top"><p>86 (17%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>NR</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.62 (0.44, 0.87)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.0024<sup>&sect;</sup></p></td></tr><tr><td style="vertical-align:top"><p>12-month OS rate (95% CI)</p></td><td style="vertical-align:top"><p>99% (97, 99)</p></td><td style="vertical-align:top"><p>98% (96, 99)</p></td></tr><tr><td style="vertical-align:top"><p>24-month OS rate (95% CI)</p></td><td style="vertical-align:top"><p>96% (94, 98)</p></td><td style="vertical-align:top"><p>94% (91, 96)</p></td></tr><tr><td style="vertical-align:top"><p>36-month OS rate (95% CI)</p></td><td style="vertical-align:top"><p>94% (91, 96)</p></td><td style="vertical-align:top"><p>90% (86, 92)</p></td></tr><tr><td style="vertical-align:top"><p>48-month OS rate (95% CI)</p></td><td style="vertical-align:top"><p>91% (88, 93)</p></td><td style="vertical-align:top"><p>86% (83, 89)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>*</strong><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Based on the stratified Cox proportional hazard model</p><p><sup>&dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Based on stratified log-rank test</p><p>NR = not reached</p><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>Figure&nbsp;30: Kaplan-Meier Curve for Disease-Free Survival by Treatment Arm in KEYNOTE‑564</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>DFS rate at 24 months&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DFS rate at 48 months &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HR (95% CI)</u></strong></p><p><strong>KEYTRUDA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 65%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.72 (0.59, 0.87)</strong></p><p><strong>Placebo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 67%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 57%</strong></p></td></tr></tbody></table><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-family:Arial'>Disease-Free
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Disease-Free Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Number at Risk</strong></p><p>KEYTRUDA</p><p>Placebo</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Figure&nbsp;31: Kaplan-Meier Curve for Overall Survival by Treatment Arm in KEYNOTE‑564</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Number at Risk</strong></p><p>KEYTRUDA</p><p>Placebo</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>OS rate at 24 months&nbsp;&nbsp; OS rate at 48 months&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HR (95% CI)&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;p-value</u></strong></p><p><strong>KEYTRUDA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 96%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 91%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.62 (0.44, 0.87)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.0024</strong></p><p><strong>Placebo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 94%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 86%</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-family:Arial'>Overall
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Overall Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><em><u>KEYNOTE‑564: Placebo-controlled study for the adjuvant treatment of patients with resected RCC</u></em></p><p>The efficacy of KEYTRUDA was investigated as adjuvant therapy for RCC in KEYNOTE‑564, a multicentre, randomised, double-blind, placebo-controlled study in 994&nbsp;patients with increased risk of recurrence defined as intermediate‑high or high risk, or M1 with no evidence of disease (NED). The intermediate‑high risk category included: pT2 with Grade&nbsp;4 or sarcomatoid features; pT3, any Grade without nodal involvement (N0) or distant metastases (M0). The high risk category included: pT4, any Grade&nbsp;N0 and M0; any pT, any Grade with nodal involvement and M0. The M1 NED category included patients with metastatic disease who had undergone complete resection of primary and metastatic lesions. Patients must have undergone a partial nephroprotective or radical complete nephrectomy (and complete resection of solid, isolated, soft tissue metastatic lesion(s) in M1 NED participants) with negative surgical margins &ge;&nbsp;4&nbsp;weeks prior to the time of screening. The study excluded patients with active autoimmune disease or a medical condition that required immunosuppression. Patients with RCC with clear cell component were randomised (1:1) to receive KEYTRUDA 200&nbsp;mg every 3&nbsp;weeks (n=496) or placebo (n=498) for up to 1&nbsp;year until disease recurrence or until unacceptable toxicity. Randomisation was stratified by metastasis status (M0, M1&nbsp;NED), and within M0 group, further stratified by ECOG PS (0,1), and geographic region (US, non‑US). Starting from randomisation, patients underwent imaging every 12&nbsp;weeks for the first 2&nbsp;years, then every 16&nbsp;weeks from year 3 to 5, and then every 24&nbsp;weeks annually.</p><p>&nbsp;</p><p>Among the 994&nbsp;patients, the baseline characteristics were: median age of 60&nbsp;years (range: 25 to 84), 33% age&nbsp;65 or older; 71%&nbsp;male; and 85% ECOG PS of 0 and 15% ECOG PS of 1. Ninety-four percent were N0; 83% had no sarcomatoid features; 86% were pT2 with Grade&nbsp;4 or sarcomatoid features or pT3; 8% were pT4 or with nodal involvement; and 6% were M1&nbsp;NED. Baseline characteristics and demographics were generally comparable between the KEYTRUDA and placebo arms.</p><p>&nbsp;</p><p>The primary efficacy outcome measure was investigator‑assessed DFS. The key secondary outcome measure was OS. At the pre‑specified interim analysis with a median follow‑up time of 23.9&nbsp;months, the study demonstrated a statistically significant improvement in DFS&nbsp;(HR&nbsp;0.68; 95% CI&nbsp;0.53, 0.87; p‑Value =&nbsp;0.0010) for patients randomised to the KEYTRUDA arm compared with placebo. Updated efficacy results with a median follow‑up time of 29.7&nbsp;months are summarised in Table&nbsp;40 and Figure&nbsp;32.</p><p><strong>&nbsp;</strong></p><p><strong>Table&nbsp;40: Efficacy results in KEYNOTE‑564</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:486px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA</strong></p><p><strong>200&nbsp;mg every 3&nbsp;weeks</strong></p><p><strong>n=496</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>n=498</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>DFS</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>114 (23%)</p></td><td style="vertical-align:top"><p>169 (34%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>NR</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>*</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.63 (0.50, 0.80)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on the stratified Cox proportional hazard model</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nominal p‑Value based on stratified log-rank test</p><p>NR = not reached</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Figure&nbsp;32: Kaplan-Meier curve for disease-free survival by treatment arm in KEYNOTE‑564 </strong><strong>(intent to treat population)</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Number at Risk</strong></p><p>KEYTRUDA Placebo</p></td></tr></tbody></table><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-family:"Arial",sans-serif'>Disease-Free
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Disease-Free Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp; <u>DFS rate at 12 months&nbsp;&nbsp; DFS rate at 24 months&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;p-value</u></strong></p><p><strong>KEYTRUDA&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 86%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 78%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.63 (0.50, 0.80)&nbsp;&nbsp;&nbsp;&nbsp; &lt;0.0001</strong></p><p><strong>Placebo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 76%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 67%</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p>&nbsp;</p><p><u>&nbsp;</u></p><p>At the time of the updated analysis, the DFS hazard ratio&nbsp;(95% CI) was&nbsp;0.68 (0.52, 0.89) in the subgroup of patients with M0‑intermediate‑high risk of recurrence,&nbsp;0.60&nbsp;(0.33, 1.10) in the subgroup of patients with M0‑high risk of recurrence, and&nbsp;0.28 (0.12, 0.66) in the subgroup of patients with M1 NED. OS results were not yet mature with&nbsp;23&nbsp;deaths out of 496&nbsp;patients in the KEYTRUDA arm and 43&nbsp;deaths out of 498&nbsp;patients in the placebo arm.</p><p><em><u>&nbsp;</u></em></p><p><em><u>MSI-H or dMMR cancers</u></em></p><p><em><u>Colorectal cancer</u></em></p><p><em><u>KEYNOTE‑177: Controlled study in MSI-H or dMMR CRC patients na&iuml;ve to treatment in the metastatic setting</u></em></p><p>The efficacy of KEYTRUDA was investigated in KEYNOTE‑177, a multicentre, randomised, open-label, active-controlled study that enrolled patients with previously untreated metastatic MSI-H or dMMR CRC. MSI or MMR (mismatch repair) tumour status was determined locally using polymerase chain reaction (PCR) or IHC, respectively. Patients with autoimmune disease or a medical condition that required immunosuppression were ineligible.</p><p>&nbsp;</p><p>Patients were randomised (1:1) to receive KEYTRUDA 200&nbsp;mg intravenously every 3&nbsp;weeks or investigator&rsquo;s choice of the following chemotherapy regimens given intravenously every 2&nbsp;weeks:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mFOLFOX6 (oxaliplatin, leucovorin, and FU) or mFOLFOX6 in combination with either bevacizumab or cetuximab: Oxaliplatin 85&nbsp;mg/m<sup>2</sup>, leucovorin 400&nbsp;mg/m<sup>2</sup> (or levoleucovorin 200&nbsp;mg/m<sup>2</sup>), and FU 400&nbsp;mg/m<sup>2</sup> bolus on Day&nbsp;1, then FU 2,400&nbsp;mg/m<sup>2</sup> over 46-48&nbsp;hours. Bevacizumab 5&nbsp;mg/kg bw on Day&nbsp;1 or cetuximab 400&nbsp;mg/m<sup>2</sup> on first infusion, then 250&nbsp;mg/m<sup>2</sup> weekly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FOLFIRI (irinotecan, leucovorin, and FU) or FOLFIRI in combination with either bevacizumab or cetuximab: Irinotecan 180&nbsp;mg/m<sup>2</sup>, leucovorin 400&nbsp;mg/m<sup>2</sup> (or levoleucovorin 200&nbsp;mg/m<sup>2</sup>), and FU 400&nbsp;mg/m<sup>2</sup> bolus on Day&nbsp;1, then FU 2,400&nbsp;mg/m<sup>2</sup> over 46-48&nbsp;hours. Bevacizumab 5&nbsp;mg/kg bw on Day&nbsp;1 or cetuximab 400&nbsp;mg/m<sup>2</sup> on first infusion, then 250&nbsp;mg/m<sup>2</sup> weekly.</p><p>&nbsp;</p><p>Treatment with KEYTRUDA continued until RECIST&nbsp;v1.1-defined progression of disease as determined by the investigator or unacceptable toxicity. Patients treated with KEYTRUDA without disease progression could be treated for up to 24&nbsp;months. Assessment of tumour status was performed every 9&nbsp;weeks. Patients randomised to chemotherapy were offered KEYTRUDA at the time of disease progression.</p><p>&nbsp;</p><p>A total of 307&nbsp;patients were enrolled and randomised to KEYTRUDA (n=153) or chemotherapy (n=154). The baseline characteristics of these patients were: median age of 63&nbsp;years (range: 24 to 93), 47% age 65 or older; 50%&nbsp;male; 75%&nbsp;White and 16%&nbsp;Asian; 52% and 48% had an ECOG performance status of 0 or 1, respectively. Mutation status: 25% BRAF V600E, 24% KRAS/NRAS. For 143&nbsp;patients treated with chemotherapy, 56% received mFOLFOX6 with or without bevacizumab or cetuximab and 44% received FOLFIRI with or without bevacizumab or cetuximab.</p><p>&nbsp;</p><p>The primary efficacy outcome measures were PFS assessed by BICR according to RECIST&nbsp;v1.1 and OS. Secondary outcome measures were ORR and response duration. The study demonstrated a statistically significant improvement in PFS (HR 0.60; 95% CI 0.45, 0.80; p‑Value&nbsp;0.0002) for patients randomised to the KEYTRUDA arm compared with chemotherapy at the pre‑specified final analysis for PFS. There was no statistically significant difference between KEYTRUDA and chemotherapy in the final OS analysis in which 60% of the patients who had been randomised to receive chemotherapy had crossed over to receive subsequent anti-PD‑1/PD‑L1 therapies including pembrolizumab. Table&nbsp;41 summarises the key efficacy measures and Figures&nbsp;33 and 34 show the Kaplan Meier curves for updated PFS and OS based on the final analysis with a median follow-up time of 38.1&nbsp;months (range: 0.2 to 58.7&nbsp;months).</p><p>&nbsp;</p><p><strong>Table&nbsp;41: Efficacy results in KEYNOTE‑177</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:571px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA</strong></p><p><strong>200&nbsp;mg every 3&nbsp;weeks</strong></p><p><strong>n=153</strong><strong> </strong></p></td><td style="vertical-align:top"><p><strong>Chemotherapy</strong></p><p><strong>n=154</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS</strong><strong><sup>*</sup></strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>86 (56%)</p></td><td style="vertical-align:top"><p>117 (76%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>16.5 (5.4, 38.1)</p></td><td style="vertical-align:top"><p>8.2 (6.1, 10.2)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.59 (0.45, 0.79)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>OS</strong><strong><sup>&sect;</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>62 (41%)</p></td><td style="vertical-align:top"><p>78 (51%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>NR (49.2, NR)</p></td><td style="vertical-align:top"><p>36.7 (27.6, NR)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.74 (0.53, 1.03)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&sect;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.0359</p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective response rate</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ORR % (95% CI)</p></td><td style="vertical-align:top"><p>45% (37.1, 53.3)</p></td><td style="vertical-align:top"><p>33% (25.8, 41.1)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>13%</p></td><td style="vertical-align:top"><p>4%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>32%</p></td><td style="vertical-align:top"><p>29%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response duration</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>NR (2.3+, 53.5+)</p></td><td style="vertical-align:top"><p>10.6 (2.8, 48.3+)</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;&nbsp;24&nbsp;months<sup>&para;</sup></p></td><td style="vertical-align:top"><p>84%</p></td><td style="vertical-align:top"><p>34%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; With additional 12&nbsp;months of follow‑up after the pre‑specified final analysis for PFS.</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Cox regression model</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p‑Value is nominal.</p><p><sup>&sect;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not statistically significant after adjustment for multiplicity</p><p><sup>&para;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan-Meier estimation</p><p>NR = not reached</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Figure&nbsp;33: Kaplan‑Meier curve for progression-free survival by treatment arm in </strong></p><p><strong>KEYNOTE‑177 (intent to treat population)</strong></p><p><u>&nbsp;</u></p><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-family:"Arial",sans-serif'>Progression-Free
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Progression-Free Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>N<strong>umber at Risk</strong></p><p>KEYTRUDA</p><p>Chemotherapy</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp; <u>PFS rate at 24 months&nbsp;&nbsp;&nbsp; PFS rate at 36 months&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;HR (95% CI)&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nominal p-value</u></strong></p><p><strong>KEYTRUDA&nbsp;&nbsp;&nbsp; 48%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;42%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.59 (0.45, 0.79)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.0001</strong></p><p><strong>Chemotherapy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11%</strong></p></td></tr></tbody></table><p>&nbsp;</p><p><u>&nbsp;</u></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Figure&nbsp;34: Kaplan‑Meier curve for overall survival by treatment arm in </strong></p><p><strong>KEYNOTE‑177 (intent to treat population)</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Number at Risk</strong></p><p>KEYTRUDA</p><p>Chemotherapy</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>&nbsp;&nbsp;&nbsp; Treatment arm&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>OS rate at 24 months&nbsp;&nbsp;&nbsp; OS rate at 36 months&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;HR (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p-value*</u></strong></p><p><strong>&nbsp;&nbsp;&nbsp; KEYTRUDA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 68%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 61%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.74 (0.53, 1.03) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;0.0359</strong></p><p><strong>&nbsp;&nbsp;&nbsp; Chemotherapy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 60%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50%</strong></p></td></tr></tbody></table><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-family:Arial'>Overall
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Overall Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><p>&nbsp;</p><p><sup>*</sup><sup> </sup>Not statistically significant after adjustment for multiplicity</p><p><u>&nbsp;</u></p><p>Biliary Tract Carcinoma</p><p><em><u>KEYNOTE-966</u></em><em><u>: Controlled trial of combination therapy in patients with locally advanced unresectable or metastatic biliary tract carcinoma</u></em></p><p>The efficacy of KEYTRUDA in combination with gemcitabine and cisplatin was investigated in KEYNOTE‑966, a multicenter, randomized, double-blind, placebo-controlled trial that enrolled 1069&nbsp;patients with locally advanced unresectable or metastatic BTC, who had not received prior systemic therapy in the advanced disease setting. Patients with autoimmune disease that required systemic therapy within 2&nbsp;years of treatment or a medical condition that required immunosuppression were ineligible. Randomization was stratified by region (Asia vs. non-Asia), locally advanced vs. metastatic, and site of origin (gallbladder, intrahepatic or extrahepatic cholangiocarcinoma).</p><p>Patients were randomized (1:1) to one of the two treatment groups:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; KEYTRUDA 200&nbsp;mg on Day&nbsp;1 plus gemcitabine 1000&nbsp;mg/m<sup>2</sup> and cisplatin 25&nbsp;mg/m<sup>2</sup> on Day&nbsp;1 and Day&nbsp;8 every 3&nbsp;weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Placebo on Day&nbsp;1 plus gemcitabine 1000&nbsp;mg/m<sup>2</sup> and cisplatin 25&nbsp;mg/m<sup>2</sup> on Day&nbsp;1 and Day&nbsp;8 every 3&nbsp;weeks</p><p>All study medications were administered via intravenous infusion. Treatment was continued until unacceptable toxicity or disease progression. For pembrolizumab, treatment was continued for a maximum of 35 cycles, or approximately 24 months. For cisplatin, treatment could be administered for a maximum of 8 cycles and for gemcitabine, treatment could be continued beyond 8 cycles.</p><p>&nbsp;</p><p>Administration of KEYTRUDA with chemotherapy was permitted beyond RECIST-defined disease progression if the patient was clinically stable and considered by the investigator to be deriving clinical benefit. Assessment of tumor status was performed at baseline and then every 6&nbsp;weeks through 54&nbsp;weeks, followed by every 12&nbsp;weeks thereafter.</p><p>&nbsp;</p><p>The study population characteristics were median age of 64&nbsp;years (range: 23 to 85), 47%&nbsp;age&nbsp;65 or older; 52%&nbsp;male; 49%&nbsp;White, 46%&nbsp;Asian; 46%&nbsp;ECOG PS of 0 and 54%&nbsp;ECOG PS of 1; 31% of patients had a history of hepatitis B infection, and 3% had a history of hepatitis C infection.</p><p>&nbsp;</p><p>The primary efficacy outcome measure was OS and the secondary efficacy measures were PFS, ORR and DOR as assessed by BICR according to RECIST&nbsp;v1.1.</p><p>Table&nbsp;42 and Figures&nbsp;35 and 36 summarize the efficacy results for KEYNOTE-966.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table&nbsp;42: Efficacy Results in Patients with BTC in KEYNOTE-966</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:492px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA</strong></p><p><strong>200&nbsp;mg every 3&nbsp;weeks with gemcitabine/cisplatin</strong></p><p><strong>n=533</strong></p></td><td style="vertical-align:top"><p><strong>Placebo with gemcitabine/cisplatin</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>n=536</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>OS*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>414 (78%)</p></td><td style="vertical-align:top"><p>443 (83%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>12.7 (11.5, 13.6)</p></td><td style="vertical-align:top"><p>10.9 (9.9, 11.6)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.83 (0.72, 0.95)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.0034</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>PFS</strong><sup>&sect;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>361 (68%)</p></td><td style="vertical-align:top"><p>391 (73%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>6.5 (5.7, 6.9)</p></td><td style="vertical-align:top"><p>5.6 (5.1, 6.6)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.86 (0.75, 1.00)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.0225</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Objective Response Rate</strong><sup>&sect;</sup></p></td></tr><tr><td style="vertical-align:top"><p>ORR<sup>&para;</sup> (95% CI)</p></td><td style="vertical-align:top"><p>28.7% (24.9, 32.8)</p></td><td style="vertical-align:top"><p>28.5% (24.8, 32.6)</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of complete responses</p></td><td style="vertical-align:top"><p>11 (2.1%)</p></td><td style="vertical-align:top"><p>7 (1.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of partial responses</p></td><td style="vertical-align:top"><p>142 (26.6%)</p></td><td style="vertical-align:top"><p>146 (27.2%)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>#</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.4735</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of Response*</strong><sup>, &THORN;</sup></p></td><td style="vertical-align:top"><p>n=156</p></td><td style="vertical-align:top"><p>n=152</p></td></tr><tr><td style="vertical-align:top"><p>Median in months<sup> </sup>(range)</p></td><td style="vertical-align:top"><p>8.3 (1.2+ - 33.0+)</p></td><td style="vertical-align:top"><p>6.8 (1.1+ - 30.0+)</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;6 months<sup> </sup></p></td><td style="vertical-align:top"><p>65%</p></td><td style="vertical-align:top"><p>55%</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;12 months<sup> </sup></p></td><td style="vertical-align:top"><p>38%</p></td><td style="vertical-align:top"><p>27%</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;24 months<sup> </sup></p></td><td style="vertical-align:top"><p>18%</p></td><td style="vertical-align:top"><p>6%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Results at the pre-specified final OS analysis</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on the stratified Cox proportional hazard model</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One-sided p-Value based on a stratified log-rank test</p><p><sup>&sect;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Results at pre-specified interim analysis</p><p><sup>&para;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confirmed complete response or partial response</p><p><sup>#</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One-sided p-Value based on the stratified Miettinen and Nurminen analysis</p><p><sup>&THORN;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan-Meier estimate</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Figure&nbsp;35: Kaplan-Meier Curve for Overall Survival in KEYNOTE‑966*</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>OS Rate at 12 months&nbsp;&nbsp;&nbsp; OS Rate at 24 months&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p-value</u></strong></p><p><strong>KEYTRUDA + Chemotherapy&nbsp;&nbsp;&nbsp;&nbsp; 52%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.83 (0.72, 0.95)&nbsp;&nbsp;&nbsp;&nbsp; 0.0034</strong></p><p><strong>Placebo + Chemotherapy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 44%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18%</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA + Chemotherapy</p><p>Placebo + Chemotherapy</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-family:Arial'>Overall
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Overall Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA + Chemotherapy</p><p>Placebo + Chemotherapy</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p>&nbsp;</p><p>*Based on the pre-specified final OS analysis</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Figure&nbsp;36: Kaplan-Meier Curve for Progression-Free Survival in KEYNOTE-966*</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>PFS Rate at 6 months&nbsp;&nbsp;&nbsp; PFS Rate at 12 months&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp; p-value</u></strong></p><p><strong>KEYTRUDA + Chemotherapy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 52%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.86 (0.75, 1.00)&nbsp;&nbsp; 0.0225</strong></p><p><strong>Placebo + Chemotherapy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 46%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20%</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA + Chemotherapy</p><p>Placebo + Chemotherapy</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-family:Arial'>Progression-Free
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Progression-Free Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><p>&nbsp;</p><p>*Based on the pre-specified interim analysis data cut-off</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>From baseline to Week 18, pre-specified exploratory patient-reported outcomes (PROs) using the EORTC QLQ‑C30 (global health status/quality of life, physical functioning, role functioning), EORTC QLQ-BIL21 (pain and jaundice scores), and EQ-5D-5L visual analog scale (VAS) for patients receiving KEYTRUDA in combination with gemcitabine/cisplatin were similar to those treated with placebo and gemcitabine/cisplatin.&nbsp;From baseline to Week 18, health-related quality of life (HRQoL) was maintained when KEYTRUDA was added to gemcitabine/cisplatin.</p><p><em><u>&nbsp;</u></em></p><p><em><u>KEYNOTE‑164: </u></em><em><u>Open‑label study in patients with unresectable or metastatic MSI</u></em><em><u>‑H </u></em><em><u>or dMMR CRC </u></em><em><u>who have received prior therapy</u></em></p><p>The efficacy of KEYTRUDA was investigated in KEYNOTE‑164, a multicentre, non-randomised, open-label, multi‑cohort Phase II study that enrolled patients with unresectable or metastatic MSI‑H or dMMR CRC that progressed following prior fluoropyrimidine‑based therapy in combination with irinotecan and/or oxaliplatin.</p><p>&nbsp;</p><p>Patients received KEYTRUDA 200&nbsp;mg every 3&nbsp;weeks until unacceptable toxicity or disease progression. Clinically stable patients with initial evidence of disease progression were permitted to remain on treatment until disease progression was confirmed. Patients without disease progression were treated for up to 24&nbsp;months (up to 35&nbsp;cycles). Assessment of tumour status was performed every 9&nbsp;weeks.</p><p>&nbsp;</p><p>Among the 124&nbsp;patients enrolled in KEYNOTE‑164, the baseline characteristics were: median age 56&nbsp;years (35% age 65 or older); 56% male; 68% White, 27% Asian; 41% and 59% had an ECOG performance status of 0 and 1, respectively. Twelve percent of patients had BRAF mutations and 36% had RAS mutations; 39% and 34% were undetermined for BRAF and RAS mutations, respectively. Ninety-seven percent of the patients had M1 disease and 3% had M0 disease (locally advanced unresectable). Seventy-six percent of patients received 2 or more prior lines of therapy.</p><p>&nbsp;</p><p>The primary efficacy outcome measure was ORR as assessed by BICR using RECIST 1.1. Secondary efficacy outcome measures included response duration, PFS, and OS. The median follow‑up time in months was 37.3 (range: 0.1 to 65.2). Efficacy results are summarised in Table&nbsp;43.</p><p>&nbsp;</p><p><strong>Table&nbsp;</strong><strong>43</strong><strong>: Efficacy results in KEYNOTE‑164</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:414px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>n=124</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective response</strong><strong><sup>* </sup></strong><strong>rate</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ORR % (95% CI)</p></td><td style="vertical-align:top"><p>34% (25.6, 42.9)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>10%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>24%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response duration<sup>*</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>NR (4.4, 58.5+)</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;&nbsp;36&nbsp;months<sup>#</sup></p></td><td style="vertical-align:top"><p>92%</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp; Based on patients with a best objective response as confirmed complete or partial response</p><p><sup>#</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan‑Meier estimation</p><p>+&nbsp;&nbsp;&nbsp;&nbsp; Denotes there is no progressive disease by the time of last disease assessment</p><p>NR = not reached</p></td></tr></tbody></table><p><em><u>&nbsp;</u></em></p><p>Objective responses were observed regardless of BRAF or RAS mutation status.</p><p>&nbsp;</p><p><em><u>Non-colorectal cancers</u></em></p><p><em><u>KEYNOTE‑158: Open‑label study in patients with unresectable or metastatic </u></em><em><u>MSI‑H or dMMR endometrial, gastric, small intestine, or biliary cancer who have received prior therapy </u></em></p><p>The efficacy of KEYTRUDA was investigated in 355&nbsp;patients with unresectable or metastatic MSI‑H or dMMR non‑CRC solid tumours enrolled in a multicentre, non-randomised, open‑label Phase II study (KEYNOTE‑158), including patients with endometrial, gastric, small intestine, or biliary cancer. MSI or MMR tumour status was determined prospectively using PCR or IHC, respectively.</p><p>&nbsp;</p><p>Patients received KEYTRUDA 200&nbsp;mg every 3&nbsp;weeks until unacceptable toxicity or disease progression. Clinically stable patients with initial evidence of disease progression were permitted to remain on treatment until disease progression was confirmed. Patients without disease progression were treated for up to 24&nbsp;months (up to 35&nbsp;cycles). Assessment of tumour status was performed every 9&nbsp;weeks through the first year, then every 12&nbsp;weeks thereafter.</p><p>&nbsp;</p><p>Among the 83&nbsp;patients with endometrial cancer, the baseline characteristics were: median age of 64&nbsp;years (range: 42 to 86), 46% age 65 or older; 84% White, 6% Asian, and 4% Black; and ECOG PS 0 (46%) and 1 (54%). Ninety-eight percent of the patients had M1 disease and 2% had M0 disease. Forty-seven percent of patients received 2 or more prior lines of therapy.</p><p>&nbsp;</p><p>Among the 51&nbsp;patients with gastric cancer, the baseline characteristics were: median age 67&nbsp;years (range: 41 to 89); 57% age 65 or older; 65% male, 63% White, 28% Asian; and ECOG PS 0 (45%) and 1 (55%). All patients had M1 disease. Forty‑five percent of patients received 2 or more prior lines of therapy.</p><p>&nbsp;</p><p>Among the 27&nbsp;patients with small intestinal cancer, the baseline characteristics were: median age 58&nbsp;years (range: 21 to 77); 33% age 65 or older; 63% male, 81% White, 11% Asian; and ECOG PS 0 (56%) and 1 (44%). Ninety-six percent of patients had M1 disease and 4% M0 disease. Thirty-seven percent of patients received 2 or more prior lines of therapy. All patients had a tumour histology of adenocarcinoma.</p><p>&nbsp;</p><p>Among the 22&nbsp;patients with biliary cancer, the baseline characteristics were: median age 61&nbsp;years (range: 40 to 77); 41% age 65 or older; 73% male, 91% White, 9% Asian; ECOG PS 0 (45%) and 1 (55%); and 82%&nbsp;M1 disease and 18% M0&nbsp;disease. Forty‑one percent of patients received 2 or more prior lines of therapy.</p><p>&nbsp;</p><p>The primary efficacy outcome measure was ORR as assessed by BICR using RECIST 1.1. Secondary efficacy outcome measures included response duration, PFS, and OS. The median follow‑up time in months was 21.9 (range: 1.5 to 64.0) for endometrial, 13.9 (range: 1.1 to 66.9) for gastric, 29.1 (4.2 to 67.7) for small intestine, and 19.4 (range: 1.1 to 60.8) for biliary cancer. Efficacy results are summarised in Table&nbsp;44.</p><p>&nbsp;</p><p><strong>Table&nbsp;</strong><strong>44</strong><strong>: Efficacy results in KEYNOTE‑158</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Endometrial</strong></p><p><strong>n=83</strong></p></td><td style="vertical-align:top"><p><strong>Gastric</strong></p><p><strong>n=51</strong></p></td><td style="vertical-align:top"><p><strong>Small Intestine</strong></p><p><strong>n=27</strong></p></td><td style="vertical-align:top"><p><strong>Biliary</strong></p><p><strong>n=22</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective response</strong><strong><sup>*</sup></strong><strong> rate</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ORR %</p><p>&nbsp;(95% CI)</p></td><td style="vertical-align:top"><p>51%</p><p>(39.4, 61.8)</p></td><td style="vertical-align:top"><p>37%</p><p>(24.1, 51.9)</p></td><td style="vertical-align:top"><p>56%</p><p>(35.3, 74.5)</p></td><td style="vertical-align:top"><p>41%</p><p>(20.7, 63.6)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>16%</p></td><td style="vertical-align:top"><p>14%</p></td><td style="vertical-align:top"><p>15%</p></td><td style="vertical-align:top"><p>14%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>35%</p></td><td style="vertical-align:top"><p>24%</p></td><td style="vertical-align:top"><p>41%</p></td><td style="vertical-align:top"><p>27%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response duration</strong><strong><sup>*</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>NR</p><p>(2.9, 60.4+)</p></td><td style="vertical-align:top"><p>NR</p><p>(6.2, 63.0+)</p></td><td style="vertical-align:top"><p>NR</p><p>(3.7+, 57.3+)</p></td><td style="vertical-align:top"><p>30.6</p><p>(6.2, 46.0+)</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;&nbsp;12 months<sup>#</sup></p></td><td style="vertical-align:top"><p>85%</p></td><td style="vertical-align:top"><p>90%</p></td><td style="vertical-align:top"><p>93%</p></td><td style="vertical-align:top"><p>89%</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;&nbsp;36 months<sup>#</sup></p></td><td style="vertical-align:top"><p>60%</p></td><td style="vertical-align:top"><p>81%</p></td><td style="vertical-align:top"><p>73%</p></td><td style="vertical-align:top"><p>42%</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on patients with a best objective response as confirmed complete or partial response</p><p><sup>#</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan‑Meier estimation</p><p>+&nbsp;&nbsp;&nbsp;&nbsp; Denotes there is no progressive disease by the time of last disease assessment</p><p>NR = not reached</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><em><u>&nbsp;</u></em></p><p>Gastric Cancer</p><p><em><u>KEYNOTE-859: Controlled trial of combination therapy in HER2‑negative gastric cancer patients na&iuml;ve to treatment</u></em></p><p>The efficacy of KEYTRUDA in combination with fluoropyrimidine and platinum chemotherapy was investigated in KEYNOTE-859, a multicenter, randomized, double-blind, placebo-controlled trial that enrolled 1579 patients with HER2‑negative advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma regardless of PD-L1 expression status, who had not previously received systemic therapy for metastatic disease. Patients with an autoimmune disease that required systemic therapy within 2&nbsp;years of treatment or a medical condition that required immunosuppression were ineligible. Randomization was stratified by PD-L1 expression (CPS &ge;1 or &lt;1), chemotherapy regimen (5-FU plus cisplatin [FP] or capecitabine plus oxaliplatin [CAPOX]), and geographic region (Europe/ Israel/ North America/ Australia, Asia or Rest of the World). Patients were randomized (1:1) to one of the following treatment arms; all study medications, except oral capecitabine, were administered as an intravenous infusion for every 3‑week cycle:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; KEYTRUDA 200&nbsp;mg, investigator&rsquo;s choice of combination chemotherapy of cisplatin 80&nbsp;mg/m<sup>2</sup> and 5-FU 800&nbsp;mg/m<sup>2</sup>/day for 5&nbsp;days (FP) or oxaliplatin 130&nbsp;mg/m<sup>2</sup> and capecitabine 1000&nbsp;mg/m<sup>2</sup> bid for 14&nbsp;days (CAPOX) for up to 35 cycles. KEYTRUDA was administered prior to chemotherapy on Day&nbsp;1 of each cycle.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Placebo, investigator&rsquo;s choice of combination chemotherapy of cisplatin 80&nbsp;mg/m<sup>2</sup> and 5‑FU 800&nbsp;mg/m<sup>2</sup>/day for 5&nbsp;days (FP) or oxaliplatin 130&nbsp;mg/m<sup>2</sup> and capecitabine 1000&nbsp;mg/m<sup>2</sup> bid for 14&nbsp;days (CAPOX) for up to 35 cycles. Placebo was administered prior to chemotherapy on Day&nbsp;1 of each cycle.</p><p>&nbsp;</p><p>Treatment with KEYTRUDA and chemotherapy or placebo and chemotherapy continued until RECIST v1.1‑defined progression of disease as determined by BICR, unacceptable toxicity, or a maximum of 24&nbsp;months. Treatment was permitted beyond RECIST‑defined disease progression if the patient was clinically stable and deriving clinical benefit as determined by the investigator. Assessment of tumor status was performed every 6&nbsp;weeks. The primary efficacy outcome measure was OS. Additional secondary efficacy outcome measures included PFS, ORR, and DOR as assessed by BICR using RECIST v1.1.</p><p>&nbsp;</p><p>The population characteristics were: median age of 62&nbsp;years (range: 21 to 86), 39% age 65 or older; 68% male; 55% White and 34% Asian; 37% ECOG PS of 0 and 63% ECOG PS of 1. Ninety-seven percent of patients had metastatic disease (stage IV) and 3% had locally advanced unresectable disease. Seventy-eight percent had tumors that expressed PD-L1 with a CPS &ge;1 and 5% (n=74) of patients had tumors that were MSI-H. Eighty-six percent of patients received CAPOX.</p><p>&nbsp;</p><p>A statistically significant improvement in OS, PFS and ORR was demonstrated in patients randomized to KEYTRUDA in combination with chemotherapy compared with placebo in combination with chemotherapy. Efficacy results are summarized in Table&nbsp;45.</p><p>&nbsp;</p><p><strong>Table</strong>&nbsp;<strong>45: Efficacy Results for KEYNOTE-859</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:536px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA</strong></p><p><strong>200</strong><strong>&nbsp;</strong><strong>mg every 3</strong><strong>&nbsp;</strong><strong>weeks</strong></p><p><strong>&nbsp;</strong></p><p><strong>FP or CAPOX </strong></p><p><strong>n=790</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>&nbsp;</strong></p><p><strong>FP or CAPOX </strong></p><p><strong>n=789</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>OS</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>603 (76)</p></td><td style="vertical-align:top"><p>666 (84)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months* (95% CI)</p></td><td style="vertical-align:top"><p>12.9 (11.9,14.0)</p></td><td style="vertical-align:top"><p>11.5 (10.6,12.1)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.78 (0.70, 0.87)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value (stratified log-rank)<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>572 (72)</p></td><td style="vertical-align:top"><p>608 (77)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months* (95% CI)</p></td><td style="vertical-align:top"><p>6.9 (6.3, 7.2)</p></td><td style="vertical-align:top"><p>5.6 (5.5, 5.7)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.76 (0.67, 0.85)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value (stratified log-rank)<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective Response Rate</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ORR<sup>&sect;</sup> (95% CI)</p></td><td style="vertical-align:top"><p>51% (47.7, 54.8)</p></td><td style="vertical-align:top"><p>42% (38.5, 45.5)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response rate</p></td><td style="vertical-align:top"><p>9%</p></td><td style="vertical-align:top"><p>6%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response rate</p></td><td style="vertical-align:top"><p>42%</p></td><td style="vertical-align:top"><p>36%</p></td></tr><tr><td style="vertical-align:top"><p>Difference (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>9% (4.4, 14.1)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&para;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.00009</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response Duration</strong></p></td><td style="vertical-align:top"><p>n=405</p></td><td style="vertical-align:top"><p>n=331</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>8.0 (1.2+ - 41.5+)</p></td><td style="vertical-align:top"><p>5.7 (1.3+ - 34.7+)</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge; 12 months*</p></td><td style="vertical-align:top"><p>39%</p></td><td style="vertical-align:top"><p>26%</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge; 24 months*</p></td><td style="vertical-align:top"><p>27%</p></td><td style="vertical-align:top"><p>13%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan-Meier estimation</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on the stratified Cox proportional hazard model</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One-sided p-Value based on stratified log-rank test</p><p><sup>&sect;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Response: Best objective response as confirmed complete response or partial response</p><p><sup>&para;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One-sided p-Value based on stratified Miettinen &amp; Nurminen method</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Figure&nbsp;37: Kaplan-Meier Curve for Overall Survival by Treatment Arm in KEYNOTE‑859</strong></p><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-family:Arial'>Overall
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Overall Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>OS Rate at 12 months&nbsp;&nbsp; OS Rate at 24 months&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HR (95% CI)&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;p-value</u></strong></p><p><strong>KEYTRUDA + Chemo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 53%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 28%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.78 (0.70, 0.87)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;0.0001</strong></p><p><strong>Chemo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 47%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 19%</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Number at Risk</strong></p><p>KEYTRUDA + Chemo</p><p>Chemo</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Figure&nbsp;38: Kaplan-Meier Curve for Progression-Free Survival by Treatment Arm in KEYNOTE‑859</strong></p><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-family:Arial'>Progression-Free
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Progression-Free Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>PFS Rate at 12 months&nbsp;&nbsp; PFS Rate at 24 months &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HR (95% CI)&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;p-value</u></strong></p><p><strong>KEYTRUDA + Chemo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.76 (0.67, 0.85)&nbsp;&nbsp;&nbsp; &lt;0.0001</strong></p><p><strong>Chemo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 19%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9%</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Number at Risk</strong></p><p>KEYTRUDA + Chemo</p><p>Chemo</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>&nbsp;</u></em></p><p><em><u>Gastric or gastro-oesophageal junction (GEJ) adenocarcinoma</u></em></p><p><em><u>KEYNOTE-811: Controlled study of combination therapy in locally advanced unresectable or metastatic HER2‑positive gastric or gastro-oesophageal junction adenocarcinoma patients na&iuml;ve to treatment</u></em></p><p><em><u>&nbsp;</u></em></p><p>The efficacy of KEYTRUDA in combination with trastuzumab plus fluoropyrimidine and platinum- containing chemotherapy was investigated in KEYNOTE-811, a multicentre, randomised, double-blind, placebo-controlled study that enrolled 698&nbsp;patients with HER2‑positive advanced gastric or GEJ adenocarcinoma regardless of PD-L1 expression status, who had not previously received systemic therapy for metastatic disease. Patients with an autoimmune disease that required systemic therapy within 2&nbsp;years of treatment or a medical condition that required immunosuppression were ineligible.</p><p>&nbsp;</p><p>Randomisation was stratified by PD-L1 expression (CPS&nbsp;&ge;&nbsp;1 or&nbsp;&lt;&nbsp;1), chemotherapy regimen (5-FU plus cisplatin [FP] or capecitabine plus oxaliplatin [CAPOX]), and geographic region (Europe/Israel/North America/Australia, Asia or Rest of the World). Patients were randomised (1:1) to one of the following treatment arms; all study medications, except oral capecitabine, were administered as an intravenous infusion for every 3‑week treatment cycle:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; KEYTRUDA 200&nbsp;mg, trastuzumab 8&nbsp;mg/kg on first infusion and 6&nbsp;mg/kg in subsequent cycles, followed by investigator&rsquo;s choice of combination chemotherapy of cisplatin 80&nbsp;mg/m<sup>2</sup> for up to 6&nbsp;cycles and 5-FU 800&nbsp;mg/m<sup>2</sup>/day for 5&nbsp;days (FP) or oxaliplatin 130&nbsp;mg/m<sup>2</sup> up to 6-8&nbsp;cycles and capecitabine 1,000&nbsp;mg/m<sup>2</sup> bid for 14&nbsp;days (CAPOX). KEYTRUDA was administered prior to trastuzumab and chemotherapy on Day 1 of each cycle.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Placebo, trastuzumab 8&nbsp;mg/kg on first infusion and 6&nbsp;mg/kg in subsequent cycles, followed by investigator&rsquo;s choice of combination chemotherapy of cisplatin 80&nbsp;mg/m<sup>2</sup> for up to 6&nbsp;cycles and 5‑FU 800&nbsp;mg/m<sup>2</sup>/day for 5&nbsp;days (FP) or oxaliplatin 130&nbsp;mg/m<sup>2</sup> up to 6-8&nbsp;cycles and capecitabine 1,000&nbsp;mg/m<sup>2</sup> bid for 14&nbsp;days (CAPOX). Placebo was administered prior to trastuzumab and chemotherapy on Day 1 of each cycle.</p><p>&nbsp;</p><p>Treatment with KEYTUDA, trastuzumab and chemotherapy or placebo, trastuzumab and chemotherapy continued until RECIST v1.1‑defined progression of disease as determined by BICR, unacceptable toxicity, or a maximum of 24&nbsp;months. Assessment of tumour status was performed every 6&nbsp;weeks.</p><p>&nbsp;</p><p>Among the 698&nbsp;patients randomised in KEYNOTE-811, 594 (85%) had tumours that expressed PD-L1 with a CPS&nbsp;&ge;&nbsp;1 based on the PD-L1 IHC 22C3 pharmDx<sup>TM</sup> kit. The baseline characteristics of the 594&nbsp;patients with tumour PD-L1 expression CPS&nbsp;&ge;&nbsp;1 included: median age of 63&nbsp;years (range: 19 to 85), 43% age 65 or older; 80% male; 63% White, 33% Asian, and 0.7 % Black; 42% ECOG PS of 0 and 58% ECOG PS of 1. Ninety-eight percent of patients had metastatic disease (stage IV) and 2% had locally advanced unresectable disease. Ninety-five percent (n=562) had tumours that were not MSI H, 1% (n=8) had tumours that were MSI H, and in 4% (n=24) the status was not known. Eighty-five percent of patients received CAPOX.</p><p>&nbsp;</p><p>The primary efficacy outcome measures were PFS based on BICR using RECIST 1.1, and OS. Secondary efficacy outcome measures included ORR and DoR based on BICR using RECIST 1.1.</p><p>At the second interim analysis in the overall population, the study demonstrated a statistically significant improvement in PFS (HR 0.72; 95% CI 0.60, 0.87; p-Value 0.0002) for patients randomised to the KEYTRUDA arm in combination with trastuzumab and chemotherapy compared with placebo in combination with trastuzumab and chemotherapy. At this interim analysis, there was no statistically significant difference with respect to OS. The median follow‑up time was 15.4&nbsp;months (range:&nbsp;0.3 to 41.6&nbsp;months). At the first interim analysis conducted on the first 264&nbsp;patients randomised in the overall population (133&nbsp;patients in the KEYTRUDA arm and 131 in the placebo arm), a statistically significant improvement was observed in ORR (74.4% vs. 51.9%, representing a 22.7% difference in ORR, [95%CI: 11.2, 33.7]; p-Value 0.00006).</p><p>Table&nbsp;46 summarises key efficacy results at the second interim analysis for the pre-specified subgroup of patients whose tumours expressed PD‑L1 with a CPS&nbsp;&ge;&nbsp;1 and Figures&nbsp;39 and 40 show the Kaplan‑Meier curves for PFS and OS.</p><p>&nbsp;</p><p><strong>Table&nbsp;46: Efficacy results for KEYNOTE-811 for patients with PD‑L1 expression (CPS&nbsp;&ge;&nbsp;1)</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:586px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA</strong></p><p><strong>Trastuzumab</strong></p><p><strong>and Chemotherapy</strong></p><p><strong>n=298</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>Trastuzumab</strong></p><p><strong>and Chemotherapy</strong></p><p><strong>n=296</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>199 (67%)</p></td><td colspan="2" style="vertical-align:top"><p>215 (73%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>10.8 (8.5, 12.5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>7.2 (6.8, 8.4)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>*</sup> (95% CI)</p></td><td colspan="3" style="vertical-align:top"><p>0.7 (0.58, 0.85)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&dagger;</sup></p></td><td colspan="3" style="vertical-align:top"><p>0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>OS</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td colspan="2" style="vertical-align:top"><p>167 (56%)</p></td><td style="vertical-align:top"><p>183 (62%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>20.5 (18.2, 24.3)</p></td><td style="vertical-align:top"><p>15.6 (13.5, 18.6)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>*</sup> (95% CI)</p></td><td colspan="3" style="vertical-align:top"><p>0.79 (0.64, 0.98)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&dagger;</sup></p></td><td colspan="3" style="vertical-align:top"><p>0.0143</p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective response rate</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ORR<sup>&Dagger; </sup>% (95% CI)</p></td><td style="vertical-align:top"><p>73% (67.7, 78.1)</p></td><td colspan="2" style="vertical-align:top"><p>58% (52.6, 64.1)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>14%</p></td><td colspan="2" style="vertical-align:top"><p>10%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>59%</p></td><td colspan="2" style="vertical-align:top"><p>49%</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>#</sup></p></td><td colspan="3" style="vertical-align:top"><p>0.00008&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response duration</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>11.3 (1.1+, 40.1+)&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>9.5 (1.4+, 38.3+)&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;&nbsp;6&nbsp;months<sup>&para;</sup></p></td><td style="vertical-align:top"><p>75%</p></td><td colspan="2" style="vertical-align:top"><p>67%</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;&nbsp;12&nbsp;months<sup>&para;</sup></p></td><td style="vertical-align:top"><p>49%</p></td><td colspan="2" style="vertical-align:top"><p>41%</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on unstratified Cox proportional hazard model</p><p><sup>&dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Nominal p-value based on unstratified log-rank test; no formal test was performed in patients with PD-L1 expression (CPS&nbsp;&ge;&nbsp;1).</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Response: Best objective response as confirmed complete response or partial response</p><p><sup>#&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Nominal p-value based on unstratified Miettinen and Nurminen method; no formal test was performed in patients with PD-L1 expression (CPS&nbsp;&ge;&nbsp;1).</p><p><sup>&para;</sup> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan‑Meier estimation</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Figure&nbsp;39: Kaplan-Meier curve for progression free survival by treatment arm in KEYNOTE-811 patients with PD-L1 expression (CPS&nbsp;&ge;&nbsp;1)</strong></p><p>&nbsp;</p><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-family:"Cambria Math",serif;
    mso-bidi-font-family:"Cambria Math"'>Progression-Free Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Progression-Free Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>PFS Rate at 12 months&nbsp;&nbsp; PFS Rate at 24 months&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p-value</u></strong></p><p><strong>KEYTRUDA + SOC&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; 45.7%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 27.0%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.70 (0.58, 0.85)&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;0.0001</strong></p><p><strong>SOC&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 32.9%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13.3%</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA + SOC</p><p>SOC</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Figure&nbsp;40: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-811 patients with PD-L1 expression (CPS&nbsp;&ge;&nbsp;1)</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<u>OS Rate at 12 months&nbsp;&nbsp; OS Rate at 18 months &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p-value</u></strong></p><p><strong>KEYTRUDA+ SOC&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 69.2%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 56.9%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.79 (0.64, 0.98)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.0143</strong></p><p><strong>SOC&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 60.6%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 45.6%</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA + SOC</p><p>SOC</p></td></tr></tbody></table><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-family:"Cambria Math",serif;
    mso-bidi-font-family:"Cambria Math"'>Overall Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Overall Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><em><u>Oesophageal carcinoma</u></em></p><p><em><u>KEYNOTE-590: Controlled study of combination therapy in oesophageal carcinoma patients na&iuml;ve to treatment</u></em></p><p>The efficacy of KEYTRUDA in combination with chemotherapy was investigated in KEYNOTE‑590, a multicentre, randomised, double-blind, placebo-controlled study in patients with locally advanced unresectable or metastatic oesophageal carcinoma or gastroesophageal junction carcinoma (Siewert type I). Patients with active autoimmune disease, a medical condition that required immunosuppression, or known HER-2 positive GEJ adenocarcinoma patients were ineligible for the study. Randomisation was stratified by tumour histology (squamous cell carcinoma vs. adenocarcinoma), geographic region (Asia vs. ex-Asia), and ECOG performance status (0 vs. 1).</p><p><u>&nbsp;</u></p><p>Patients were randomised (1:1) to one of the following treatment arms:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; KEYTRUDA 200&nbsp;mg on Day&nbsp;1 of each three-week cycle in combination with cisplatin 80&nbsp;mg/m<sup>2</sup> IV on Day&nbsp;1 of each three-week cycle for up to six cycles and 5‑FU 800&nbsp;mg/m<sup>2</sup> IV per day on Day&nbsp;1 to Day&nbsp;5 of each three-week cycle, or per local standard for 5‑FU administration.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Placebo on Day&nbsp;1 of each three-week cycle in combination with cisplatin 80&nbsp;mg/m<sup>2</sup> IV on Day&nbsp;1 of each three-week cycle for up to six cycles and 5‑FU 800&nbsp;mg/m<sup>2</sup> IV per day on Day&nbsp;1 to Day&nbsp;5 of each three-week cycle, or per local standard for 5‑FU administration.</p><p><u>&nbsp;</u></p><p>Treatment with KEYTRUDA or chemotherapy continued until unacceptable toxicity or disease progression or a maximum of 24&nbsp;months. Patients randomised to KEYTRUDA were permitted to continue beyond the first RECIST&nbsp;v1.1-defined disease progression if clinically stable until the first radiographic evidence of disease progression was confirmed at least 4&nbsp;weeks later with repeat imaging. Assessment of tumour status was performed every 9&nbsp;weeks.</p><p>&nbsp;</p><p>Among the 749&nbsp;patients in KEYNOTE-590, 383 (51%) had tumours that expressed PD‑L1 with a CPS&nbsp;&ge;&nbsp;10 based on the PD‑L1 IHC 22C3 pharmDx<sup>TM</sup> Kit. The baseline characteristics of these 383&nbsp;patients were: median age of 63&nbsp;years (range: 28 to 89), 41% age 65 or older; 82%&nbsp;male; 34%&nbsp;White and 56%&nbsp;Asian; 43% and 57% had an ECOG performance status of 0 and 1, respectively. Ninety-three percent had M1 disease. Seventy-five percent had a tumour histology of squamous cell carcinoma, and 25% had adenocarcinoma.</p><p>The primary efficacy outcome measures were OS and PFS as assessed by the investigator according to RECIST&nbsp;1.1 in squamous cell histology, CPS &ge;&nbsp;10, and in all patients. The study demonstrated a statistically significant improvement in OS and PFS for all pre-specified study populations. In all patients randomised to KEYTRUDA in combination with chemotherapy, compared to chemotherapy the OS HR was 0.73 (95% CI 0.62-0.86) and the PFS HR was 0.65 (95% CI 0.55-0.76). Secondary efficacy outcome measures were ORR and duration of response, according to RECIST&nbsp;1.1 as assessed by the investigator. Table&nbsp;47 summarises key efficacy measures from the pre-specified analysis in patients whose tumours expressed PD‑L1 with a CPS &ge;&nbsp;10 in KEYNOTE-590 performed at a median follow‑up time of 13.5&nbsp;months (range: 0.5 to 32.7&nbsp;months). The Kaplan-Meier curve for OS and PFS are shown in Figures&nbsp;41 and 42.</p><p><u>&nbsp;</u></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Table&nbsp;47: Efficacy results for KEYTRUDA plus chemotherapy in KEYNOTE‑590 with PD‑L1 expression (CPS&nbsp;&ge;&nbsp;10)</strong></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:576px"><thead><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Pembrolizumab</strong></p><p><strong>Cisplatin Chemotherapy</strong></p><p><strong>5-FU</strong></p><p><strong>n=186</strong></p></td><td style="vertical-align:top"><p><strong>Standard</strong></p><p><strong>Treatment</strong><strong><sup>*</sup></strong></p><p><strong>&nbsp;</strong></p><p><strong>n=197</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>OS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>124 (66.7%)</p></td><td style="vertical-align:top"><p>165 (83.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months<sup>&dagger;</sup> (95% CI)</p></td><td style="vertical-align:top"><p>13.5 (11.1, 15.6)</p></td><td style="vertical-align:top"><p>9.4 (8.0, 10.7)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&Dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.62 (0.49, 0.78)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&sect;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>PFS<sup>&para;</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>140 (75.3%)</p></td><td style="vertical-align:top"><p>174 (88.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months<sup>&dagger;</sup> (95% CI)</p></td><td style="vertical-align:top"><p>7.5 (6.2, 8.2)</p></td><td style="vertical-align:top"><p>5.5 (4.3, 6.0)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&Dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.51 (0.41, 0.65)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&sect;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Objective response rate<sup>&para;</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR<sup>&sect;</sup> % (95% CI)</p></td><td style="vertical-align:top"><p>51.1 (43.7, 58.5)</p></td><td style="vertical-align:top"><p>26.9 (20.8, 33.7)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>5.9%</p></td><td style="vertical-align:top"><p>2.5%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>45.2%</p></td><td style="vertical-align:top"><p>24.4%</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>#</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Response duration</strong><strong><sup>&para;,&THORN;</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>10.4 (1.9, 28.9+)</p></td><td style="vertical-align:top"><p>5.6 (1.5+, 25.0+)</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;&nbsp;6&nbsp;months<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>80.2%</p></td><td style="vertical-align:top"><p>47.7%</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;&nbsp;12&nbsp;months<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>43.7%</p></td><td style="vertical-align:top"><p>23.2%</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;&nbsp;18&nbsp;months<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>33.4%</p></td><td style="vertical-align:top"><p>10.4%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Cisplatin and 5-FU</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan-Meier estimation</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on the stratified Cox proportional hazard model</p><p><sup>&sect;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One-sided p-Value based on log-rank test stratified by geographic region (Asia versus Rest of the World) and tumour histology (Adenocarcinoma versus Squamous Cell Carcinoma) and ECOG performance status (0 versus 1)</p><p><sup>&para;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Assessed by investigator using RECIST 1.1</p><p><sup>#</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One-sided p-Value for testing. H0: difference in % = 0 versus H1: difference in % &gt;&nbsp;0</p><p><sup>&THORN;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Best objective response as confirmed complete response or partial response.</p></td></tr></tbody></table><p><strong><u>&nbsp;</u></strong></p><p>A total of 32&nbsp;patients aged &ge;&nbsp;75&nbsp;years for PD-L1 CPS &ge;&nbsp;10 were enrolled in KEYNOTE‑590 (18 in the KEYTRUDA combination and 14 in the control). Data about efficacy of KEYTRUDA in combination with chemotherapy are too limited in this patient population.</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><strong>Figure</strong><strong>&nbsp;41: Kaplan‑Meier curve for overall survival by treatment arm in</strong></p><p><strong>KEYNOTE‑590 with PD-L1 expression (CPS &ge;</strong>&nbsp;<strong>10)</strong></p><p>&nbsp;</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong><u>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OS rate at 12 months&nbsp;&nbsp; OS rate at 24 months&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p-value</u></strong></p><p><strong>KEYTRUDA +SOC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;54%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;31%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.62 (0.49, 0.78) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&lt;0.0001</strong></p><p><strong>SOC&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;37%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15%</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>SOC</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>KEYTRUDA +SOC</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-family:"Arial",sans-serif'>Overall
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Overall Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><p>&nbsp;</p><p><strong>Figure</strong><strong>&nbsp;42: Kaplan‑Meier curve for progression-free survival by treatment arm in</strong></p><p><strong>KEYNOTE‑590 with PD-L1 expression (CPS &ge;</strong>&nbsp;<strong>10)</strong></p><p><u>&nbsp;</u></p><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-family:"Arial",sans-serif'>Progression-Free
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Progression-Free Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>PFS rate at 12 months&nbsp;&nbsp; PFS rate at 18 months&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p-value</u></strong></p><p><strong>KEYTRUDA +SOC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.51 (0.41, 0.65) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&lt;0.0001</strong></p><p><strong>SOC&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5%</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>SOC</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>KEYTRUDA +SOC</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p><em><u>Triple‑negative breast cancer</u></em></p><p>&nbsp;</p><p><em><u>KEYNOTE‑522: Controlled study of neoadjuvant and adjuvant therapy in patients with locally advanced, inflammatory, or early‑stage triple‑negative breast cancer at high risk of recurrence</u></em></p><p>The efficacy of KEYTRUDA in combination with chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery was investigated in the randomised, double‑blind, multicentre, placebo‑controlled study KEYNOTE‑522. If indicated, patients received adjuvant radiation therapy prior to or concurrent with adjuvant KEYTRUDA or placebo. The key eligibility criteria for this study were locally advanced, inflammatory, or early‑stage TNBC at high risk of recurrence (tumour size &gt;&nbsp;1&nbsp;cm but &le;&nbsp;2&nbsp;cm in diameter with nodal involvement or tumour size&nbsp;&gt;&nbsp;2&nbsp;cm in diameter regardless of nodal involvement), regardless of tumour PD‑L1 expression. Patients with active autoimmune disease that required systemic therapy within 2&nbsp;years of treatment or a medical condition that required immunosuppression were ineligible for the study. Randomisation was stratified by nodal status (positive vs. negative), tumour size (T1/T2 vs. T3/T4), and choice of carboplatin (dosed every 3&nbsp;weeks vs.&nbsp;weekly). Patients were randomised (2:1) to receive either KEYTRUDA or placebo via intravenous infusion:</p><p>&nbsp;</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Four cycles of neoadjuvant KEYTRUDA 200&nbsp;mg every 3&nbsp;weeks or placebo on Day&nbsp;1 of cycles 1‑4 of treatment regimen in combination with:</p><p>&sect;&nbsp; Carboplatin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; AUC&nbsp;5&nbsp;mg/mL/min every 3&nbsp;weeks on Day&nbsp;1 of cycles 1‑4 of treatment regimen</p><p><strong>or </strong>AUC 1.5&nbsp;mg/mL/min every week on Day&nbsp;1, 8, and 15 of cycles 1‑4 of treatment regimen<strong> and</strong></p><p>&sect;&nbsp;&nbsp;&nbsp; Paclitaxel 80&nbsp;mg/m<sup>2</sup> every week on Day&nbsp;1, 8, and 15 of cycles 1‑4 of treatment regimen</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Followed by four additional cycles of neoadjuvant KEYTRUDA 200&nbsp;mg every 3&nbsp;weeks or placebo on Day&nbsp;1 of cycles 5‑8 of treatment regimen in combination with:</p><p>&sect;&nbsp;&nbsp;&nbsp; Doxorubicin 60&nbsp;mg/m<sup>2</sup> <strong>or</strong> epirubicin 90&nbsp;mg/m<sup>2</sup> every 3&nbsp;weeks on Day&nbsp;1 of cycles&nbsp;5‑8 of treatment regimen <strong>and</strong></p><p>&sect;&nbsp;&nbsp;&nbsp; Cyclophosphamide 600&nbsp;mg/m<sup>2</sup> every 3&nbsp;weeks on Day&nbsp;1 of cycles 5‑8 of treatment regimen</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Following surgery, 9&nbsp;cycles of adjuvant KEYTRUDA 200&nbsp;mg every 3&nbsp;weeks or placebo were administered.</p><p>&nbsp;</p><p>Treatment with KEYTRUDA or placebo continued until completion of the treatment (17&nbsp;cycles), disease progression that precludes definitive surgery, disease recurrence in the adjuvant phase, or unacceptable toxicity.</p><p>&nbsp;</p><p>A total of 1,174&nbsp;patients were randomised. The study population characteristics were: median age of 49&nbsp;years (range: 22 to 80); 11%&nbsp;age 65 or older; 99.9%&nbsp;female; 64%&nbsp;White; 20%&nbsp;Asian, 5%&nbsp;Black, and 2%&nbsp;American Indian or Alaska Native; ECOG performance status of 0&nbsp;(87%) and 1&nbsp;(13%); 56%&nbsp;were pre‑menopausal status and 44% were post‑menopausal status; 7% were primary Tumour&nbsp;1&nbsp;(T1), 68%&nbsp;T2, 19%&nbsp;T3, and 7%&nbsp;T4; 49% were nodal involvement 0&nbsp;(N0), 40%&nbsp;N1, 11%&nbsp;N2, and 0.2%&nbsp;N3; 1.4% of patients had inflammatory breast cancer; 75% of patients were overall Stage&nbsp;II and 25% were Stage&nbsp;III.</p><p>&nbsp;</p><p>The dual primary efficacy outcome measures were pCR rate and EFS. pCR was defined as absence of invasive cancer in the breast and lymph nodes (ypT0/Tis ypN0) and was assessed by the blinded local pathologist at the time of definitive surgery. EFS was defined as the time from randomisation to the first occurrence of any of the following events: progression of disease that precludes definitive surgery, local or distant recurrence, second primary malignancy, or death due to any cause. The study demonstrated a statistically significant improvement in pCR rate difference at its pre‑specified primary analysis (n=602), the pCR&nbsp;rates were 64.8% (95% CI: 59.9%, 69.5%) in the KEYTRUDA arm and 51.2 % (95% CI:&nbsp;44.1%, 58.3%) in the placebo arm, with a treatment difference of 13.6 % (95% CI: 5.4%, 21.8%;&nbsp;p‑Value 0.00055). The study also demonstrated a statistically significant improvement in EFS at its pre‑specified analysis. A secondary efficacy outcome measure was OS. At the time of EFS analysis, OS results were not yet mature&nbsp;(45% of the required events for final analysis). At a pre‑specified interim analysis, the median follow‑up time for all patients was 37.8&nbsp;months&nbsp;(range:&nbsp;2.7‑48&nbsp;months). Table&nbsp;48 summarises key efficacy measures from the pre‑specified analyses. The Kaplan‑Meier curve for EFS and OS are shown in Figures&nbsp;43 and 44.</p><p>&nbsp;</p><p><strong>Table&nbsp;</strong><strong>48</strong><strong>: Efficacy results in KEYNOTE‑522</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:600px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA with Chemotherapy/Pembrolizumab</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Placebo with Chemotherapy/Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>pCR (ypT0/Tis ypN0)<sup>*</sup></strong></p></td><td style="vertical-align:top"><p><strong>n=669</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>n=333</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of patients with pCR</p></td><td style="vertical-align:top"><p>428</p></td><td colspan="2" style="vertical-align:top"><p>182</p></td></tr><tr><td style="vertical-align:top"><p>pCR Rate (%) (95% CI)</p></td><td style="vertical-align:top"><p>64.0 (60.2, 67.6)</p></td><td colspan="2" style="vertical-align:top"><p>54.7 (49.1, 60.1)</p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference (%) estimate (95% CI)<sup>&dagger;</sup></p></td><td colspan="3" style="vertical-align:top"><p>9.2 (2.8, 15.6)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<strong><sup>&Dagger;</sup></strong></p></td><td colspan="3" style="vertical-align:top"><p>0.00221</p></td></tr><tr><td style="vertical-align:top"><p><strong>EFS<sup>&sect;</sup></strong></p></td><td style="vertical-align:top"><p><strong>n=784</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>n=390</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>123 (15.7%)</p></td><td colspan="2" style="vertical-align:top"><p>93 (23.8%)</p></td></tr><tr><td style="vertical-align:top"><p>24&nbsp;month EFS rate (95% CI)</p></td><td style="vertical-align:top"><p>87.8 (85.3, 89.9)</p></td><td colspan="2" style="vertical-align:top"><p>81.0 (76.8, 84.6)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)<sup>&para;</sup></p></td><td colspan="3" style="vertical-align:top"><p>0.63 (0.48, 0.82)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>#</sup></p></td><td colspan="3" style="vertical-align:top"><p>0.00031</p></td></tr><tr><td style="vertical-align:top"><p><strong>OS<sup>&THORN;</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td colspan="2" style="vertical-align:top"><p>80 (10.2%)</p></td><td style="vertical-align:top"><p>55 (14.1%)</p></td></tr><tr><td style="vertical-align:top"><p>24‑month OS rate (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>92.3 (90.2, 94.0)</p></td><td style="vertical-align:top"><p>91.0 (87.7, 93.5)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)<sup>&para;</sup></p></td><td colspan="3" style="vertical-align:top"><p>0.72 (0.51, 1.02)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Based on a pre‑specified pCR final analysis (compared to a significance level of 0.0028)</p><p><sup>&dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Based on Miettinen and Nurminen method stratified by nodal status, tumour size, and choice of carboplatin</p><p><sup>&Dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>One-sided p‑Value for testing. H0: difference in % = 0 versus H1: difference in %&nbsp;&gt;&nbsp;0</p><p><sup>&sect;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on a pre‑specified EFS interim analysis (compared to a significance level of 0.0052)</p><p><sup>&para;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Cox regression model with Efron&rsquo;s method of tie handling with treatment as a covariate stratified by nodal status, tumour size, and choice of carboplatin</p><p><sup>#</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One‑sided p‑Value based on log‑rank test stratified by nodal status, tumour size, and choice of carboplatin</p><p><sup>&THORN;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OS results at interim analysis did not meet the pre‑specified efficacy boundary of 0.00085861 for statistical significance.</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><u>&nbsp;</u></p><p><strong>Figure&nbsp;</strong><strong>43</strong><strong>: Kaplan‑Meier curve for event‑free survival by treatment arm in</strong></p><p><strong>KEYNOTE‑522 (intent to treat population)</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>EFS rate at 24 months&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HR (95% CI)&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;p-value</u></strong></p><p><strong>KEYTRUDA + Chemo/KEYTRUDA &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;88%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.63 (0.48, 0.82)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.0003093</strong></p><p><strong>Placebo + Chemo/Placebo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;81%</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA + Chemo/Pembrolizumab:</p><p>Placebo + Chemo/Placebo:</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-family:"Arial",sans-serif'>Event-Free
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Event-Free Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Figure&nbsp;</strong><strong>44</strong><strong>: Kaplan‑Meier curve for </strong><strong>overall survival by treatment arm in</strong></p><p><strong>KEYNOTE‑522 (intent to treat population)</strong></p><p>&nbsp;</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>OS rate at 24 months&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;p-value</u></strong></p><p><strong>KEYTRUDA + Chemo/KEYTRUDA &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;92%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.72 (0.51, 1.02)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.0321377</strong></p><p><strong>Placebo + Chemo/Placebo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 91%</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Number at Risk</strong></p><p>KEYTRUDA + Chemo/Pembrolizumab</p><p>Placebo + Chemo/Placebo</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-family:"Arial",sans-serif'>Overall
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Overall Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><p>&nbsp;</p><p><em><u>&nbsp;</u></em></p><p><em><u>KEYNOTE‑355: Controlled study of combination therapy in TNBC patients previously untreated for metastatic disease</u></em></p><p>The efficacy of KEYTRUDA in combination with paclitaxel, nab‑paclitaxel, or gemcitabine and carboplatin was investigated in KEYNOTE‑355, a randomised, double‑blind, multicentre, placebo‑controlled study. Key eligibility criteria were locally recurrent unresectable or metastatic TNBC, regardless of tumour PD‑L1 expression, not previously treated with chemotherapy in the advanced setting. Patients with active autoimmune disease that required systemic therapy within 2&nbsp;years of treatment or a medical condition that required immunosuppression were ineligible. Randomisation was stratified by chemotherapy treatment (paclitaxel or nab‑paclitaxel vs. gemcitabine and carboplatin), tumour PD‑L1 expression (CPS&nbsp;&ge;&nbsp;1 vs. CPS&nbsp;&lt;&nbsp;1), and prior treatment with the same class of chemotherapy in the neoadjuvant setting (yes vs. no). Patients were randomised (2:1) to one of the following treatment arms via intravenous infusion:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; KEYTRUDA 200&nbsp;mg on Day&nbsp;1 every 3&nbsp;weeks in combination with nab‑paclitaxel 100&nbsp;mg/m<sup>2</sup> on Days&nbsp;1, 8 and 15 every 28&nbsp;days, or paclitaxel 90&nbsp;mg/m<sup>2</sup> on Days&nbsp;1, 8, and 15 every 28&nbsp;days, or gemcitabine 1,000&nbsp;mg/m<sup>2</sup> and carboplatin AUC&nbsp;2&nbsp;mg/mL/min on Days&nbsp;1 and 8 every 21&nbsp;days.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Placebo on Day&nbsp;1 every 3&nbsp;weeks in combination with nab‑paclitaxel 100&nbsp;mg/m<sup>2</sup> on Days&nbsp;1, 8 and 15 every 28&nbsp;days, or paclitaxel 90&nbsp;mg/m<sup>2</sup> on Days&nbsp;1, 8, and 15 every 28&nbsp;days, or gemcitabine 1,000&nbsp;mg/m<sup>2</sup> and carboplatin AUC&nbsp;2&nbsp;mg/mL/min on Days&nbsp;1 and 8 every 21&nbsp;days.</p><p>&nbsp;</p><p>Treatment with KEYTRUDA or placebo, both in combination with chemotherapy, continued until RECIST&nbsp;1.1‑defined progression of disease as determined by the investigator, unacceptable toxicity, or a maximum of 24&nbsp;months. Chemotherapy could continue per standard of care. Administration of KEYTRUDA was permitted beyond RECIST‑defined disease progression if the patient was clinically stable and deriving clinical benefit as determined by the investigator. Assessment of tumour status was performed at Weeks&nbsp;8, 16, and 24, then every 9&nbsp;weeks for the first year, and every 12&nbsp;weeks thereafter.</p><p>&nbsp;</p><p>Among the 847&nbsp;patients randomised in KEYNOTE‑355, 636&nbsp;(75%) had tumours that expressed PD‑L1 with a CPS&nbsp;&ge;&nbsp;1 and 323 (38%) had tumour PD‑L1 expression CPS&nbsp;&ge;&nbsp;10 based on the PD‑L1 IHC&nbsp;22C3&nbsp;pharmDx<sup>TM</sup> Kit. The baseline characteristics of the 323&nbsp;patients with tumour PD‑L1 expression CPS&nbsp;&ge;&nbsp;10 included: median age of 53&nbsp;years (range: 22 to 83); 20% age&nbsp;65 or older; 100%&nbsp;female; 69%&nbsp;White, 20%&nbsp;Asian, and 5%&nbsp;Black; ECOG performance status of 0 (61%) and 1&nbsp;(39%); 67% were post‑menopausal status; 3% had a history of brain metastases; and 20% had disease‑free interval of &lt;&nbsp;12&nbsp;months.</p><p>&nbsp;</p><p>The dual primary efficacy outcome measures were PFS as assessed by BICR using RECIST 1.1 and OS. Secondary efficacy outcome measures were ORR and response duration as assessed by BICR using RECIST 1.1. The study demonstrated a statistically significant improvement in PFS at its pre‑specified interim analysis (HR 0.65; 95% CI 0.49, 0.86; p‑Value&nbsp;0.0012) and OS at final analysis for patients with tumour PD‑L1 expression CPS&nbsp;&ge;&nbsp;10 randomised to the KEYTRUDA in combination with chemotherapy arm compared with placebo in combination with chemotherapy. Table&nbsp;49 summarises key efficacy measures and Figures&nbsp;45 and 46 show the Kaplan‑Meier curves for PFS and OS based on the final analysis with a median follow-up time of 20.2&nbsp;months (range: 0.3 to 53.1&nbsp;months) for patients with tumour PD‑L1 expression CPS&nbsp;&ge;&nbsp;10.</p><p>&nbsp;</p><p><strong>Table&nbsp;</strong><strong>49</strong><strong>: Efficacy results in KEYNOTE‑355 patients with CPS&nbsp;&ge;&nbsp;10</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:563px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA</strong></p><p><strong>with chemotherapy</strong><strong><sup>*</sup></strong></p><p><strong>n=220</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>with chemotherapy</strong><strong><sup>*</sup></strong></p><p><strong>n=103</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS<sup>&dagger;</sup></strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>144 (65%)</p></td><td colspan="2" style="vertical-align:top"><p>81 (79%)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&Dagger;</sup> (95% CI)</p></td><td colspan="3" style="vertical-align:top"><p>0.66 (0.50, 0.88)</p></td></tr><tr><td style="vertical-align:top"><p>p‑Value<sup>&sect;</sup></p></td><td colspan="3" style="vertical-align:top"><p>0.0018</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>9.7 (7.6, 11.3)</p></td><td style="vertical-align:top"><p>5.6 (5.3, 7.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>OS</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td colspan="2" style="vertical-align:top"><p>155 (70%)</p></td><td style="vertical-align:top"><p>84 (82%)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&Dagger;</sup> (95% CI)</p></td><td colspan="3" style="vertical-align:top"><p>0.73 (0.55, 0.95)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&para;</sup></p></td><td colspan="3" style="vertical-align:top"><p>0.0093</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>23.0 (19.0, 26.3)</p></td><td style="vertical-align:top"><p>16.1 (12.6, 18.8)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective response rate<sup>&dagger;</sup></strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ORR % (95% CI)</p></td><td style="vertical-align:top"><p>53% (46, 59)</p></td><td colspan="2" style="vertical-align:top"><p>41% (31, 51)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>17%</p></td><td colspan="2" style="vertical-align:top"><p>14%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>35%</p></td><td colspan="2" style="vertical-align:top"><p>27%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response duration<sup>&dagger;</sup></strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>12.8 (1.6+, 45.9+)</p></td><td colspan="2" style="vertical-align:top"><p>7.3 (1.5, 46.6+)</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;&nbsp;6&nbsp;months<sup>#</sup></p></td><td style="vertical-align:top"><p>82%</p></td><td colspan="2" style="vertical-align:top"><p>60%</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;&nbsp;12&nbsp;months<sup>#</sup></p></td><td style="vertical-align:top"><p>56%</p></td><td colspan="2" style="vertical-align:top"><p>38%</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp; Chemotherapy: paclitaxel, nab‑paclitaxel, or gemcitabine and carboplatin</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp; Assessed by BICR using RECIST&nbsp;1.1</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Cox regression model with Efron&rsquo;s method of tie handling with treatment as a covariate stratified by chemotherapy on study (taxane vs. gemcitabine and carboplatin) and prior treatment with same class of chemotherapy in the neoadjuvant setting (yes vs. no)</p><p><sup>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Nominal p‑Value based on log-rank test stratified by chemotherapy on study (taxane vs. gemcitabine and carboplatin) and prior treatment with same class of chemotherapy in the neoadjuvant setting (yes vs. no). At the pre‑specified interim analysis of PFS (median follow-up time of 19.2&nbsp;months), statistically significant superiority was achieved for PFS comparing pembrolizumab/chemotherapy with placebo/chemotherapy p-Value 0.0012.</p><p><sup>&para;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>One-sided p‑Value based on log-rank test stratified by chemotherapy on study (taxane vs. gemcitabine and carboplatin) and prior treatment with same class of chemotherapy in the neoadjuvant setting (yes vs. no). OS results met the pre-specified efficacy boundary of 0.0113 for statistical significance.</p><p><sup>#</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; From product‑limit (Kaplan-Meier) method for censored data</p><p>+&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Denotes there is no progressive disease by the time of last disease assessment</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure&nbsp;</strong><strong>45</strong><strong>: </strong><strong>Kaplan‑Meier curve for progression‑free survival by treatment arm in KEYNOTE‑355 patients with PD‑L1 expression (CPS&nbsp;&ge;&nbsp;10)</strong></p><p>&nbsp;</p><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-family:"Arial",sans-serif'>Progression-Free
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Progression-Free Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA + Chemotherapy</p><p>Placebo + Chemotherapy</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>PFS rate at 12 months&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;p-value</u></strong></p><p><strong>KEYTRUDA + Chemotherapy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 39%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.66 (0.50, 0.88)&nbsp;&nbsp; 0.0018</strong></p><p><strong>Placebo + Chemotherapy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23%</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p><p>Placebo + Chemo:</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p>&nbsp;</p><p><strong>Figure&nbsp;</strong><strong>46: </strong><strong>Kaplan‑Meier curve for overall survival by treatment arm in KEYNOTE‑355 patients with PD‑L1 expression (CPS&nbsp;&ge;&nbsp;10)</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>OS rate at 24 months&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;HR (95% CI)&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;p-value</u></strong></p><p><strong>KEYTRUDA + Chemotherapy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 48%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.73 (0.55, 0.95)&nbsp;&nbsp;&nbsp;&nbsp; 0.0093</strong></p><p><strong>Placebo + Chemotherapy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 34%</strong></p></td></tr></tbody></table><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-family:"Arial",sans-serif'>Overall
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Overall Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA + Chemotherapy</p><p>Placebo + Chemotherapy</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Endometrial carcinoma</u></em></p><p><em><u>KEYNOTE-868/NRG-GY018: Controlled trial of combination therapy for treatment of patients with primary advanced or recurrent endometrial carcinoma</u></em></p><p>The efficacy of KEYTRUDA in combination with paclitaxel and carboplatin was investigated in KEYNOTE‑868, a multicenter, randomized, double‑blind, placebo‑controlled trial in 810 patients with advanced or recurrent endometrial carcinoma including those with dMMR and pMMR tumors. Patients had not received prior systemic therapy or had received prior chemotherapy in the adjuvant setting. Patients who had received prior adjuvant chemotherapy were eligible if their chemotherapy‑free interval was at least 12 months. Patients with endometrial sarcoma, including carcinosarcoma, or patients with active autoimmune disease or a medical condition that required immunosuppression were ineligible. Randomization was stratified according to MMR status, ECOG PS (0 or 1 vs. 2), and prior adjuvant chemotherapy. Patients were randomized (1:1) to one of the following treatment arms:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; KEYTRUDA 200&nbsp;mg every 3&nbsp;weeks, paclitaxel 175 mg/m<sup>2</sup> and carboplatin AUC 5 mg/mL/min for 6 cycles, followed by KEYTRUDA 400&nbsp;mg every 6&nbsp;weeks for up to 14 cycles.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Placebo every 3 weeks, paclitaxel 175 mg/m<sup>2</sup> and carboplatin AUC 5 mg/mL/min for 6 cycles, followed by placebo every 6 weeks for up to 14 cycles.</p><p>All study medications were administered as an intravenous infusion on Day 1 of each treatment cycle. Treatment continued until disease progression, unacceptable toxicity, or a maximum of 20 cycles (up to approximately 24 months). Patients with measurable disease who had RECIST‑defined stable disease or partial response at the completion of cycle 6 were permitted to continue receiving paclitaxel and carboplatin with KEYTRUDA or placebo for up to 10 cycles as determined by the investigator. Assessment of tumor status was performed every 9 weeks for the first 9 months and then every 12 weeks thereafter.</p><p>Among the 810 randomized patients, 222 (27%) had dMMR tumor status and 588 (73%) had pMMR tumor status.</p><p>The dMMR population characteristics were: median age of 66 years (range: 37 to 86), 55% age 65 or older; 79% White, 9% Black, and 3% Asian; 5% Hispanic or Latino; 64% ECOG PS of 0, 33% ECOG PS of 1, and 3% ECOG PS of 2; 61% had recurrent disease and 39% had primary or persistent disease; 5% received prior adjuvant chemotherapy and 43% received prior radiotherapy. The histologic subtypes were endometrioid carcinoma (24% grade 1, 43% grade 2, 14% grade 3), adenocarcinoma NOS (11%), and other (8% including dedifferentiated/undifferentiated, serous, and mixed epithelial).</p><p>The pMMR population characteristics were: median age of 66 years (range: 29 to 94), 54% age 65 or older; 72% White, 16% Black, and 5% Asian; 6% Hispanic or Latino; 67% ECOG PS of 0, 30% ECOG PS of 1, and 3% ECOG PS of 2; 56% had recurrent disease and 44% had primary or persistent disease; 26% received prior adjuvant chemotherapy and 41% received prior radiotherapy. The histologic subtypes were endometrioid carcinoma (17% grade 1, 19% grade 2, 16% grade 3), serous (26%), adenocarcinoma NOS (10%), clear cell carcinoma (7%), and other (5% including mixed epithelial and dedifferentiated/undifferentiated).</p><p>The primary efficacy outcome measure was PFS as assessed by the investigator according to RECIST 1.1. Secondary efficacy outcome measures included OS, ORR, and DoR. The trial demonstrated statistically significant improvements in PFS for patients randomized to KEYTRUDA in combination with chemotherapy compared to placebo in combination with chemotherapy in both the dMMR and pMMR populations. The median follow-up time was 13.6 months (range: 0.6 to 39.4 months) and 8.7 months (range: 0.1 to 37.2 months) in the dMMR and pMMR populations, respectively. OS endpoint was not formally assessed within multiplicity control. OS maturity was 12.2% in the dMMR population and 16.8% in the pMMR population. Among the patients who had been randomized to receive placebo in combination with chemotherapy and discontinued from the study, 55% from the dMMR population and 45% from the pMMR population subsequently received post-study therapies that incorporated anti‑PD‑1/PD‑L1 therapy. Table 50 and Figures 47 and 48 summarize the efficacy results for KEYNOTE‑868 by MMR status.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table&nbsp;50: Efficacy Results in KEYNOTE‑868</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:683px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td colspan="2"><p><strong>dMMR Population</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>pMMR Population</strong></p></td></tr><tr><td><p><strong>KEYTRUDA</strong></p><p><strong>with chemotherapy*</strong></p><p><strong>n=110</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>with chemotherapy*</strong></p><p><strong>n=112</strong></p></td><td><p><strong>KEYTRUDA</strong></p><p><strong>with chemotherapy*</strong></p><p><strong>n=294</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>with chemotherapy*</strong></p><p><strong>n=294</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>PFS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>29 (26%)</p></td><td style="vertical-align:top"><p>60 (54%)</p></td><td style="vertical-align:top"><p>95 (32%)</p></td><td style="vertical-align:top"><p>138 (47%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>NR (30.7, NR)</p></td><td style="vertical-align:top"><p>8.3 (6.5, 12.3)</p></td><td style="vertical-align:top"><p>13.1 (10.6, 19.5)</p></td><td style="vertical-align:top"><p>8.7 (8.4, 11.0)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.34 (0.22, 0.53)</p></td><td colspan="2" style="vertical-align:top"><p>0.57 (0.44, 0.74)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>OS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>10 (9%)</p></td><td style="vertical-align:top"><p>17 (15%)</p></td><td style="vertical-align:top"><p>45 (15%)</p></td><td style="vertical-align:top"><p>54 (18%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>NR (NR, NR)</p></td><td style="vertical-align:top"><p>NR (NR, NR)</p></td><td style="vertical-align:top"><p>28.0 (21.4, NR)</p></td><td style="vertical-align:top"><p>27.4 (19.5, NR)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.55 (0.25, 1.19)</p></td><td colspan="2" style="vertical-align:top"><p>0.79 (0.53, 1.17)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&sect;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.0617</p></td><td colspan="2" style="vertical-align:top"><p>0.1157</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chemotherapy (paclitaxel and carboplatin)</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on the stratified Cox proportional hazard model</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on stratified log-rank test (compared to an alpha boundary of 0.00207 for dMMR and 0.00116 for pMMR)</p><p><sup>&sect;</sup> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nominal p-Value; no multiplicity adjustment</p><p>NR=not reached</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Figure&nbsp;47: Kaplan-Meier Curve for Progression-Free Survival in KEYNOTE‑868 (dMMR Population)</strong></p><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-family:Arial'>Progression-Free
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Progression-Free Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA+Chemotherapy</p><p>Chemotherapy</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>PFS Rate at 12 months&nbsp;&nbsp; PFS Rate at 18 months&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p-value</u></strong></p><p><strong>KEYTRUDA+Chemotherapy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 73%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 65%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.34 (0.22, 0.53)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;0.0001</strong></p><p><strong>Chemotherapy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 33%</strong></p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Figure&nbsp;48: Kaplan-Meier Curve for Progression-Free Survival in KEYNOTE‑868 (pMMR Population)</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number at Risk</p><p>KEYTRUDA+Chemotherapy</p><p>Chemotherapy</p></td></tr></tbody></table><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-family:Arial'>Progression-Free
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Progression-Free Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>PFS Rate at 12 months&nbsp;&nbsp; PFS Rate at 18 months&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p-value</u></strong></p><p><strong>KEYTRUDA+Chemotherapy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 52%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 44%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.57 (0.44, 0.74)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;0.0001</strong></p><p><strong>Chemotherapy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 21%</strong></p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>&nbsp;</u></em></p><p><em><u>&nbsp;</u></em></p><p><em><u>KEYNOTE‑775: Controlled study of combination therapy in advanced EC patients previously treated with systemic chemotherapy</u></em></p><p>The efficacy of KEYTRUDA in combination with lenvatinib was investigated in KEYNOTE-775, a multicenter, open-label, randomized, active-controlled trial that enrolled 827&nbsp;patients with advanced endometrial carcinoma who had been previously treated with at least one prior platinum-based chemotherapy regimen in any setting, including in the neoadjuvant and adjuvant settings. Patients with endometrial sarcoma, including carcinosarcoma, or patients who had active autoimmune disease or a medical condition that required immunosuppression were ineligible. Patients with endometrial carcinoma that were pMMR or not MSI-H were stratified by ECOG performance status, geographic region, and history of pelvic radiation. Patients were randomized (1:1) to one of the following treatment arms:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; KEYTRUDA 200&nbsp;mg intravenously every 3&nbsp;weeks in combination with lenvatinib 20&nbsp;mg orally once daily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Investigator&rsquo;s choice, consisting of either doxorubicin 60&nbsp;mg/m<sup>2</sup> every 3&nbsp;weeks or paclitaxel 80&nbsp;mg/m<sup>2</sup> given weekly, 3&nbsp;weeks on/1&nbsp;week off.</p><p>Treatment with KEYTRUDA and lenvatinib continued until RECIST v1.1-defined progression of disease as verified by BICR, unacceptable toxicity, or for KEYTRUDA, a maximum of 24 months. Treatment was permitted beyond RECIST&nbsp;v1.1-defined disease progression if the treating investigator considered the patient to be deriving clinical benefit, and the treatment was tolerated. Assessment of tumor status was performed every 8&nbsp;weeks. The major efficacy outcome measures were OS and PFS as assessed by BICR according to RECIST&nbsp;v1.1, modified to follow a maximum of 10&nbsp;target lesions and a maximum of 5&nbsp;target lesions per organ. Additional efficacy outcome measures included ORR and DoR, as assessed by BICR.</p><p>Among the 697 pMMR patients, 346&nbsp;patients were randomized to KEYTRUDA in combination with lenvatinib, and 351 patients were randomized to investigator&rsquo;s choice of doxorubicin (n=254) or paclitaxel (n=97). The pMMR population characteristics were: median age of 65&nbsp;years (range: 30 to 86), 52% age 65 or older; 62%&nbsp;White, 22% Asian, and 3%&nbsp;Black; 60% ECOG PS of 0 and 40% ECOG PS of 1. The histologic subtypes were endometrioid carcinoma (55%), serous (30%), clear cell carcinoma (7%), mixed (4%), and other (3%). All 697 of these patients received prior systemic therapy for endometrial carcinoma: 67% had one, 30% had two, and 3% had three or more prior systemic therapies. Thirty-seven percent of patients received only prior neoadjuvant or adjuvant therapy.</p><p>Efficacy results for the pMMR or not MSI-H patients are summarized in Table&nbsp;51 and Figures&nbsp;49 and 50.</p><p><strong>Table&nbsp;51: Efficacy Results in KEYNOTE‑775</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:468px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Endometrial Carcinoma (pMMR or not MSI-H)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td><p><strong>KEYTRUDA</strong></p><p><strong>200 mg every 3 weeks</strong></p><p><strong>and Lenvatinib</strong></p><p><strong>n=346</strong></p></td><td><p><strong>Doxorubicin or Paclitaxel</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>n=351</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>OS</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>165 (48%)</p></td><td style="vertical-align:top"><p>203 (58%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>17.4 (14.2, 19.9)</p></td><td style="vertical-align:top"><p>12.0 (10.8, 13.3)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio* (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.68 (0.56, 0.84)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>247 (71%)</p></td><td style="vertical-align:top"><p>238 (68%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>6.6 (5.6, 7.4)</p></td><td style="vertical-align:top"><p>3.8 (3.6, 5.0)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio* (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.60 (0.50, 0.72)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective Response Rate</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ORR<sup>&Dagger;</sup> (95% CI)</p></td><td style="vertical-align:top"><p>30% (26, 36)</p></td><td style="vertical-align:top"><p>15% (12, 19)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response rate</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response rate</p></td><td style="vertical-align:top"><p>25%</p></td><td style="vertical-align:top"><p>13%</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&sect;</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of Response</strong></p></td><td style="vertical-align:top"><p>n=105</p></td><td style="vertical-align:top"><p>n=53</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>9.2 (1.6+, 23.7+)</p></td><td style="vertical-align:top"><p>5.7 (0.0+, 24.2+)&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*&nbsp;&nbsp;&nbsp; Based on the stratified Cox regression model</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp; Based on stratified log-rank test</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp; Response: Best objective response as confirmed complete response or partial response</p><p><sup>&sect;</sup>&nbsp;&nbsp;&nbsp;&nbsp; Based on Miettinen and Nurminen method stratified by ECOG performance status, geographic region, and history of pelvic radiation</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Figure&nbsp;49: Kaplan-Meier Curve for Overall Survival in KEYNOTE‑775 </strong></p><p><strong>(pMMR or Not MSI-H)</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong><u>&nbsp; OS rate at 12 months&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OS rate at 18 months&nbsp;&nbsp;&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p-value</u></strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 62%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 48%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.68 (0.56, 0.84)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.0001</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 29%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Figure&nbsp;50: Kaplan-Meier Curve for Progression-Free Survival in KEYNOTE‑775</strong></p><p><strong>(pMMR or Not MSI-H)</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong><u>&nbsp;PFS rate at 6 months&nbsp; PFS rate at 12 months&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p-value</u></strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 52%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 28%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.60 (0.50, 0.72)&nbsp;&nbsp; &lt;0.0001</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 36%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p>&nbsp;</p><p><u>&nbsp;</u></p><p><em><u>Cervical cancer</u></em></p><p><em><u>KEYNOTE-A18: Controlled trial of combination therapy with chemoradiotherapy in patients with high-risk, locally advanced cervical cancer</u></em></p><p>The efficacy of KEYTRUDA in combination with cisplatin and external beam radiation therapy (EBRT) followed by brachytherapy (BT) was investigated in KEYNOTE-A18, a multicenter, randomized, double‑blind, placebo‑controlled trial that enrolled 1060 patients with high-risk, locally advanced cervical cancer who had not previously received any definitive surgery, radiation, or systemic therapy for cervical cancer. There were 601 patients with FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III &ndash; IVA (tumor involvement of the lower vagina with or without extension onto pelvic sidewall or hydronephrosis/non-functioning kidney or has spread to adjacent pelvic organs) with either node-positive or node-negative disease And 459 patients with FIGO 2014 Stage IB2 &ndash; IIB (tumor lesions &gt;4 cm or clinically visible lesions that have spread beyond the uterus but have not extended onto the pelvic wall or to the lower third of vagina) with node-positive disease. Patients with autoimmune disease that required systemic therapy within 2&nbsp;years of treatment or a medical condition that required immunosuppression were ineligible. Randomization was stratified by planned type of EBRT (Intensity‑modulated radiation therapy [IMRT] or volumetric modulated arc therapy [VMAT] vs. non-IMRT and non‑VMAT), stage at screening of cervical cancer (FIGO 2014 Stage IB2-IIB vs. Stage III-IVA), and planned total radiotherapy dose ([EBRT + BT dose] of &lt;70&nbsp;Gy vs. &ge;70&nbsp;Gy as per equivalent dose [EQD2]). Patients were randomized (1:1) to one of two treatment arms:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; KEYTRUDA 200&nbsp;mg IV every 3&nbsp;weeks (5&nbsp;cycles) concurrent with cisplatin 40&nbsp;mg/m<sup>2</sup> IV weekly (5&nbsp;cycles, an optional sixth infusion could be administered per local practice) and radiotherapy (EBRT followed by BT), followed by KEYTRUDA 400&nbsp;mg IV every 6&nbsp;weeks (15&nbsp;cycles)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Placebo IV every 3&nbsp;weeks (5&nbsp;cycles) concurrent with cisplatin 40&nbsp;mg/m<sup>2</sup> IV weekly (5&nbsp;cycles, an optional sixth infusion could be administered per local practice), and radiotherapy (EBRT followed by BT), followed by placebo IV every 6&nbsp;weeks (15&nbsp;cycles)</p><p>Treatment continued until RECIST&nbsp;v1.1-defined progression of disease as determined by investigator or unacceptable toxicity. Assessment of tumor status was performed every 12&nbsp;weeks for the first two years, every 24&nbsp;weeks in year 3, and then annually.</p><p>&nbsp;</p><p>Among the 601 patients with FIGO 2014 Stage III &ndash; IVA disease enrolled in KEYNOTE-A18, the baseline characteristics were: median age of 51&nbsp;years (range: 22 to 87); 16%&nbsp;age 65 or older, 36%&nbsp;White, 1%&nbsp;Black, 34%&nbsp;Asian; 38%&nbsp;Hispanic or Latino; 68%&nbsp;ECOG PS&nbsp;0 and 32%&nbsp;ECOG PS&nbsp;1; 93%&nbsp;with CPS&nbsp;&ge;1; 71%&nbsp;had positive pelvic and/or positive para‑aortic lymph node(s), 29%&nbsp;had neither positive pelvic nor para-aortic lymph node, 86%&nbsp;IMRT or VMAT EBRT, 90%&nbsp;&ge;70 Gy (EQD2). Eighty-four&nbsp;percent had squamous cell carcinoma and 16%&nbsp;had non‑squamous histology.</p><p>&nbsp;</p><p>The primary efficacy outcomes were PFS (as assessed by investigator according to RECIST v1.1 or histopathologic confirmation) and OS. The trial demonstrated statistically significant improvements in PFS [0.70 (95% CI 0.55, 0.89; p-Value 0.0020)] from the first &nbsp;pre-specified interim analysis and OS [0.67 (95% CI 0.50, 0.90; p-Value 0.0040)] from the second &nbsp;pre-specified interim analysis in the overall population for patients randomized to KEYTRUDA with CRT compared to placebo with CRT. Table 52 summarizes key efficacy measures from the second pre-specified interim analysis in patients with FIGO 2014 Stage III &ndash; IVA disease with a median follow-up time of 26.6&nbsp;months (range:&nbsp;0.9 to 41.7&nbsp;months). The Kaplan-Meier curves in patients with FIGO 2014 Stage III &ndash; IVA disease for OS and PFS based on this analysis are shown in Figures 51 and 52.</p><p>&nbsp;</p><p><strong>Table 52: Efficacy Results for Patients in KEYNOTE-A18</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:570px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA</strong></p><p><strong>200 mg every 3 weeks and 400 mg every 6 weeks with CRT</strong></p><p><strong>n=296</strong></p></td><td style="vertical-align:top"><p><strong>Placebo </strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>with CRT</strong></p><p><strong>n=305</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>OS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of patients with event (%)</p></td><td style="vertical-align:top"><p>43 (15%)</p></td><td style="vertical-align:top"><p>73 (24%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>NR (NR, NR)</p></td><td style="vertical-align:top"><p>NR (NR, NR)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio* (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.57 (0.39, 0.83)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>PFS by Investigator</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of patients with event (%)</p></td><td style="vertical-align:top"><p>79 (27%)</p></td><td style="vertical-align:top"><p>125 (41%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>NR (NR, NR)</p></td><td style="vertical-align:top"><p>NR (26.3, NR)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio* (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.57 (0.43, 0.76)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*<sup> </sup>Based on the unstratified Cox proportional hazard model</p><p>CRT = Chemoradiotherapy</p><p>NR = Not reached</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Figure&nbsp;51: Kaplan-Meier Curve for Overall Survival </strong><strong>by Treatment Arm </strong><strong>in KEYNOTE-A18 for Patients with FIGO 2014 Stage III &ndash; IVA Cervical Cancer</strong></p><p>&nbsp;</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>HR (95% CI) </u></strong></p><p><strong>Pembrolizumab + CRT&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.57 (0.39, 0.83)</strong></p><p><strong>CRT&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Number at Risk</strong></p><p>Pembrolizumab + CRT</p><p>CRT</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-family:"Arial",sans-serif'>Overall
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Overall Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><p>&nbsp;</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Figure&nbsp;52: Kaplan-Meier Curve for Progression-Free Survival by Treatment Arm in KEYNOTE-A18 for Patients with FIGO 2014 Stage III-IVA Cervical Cancer</strong></p><p>&nbsp;</p><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-family:"Arial",sans-serif'>Progression-Free
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Progression-Free Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>HR (95% CI) </u></strong></p><p><strong>Pembrolizumab + CRT&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.57 (0.43, 0.76)</strong></p><p><strong>CRT&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Number at Risk</strong></p><p>Pembrolizumab + CRT</p><p>CRT</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><em><u>KEYNOTE‑826: Controlled study of combination therapy in patients with persistent, recurrent, or metastatic cervical cancer</u></em></p><p>The efficacy of KEYTRUDA in combination with paclitaxel and cisplatin or paclitaxel and carboplatin, with or without bevacizumab, was investigated in KEYNOTE‑826, a multicentre, randomised, double‑blind, placebo-controlled study that enrolled 617&nbsp;patients with persistent, recurrent, or first‑line metastatic cervical cancer who had not been treated with chemotherapy except when used concurrently as a radio‑sensitising agent. Patients were enrolled regardless of tumour PD‑L1 expression status. Patients with autoimmune disease that required systemic therapy within 2&nbsp;years of treatment or a medical condition that required immunosuppression were ineligible. Randomisation was stratified by metastatic status at initial diagnosis, investigator decision to use bevacizumab, and PD‑L1 status (CPS&nbsp;&lt;&nbsp;1 vs. CPS&nbsp;1 to &lt;&nbsp;10 vs. CPS&nbsp;&ge;&nbsp;10). Patients were randomised (1:1) to one of the two treatment groups:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment Group 1: KEYTRUDA 200&nbsp;mg plus chemotherapy with or without bevacizumab</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment Group 2: Placebo plus chemotherapy with or without bevacizumab</p><p>&nbsp;</p><p>The investigator selected one of the following four treatment regimens prior to randomisation:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paclitaxel 175&nbsp;mg/m<sup>2</sup> + cisplatin 50&nbsp;mg/m<sup>2</sup></p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paclitaxel 175&nbsp;mg/m<sup>2</sup> + cisplatin 50&nbsp;mg/m<sup>2</sup> + bevacizumab 15&nbsp;mg/kg</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paclitaxel 175&nbsp;mg/m<sup>2</sup> + carboplatin AUC 5&nbsp;mg/mL/min</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paclitaxel 175&nbsp;mg/m<sup>2</sup> + carboplatin AUC 5&nbsp;mg/mL/min + bevacizumab 15&nbsp;mg/kg</p><p>&nbsp;</p><p>All study medications were administered as an intravenous infusion. All study treatments were administered on Day&nbsp;1 of each 3‑week treatment cycle. Cisplatin could be administered on Day&nbsp;2 of each 3‑week treatment cycle. The option to use bevacizumab was by investigator choice prior to randomisation. Treatment with KEYTRUDA continued until RECIST&nbsp;v1.1‑defined progression of disease, unacceptable toxicity, or a maximum of 24&nbsp;months. Administration of KEYTRUDA was permitted beyond RECIST‑defined disease progression if the patient was clinically stable and considered to be deriving clinical benefit by the investigator. Assessment of tumour status was performed at Week&nbsp;9 and then every 9&nbsp;weeks for the first year, followed by every 12&nbsp;weeks thereafter.</p><p>&nbsp;</p><p>Of the 617&nbsp;enrolled patients, 548&nbsp;patients (89%) had tumours expressing PD‑L1with a CPS&nbsp;&ge;&nbsp;1 based on the PD‑L1 IHC 22C3 pharmDx<sup>TM</sup> Kit. Among these 548&nbsp;enrolled patients with tumours expressing PD‑L1, 273&nbsp;patients were randomised to KEYTRUDA in combination with chemotherapy with or without bevacizumab, and 275&nbsp;patients were randomised to placebo in combination with chemotherapy with or without bevacizumab. The baseline characteristics of these 548&nbsp;patients were: median age of 51&nbsp;years (range: 22 to 82), 16%&nbsp;age 65 or older; 59%&nbsp;White, 18%&nbsp;Asian, and 1%&nbsp;Black; 37%&nbsp;Hispanic or Latino; 56% and 43%&nbsp;ECOG performance status of&nbsp;0 or 1, respectively; 63% received bevacizumab as study treatment; 21% with adenocarcinoma and 5% with adenosquamous histology; for patients with persistent or recurrent disease with or without distant metastases, 39% had received prior chemoradiation only and 17% had received prior chemoradiation plus surgery.</p><p>&nbsp;</p><p>The primary efficacy outcome measures were OS and PFS as assessed by investigator according to RECIST&nbsp;v1.1. Secondary efficacy outcome measures were ORR and duration of response, according to RECIST&nbsp;v1.1, as assessed by investigator. The study demonstrated statistically significant improvements in OS and PFS for patients randomised to KEYTRUDA in combination with chemotherapy with or without bevacizumab compared to placebo in combination with chemotherapy with or without bevacizumab at a pre‑specified interim analysis in the overall population. The median follow‑up time was 17.2&nbsp;months (range:&nbsp;0.3 to 29.4&nbsp;months). Table&nbsp;53 summarises key efficacy measures for patients whose tumours expressed PD‑L1 with a CPS &ge;&nbsp;1 in KEYNOTE‑826 from the pre‑specified interim analysis. The Kaplan‑Meier curves for OS and PFS are shown in Figures&nbsp;53 and&nbsp;54.</p><p><strong>Table&nbsp;53: Efficacy results </strong><strong>in </strong><strong>KEYNOTE‑826 for patients with </strong><strong>PD-L1 expression (CPS </strong><strong>&ge;&nbsp;1)</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:634px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>KEYTRUDA</strong></p><p><strong>200&nbsp;mg every 3&nbsp;weeks</strong></p><p><strong>plus Chemotherapy<sup>*</sup> with or without bevacizumab</strong></p><p><strong>n=273</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Placebo </strong></p><p><strong>&nbsp;</strong></p><p><strong>plus Chemotherapy<sup>*</sup> with or without bevacizumab</strong></p><p><strong>n=275</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>OS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>118 (43%)</p></td><td colspan="2" style="vertical-align:top"><p>154 (56%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>NR (19.8, NR)</p></td><td colspan="2" style="vertical-align:top"><p>16.3 (14.5, 19.4)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="3" style="vertical-align:top"><p>0.64 (0.50, 0.81)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&Dagger;</sup></p></td><td colspan="3" style="vertical-align:top"><p>0.0001</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>PFS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of patients with event</p></td><td style="vertical-align:top"><p>157 (58%)</p></td><td colspan="2" style="vertical-align:top"><p>198 (72%)</p></td></tr><tr><td style="vertical-align:top"><p>Median in months (95% CI)</p></td><td style="vertical-align:top"><p>10.4 (9.7, 12.3)</p></td><td colspan="2" style="vertical-align:top"><p>8.2 (6.3, 8.5)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>&dagger;</sup> (95% CI)</p></td><td colspan="3" style="vertical-align:top"><p>0.62 (0.50, 0.77)</p></td></tr><tr><td style="vertical-align:top"><p>p-Value<sup>&sect;</sup></p></td><td colspan="3" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Objective response rate</strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR<sup>&para;</sup> % (95% CI)</p></td><td style="vertical-align:top"><p>68% (62, 74)</p></td><td colspan="2" style="vertical-align:top"><p>50% (44, 56)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>23%</p></td><td colspan="2" style="vertical-align:top"><p>13%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>45%</p></td><td colspan="2" style="vertical-align:top"><p>37%</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Duration of response</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median in months (range)</p></td><td style="vertical-align:top"><p>18.0 (1.3+, 24.2+)</p></td><td colspan="2" style="vertical-align:top"><p>10.4 (1.5+, 22.0+)</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;&nbsp;12&nbsp;months<sup>#</sup></p></td><td><p>56</p></td><td colspan="2"><p>46</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chemotherapy (paclitaxel and cisplatin or paclitaxel and carboplatin)</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on the stratified Cox proportional hazard model</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on stratified log‑rank test (compared to an alpha boundary of 0.00549)</p><p><sup>&sect;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on stratified log-rank test (compared to an alpha boundary of 0.00144)</p><p><sup>&para;</sup> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Response: Best objective response as confirmed complete response or partial response</p><p><sup>#</sup> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan‑Meier estimation</p><p>NR = not reached</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>&nbsp;</sup></p><p>&nbsp;</p><p><sup>&nbsp;</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong>Figure&nbsp;</strong><strong>53</strong><strong>: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE‑826 patients with PD-L1 expression (</strong><strong>CPS &ge;&nbsp;1</strong><strong>)</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Number at Risk</strong></p><p>KEYTRUDA +Chemotherapy*</p><p>Chemotherapy*</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>OS rate at 12 months&nbsp;&nbsp; OS rate at 24 months&nbsp;&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;p-value</u></strong></p><p><strong>&nbsp;KEYTRUDA+Chemotherapy*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;75%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 53%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.64 (0.50, 0.81)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.0001</strong></p><p><strong>Chemotherapy*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 63%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 42%</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Number at Risk</strong></p><p>Pembrolizumab+Chemotherapy*</p><p>Chemotherapy*</p></td></tr></tbody></table><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-family:"Arial",sans-serif'>Overall
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Overall Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p>&nbsp;</p><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chemotherapy (paclitaxel and cisplatin or paclitaxel and carboplatin) with or without bevacizumab</p><p><strong>&nbsp;</strong></p><p><strong>Figure&nbsp;</strong><strong>54</strong><strong>: Kaplan-Meier curve for progression free survival by treatment arm in KEYNOTE‑826 patients with PD-L1 expression (</strong><strong>CPS &ge;&nbsp;1</strong><strong>)</strong></p><p>&nbsp;</p><p><!--[if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-family:"Arial",sans-serif'>Progression-Free
    Survival (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]--><img width="44" height="4" alt="Text Box: Progression-Free Survival (%)" src="file:///C:/Users/aljaser/AppData/Local/Temp/msohtmlclip1/01/clip_image025.png" /></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Number at Risk</strong></p><p>KEYTRUDA+Chemotherapy*</p><p>Chemotherapy*</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Treatment arm&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>PFS rate at 12 months&nbsp;&nbsp; PFS rate at 24 months&nbsp;&nbsp;&nbsp; HR (95% CI)&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;p-value</u></strong></p><p><strong>KEYTRUDA+Chemotherapy*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;46%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 33%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.62 (0.50, 0.77)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;0.0001</strong></p><p><strong>Chemotherapy*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;34%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14%</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time in Months</p></td></tr></tbody></table><p>&nbsp;</p><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chemotherapy (paclitaxel and cisplatin or paclitaxel and carboplatin) with or without bevacizumab</p><p>&nbsp;</p><p><u>Elderly population</u></p><p>No overall differences in safety were observed in patients &ge;&nbsp;75&nbsp;years of age compared to younger patients receiving KEYTRUDA monotherapy. Based on limited safety data from patients &ge;&nbsp;75&nbsp;years of age, when administrated in combination with chemotherapy, KEYTRUDA showed less tolerability in patients &ge;&nbsp;75&nbsp;years of age compared to younger patients. For efficacy data in patients &ge;&nbsp;75&nbsp;years of age please refer to the relevant section of each indication.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>In KEYNOTE-051, 161&nbsp;paediatric patients (62&nbsp;children aged 9&nbsp;months to less than 12&nbsp;years and 99&nbsp;adolescents aged 12&nbsp;years to 17&nbsp;years) with advanced melanoma or PD-L1 positive advanced, relapsed, or refractory solid tumours or lymphoma were administered KEYTRUDA 2&nbsp;mg/kg bw every 3&nbsp;weeks. All patients received KEYTRUDA for a median of 4&nbsp;doses (range 1‑35&nbsp;doses), with 138&nbsp;patients (85.7%) receiving KEYTRUDA for 2&nbsp;doses or more. Participants were enrolled across 28&nbsp;tumour types by primary diagnosis. The most common tumour types by histology were Hodgkin lymphoma&nbsp;(13.7%), glioblastoma multiforme&nbsp;(9.3%), neuroblastoma&nbsp;(6.2%), osteosarcoma&nbsp;(6.2%) and melanoma&nbsp;(5.6%). Of the 161&nbsp;patients, 137&nbsp;were enrolled with solid tumours, 22&nbsp;with Hodgkin lymphoma, and 2&nbsp;with other lymphomas. In patients with solid tumours and other lymphomas, the ORR was 5.8%, no patient had a complete response and 8&nbsp;patients (5.8%) had a partial response. In the Hodgkin lymphoma population (n=22), in patients aged 11&nbsp;years to 17&nbsp;years, the baseline characteristics were median age 15&nbsp;years; 64%&nbsp;male; 68%&nbsp;White; 77% had a Lansky/Karnofsky scale 90‑100 and 23% had scale 70‑80. Eighty-six percent had two or more prior lines of therapy and 64% had Stage 3 or higher. In these paediatric patients with cHL, the ORR assessed by BICR according to the IWG 2007 criteria was 54.5%, 1&nbsp;patient (4.5%) had a complete response and 11&nbsp;patients (50.0%) had a partial response, and the ORR assessed by the Lugano 2014 criteria was 63.6%, 4&nbsp;patients (18.2%) had a complete response and 10&nbsp;patients (45.5%) had a partial response. Data from clinical trials in adolescent melanoma patients is very limited and extrapolation from adult data has been used to establish efficacy. Among the 5 adolescent participants with advanced melanoma treated on KEYNOTE-051, no patient had a complete or a partial response, and 1 patient had stable disease.</p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with KEYTRUDA in one or more subsets of the paediatric population in treatment of Hodgkin lymphoma (see section&nbsp;4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of pembrolizumab was studied in 2,993&nbsp;patients with metastatic or unresectable melanoma, NSCLC, or carcinoma who received doses in the range of 1 to 10&nbsp;mg/kg bw every 2&nbsp;weeks, 2&nbsp;to 10&nbsp;mg/kg bw every 3&nbsp;weeks, or 200&nbsp;mg every 3&nbsp;weeks.</p><p><u>&nbsp;</u></p><p><u>Absorption</u></p><p>Pembrolizumab is administered via the intravenous route and therefore is immediately and completely bioavailable.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>Consistent with a limited extravascular distribution, the volume of distribution of pembrolizumab at steady‑state is small (~6.0&nbsp;L; CV: 20%). As expected for an antibody, pembrolizumab does not bind to plasma proteins in a specific manner.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Pembrolizumab is catabolised through non‑specific pathways; metabolism does not contribute to its clearance.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Pembrolizumab CL is approximately 23% lower (geometric mean, 195&nbsp;mL/day [CV%: 40%]) after achieving maximal change at steady‑state compared with the first dose (252&nbsp;mL/day [CV%: 37%]); this decrease in CL with time is not considered clinically meaningful. The geometric mean value (CV%) for the terminal half‑life is 22&nbsp;days (32%) at steady‑state.</p><p>&nbsp;</p><p><u>Linearity/non‑linearity</u></p><p>Exposure to pembrolizumab as expressed by peak concentration (C<sub>max</sub>) or area under the plasma concentration time curve (AUC) increased dose proportionally within the dose range for efficacy. Steady‑state concentrations of pembrolizumab were reached by 16&nbsp;weeks of repeated dosing with an every 3&nbsp;week regimen and the systemic accumulation was 2.1‑fold. The median trough concentrations (C<sub>min</sub>) at steady‑state were approximately 22&nbsp;mcg/mL at a dose of 2&nbsp;mg/kg bw every 3&nbsp;weeks and 29&nbsp;mcg/mL at a dose of 200&nbsp;mg every 3&nbsp;weeks. The median area under the concentration time curve at steady‑state over 3&nbsp;weeks (AUC<sub>0‑3weeks</sub>) was 794&nbsp;mcg∙day/mL at a dose of 2&nbsp;mg/kg bw every 3&nbsp;weeks and 1,053&nbsp;mcg∙day/mL at a dose of 200&nbsp;mg every 3&nbsp;weeks.</p><p>&nbsp;</p><p>Following administration of pembrolizumab 200&nbsp;mg every 3&nbsp;weeks in patients with cHL, the observed median C<sub>min</sub> at steady‑state was up to 40% higher than that in other tumour types treated with the same dosage; however, the range of trough concentrations is similar. There are no notable differences in median C<sub>max</sub> between cHL and other tumour types. Based on available safety data in cHL and other tumour types, these differences are not clinically meaningful.</p><p><u>&nbsp;</u></p><p><u>Special populations</u></p><p>The effects of various covariates on the pharmacokinetics of pembrolizumab were assessed in population pharmacokinetic analyses. The following factors had no clinically important effect on the clearance of pembrolizumab: age (range 15‑94&nbsp;years), gender, race, mild or moderate renal impairment, mild or moderate hepatic impairment and tumour burden. The relationship between body weight and clearance supports the use of either fixed dose or body weight‑based dosing to provide adequate and similar control of exposure. Pembrolizumab exposure with weight‑based dosing at 2&nbsp;mg/kg bw every 3&nbsp;weeks in paediatric patients (&ge;&nbsp;3 to 17&nbsp;years) are comparable to those of adults at the same dose.</p><p><u>&nbsp;</u></p><p><u>Renal impairment</u></p><p>The effect of renal impairment on the clearance of pembrolizumab was evaluated by population pharmacokinetic analyses in patients with mild or moderate renal impairment compared to patients with normal renal function. No clinically important differences in the clearance of pembrolizumab were found between patients with mild or moderate renal impairment and patients with normal renal function. Pembrolizumab has not been studied in patients with severe renal impairment (see section&nbsp;4.2).</p><p><u>&nbsp;</u></p><p><u>Hepatic impairment</u></p><p>The effect of hepatic impairment on the clearance of pembrolizumab was evaluated by population pharmacokinetic analyses in patients with mild and moderate hepatic impairment (as defined using the US National Cancer Institute criteria of hepatic dysfunction) compared to patients with normal hepatic function. No clinically important differences in the clearance of pembrolizumab were found between patients with mild or moderate hepatic impairment and normal hepatic function. Pembrolizumab has not been studied in patients with severe hepatic impairment (see section&nbsp;4.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety of pembrolizumab was evaluated in a 1‑month and a 6‑month repeat‑dose toxicity study in Cynomolgus monkeys administered intravenous doses of 6, 40 or 200&nbsp;mg/kg bw once a week in the 1‑month study and once every two weeks in the 6‑month study, followed by a 4‑month treatment‑free period. No findings of toxicological significance were observed and the no observed adverse effect level (NOAEL) in both studies was &ge;&nbsp;200&nbsp;mg/kg bw, which produced exposure multiples of 19 and 94&nbsp;times the exposure in humans at doses of 10 and 2&nbsp;mg/kg bw, respectively. The exposure multiple between the NOAEL and a human dose of 200&nbsp;mg was 74.</p><p>&nbsp;</p><p>Animal reproduction studies have not been conducted with pembrolizumab. The PD‑1/PD‑L1 pathway is thought to be involved in maintaining tolerance to the foetus throughout pregnancy. Blockade of PD‑L1 signalling has been shown in murine models of pregnancy to disrupt tolerance to the foetus and to result in an increase in foetal loss.</p><p>&nbsp;</p><p>Animal fertility studies have not been conducted with pembrolizumab. In 1&nbsp;month and 6&nbsp;month repeat‑dose toxicology studies in monkeys, there were no notable effects in the male and female reproductive organs; however, many animals in these studies were not sexually mature.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>L‑histidine</p><p>L‑histidine hydrochloride monohydrate</p><p>Sucrose</p><p>Polysorbate&nbsp;80 (E433)</p><p>Water for injections</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products except those mentioned in section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial
2 years.

After preparation of infusion
From a microbiological point of view, the product, once diluted, should be used immediately. The diluted solution must not be frozen. If not used immediately, chemical and physical in use stability of KEYTRUDA has been demonstrated for 96 hours at 2°C to 8°C. This 96 hour hold may include up to 6 hours at room temperature (at or below 25°C). If refrigerated, the vials and/or intravenous bags must be allowed to come to room temperature prior to use.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C&nbsp;&ndash;&nbsp;8&deg;C).</p><p>Do not freeze.</p><p>Store in the original carton in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after dilution of the medicinal product, see section&nbsp;6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4&nbsp;mL of concentrate in a 10&nbsp;mL Type I clear glass vial, with a coated grey chlorobutyl or bromobutyl stopper and an aluminium seal with a dark blue coloured flip‑off cap, containing 100&nbsp;mg pembrolizumab.</p><p>&nbsp;</p><p>Each carton contains one vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Preparation and administration of the infusion</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not shake the vial.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Equilibrate the vial to room temperature (at or below 25&deg;C).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prior to dilution, the vial of liquid can be out of refrigeration (temperatures at or below 25&deg;C) for up to 24&nbsp;hours.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Parenteral medicinal products should be inspected visually for particulate matter and discolouration prior to administration. The concentrate is a clear to slightly opalescent, colourless to slightly yellow solution. Discard the vial if visible particles are observed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withdraw the required volume up to 4&nbsp;mL (100&nbsp;mg) of concentrate and transfer into an intravenous bag containing sodium chloride 9&nbsp;mg/mL (0.9%) or glucose 50&nbsp;mg/mL (5%) to prepare a diluted solution with a final concentration ranging from 1 to 10&nbsp;mg/mL. Each vial contains an excess fill of 0.25&nbsp;mL (total content per vial 4.25&nbsp;mL) to ensure the recovery of 4&nbsp;mL of concentrate. Mix diluted solution by gentle inversion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; From a microbiological point of view, the product, once diluted, should be used immediately. The diluted solution must not be frozen. If not used immediately, chemical and physical in‑use stability of KEYTRUDA has been demonstrated for 96&nbsp;hours at 2&deg;C to 8&deg;C. This 96‑hour hold may include up to 6&nbsp;hours at room temperature (at or below 25&deg;C). If refrigerated, the vials and/or intravenous bags must be allowed to come to room temperature prior to use. Translucent to white proteinaceous particles may be seen in diluted solution. Administer the infusion solution intravenously over 30&nbsp;minutes using a sterile, non‑pyrogenic, low‑protein binding 0.2 to 5&nbsp;&micro;m in‑line or add‑on filter.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not co‑administer other medicinal products through the same infusion line.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; KEYTRUDA is for single use only. Discard any unused portion left in the vial.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder: 
Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
The Netherlands

Manufacturer: 
MSD Ireland (Carlow) 
Dublin Road, Carlow, Ireland
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>